WorldWideScience

Sample records for citalopram promethazine risperidone

  1. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence.

    Science.gov (United States)

    Marcus, Monica M; Jardemark, Kent; Malmerfelt, Anna; Gertow, Jens; Konradsson-Geuken, Asa; Svensson, Torgny H

    2012-04-01

    Antidepressant drugs are frequently used to treat affective symptoms in schizophrenia. We have recently shown that escitalopram, but not citalopram or R-citalopram, increases firing rate and burst firing of midbrain dopamine neurons, potentiates cortical N-methyl-D-aspartate (NMDA) receptor-mediated transmission and enhances cognition, effects that might influence the outcome of concomitant antipsychotic medication. Here, we studied, in rats, the behavioral and neurobiological effects of adding escitalopram, citalopram, or R-citalopram to the second-generation antipsychotic drug risperidone. We examined antipsychotic efficacy using the conditioned avoidance response (CAR) test, extrapyramidal side effect (EPS) liability using a catalepsy test, dopamine outflow in the medial prefrontal cortex (mPFC) and nucleus accumbens using in vivo microdialysis in freely moving animals, and NMDA receptor-mediated transmission in the mPFC using intracellular electrophysiological recording in vitro. Only escitalopram (5 mg/kg), but not citalopram (10 mg/kg), or R-citalopram (10 mg/kg), dramatically enhanced the antipsychotic-like effect of a low dose of risperidone (0.25 mg/kg), without increasing catalepsy. Given alone, escitalopram, but not citalopram or R-citalopram, markedly enhanced both cortical dopamine output and NMDA receptor-mediated transmission. Addition of escitalopram and to some extent R-citalopram, but not citalopram, significantly enhanced both cortical dopamine output and cortical NMDA receptor-mediated transmission induced by a suboptimal dose/concentration of risperidone. These results suggest that adjunct treatment with escitalopram, but not citalopram, may enhance the effect of a subtherapeutic dose of risperidone on positive, negative, cognitive, and depressive symptoms in schizophrenia, yet without increased EPS liability.

  2. Risperidone

    Science.gov (United States)

    ... bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Risperidone is also used to treat behavior problems such as aggression, self-injury, and ... repetitive behavior, difficulty interacting with others, and problems ...

  3. 小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究%Efficacy and safety of low dosage risperidone added on valproate and citalopram in the treatment of acute bipolar depression

    Institute of Scientific and Technical Information of China (English)

    王健; 王刚; 马辛

    2014-01-01

    目的考察小剂量利培酮强化抗抑郁剂治疗对双相抑郁发作的疗效和安全性。方法符合入组标准的住院患者,先接受2周的丙戊酸钠( valproate,VPA)合并西酞普兰( citalopram,CIT)治疗。2周末相对于基线的蒙哥马利抑郁量表( Montgomery and Asberg Depression Scale,MADRS)减分率0.05)。 CGI-I 2组对比,差异具有统计学意义(P0.05)。随机治疗第1周末BPRS阳性因子评分VPA+CIT+RIS组较VPA+CIT组明显降低,差异有统计学意义(P<0.05),显示VPA+CIT+RIS组较VPA+CIT组在改善阳性精神病性症状方面起效更快。在随机治疗第2周,VPA+CIT+RIS组有效率为66.0%,VPA+CIT组为33.3%,显示VPA+CIT+RIS组较VPA+CIT组起效更快。结论 VPA+CIT+RIS与VPA+CIT治疗双相抑郁发作均安全有效。在快速起效及降低转相风险方面,VPA+CIT+RIS组优于VPA+CIT组。%Objective To evaluate the augmentation efficacy and safety of low dosage risperidone, added on the usual treatment ( valproate and citalopram) in the acute treatment of bipolar depression. Methods A total of 46 inpatients with a diagnostic criteria for acute depression episode with bipolar disorder according to DSM-IV-TR were first given valproate and citalopram treatment. The subjects who achieve little clinical response( i. e. reduction from baseline in total MADRS score by<50%) at the end of 2-week will enter into the randomized open-label 6-week treatment phase. The eligible subjects will be randomized to treatment with valproate & citalopram or valproate & citalopram & risperidone in a 1:1 ratio. Efficacy rating scales to be used in the study include MADRS, YMRS, BPRS( total score and positive subscale), CGI-S, and CGI-I. The evaluations of safety and tolerability include SAS, treatment-emergent mania, clinical laboratory tests, vital signs , ECG, and adverse events reports. Results At the end of treatment, the scores of MADRS, BPRS, GIC-I, and CGI-S in both treatment groups decreased significantly compared

  4. Promethazine

    Science.gov (United States)

    ... also used to prevent and control nausea and vomiting that may occur after surgery, and with other ... that do not exist) confusion overwhelming or unmanageable fear or emotion seizures uncontrollable shaking of a part ...

  5. Antinociceptive Effect of Promethazine in Mice

    Directory of Open Access Journals (Sweden)

    Amir Farshchi

    2009-09-01

    Full Text Available Objective(sThe present study was undertaken to investigate the nociception activity of promethazine, a tranquillizer devoid of hypnotic activity in mice.Materials and MethodsAntinociception was evaluated, using the acetic acid-induced writhing, tail flick, hot plate and formalin pain tests.ResultsPromethazine (4 and 6 mg/kg and acetylsalicylic acid (100 mg/kg produced a significant inhibition of the second phase response in the formalin pain model (P0.05 and administration of naloxone (0.1 mg/kg couldn't block the antinociceptive effect of promethazine.ConclusionThe data obtained suggest that antinociceptive effects of the promethazine may be mediated via peripheral and not central mechanisms.

  6. Compound list: promethazine [Open TG-GATEs

    Lifescience Database Archive (English)

    Full Text Available promethazine PMZ 00110 ftp://ftp.biosciencedbc.jp/archive/open-tggates/LATEST/Human/in_vitro/prometh...azine.Human.in_vitro.Liver.zip ftp://ftp.biosciencedbc.jp/archive/open-tggates/LATEST/Rat/in_vitro/prometh...azine.Rat.in_vitro.Liver.zip ftp://ftp.biosciencedbc.jp/archive/open-tggates/LATEST/Rat/in_vivo/Liver/Single/prometh....jp/archive/open-tggates/LATEST/Rat/in_vivo/Liver/Repeat/promethazine.Rat.in_vivo.Liver.Repeat.zip ...

  7. Bioavailability of Promethazine during Spaceflight

    Science.gov (United States)

    Boyd, Jason L.; Wang, Zuwei; Putcha, Lakshmi

    2009-01-01

    Promethazine (PMZ) is the choice anti-motion sickness medication for treating space motion sickness (SMS) during flight. The side effects associated with PMZ include dizziness, drowsiness, sedation, and impaired psychomotor performance which could impact crew performance and mission operations. Early anecdotal reports from crewmembers indicate that these central nervous system side effects of PMZ are absent or greatly attenuated in microgravity, potentially due to changes in pharmacokinetics (PK) and pharmacodynamics in microgravity. These changes could also affect the therapeutic effectiveness of drugs in general and PMZ, in particular. In this investigation, we examined bioavailability and associated pharmacokinetics of PMZ in astronauts during and after space flight. Methods. Nine astronauts received, per their preference, PMZ (25 or 50 mg as intramuscular injection, oral tablet, or rectal suppository) on flight day one for the treatment of SMS and subsequently collected saliva samples and completed sleepiness scores for 72 h post dose. Thirty days after the astronauts returned to Earth, they repeated the protocol. Bioavailability and PK parameters were calculated and compared between flight and ground. Results. Maximum concentration (Cmax) was lower and time to reach Cmax (tmax) was longer in flight than on the ground. Area under the curve (AUC), a measure of bioavailability, was lower and biological half-life (t1/2) was longer in flight than on the ground. Conclusion. Results indicate that bioavailability of PMZ is reduced during spaceflight. Number of samples, sampling method, and sampling schedule significantly affected PK parameter estimates.

  8. Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice.

    Science.gov (United States)

    Rogóż, Zofia; Kabziński, Marcin

    2011-01-01

    The aim of the present study was to examine the effect of antidepressants (ADs) belonging to different pharmacological groups and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J mice. The antidepressants: citalopram, fluvoxamine, sertraline, reboxetine, milnacipran (5 and 10 mg/kg), or risperidone in low doses (0.05 and 0.1 mg/kg) given alone did not change the immobility time of mice in the forced swimming test. Co-treatment with reboxetine or milnacipran (10 mg/kg) and risperidone in a lower dose of 0.05 mg/kg or with sertraline, reboxetine (5 and 10 mg/kg), citalopram, fluvoxamine, milnacipran (10 mg/kg) and risperidone in a higher dose of 0.1 mg/kg produced antidepressant-like effect in the forced swimming test. WAY100635 (a 5-HT(1A) receptor antagonist) inhibited the effects induced by co-administration of ADs and risperidone. Active behavior in the forced swimming test was not a consequence of an increased general activity, since the combined treatment with ADs and risperidone failed to enhance the locomotor activity of mice. The obtained results indicate that a low dose of risperidone enhances the activity of ADs in an animal model of depression, and that, among other mechanisms, 5-HT(1A) receptors may play a role in these effects.

  9. Pharm GKB: citalopram [PharmGKB

    Lifescience Database Archive (English)

    Full Text Available ine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxep...hlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan...ne citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin duloxetine es...ne clozapine codeine debrisoquine desipramine dextromethorphan doxepin escitalopram flecainide fluoxetine fl...e chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan

  10. Interpreting serum risperidone concentrations.

    Science.gov (United States)

    Boerth, Joel M; Caley, Charles F; Goethe, John W

    2005-02-01

    Risperidone is an atypical antipsychotic commonly used for treatment of schizophrenia and other psychotic disorders. Although therapeutic drug monitoring is not routine for any of the atypical antipsychotics, serum antipsychotic concentrations are measured routinely to assess treatment nonadherence. In humans, risperidone is metabolized by cytochrome P450 2D6 to 9-hydroxyrisperidone; together these constitute the active moiety. Dose-proportional increases in serum concentrations have not been reported for the parent drug, but have been reported for 9-hydroxyrisperidone and the active moiety (i.e., the combined concentrations of risperidone and 9-hydroxyrisperidone). We describe a 34-year-old Caucasian man of Sicilian descent with a history of schizophrenia, disorganized type. He was suspected to be noncompliant with his risperidone therapy. Initially, active moiety risperidone concentrations increased linearly with prescribed dosage increases. However, with continued increases, active moiety concentrations adjusted downward and remained 17-36% below anticipated levels. We propose a method for estimating target active moiety concentrations of risperidone based on dosage-a method that may be used to guide clinicians in assessing nonadherence to risperidone treatment.

  11. Comparison of oral Midazolam-Ketamine and Midazolam-Promethazine as sedative agents in pediatric dentistry

    Directory of Open Access Journals (Sweden)

    Mojtaba Vahid Golpayegani

    2012-01-01

    Conclusion: Under the current circumstances, Ketamine/Midazolam combination provided sufficient sedative effect in lower doses. However, Midazolam/Promethazine combination did not produce similar results.

  12. Endogenous histamine and promethazine-induced gastric ulcers in the guinea pig

    Science.gov (United States)

    Djahanguiri, B.; Hemmati, M.

    1978-01-01

    Experiments performed with an inhibitor of diaminoxydase, aminoguanidine and an inhibitor of histidine decarboxylase, NSD 1055, showed that the frequency of gastric ulcers induced by promethazine was increased with the first inhibitor and decreased with the second. It is suggested that ulcers induced by promethazine in guinea pigs might be due to histamino-liberator effect of the antihistaminio compound.

  13. Citalopram in the treatment of dysthymic disorder.

    Science.gov (United States)

    Hellerstein, David J; Batchelder, Sarai; Miozzo, Ruben; Kreditor, David; Hyler, Steven; Gangure, Dinu; Clark, Joy

    2004-05-01

    This study aimed to provide preliminary data on the tolerability and effectiveness of citalopram for patients with dysthymic disorder. Twenty-one adult subjects meeting DSM-IV criteria for dysthymic disorder were enrolled in this 12-week open-label study, of whom 15 had pure dysthymia (e.g. no major depression in the past 2 years). Citalopram was initiated at 20 mg/day, and increased to a maximum of 60 mg/day. Response was defined as 50% or greater drop in score on the Hamilton Depression Rating Scale (HDRS) and a Clinical Global Impressions-I score of 1 ('very much improved') or 2 ('much improved'). Of these 15 pure dysthymic disorder subjects, all completed the trial, and 11 (73.3%) were treatment responders. All paired sample t-tests were highly significant, demonstrating significant average improvement on all measures of symptomatology and functioning. Scores on the 24-item HDRS decreased from 22.3+/-4.3 at baseline to 9.1+/-7.8 at week 12 [t(14)=6.1, P<0.001]. In addition, improvement was noted in self-reported measures of temperament and social functioning. The average final dose of citalopram was 39 mg/day. Side-effects were reported by nine of 15 subjects (60%), most frequently gastrointestinal symptoms (n=5), dry mouth (n=5) and sexual side-effects (n=3). These findings suggest the effectiveness and tolerability of citalopram in treating dysthymic disorder. Double-blind prospective studies are needed comparing citalopram both to placebo and to other medications, assessing both initial and sustained response to treatment.

  14. Postmortem Femoral Blood Concentrations of Risperidone

    DEFF Research Database (Denmark)

    Linnet, Kristian; Johansen, Sys Stybe

    2014-01-01

    Postmortem femoral blood concentrations of the antipsychotic drug risperidone and the active metabolite 9-hydroxyrisperidone were determined by an achiral LC-MS/MS method in 38 cases. The cause of death was classified as unrelated to risperidone in 30 cases, in which the sum of the concentration ...

  15. Promethazine as a Novel Prophylaxis and Treatment for Nerve Agent Poisoning

    Science.gov (United States)

    2008-12-01

    21010-5400 ABSTRACT The present study evaluated promethazine, an FDA-approved antihistamine , for treating the toxic effects of soman (GD...adjunct or alone is an effective countermeasure against GD poisoning. Moreover, as an FDA-approved drug , promethazine could be transitioned quickly...these findings suggest that antihistamine treatment could be beneficial in reducing the incidence of HPE and mortality following GD poisoning. The

  16. Citalopram/Escitalopram (Celexa/Lexapro) and Pregnancy

    Science.gov (United States)

    Citalopram | Escitalopram (Celexa®|Lexapro®) In every pregnancy, a woman starts out with a 3-5% chance of having a ... risk. This sheet talks about whether exposure to citalopram/escitalopram may increase the risk for birth defects ...

  17. Efficacy of escitalopram compared to citalopram: a meta-analysis.

    Science.gov (United States)

    Montgomery, Stuart; Hansen, Thomas; Kasper, Siegfried

    2011-03-01

    The aim of this review was to assess the clinical relevance of the relative antidepressant efficacy of escitalopram and citalopram by meta-analysis. Studies in major depressive disorder (MDD) with both escitalopram and citalopram treatment arms were identified. Adult patients had to meet DSM-IV criteria for MDD. The primary outcome measure was the treatment difference in Montgomery-Asberg Depression Rating Scale (MADRS) total score at week 8 (or last assessment if escitalopram, n=995; citalopram, n=1014). Escitalopram was significantly more effective than citalopram in overall treatment effect, with an estimated mean treatment difference of 1.7 points at week 8 (or last assessment if escitalopram. In this meta-analysis, the statistically significant superior efficacy of escitalopram compared to citalopram was shown to be clinically relevant.

  18. Development of Risperidone PLGA Microspheres

    Directory of Open Access Journals (Sweden)

    Susan D’Souza

    2014-01-01

    Full Text Available The aim of this study was to design and evaluate biodegradable PLGA microspheres for sustained delivery of Risperidone, with an eventual goal of avoiding combination therapy for the treatment of schizophrenia. Two PLGA copolymers (50 : 50 and 75 : 25 were used to prepare four microsphere formulations of Risperidone. The microspheres were characterized by several in vitro techniques. In vivo studies in male Sprague-Dawley rats at 20 and 40 mg/kg doses revealed that all formulations exhibited an initial burst followed by sustained release of the active moiety. Additionally, formulations prepared with 50 : 50 PLGA had a shorter duration of action and lower cumulative AUC levels than the 75 : 25 PLGA microspheres. A simulation of multiple dosing at weekly or 15-day regimen revealed pulsatile behavior for all formulations with steady state being achieved by the second dose. Overall, the clinical use of Formulations A, B, C, or D will eliminate the need for combination oral therapy and reduce time to achieve steady state, with a smaller washout period upon cessation of therapy. Results of this study prove the suitability of using PLGA copolymers of varying composition and molecular weight to develop sustained release formulations that can tailor in vivo behavior and enhance pharmacological effectiveness of the drug.

  19. Risperidone for Aggressive Behavior in ADHD

    Directory of Open Access Journals (Sweden)

    J Gordon Millichap

    2007-05-01

    Full Text Available The effects of risperidone augmentation for treatment-resistant aggression in children with ADHD were evaluated in a placebo-controlled pilot study at the University of Miami Miller School of Medicine, FL.

  20. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.

    Science.gov (United States)

    Holzer, Laurent; Eap, Chin B

    2006-04-01

    Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea. However, the largest study performed in children and adolescents showed a weak effect of risperidone on prolactin concentrations during short-term treatment and a negligible effect during long-term treatment, which was probably because of the relatively low dosages of risperidone used [approximately 0.04 mg/(kg x d)]. Among the 10 psychotic adolescents treated with risperidone in our unit, we had 3 cases of gynecomastia in 3 male patients and 2 cases of galactorrhea in 2 female patients. The prolactin blood levels in these cases and in 3 other patients without apparent prolactin-related side effects were all above the normal range (median, 59 ng/mL; range, 30-123 ng/mL). Thus, risperidone administered to adolescents at doses commonly used for the treatment of psychotic symptoms can strongly increase prolactin levels, with clinical consequences such as gynecomastia and/or galactorrhea. Given that the long-term effects of antipsychotic drug-induced hyperprolactinemia are not well documented, especially regarding osteopenia, infertility, growth, and pubertal delay, risperidone should be administered with caution to children and adolescents.

  1. The prevention of postoperative vomiting following strabismus surgery in children with using Promethazine and Droperidol

    Directory of Open Access Journals (Sweden)

    Shaigh al Islam V

    1996-07-01

    Full Text Available Children undergoing general anesthesia for strabismus surgery have a higher incidence of postoperative vomiting than those receiving the same anaesthesia for other types of ambulatory surgical procedures. Droperidol (0/0 75 mg/kg IV and promethazine (0.05-1.0 mg/kg were used in 100 children between 2-15 years old. Promethazine which has sedative property, anticholinergic antihistaminic, antiemetic and anti-motion sickness effects is recommended for children 0.05 mg-1.0 mg/kg of body weight IV. After induction of anesthesia and before operation and manipulation of the eye and combined with 0.5 mg/kg IM promethazine after operation. The incidence of vomiting following strabismus surgery might be reduced more than with intravenous droperidol

  2. Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use

    Science.gov (United States)

    Kirpekar, Vivek C.; Joshi, Prashant P.

    2005-01-01

    Selective serotonin reuptake inhibitors (SSRIs) can cause the syndrome of inappropriate antidiuretic hormone secretion (SIADH). SIADH is associated with hyponatraemia without oedema. We report the case of a patient who developed acute-onset hyponatraemia that progressed rapidly to serious neurological dysfunction shortly after the introduction of citalopram. All SSRIs including citalopram should be used with care in the elderly. The water and electrolyte balance should be monitored carefully during SSRI therapy. PMID:20711296

  3. Pharm GKB: risperidone [PharmGKB

    Lifescience Database Archive (English)

    Full Text Available pram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine ...lorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan...m clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine flu...ne clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gef...ine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine ge

  4. Gynecomastia with risperidone-fluoxetine combination.

    Science.gov (United States)

    Benazzi, F

    1999-01-01

    Gynecomastia (breast enlargement) is a side effect of neuroleptic antipsychotic drugs, related to prolactin elevation caused by dopamine D2 receptor blockade (Richelson, 1996). The atypical antipsychotic risperidone is less likely to cause gynecomastia at low doses (Casey, 1996). It can cause a dose-dependent increase in serum prolactin concentration (Peuskens, 1995), by blocking dopamine D2 receptors (Richelson, 1996). I would like to describe a patient who did not have gynecomastia with risperidone at a dose of 3 mg/day, but had it when risperidone, at a dose of 0.5 mg/day, was combined with fluoxetine. A MEDLINE search failed to find any reports about such an interaction.

  5. Risperidone associated paralytic ileus in schizophrenia

    Directory of Open Access Journals (Sweden)

    Parthasarathy Ramamourthy

    2013-01-01

    Full Text Available A 32-year-old man, diagnosed with catatonic schizophrenia, was treated with risperidone and lorazepam in the general hospital psychiatry setup. He developed signs of intestinal obstruction, which was diagnosed as paralytic ileus and was treated conservatively along with stopping the offending drug. Risperidone is said to be devoid of anticholinergic side effects, but prevalence of these varies from 7% to 13% in patients receiving treatment for schizophrenia. Constipation has been reported but fatal adverse effect like paralytic ileus with risperidone is rarely reported. Timely diagnosis can save the need for surgical interventions and fatal complications. This predisposition in schizophrenia could be due to neurodevelopmentally shared abnormality of brain and gut nervous system.

  6. Usefulness of serotoninergic challenge with oral citalopram Utilidade do desafio serotoninérgico com citalopram oral

    Directory of Open Access Journals (Sweden)

    Paulo Mattos

    2006-09-01

    Full Text Available OBJECTIVE: Challenge tests designed to evaluate serotoninergic pathways have widely used intravenous citalopram. Oral citalopram has also been used, but unsatisfactory results were obtained with a dose of 20 mg. The objective of this study was to determine whether a higher oral dose would reproduce similar to those described for intravenous administration. To that end, we evaluated cortisol, growth hormone and prolactin levels. METHOD: Eight healthy male volunteers were evaluated in a randomized crossover challenge test with 40 mg of oral citalopram or placebo. RESULTS: Cortisol levels increased at 2-4h after the oral citalopram intake, with a small amplitude peak occurring in two-thirds of the subjects. Levels of prolactin and growth hormone remained unchanged throughout the study. CONCLUSION: The use of oral citalopram might present an alternative in serotoninergic challenge tests, but higher doses are required.OBJETIVO: Testes-desafio desenvolvidos para avaliar as vias serotoninérgicas utilizaram amplamente citalopram intravenoso. Citalopram oral também foi utilizado, mas obtiveram-se resultados insatisfatórios com uma dose de 20 mg. O objetivo deste estudo foi o de determinar se uma dose oral mais elevada poderia reproduzir resultados similares aos descritos para administração intravenosa. Com esta finalidade, avaliamos os níveis de cortisol, de hormônio do crescimento e de prolactina. MÉTODO: Oito voluntários do sexo masculino saudáveis foram avaliados em um teste-desafio cruzado, aleatorizado, com 40 mg de citalopram oral ou placebo. RESULTADOS: Os níveis de cortisol aumentaram após 2-4 horas da ingestão de citalopram oral, com um pequeno pico de amplitude ocorrendo em dois terços dos indivíduos. Os níveis de prolactina e de hormônio de crescimento permaneceram inalterados ao longo do estudo. CONCLUSÃO: O uso de citalopram oral poderia apresentar uma alternativa em testes-desafio serotoninérgicos, mas doses maiores s

  7. [Escitalopram and citalopram: the unexpected role of the R-enantiomer].

    Science.gov (United States)

    Jacquot, C; David, D J; Gardier, A M; Sánchez, C

    2007-01-01

    Citalopram, a selective serotonin reuptake inhibitor, is composed of 2 enantiomers, R-citalopram and S-citalopram, 2 different non-superimposable mirror image forms of the same molecule. Separating these 2 enantiomers has enabled studying their individual properties. Citalopram's pharmacologic activity is centered on the S enantiomer's high affinity for the serotonin transporter which is twice as high as citalopram's and 30 to 40 times higher than R-citalopram. This leads to an inhibition of serotonin reuptake two times higher for escitalopram compared with citalopram and confirms that citalopram's pharmacologic activity is due to the S-enantiomer. Contrary to what might be expected, the effect of escitalopram (DCI of S-citalopram) is not superimposable on an equivalent dose of citalopram but is superior. Several hypotheses could explain this superiority. First, conversions of the S-enantiomer into the R-enantiomer may occur, but there is no reason why this phenomenon would happen more when both enantiomers are present than when escitalopram is alone. Furthermore, pharmacokinetic studies have shown that S or R configurations are stable in vivo. Second, a particular action of R-citalopram may influence the S-enantiomer's kinetic from intestinal absorption to blood-brain barrier. But concentrations of both enantiomers in the frontal cortex are the same. Therefore, R-citalopram does not interfere with escitalopram's kinetic. Finally, interactions may appear at the synaptic level. Results of experimentation, after in situ injection to the cortex level, confirm that an interaction between the 2 enantiomers takes place at that level. A direct negative interaction of R-citalopram on one or several effectors that create the antidepressive effect seems justified. This negative interaction has been studied in depth. Animal models have shown that the R-enantiomer has no antidepressive potential and when associated with escitalopram prohedonic effects disappear. Escitalopram

  8. Cardiac safety of citalopram: prospective trials and retrospective analyses

    DEFF Research Database (Denmark)

    Rasmussen, Søren Poul Lind; Overø, K F; Tanghøj, P

    1999-01-01

    of citalopram on ECG parameters. Results of both prospective and retrospective analyses showed that the only effect of citalopram on ECG findings is a small reduction in heart rate (... in volunteers and patients and in retrospective evaluations of all electrocardiographic (ECG) data from all clinical trials conducted from 1978 through 1996 (a total of 40 studies). A randomized, double-blind, placebo-controlled study was conducted in healthy volunteers (N = 23) to assess intraindividual...... variability of the QTc interval, as well as possible changes during treatment with placebo or citalopram, and its correlation to plasma drug levels. To document any dose-related changes, ECGs were performed at baseline and at the end of study in three randomized, double-blind, placebo- or active...

  9. Risperidone treatment increases CB1 receptor binding in rat brain

    DEFF Research Database (Denmark)

    Secher, Anna; Husum, Henriette; Holst, Birgitte

    2010-01-01

    , the ghrelin receptor, neuropeptide Y, adiponectin and proopiomelanocortin. We investigated whether the expression of these factors was affected in rats chronically treated with the antipsychotic risperidone. METHODS: Male Sprague-Dawley rats were treated with risperidone (1.0 mg/kg/day) or vehicle (20......% hydroxypropyl beta-cyclodextrin) for 28 days. Expression of the aforementioned factors were examined together with plasma prolactin and ghrelin levels. RESULTS: No difference in body weight gained during treatment was observed between risperidone and vehicle treated rats, but plasma risperidone levels...... positively correlated with visceral fat mass. Risperidone treatment increased CB(1) receptor binding in the arcuate nucleus (40%), hippocampus (25-30%) and amygdala (35%) without concurrent alterations in the CB(1) receptor mRNA. Risperidone treatment increased adiponectin mRNA. CONCLUSION: The present study...

  10. A Comparative Study on the Efficacy of Prednisolone and Promethazine in the Treatment of Hyperemesis Gravidarum

    Directory of Open Access Journals (Sweden)

    F Mardanian

    2004-04-01

    Full Text Available Background: Severe nausea and vomiting during pregnancy is one of the most frequent and difficult to treat obstetric problems. Different drugs and techniques have been suggested for its treatment with variable success rates. This study was designed to compare the efficacy of prednisolone with promethazine for treatment of hyperemesis gravidarum. Methods: Fifty six pregnant women with hyperemesis gravidarum were randomly divided into two groups to receive either prednisolone or promethazine orally. Severity of nausea and vomiting, severity of malaise, body weight and serum electrolytes were measured and compared before and after treatment. Results: The severity of nausea and vomiting decreased significantly in both groups, but the decrease was significantly higher in the prednisolone group. Conclusion: The result of this study shows that oral prednisolone is a better choice for the treatment of hyperemesis gravidarum. Keywords: Hyperemesis Gravidarum, Pregnancy, Obstetric Complication, Nausea and Vomiting

  11. Galactorrhea Following Citalopram Treatment: A Case Report and Discussion

    Directory of Open Access Journals (Sweden)

    Horst J. Koch

    2011-01-01

    Full Text Available We report the case of a 25-year-old women suffering from major depression who was treated with citalopram for several weeks with doses between 20 mg and 60 mg. She gradually developed marked mydriasis within 2 months after treatment and subsequently neuritis nervi optici. Moreover, abrupt galactorrhea occurred after 2 months of treatment. All neuro-ophthalmological, neurophysiological, clinical laboratory, and neuroradiological diagnostic efforts did not reveal an underlying organic pathophysiology. The ocular symptoms disappeared rapidly after the discontinuation of citalopram and pulse therapy with methyl-prednisolone. However, galactorrhea persisted for a few weeks necessitating treatment with bromocriptine.

  12. [Citalopram, escitalopram and prolonged QT: warning or alarm?].

    Science.gov (United States)

    Alvarez, Enric; Vieira, Sara; Garcia-Moll, Xavier

    2014-01-01

    The alerts issued by regulatory agencies on the potential cardiac toxicity of citalopram and escitalopram have caused alarm among clinicians. A review of the data concerning this topic shows that the alarm should be limited to patients with a history of syncope or poisoning. As a precautionary measure, an electrocardiogram should be performed on elderly patients.

  13. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram.

    Science.gov (United States)

    Lundberg, Johan; Christophersen, Jacob Strøyer; Petersen, Kamilla Buchberg; Loft, Henrik; Halldin, Christer; Farde, Lars

    2007-12-01

    The selective serotonin reuptake inhibitor (SSRI) citalopram (R,S-citalopram) is a racemic compound of two enantiomers. On the basis of in-vitro studies, inhibition of the human serotonin transporter (5-HTT) is achieved by the S-enantiomer (S-citalopram or escitalopram). The aim of the present PET study was to compare 5-HTT occupancy after single equimolar doses (with respect to S-enantiomer) in humans in vivo using R,S-citalopram (20 mg) and S-citalopram (10 mg) using PET and the radioligand [(11)C]MADAM. The design was a single-dose, double-blind, two-way crossover study in eight healthy male subjects. The 5-HTT binding potential at baseline and after single doses of study drugs was used to calculate 5-HTT occupancy in seven brain regions. Serum concentrations of the study drugs were determined in order to calculate the apparent inhibition constant (K(i),(app)), a secondary parameter of interest for the comparison. In all brain regions examined, occupancy was numerically higher after treatment with R,S-citalopram [66+/-19% to 78+/-17% (mean+/-s.d.) depending on the region] than after S-citalopram (59+/-15% to 69+/-13%; overall comparison: F=14.8, d.f.=1, 90, p<0.001). In line with this the apparent inhibition constant was significantly lower for R,S-citalopram than for S-citalopram (overall comparison: F=6.7, d.f.=1, 90, p<0.05). The small but significant difference in occupancy and K(i),(app) found between R,S-citalopram and S-citalopram suggests that not only S-citalopram but also R-citalopram to some degree occupies the 5-HTT in the human brain in vivo.

  14. RISPERIDONE - INDUCED TARDIVE DYSKINESIA : CASE REPORT AND REVIEW OF LITERATURE

    OpenAIRE

    Kumar, P.N. Suresh; Andrade, Chittaranjan

    2001-01-01

    Risperidone is an atypical antipsychotic with broad spectrum of antipsychotic activity and lower potential for extrapyramidal side effects at therapeutic doses. This case report illustrates the development of tardive dyskinesia with therapeutic dose of risperidone in a paranoid schizophrenic patient who was not on any antipsychotic medication previously.

  15. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.

    Science.gov (United States)

    Pratheesh, P J; Praharaj, Samir Kumar; Srivastava, Ashish

    2011-01-01

    Risperidone is associated with hyperprolactinemia and its consequent symptoms such as gynecomastia, galactorrhea and sexual dysfunction in adults, and less so in adolescents. Rarely, serotonin reuptake inhibitors are also associated with such adverse effects. We report a case of gynecomastia and galactorrhea in an adolescent male while on a combination of risperidone and fluvoxamine, although the serum prolactin was within normal range.

  16. Citalopram increases the differentiation efifcacy of bone marrow mesenchymal stem cells into neuronal-like cells

    Institute of Scientific and Technical Information of China (English)

    Javad Verdi; Seyed Abdolreza Mortazavi-Tabatabaei; Shiva Sharif; Hadi Verdi; Alireza Shoae-Hassani

    2014-01-01

    Several studies have demonstrated that selective serotonin reuptake inhibitor antidepressants can promote neuronal cell proliferation and enhance neuroplasticity both in vitro and in vivo. It is hypothesized that citalopram, a selective serotonin reuptake inhibitor, can promote the neuronal differentiation of adult bone marrow mesenchymal stem cells. Citalopram strongly enhanced neuronal characteristics of the cells derived from bone marrow mesenchymal stem cells. The rate of cell death was decreased in citalopram-treated bone marrow mesenchymal stem cells than in control cells in neurobasal medium. In addition, the cumulative population doubling level of the citalopram-treated cells was signiifcantly increased compared to that of control cells. Also BrdU incorporation was elevated in citalopram-treated cells. These ifndings suggest that citalopram can improve the neuronal-like cell differentiation of bone marrow mesenchymal stem cells by increasing cell proliferation and survival while maintaining their neuronal characteristics.

  17. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram

    DEFF Research Database (Denmark)

    Sánchez, Connie; Kreilgaard, Mads

    2004-01-01

    Escitalopram mediates the serotonin re-uptake inhibitory and antidepressant effect of citalopram racemate. However, recent studies have shown that R-citalopram inhibits the escitalopram-induced increase of extracellular 5-HT levels in the frontal cortex of rats. Here, we investigated the inhibitory...... effect of R-citalopram on the escitalopram-induced increase of 5-HT neurotransmission at the behavioural [potentiation of 5-hydroxytryptophan (5-HTP)-induced behavioural changes in mice and rats] and functional (increase in serum corticosterone in rats) levels. The effect of escitalopram was inhibited...... by R-citalopram in all three models, and R-citalopram, given alone, was inactive. The effects were more pronounced using an escitalopram to R-citalopram ratio of 1:4 than ratios of 1:2 and 1:1, suggesting a dose-dependent effect. The ED(50)-value of escitalopram in mouse 5-HTP potentiation studies...

  18. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.

    Science.gov (United States)

    Fantino, Bruno; Moore, Nicholas; Verdoux, Hélène; Auray, Jean-Paul

    2007-03-01

    Clinical trials have shown better efficacy of escitalopram over citalopram, and review-based economic models the cost-effectiveness of escitalopram vs. citalopram (brand and generic). No head-to-head clinical trial has, however, evaluated the cost-effectiveness of both drugs so far. The aim of this study was to assess the relative cost-effectiveness of escitalopram compared with citalopram in patients with major depressive disorder. An economic evaluation was conducted alongside a double-blind randomized clinical trial conducted by general practitioners and psychiatrists comparing fixed doses of escitalopram (20 mg/day) or citalopram (40 mg/day) over 8 weeks in ambulatory care patients with major depressive disorder (baseline Montgomery-Asberg Depression Rating Scale score > or =30). Resources use was recorded using a standardized form recording use of healthcare services and days of sick leave for the 2-month prestudy period and for the 8-week study period. Statistically significant improvements were observed in patients treated with escitalopram. Mean per-patient costs for the escitalopram group, compared with the citalopram group, were 41% lower (96 euro vs. 163 euro; Pescitalopram compared with citalopram recipients, assuming a parity price between escitalopram and citalopram. Bootstrapped distributions of the cost-effectiveness ratios also showed better effectiveness and lower costs for escitalopram compared with citalopram. Escitalopram is significantly more effective than citalopram, and is associated with lower healthcare costs. This prospective economic analysis demonstrated that escitalopram is a cost-effective first-line treatment option for major depressive disorder.

  19. Discovering risperidone: the LSD model of psychopathology.

    Science.gov (United States)

    Colpaert, Francis C

    2003-04-01

    In the 1970s and 1980s, Janssen Pharmaceutica Research, which had a broad interest in central nervous system disorders and nurtured intellectual freedom, developed original, and at times heretical, concepts. It took decades for the scientific community to endorse some of these concepts. Among them were such notions as an elementary particle of behaviour, the introduction of response quality in receptor theory, and the idea that tolerance does not develop to opioids. These concepts enabled the discovery of the antipsychotic risperidone, a unique full antagonist of the interoceptive effects of LSD.

  20. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments

    DEFF Research Database (Denmark)

    Ejsing, Thomas B.; Pedersen, Anne D.; Linnet, Kristian

    2005-01-01

    P-glycoprotein, risperidone, nortriptyline, cyclosporine A, drug-drug interaction, blood-brain barrier, knock-out mice......P-glycoprotein, risperidone, nortriptyline, cyclosporine A, drug-drug interaction, blood-brain barrier, knock-out mice...

  1. Prolactin levels and adverse events in patients treated with risperidone.

    Science.gov (United States)

    Kleinberg, D L; Davis, J M; de Coster, R; Van Baelen, B; Brecher, M

    1999-02-01

    Hyperprolactinemia is a common clinical disorder that may lead to sexual dysfunction or galactorrhea. It may arise from a variety of etiologies, including the use of antipsychotic agents, presumably because of a dopamine receptor blockade. This analysis was designed to characterize the relationship between risperidone, serum prolactin levels, and possible clinical sequelae. All data from randomized, double-blind studies of risperidone in patients with chronic schizophrenia were analyzed. The two largest studies (the North American and multinational trials) included 841 patients (259 women, 582 men) with paired prolactin level data and 1,884 patients (554 women, 1,330 men) with data on six adverse events possibly associated with increased prolactin levels (amenorrhea, galactorrhea, and decreased libido in women; erectile dysfunction, ejaculatory dysfunction, gynecomastia, and decreased libido in men). Both risperidone and haloperidol produced dose-related increases in plasma prolactin levels in men and women. Among women, the risperidone dose was not correlated with adverse events, nor were the adverse events correlated with endpoint prolactin levels. Among men, the incidence of adverse events was positively correlated with risperidone dose; however, at risperidone doses of 4 to 10 mg/day the incidence of adverse events was not significantly higher than that observed in patients receiving placebo. Furthermore, adverse events in men were unrelated to plasma prolactin levels. Risperidone-associated increase in serum prolactin levels was not significantly correlated to the emergence of possible prolactin-related side effects.

  2. Severe symptomatic hyponatremia during citalopram therapy - a case report

    Directory of Open Access Journals (Sweden)

    Vergara Jesus

    2004-01-01

    Full Text Available Abstract Background Hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic hormone is an uncommon complication of treatment with the new class of antidepressant agents, the selective serotonin reuptake inhibitors. The risk of hyponatremia seems to be highest during the first weeks of treatment particularly, in elderly females and in patients with a lower body weight. Case Presentation A 61-year-old diabetic male was admitted to the hospital because of malaise, progressive confusion, and a tonic/clonic seizure two weeks after starting citalopram, 20 mg/day. On physical examination the patient was euvolemic and had no evidence of malignancy, cardiac, renal, hepatic, adrenal or thyroid disease. Laboratory tests results revealed hyponatremia, serum hypoosmolality, urine hyperosmolarity, and an elevated urine sodium concentration, leading to the diagnosis of inappropriate secretion of antidiuretic hormone. Citalopram was discontinued and fluid restriction was instituted. The patient was discharged after serum sodium increased from 124 mmol/L to 134 mmol/L. Two weeks after discharge the patient denied any new seizures, confusion or malaise. At that time his serum sodium was 135 mmol/L. Conclusions Because the use of serotonin reuptake inhibitors is becoming more popular among elderly depressed patients the present paper and other reported cases emphasize the need of greater awareness of the development of this serious complication and suggest that sodium serum levels should be monitored closely in elderly patients during treatment with citalopram.

  3. Structure-activity relationship studies of citalopram derivatives

    DEFF Research Database (Denmark)

    Larsen, M Andreas B; Plenge, Per; Andersen, Jacob;

    2016-01-01

    towards the S2 site. EXPERIMENTAL APPROACH: We performed a systematic structure-activity relationship study based on the scaffold of citalopram and the structurally closely related congener, talopram, that shows low-affinity S1 binding in SERT. The role of the four chemical substituents, which distinguish......-activity relationship study revealed a di-methyl citalopram, which binds to the S1 site with an affinity of 6.4 [4.7;8.8] μM (mean[SEM interval]) and shows an allosteric potency of 3.6 [3.3;3.8] μM, thus bearing ~2-fold selectivity for the allosteric site relative to the S1 site in SERT. CONCLUSIONS AND IMPLICATIONS....... The antidepressant drug citalopram displays high-affinity S1 binding and low-affinity S2 binding. To elucidate a possible therapeutic role of allosteric inhibition of SERT a drug that specifically targets the allosteric site is required. The purpose of this study was to find a compound bearing higher selectivity...

  4. Differences of promethazine and terfenadine on ion channels in guinea pig ventricular myocytes

    Institute of Scientific and Technical Information of China (English)

    LI Xue-wen; NIU Shuan-cheng; ZHANG Xuan-ping; L(U) Ji-yuan; BAI Feng; ZHANG Ling; WU Bo-wei

    2006-01-01

    @@ Promethazine, a first generation antihistamine,has an antiarrhythmic effect on ischemia-reperfusion inducing arrhythmias1 and experimental arrhythmias.2 However, terfenadine as a second generation of antihistamine, has been reported to elicit hypotension, bradycardia, prolongation of the QTc interval and torsades de pointes (TdP) like ventricular arrhythmia.3 This may be due to the blockage on rectifier postassium current (Ik) of terfenadine, resulting in the prolongation of the action potential duration (APD) and dispersion of the repolarization duration, which might provoke a specific form of polymorphic ventricular tachydysrhythmia, i.e. TdP.4 In clinical practice,however, the class Ⅲ antiarrhythmic agents, which target on the Ik and prolong the action potential duration and QTc interval, rarely lead to arrhythmias.Other actions must be considered to underlie the arrhythmogenic tendency of terfenadine besides its inhibition on Ik. Though both promethazine and terfenadine block the H1 receptor, there must be a different pharmacology profile between the two compounds on ion channels of cardiac myocytes.Whole-cell patch clamp technique was used to investigate the effects of these two antagonists of the H1 receptor on the main ion currents in cardiac electrical activities.

  5. Reduction of erythema in hairless guinea pigs after cutaneous sulfur mustard vapor exposure by pretreatment with niacinamide, promethazine and indomethacin

    Energy Technology Data Exchange (ETDEWEB)

    Yourick, J.J.; Dawson, J.S.; Mitcheltree, L.W.

    1995-12-31

    Erythema is the initial symptom that occurs after sulfur mustard (HD) cutaneous exposure. The time course of HD-induced erythema is similar to that observed after UV irradiation, which can be reduced by indomethacin. Sulfur mustard lethality is decreased by using promethazine, which is an antihistamine. Niacinamide can reduce microvesication after HD vapor exposure in hairless guinea pig (HGP) skin. The present study examines the effect of the combined administration of niacinamide, indomethacin and promethazine used alone or in all possible combinations on the degree of erythema and histopathologic skin damage after HD exposure in HGP. Niacinamide (750 mg kg%`, i.p.), promethazine (12.5 mg kg%1, i.m.) or indomethacin (4 mg kg%1, p.o.) used singly or in combination was given as a 30-min pretreatment before an 8-min HD vapor cup skin exposure. Using a combination pretreatment of niacinamide, promethazine and indomethacin, erythema was reduced at 4 (91%) and 6 (55%) h, but not 24 h after HD. The incidence of histopathological skin changes (microvesicles, follicular involvement, epidermal necrosis, intracellular edema and pustular epidermatitis) 24 h after HD was not reduced. This study indicates that HD (induced erythema) may result from several different mechanisms, including inflammation, histamine release and DNA damage. It is suggested that two phases of inflammation may occur: an early phase sensitive to antihistamines and non-steroidal antiinflammatory drugs and a late phase of extensive cell damage that was not sensitive to these drug pretreatments.

  6. Analysis of Citalopram and Desmethylcitalopram in Postmortem Fluids and Tissues Using Liquid Chromatography-Mass Spectrometry

    Science.gov (United States)

    2011-10-01

    Scan.event.2. collected.the.citalopram.product.ions.between.100-340. following. collision-induced. dissociation. ( CID ). of. the. precursor.ion.(m/z.325... Gutierrez ,.M .. and.Abramowitz,.W ..Steady-State. Pharmacokinetics. of. Citalopram. in. Young. and. Elderly. Subjects .. Pharmacotherapy,. 20:. 1441-7

  7. Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram

    NARCIS (Netherlands)

    Cremers, TIFH; Spoelstra, EN; Bosker, FJ; Mork, A; den Boer, JA; Westerink, BHC; Wikstrom, HV

    2000-01-01

    Rats were chronically treated with the selective serotonin re-uptake inhibitor citalopram [1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-5-phtalancarbonitril], by means of osmotic minipumps. Using an infusion concentration of 50 mg/ml citalopram, steady-state plasma concentrations of approximately 0.

  8. The role of adenosine receptors and endogenous adenosine in citalopram-induced cardiovascular toxicity

    Directory of Open Access Journals (Sweden)

    Kubilay Oransay

    2014-01-01

    Full Text Available Aim: We investigated the role of adenosine in citalopram-induced cardiotoxicity. Materials and Methods: Protocol 1: Rats were randomized into four groups. Sodium cromoglycate was administered to rats. Citalopram was infused after the 5% dextrose, 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX; A 1 receptor antagonist, 8-(-3-chlorostyryl-caffeine (CSC; A 2a receptor antagonist, or dimethyl sulfoxide (DMSO administrations. Protocol 2: First group received 5% dextrose intraperitoneally 1 hour prior to citalopram. Other rats were pretreated with erythro-9-(2-hydroxy-3-nonyl adenine (EHNA; inhibitor of adenosine deaminase and S-(4-Nitrobenzyl-6-thioinosine (NBTI; inhibitor of facilitated adenosine transport. After pretreatment, group 2 received 5% dextrose and group 3 received citalopram. Adenosine concentrations, mean arterial pressure (MAP, heart rate (HR,  QRS duration and QT interval were evaluated. Results: In the dextrose group, citalopram infusion caused a significant decrease in MAP and HR and caused a significant prolongation in QRS and QT. DPCPX infusion significantly prevented the prolongation of the QT interval when compared to control. In the second protocol, citalopram infusion did not cause a significant change in plasma adenosine concentrations, but a significant increase observed in EHNA/NBTI groups. In EHNA/NBTI groups, citalopram-induced MAP and HR reductions, QRS and QT prolongations were more significant than the dextrose group. Conclusions: Citalopram may lead to QT prolongation by stimulating adenosine A 1 receptors without affecting the release of adenosine.

  9. Citalopram indtaget under graviditet og barn født med Mb

    DEFF Research Database (Denmark)

    Nielsen, Sebastian Werngreen; Qvist, Niels

    2014-01-01

    Citalopram taken during pregnancy and the child born with Ugeskr Laeger 2013;175:V03130178 A woman treated with citalopram during the entirety of her pregnancy bore a child with Hirschsprung’s disease. Theories on the development of the enteric nervous system support a possible negative effect...

  10. CNS effects of citalopram, a new serotonin inhibitor antidepressant (a quantitative pharmaco-electroencephalography study).

    Science.gov (United States)

    Itil, T M; Menon, G N; Bozak, M M; Itil, K Z

    1984-01-01

    Citalopram, a new phthalane derivative and a specific serotonin re-uptake inhibitor in animal pharmacological tests, was evaluated in a double-blind, crossover, quantitative pharmaco-EEG (QPEEGTM) study in healthy human volunteers. The CNS effects of citalopram are linear, dose- and time-related, can statistically be differentiated from placebo, and indicate a rapid onset of effects with short duration. According to the Computer Data Bank, citalopram has a mode of action similar to mood elevators (antidepressants) with fewer sedative properties. Thus the therapeutic action of citalopram is predicted to be similar to desipramine and protriptyline from the tricyclics, and fluvoxamine from non-tricyclics. According to data bank assessment, it is hypothesized that the single antidepressant dose of citalopram is to be more than 25 mg, which should be given t.i.d. in clinical trials.

  11. A Case of Priapism with Risperidone

    Directory of Open Access Journals (Sweden)

    Almari Ginory

    2014-01-01

    Full Text Available Priapism is a urologic emergency defined as a prolonged, possibly painful, penile erection. There are several known causes of priapism including psychotropic medications. One of the mechanisms by which antipsychotics are believed to induce priapism is through alpha-1 antagonism. This is case of a 50-year-old male with a history of schizophrenia with previous priapism related to trazodone, who presents with new onset priapism associated with risperidone. In this case, the treatment of priapism includes discontinuation of the offending agent and drainage of the corpus cavernosum twice along with intracavernosal phenylephrine injections. It is important to educate patients on priapism as a possible side effect of medications. It is also important to consider previous episodes of medication-induced priapism when prescribing psychotropic medications as this may increase the patient’s future risk of priapism.

  12. Risperidone versus pimozide in Tourette's disorder : A comparative double-blind parallel-group study

    NARCIS (Netherlands)

    Bruggeman, R; van der Linden, C.; Buitelaar, JK; Gericke, GS; Hawkridge, SM; Temlett, JA

    2001-01-01

    Background: The treatment of Tourette's disorder with classical neuroleptics is limited by their side effects. Risperidone is a new efficacious antipsychotic with a low propensity for extrapyramidal side effects. To establish risperidone's therapeutic potential in Tourette's disorder, we studied the

  13. Neonatal administration of citalopram delays somatic maturation in rats

    Directory of Open Access Journals (Sweden)

    T.C.B.J. Deiró

    2004-10-01

    Full Text Available We investigated the somatic maturation of neonate rats treated during the suckling period with citalopram, a selective serotonin reuptake inhibitor. Groups with 6 male neonates were randomly assigned to different treatments 24 h after birth. Each litter was suckled by one of the dams until the 21st postnatal day. Body weight, head axis and tail length were measured daily from the 1st to the 21st postnatal day. Time of ear unfolding, auditory conduit opening, incisor eruption, and eye opening was determined. Pups received 5 mg (Cit5, 10 mg (Cit10 or 20 mg/kg (Cit20 citalopram sc, or saline (0.9% NaCl, w/v, sc. Compared to saline, body weight was lower (24.04%, P < 0.01 for Cit10 from the 10th to the 21st day and for Cit20 from the 6th to the 21st day (38.19%, P < 0.01. Tail length was reduced in the Cit20 group (15.48%, P < 0.001 from the 8th to the 21st day. A reduction in mediolateral head axis (10.53%, P < 0.05 was observed from the 11th to the 21st day in Cit10 and from the 6th to the 21st day in Cit20 (13.16%, P < 0.001. A reduction in anteroposterior head axis was also observed in the Cit20 group (5.28%, P < 0.05 from the 13th to the 21stday. Conversely, this axis showed accelerated growth from the 12th to the 21stday in the Cit5 group (13.05%, P < 0.05. Auditory conduit opening was delayed in the Cit5 and Cit20 groups and incisor eruption was delayed in all citalopram groups. These findings show that citalopram injected during suckling to rats induces body alterations and suggest that the activity of the serotoninergic system participates in growth mechanisms.

  14. Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children

    Science.gov (United States)

    Aman, Michael G.; Hollway, Jill A.; Leone, Sarah; Masty, Jessica; Lindsay, Ronald; Nash, Patricia; Arnold, L. Eugene

    2009-01-01

    This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a crossover study of risperidone and placebo for 2…

  15. RP-HPLC estimation of risperidone in tablet dosage forms

    Directory of Open Access Journals (Sweden)

    Bladania S

    2008-01-01

    Full Text Available A simple, specific, accurate, and precise reverse phase liquid chromatographic method was developed and validated for the estimation of risperidone in tablet dosage forms. A Phenomenex Gemini C-18, 5 µm column having 250x4.6 mm i.d. in isocratic mode, with mobile phase containing methanol: acetonitrile: 50 mM potassium dihydrogen orthophosphate (80:10:10 v/v was used. The flow rate was 1.3 ml/min and effluents were monitored at 234 nm. Clozapine was used as an internal standard. The retention time of risperidone and clozapine were 2.5 min and 3.3 min, respectively. The method was validated for linearity, accuracy, precision, specificity, limit of quantification, limit of detection, robustness and stability. The limit of detection and limit of quantification for estimation of risperidone was found to be 500 ng/ml and 990 ng/ml, respectively. Recovery of risperidone was found to be in the range of 99.02-101.68%. Proposed method was successfully applied for the quantitative determination of risperidone in tablet formulations.

  16. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests.

    Science.gov (United States)

    Henning, J; Netter, P

    2002-03-01

    The present study was conducted to investigate whether a single oral dosage of 20 mg of the selective serotonin reuptake inhibitor citalopram could be used as a tool to stimulate hormone secretion in neuroendocrine challenge paradigms. A total number of 48 healthy male subjects received either 20 mg citalopram or placebo in a randomized, double-blind cross-over design at an interval of 1 wk between both sessions. Citalopram was well tolerated without side-effects. Growth hormone (GH), prolactin (Prl) and cortisol (Cort) were determined in blood samples obtained at different time-points across the experiment according to drug kinetics. While GH and Prl were not changed after citalopram Cort levels increased as compared to the placebo condition, significantly about 2 h after drug intake. Results will be discussed in respect of the question of whether or not Prl and GH responses after treatment with i.v. applications of SSRIs reflect sertonergic involvement.

  17. Characterization of an allosteric citalopram-binding site at the serotonin transporter

    DEFF Research Database (Denmark)

    Chen, Fenghua; Breum Larsen, Mads; Neubauer, Henrik Amtoft

    2005-01-01

          rate, of [3H]S-citalopram from human SERT, is retarded by the presence of       serotonin, as well as by several antidepressants, when present in the       dissociation buffer. Dissociation of [3H]S-citalopram from SERT is most       potently inhibited by S-citalopram followed by R...... is independent of       temperature, or the presence of Na+ in the dissociation buffer.       Dissociation of [3H]S-citalopram from a complex with the SERT       double-mutant, N208Q/N217Q, which has been suggested to be unable to       self-assemble into oligomeric complexes, is retarded to an extent similar...

  18. EFFICACY OF CITALOPRAM IN TREATMENT OF PATHOLOGICAL SKIN PICKING, A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL

    Directory of Open Access Journals (Sweden)

    M Arbabi

    2008-11-01

    Full Text Available "nVarious studies suggest that selective serotonin reuptake inhibitors (SSRIs may be useful in treating pathological skin picking (PSP. This study sought to assess effectiveness of citalopram in comparison with placebo in treating PSP. Forty five individuals with PSP were recruited in a four-week, randomized clinical trial of citalopram (20 mg/day in comparison with placebo. Study measures assessing skin picking severity, mental health status, obsessive compulsive disorder and quality of life were given at baseline, weeks 2 and 4. PSP severity, general health status, obsession-compulsion severity and quality of life level were similar between two groups at baseline (P > 0.05. Treatment analyses revealed significant improvements in quality of life, general health status and obsession-compulsion severity in citalopram group compared to placebo group (P < 0.05. Mean PSP severity reduction in citalopram group was more than placebo group but this difference was not significant. Citalopram can improve general health status and quality of life in individuals with PSP but its effect on skin picking behavior doesn't differ significantly with placebo. Other trials with longer time are needed to determine the exact efficacy of citalopram on PSP

  19. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.

    Science.gov (United States)

    Kasper, Siegfried; Sacher, Julia; Klein, Nikolas; Mossaheb, Nilufar; Attarbaschi-Steiner, Trawat; Lanzenberger, Rupert; Spindelegger, Christoph; Asenbaum, Susanne; Holik, Alexander; Dudczak, Robert

    2009-05-01

    Escitalopram the S-enantiomer of the racemate citalopram, is clinically more effective than citalopram in the treatment of major depressive disorder. However, the precise mechanism by which escitalopram achieves superiority over citalopram is yet to be determined. It has been hypothesized that the therapeutically inactive R-enantiomer competes with the serotonin-enhancing S-enantiomer at a low-affinity allosteric site on serotonin reuptake transporters (SERTs), and reduces the effectiveness of the S-enantiomer at the primary, high-affinity serotonin-binding site. This study summarizes the results of two recent single-photon emission computerized tomography studies measuring SERT occupancy in citalopram-treated and escitalopram-treated healthy volunteers, after a single dose and multiple doses (i.e. under steady-state conditions). The single-dose study showed no attenuating effect of R-citalopram. After multiple dosing, however, SERT occupancy was significantly reduced in the presence of R-citalopram. Under steady-state conditions, R-enantiomer concentrations were greater than for the S-enantiomer because of slower clearance of R-citalopram. A pooled analysis suggests that build-up of the R-enantiomer after repeated citalopram dosing may lead to increased inhibition of S-enantiomer occupancy of SERT. This review adds to the growing body of evidence regarding differences in the dynamics of SERT occupancy, that is, molecular mechanisms underlying the often-observed superior clinical efficacy of escitalopram compared with citalopram in major depressive disorder.

  20. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine

    NARCIS (Netherlands)

    Schillevoort, I; de Boer, A; Herings, R M; Roos, R A; Jansen, P A; Leufkens, H G

    2001-01-01

    OBJECTIVE: To compare the risk of extrapyramidal syndrome (EPS) between risperidone, olanzapine, and haloperidol, taking into account patients' past antipsychotic drug use and past EPS. METHODS: Data were obtained from the PHARMO-database, containing filled prescriptions of 450,000 community-dwellin

  1. Costs and efficacy ofolanzapine and risperidone in schizophrenia

    Directory of Open Access Journals (Sweden)

    Vittorio Mapelli

    2007-06-01

    Full Text Available Introduction: schizophrenia is a serious and long lasting psychiatric disease. The new “atypical” antipsychotic drugs, introduced in the 90s, have substantially improved the effectiveness of medical treatments, compared to previous neuroleptic drugs. Nowadays they tend to be used as first choice drugs. The ddd cost of atypicals may differ by 20% and health authorities may have an incentive to deliver the less costly drug, especially if they are generic. However the various drugs show differential effectiveness rates and a rational choice should consider both cost and effectiveness.
Objective: the purpose of this analysis is to review the existing evidence on cost-effectiveness studies of olanzapine and risperidone, the two most prescribed drugs in Italy. Six published studies were identified, but attention was focused on two articles that reported consistent and methodologically sound results.
Results: most reviewed studies are cost-minimization analyses, since effectiveness indicators show no significant statistical difference between the two drugs, and are inconclusive since the results depend on the evaluation setting. However one observational retrospective study showed a significant severity reduction over 12 months for patients treated with olanzapine (-2.46 on HoNOS scale; p<0.05, compared to a smaller non significant reduction of the risperidone group (-0.57. Despite the higher drug cost, the average total cost per reduced severity score was lower for olanzapine than for risperidone patients (€ 4,554 vs. € 10,897. The only medical and related health care costs for risperidone patients were higher than total costs for olanzapine patients. Another study comparing cohorts of patients with similar starting severity showed a significant severity reduction and global functioning increase over 12 months for olanzapine but no significant increase for risperidone patients (-0.35, p<0.01 on CGI scale; +3.66, p <0.05 on GAF scale

  2. The effect of dexamethasone and promethazine in combination with buparvaquone in the management of East Coast fever

    Directory of Open Access Journals (Sweden)

    M. Gwamaka

    2004-11-01

    Full Text Available The effects of dexamethasone and promethazine on the amelioration of pulmonary oedema in East Coast fever were investigated. The clinical effects of these drugs were further investigated when used in conjunction with the antitheilerial drug, buparvaquone. In the first experiment, 15 crossbred (Friesian x Zebu steers were divided into four groups. With the exception of the animals in group IV, that served as a control group all the others were infected with Theileria parva sporozoites. On the second day of the febrile reaction, the steers in groups I and II were treated with dexamethasone (0.1 mg/kg and promethazine (1 mg/kg, respectively. Group III steers served as the infected untreated controls. On the fifth day of the febrile reaction the animals in groups I, II and III were infused intravenously with tattoo ink suspension and 1 h later sacrificed for post-mortem examination and tissue sampling. The clinical picture indicated that both drugs significantly mitigated dyspnoea and the post mortem examination revealed a significant reduction in morphological changes. Tattoo ink particle count reflected a significant (P < 0.01 reduction in vascular leakage in the treated animals, with promethazine being significantly (P < 0.05 more effective than dexamethasone in this respect. In the second experiment, 18 steers were infected with T. parva sporozoites, and then were randomly allotted into three groups each of which contained six animals. After the onset of ECF clinical signs, the animals in the first two groups were treated with buparvaquone in combination with either dexamethasone (group I or promethazine (group II, and the third group was treated with buparvaquone alone. The results indicated that all the animals in groups I, II and III recovered well and no significant differences were observed in clinical disposition between the groups. Two months later, serum samples were collected from the refractory animals and demonstrated the presence of

  3. Risperidone-induced enuresis in a 12-year-old child

    Directory of Open Access Journals (Sweden)

    Reetika Dikshit

    2017-01-01

    Full Text Available Risperidone has been documented to be effective in the management of behavior problems, aggression, and conduct disorder in children. While metabolic side effects like weight gain and obesity have been attributed to Risperidone use in children, side effects of the drug related to the urinary bladder are rare. We present a case of Risperidone-induced enuresis in a 12-year-old boy with conduct disorder that resolved completely after stopping the medication.

  4. Risperidone-induced Enuresis in a 12-year-old Child

    Science.gov (United States)

    Dikshit, Reetika; Karia, Sagar; De Sousa, Avinash

    2017-01-01

    Risperidone has been documented to be effective in the management of behavior problems, aggression, and conduct disorder in children. While metabolic side effects like weight gain and obesity have been attributed to Risperidone use in children, side effects of the drug related to the urinary bladder are rare. We present a case of Risperidone-induced enuresis in a 12-year-old boy with conduct disorder that resolved completely after stopping the medication. PMID:28149096

  5. Using Glycopyrrolate as an alternative option in case of Risperidone induced sialorrhoea

    Directory of Open Access Journals (Sweden)

    Dr. Hemanta Dutta

    2015-03-01

    Full Text Available Drug induced hypersalivation has been playing an unique factor in terms of noncompliance of antipsychotics. Hypersalivation has been described commonly with clozapine. Although Risperidone is also seen to be notorious to be causing hypersalivation. Use of Glycopyrrolate in Risperidone induced hypersalivation has not been covered though reported studies till yet. Here we are depicting the use of Glycopyrrolate as an alternative treatment option for hypersalivation induced by Risperidone.

  6. SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram.

    Science.gov (United States)

    Waldinger, M D; Zwinderman, A H; Olivier, B

    2001-12-01

    Selective serotonin reuptake inhibitors (SSRIs) are known to induce delayed orgasm and ejaculation. However, different SSRIs may differentially delay ejaculation. A double-blind, fixed-dose study in healthy men with lifelong rapid ejaculation was performed to evaluate potential differences between clinically relevant doses of two selective serotonin reuptake inhibitors, paroxetine and citalopram, in their effects on ejaculation. Thirty men with an intravaginal ejaculation latency time (IELT) less than 1 minute were randomly assigned to receive paroxetine (20 mg/day) and citalopram (20 mg/day) for 5 weeks, after taking half the dosage in the first week. During the 1-month baseline and 6-week treatment period, IELTs were measured at home by using a stopwatch procedure. The trial was completed by 23 men. Analysis of variance revealed a between-group difference in the evolution of IELT delay over time (p = 0.0004); the IELT after paroxetine and citalopram gradually increased from 18 and 21 seconds to approximately 170 and 44 seconds, respectively. Paroxetine 20 mg/day exerted a strong delay (8.9-fold increase), whereas citalopram 20 mg/day mildly delayed ejaculation (1.8-fold increase). These results indicate that paroxetine leads to a significant delay in orgasm and ejaculation, whereas citalopram seems to have less of an effect on it.

  7. Design and Subject Characteristics in the Federally-Funded Citalopram Trial in Children with Pervasive Developmental Disorders

    Science.gov (United States)

    Scahill, Lawrence; McCracken, James T.; Bearss, Karen; Robinson, Fay; Hollander, Eric; King, Bryan; Bregman, Joel; Sikich, Lin; Dukes, Kimberly; Sullivan, Lisa; Anagnostou, Evdokia; Donnelly, Craig; Kim, Young-Shin; Ritz, Louise; Hirtz, Deborah; Wagner, Ann

    2012-01-01

    The Studies to Advance Autism Research and Treatment Network conducted a randomized trial with citalopram in children with Pervasive developmental disorders (PDDs). We present the rationale, design and sample characteristics of the citalopram trial. Subjects (128 boys, 21 girls) had a mean age of 9.3 (plus or minus 3.12) years; 132 (88.6%) were…

  8. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    Zhi-ling ZHOU; Qiu-xiong LIN; Chuan-yue WANG; Wen-biao LI; Shu-guang LIN; Huan-de LI; Xin LI; Huai-yan PENG; Xi-yong YU; Ming YANG; Feng-li SU; Feng WANG; Rong-hua ZHU; Chun-yu DENG

    2006-01-01

    Aim: To study the multiple dose clinical pharmacokinetics of risperidone and its main active metabolite, 9-hydroxyrisperidone, in Chinese female patients with schizophrenia. Methods: The subjects were 23 Chinese female inpatients aged 18-65 years who met the CCMD-Ⅲ (third revision of the Chinese Criteria of Mental Disorders) criteria for schizophrenia. Subjects were tested after 17 d of treatment with 2 mg risperidone twice daily. Plasma concentrations of risperidone and 9-hydroxy-risperidone were assayed by using validated high performance liquid chromatography-mass spectrometry (HPLC-MS) methods. Results: Risperidone was rapidly absorbed (Tmax was 1.6 h) and its Tin in plasma was short (3.2 h).9-hydroxy-risperidone was quickly metabolized from the parent drug with a mean Tmax of 2.5 h. It had a long half-life of 24.7 h. The Cssav of risperidone and 9-hydroxyrisperidone were 36.9±33.1 and 110.6±30.5 μg·h·L-1, respectively, and the AUCss0-12 were 443.2±397.4 and 1327.2±402.3 μg·h·L-1, respectively. CL/F and V/F of risperidone were 8.7±6.2 L/h and 34.1±24.3 L, respectively. Interindividual variations for pharmacokinetic parameters were quite large for risperidone. All 23 subjects experienced high prolactin levels when treated with risperidone. However there was no correlation between prolactin level and the concentration of risperidone, 9-hydroxy-risperidone, or the active moiety. Conclusion: Risperidone showed large interindividual variations in pharmacokinetics. Administration of risperidone resulted in high serum prolactin levels. The results indicate that systemic exposure to risperidone and 9-hydroxy-risperidone in female Chinese schizophrenic patients is higher relative to published data for white Caucasian patients. Larger studies regarding the PK/PD relationship may be required to develop a reasonable clinical dosage regimen for Chinese female patients.

  9. Low proarrhythmic potential of citalopram and escitalopram in contrast to haloperidol in an experimental whole-heart model.

    Science.gov (United States)

    Frommeyer, Gerrit; Brücher, Benedict; von der Ahe, Henning; Kaese, Sven; Dechering, Dirk G; Kochhäuser, Simon; Bogossian, Harilaos; Milberg, Peter; Eckardt, Lars

    2016-10-05

    In several case reports proarrhythmic effects of citalopram and escitalopram have been reported. Systematic analyses on prorarrhythmic effects of these drugs are not yet available. The aim of the present study was to investigate if application of citalopram, escitalopram or haloperidol provokes polymorphic ventricular tachycardia in a sensitive model of proarrhythmia. In isolated rabbit hearts monophasic action potentials and ECG showed a significant QT-prolongation after application of citalopram (2µM: +47ms, 4µM: +56ms, Pescitalopram also increased QT-interval (2µM: +3ms, 4µM: +30ms, Pescitalopram demonstrated a rather safe electrophysiologic profile despite significant QT prolongation. In contrast, haloperidol led to significant increase of dispersion of repolarization while this parameter remained stable under the influence of citalopram or escitalopram. These results imply that application of citalopram or escitalopram is not as proarrhythmic as some case reports might suggest while haloperidol is torsadogenic.

  10. A Comparative Study on the Sedative Effect of Oral Midazolam and Oral Promethazine Medication in Lumbar Puncture

    Directory of Open Access Journals (Sweden)

    Hojjat DERAKHSHANFAR

    2013-06-01

    Full Text Available How to Cite This Article: Derakhshanfar H, Modanlookordi M, Amini A, Shahrami A. A Comparative Study of the Sedative Effect of Oral Midazolam and Oral Promethazine Medication in Lumbar Puncture. Iran J Child Neurol. 2013 Spring;7(2:11-16. ObjectiveLumbar puncture (LP essentially is a painful and stressful procedure that indicated for diagnosis and therapeutic purposes. One way to reduce the anxiety is to administer an oral premedication. The aim of this study is to compare clinical effects of oral midazolam and oral promethazine in LP.Materials & MethodsThis prospective randomized controlled clinical trial study wasperformed on 80 children aged 2-7 years that were candidate for LP. They were divided into two randomized equal groups. First group received oral midazolam syrup 0.5 mg/kg and the other group received oral promethazine syrup 1mg/kg. Level of sedation, hemodynamic changes and any other complications were monitored every 5 minutes from 30 minutes before the start of the procedure.ResultsMidazolam group and promethazine group were similar in age, gender and weight. Midazolam had significantly shorter onset of sedation and also shorter duration to maximal sedation. The two groups were similar with respect to sedative effect at all time. The only complication that was significantly more in midazolam group was nausea and vomiting.ConclusionMidazolam syrup and promethazine syrup have same sedative effect in children. Both of these medications are easy to use in preschool children and none of them appeared to be superior to another. References1. Ellenby MS, Tegtmeyer K, Lai S, Braner DA. Lumbar Puncture. N Engl J Med 2006;28;355(13:e12.2. Crock C, Olsson C, Phillips R, Chalkiadis G, Sawyer S, Ashley D, et al. General anesthesia or conscious sedation for painful procedures in childhood cancer: The family’s perspective. Arch Dis Child 2003;88(3:253−7.3. Holdsworth MT, Raisch DW, Winter SS, Frost JD, Moro MA, Doran NH, et al. Pain and

  11. Neuroleptic malignant syndrome due to risperidone misdiagnosed as status epilepticus

    Directory of Open Access Journals (Sweden)

    Ali Ertug Arslankoylu

    2011-06-01

    Full Text Available Neuroleptic malignant syndrome (NMS is a rare but potentially fatal disease characterized by fever, muscle rigidity, delirium and autonomic instability. Here we report a child, with NMS due to the risperidone misdiagnosed as status epilepticus. Nine year old boy, who had been under high dose risperidone treatment for 8 weeks, admitted to the emergency room because of the contractions (evaluated as status epilepticus persisting for 7 hours. Since there was neuroleptic treatment in the past medical history and, unconsciousness, muscular rigidity, diaphoresis, hypertermi and, hypotension in physical examination, leucocytosis and elevated creatininphosphokinase levels in laboratory tests, the patient was evaluated as NMS and discharged without any complications. We reported this case to point out that; NMS may be misdiagnosed as status epilepticus in children when EEG monitoring is unavailable. When a child admitted to the emergency room because of suspicious convulsion neuroleptic drug use must surely be asked.

  12. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.

    Science.gov (United States)

    Hatta, Kotaro; Otachi, Taro; Sudo, Yasuhiko; Kuga, Hironori; Takebayashi, Hiroshi; Hayashi, Hideaki; Ishii, Ryusuke; Kasuya, Masataka; Hayakawa, Tatsuro; Morikawa, Fumiyoshi; Hata, Kazuya; Nakamura, Mitsuru; Usui, Chie; Nakamura, Hiroyuki; Hirata, Toyoaki; Sawa, Yutaka

    2012-07-30

    We examined whether augmentation with olanzapine would be superior to increased risperidone dose among acute schizophrenia patients showing early non-response to risperidone. We performed a rater-blinded, randomized controlled trial at psychiatric emergency sites. Eligible patients were newly admitted patients with acute schizophrenia. Early response was defined as Clinical Global Impressions-Improvement Scale score ≤3 following 2 weeks of treatment. Early non-responders were allocated to receive either augmentation with olanzapine (RIS+OLZ group) or increased risperidone dose (RIS+RIS group). The 78 patients who completed 2 weeks of treatment were divided into 52 early responders to risperidone and 26 early non-responders to risperidone (RIS+OLZ group, n=13; RIS+RIS group, n=13). No difference in the achievement of ≥50% improvement in Positive and Negative Syndrome Scale total score was observed between RIS+OLZ and RIS+RIS groups. Although time to treatment discontinuation for any cause was significantly shorter in the RIS+RIS group (6.8 weeks [95% confidence interval, 5.2-8.4]) than in early responders to risperidone (8.6 weeks [7.9-9.3]; P=0.018), there was no significant difference between the RIS+OLZ group (7.9 weeks [6.3-9.5]) and early responders to risperidone. Secondary outcomes justify the inclusion of augmentation arms in additional, larger studies comparing strategies for early non-responders.

  13. Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites

    DEFF Research Database (Denmark)

    Plenge, Per; Gether, Ulrik; Rasmussen, Søren G

    2007-01-01

    SERT and the three mutants. Further, R-citalopram previously thought of as an inactive enantiomer strongly attenuated dissociation of the wild-type [(3)H]-imipramine:hSERT complex, whereas S-citalopram had almost no effect on this complex. These results suggest that 1: The allosteric site on hSERT is distinct from...... the site to which S-citalopram binds with high affinity. 2: The allosteric effects of R-citalopram on the dissociation of [(3)H]-imipramine from hSERT indicate that R-citalopram introduces a conformational change in hSERT....

  14. Enantioseparation of citalopram analogues with sulfated β-cyclodextrin by capillary electrophoresis.

    Science.gov (United States)

    Wang, Yadi; Zhang, Shusheng; Breitbach, Zachary S; Petersen, Hans; Ellegaard, Peter; Armstrong, Daniel W

    2016-03-01

    Capillary electrophoresis methods were developed for the enantiomeric separation of 27 citalopram analogues. Sulfated β-cyclodextrin was the most broadly selective and useful chiral selector. The separations of most of the citalopram analogue compounds reported in this work have not been reported previously. Excellent enantiomeric separations were obtained for 26 out of 27 compounds, and most of the separations were achieved within 10 min. The effects of chemical parameters such as chiral selector types, buffer types, chiral selector and buffer concentrations, buffer pH and organic modifiers on the separation were investigated. The influence of analyte structure on separation also was examined and discussed.

  15. Effect of citalopram in the modified forced swim test in rats.

    Science.gov (United States)

    Kuśmider, Maciej; Solich, Joanna; Pałach, Paulina; Dziedzicka-Wasylewska, Marta

    2007-01-01

    The present study examined the effect of citalopram (7.5 and 15 mg/kg) in the modified forced swim test (FST) in Wistar rats, in comparison to the effect of desipramine at the same doses. The citalopram at both doses increased swimming behavior, at the cost of climbing and immobility. The administration of desipramine increased climbing behavior while immobility counts were decreased. The modified FST is indeed more sensitive than the conventional FST in describing precisely the behavioral effects of antidepressant drugs, allowing to roughly estimate the contribution of individual neurotransmitter system to the mechanism of action of the studied drug.

  16. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone.

    Science.gov (United States)

    Aggarwal, Geeta; Dhawan, Sanju; Hari Kumar, S L

    2013-01-01

    The efficacy of oral risperidone treatment in prevention of schizophrenia is well known. However, oral side effects and patient compliance is always a problem for schizophrenics. In this study, risperidone was formulated into matrix transdermal patches to overcome these problems. The formulation factors for such patches, including eudragit RL 100 and eudragit RS 100 as matrix forming polymers, olive oil, groundnut oil and jojoba oil in different concentrations as enhancers and amount of drug loaded were investigated. The transdermal patches containing risperidone were prepared by solvent casting method and characterized for physicochemical and in vitro permeation studies through excised rat skin. Among the tested preparations, formulations with 20% risperidone, 3:2 ERL 100 and ERS 100 as polymers, mixture of olive oil and jojoba oil as enhancer, exhibited greatest cumulative amount of drug permeated (1.87 ± 0.09 mg/cm(2)) in 72 h, so batch ROJ was concluded as optimized formulation and assessed for pharmacokinetic, pharmacodynamic and skin irritation potential. The pharmacokinetic characteristics of the optimized risperidone patch were determined using rabbits, while orally administered risperidone in solution was used for comparison. The calculated relative bioavailability of risperidone transdermal patch was 115.20% with prolonged release of drug. Neuroleptic efficacy of transdermal formulation was assessed by rota-rod and grip test in comparison with control and marketed oral formulations with no skin irritation. This suggests the transdermal application of risperidone holds promise for improved bioavailability and better management of schizophrenia in long-term basis.

  17. Clinical utility of the risperidone formulations in the management of schizophrenia

    Directory of Open Access Journals (Sweden)

    Madaan V

    2011-10-01

    Full Text Available Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use. Keywords: risperidone, schizophrenia, formulation, antipsychotic, side effects

  18. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning

    NARCIS (Netherlands)

    Knegtering, H; Boks, M; Blijd, C; Castelein, S; Van den Bosch, RJ; Wiersma, D

    2006-01-01

    The objective of this study was to compare sexual functioning in patients treated with olanzapine or risperidone. This open-label trial included 46 patients randomized to olanzapine (5-15mg/d) or risperidone (1-6mg/d) for 6 weeks. We used sexual dysfunction was assessed by a semistructured interview

  19. Risperidone in the management of agitation and aggression associated with psychiatric disorders.

    NARCIS (Netherlands)

    Deyn, P.P. de; Buitelaar, J.K.

    2006-01-01

    OBJECTIVE: This review provides an overview of the prevalence and treatment of agitation and aggression, and focuses on the use of risperidone to treat these symptoms in patients from different age groups. METHODS: MEDLINE and EMBASE databases were used to identify controlled studies of risperidone

  20. Prolactin release in children treated with risperidone - Impact and role of CYP2D6 metabolism

    NARCIS (Netherlands)

    Troost, Pieter W.; Lahuis, Bertine E.; Hermans, Mirjam H.; Buitelaar, Jan K.; van Engeland, Herman; Scahill, Lawrence; Minderaa, Ruud B.; Hoekstra, Pieter J.

    2007-01-01

    Objective: Little is known about the role of CYP2136 polymorphism in risperidone-induced prolactin release in children. Method: Twenty-five children (aged 5-15 years) with pervasive developmental disorders were genotyped for CYP2D6 polymorphisms. Serum prolactin, risperidone, and 9-hydroxyrisperidon

  1. Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment.

    Science.gov (United States)

    Karlsson, Louise; Carlsson, Björn; Hiemke, Christoph; Ahlner, Johan; Bengtsson, Finn; Schmitt, Ulrich; Kugelberg, Fredrik C

    2013-11-01

    According to both in vitro and in vivo data P-glycoprotein (P-gp) may restrict the uptake of several antidepressants into the brain, thus contributing to the poor success rate of current antidepressant therapies. The therapeutic activity of citalopram resides in the S-enantiomer, whereas the R-enantiomer is practically devoid of serotonin reuptake potency. To date, no in vivo data are available that address whether the enantiomers of citalopram and its metabolites are substrates of P-gp. P-gp knockout (abcb1ab (-/-)) and wild-type (abcb1ab (+/+)) mice underwent acute (single-dose) and chronic (two daily doses for 10 days) treatment with citalopram (10mg/kg) or escitalopram (5mg/kg) Serum and brain samples were collected 1-6h after the first or last i.p. injection for subsequent drug analysis by an enantioselective HPLC method. In brain, 3-fold higher concentrations of S- and R-citalopram, and its metabolites, were found in abcb1ab (-/-) mice than in abcb1ab (+/+) mice after both acute and chronic citalopram treatments. After escitalopram treatment, the S-citalopram brain concentration was 3-5 times higher in the knockout mice than in controls. The results provide novel evidence that the enantiomers of citalopram are substrates of P-gp. Possible clinical and toxicological implications of this finding need to be further elucidated.

  2. Novel and high affinity fluorescent ligands for the serotonin transporter based on (s)-citalopram

    DEFF Research Database (Denmark)

    Kumar, Vivek; Rahbek-Clemmensen, Troels; Billesbølle, Christian B

    2014-01-01

    Novel rhodamine-labeled ligands, based on (S)-citalopram, were synthesized and evaluated for uptake inhibition at the human serotonin, dopamine, and norepinephrine transporters (hSERT, hDAT, and hNET, respectively) and for binding at SERT, in transiently transfected COS7 cells. Compound 14 demons...

  3. Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram

    NARCIS (Netherlands)

    Bemmel, Alex L. van; Hoofdakker, Rutger H. van den; Beersma, Domien G.M.; Bouhuys, Antoinette L.

    1993-01-01

    Drug-induced improvement of depression may be mediated by changes in sleep physiology. The aim of this study was to relate changes in sleep polygraphic variables to clinical state during treatment with citalopram, a highly specific serotonin uptake inhibitor. Sixteen patients took part. The study wa

  4. Citalopram Treatment of Pediatric Recurrent Abdominal Pain and Comorbid Internalizing Disorders: An Exploratory Study

    Science.gov (United States)

    Campo, John V.; Perel, James; Lucas, Amanda; Bridge, Jeff; Ehmann, Mary; Kalas, Catherine; Monk, Kelly; Axelson, David; Birmaher, Boris; Ryan, Neal; Di Lorenzo, Carlo; Brent, David A.

    2004-01-01

    Objective: To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders. Method: Twenty-five clinically referred children and adolescents with recurrent abdominal pain aged 7 to 18 years, inclusive, participated in a 12-week,…

  5. Enhanced Antidepressant-Like Effects of Electroacupuncture Combined with Citalopram in a Rat Model of Depression

    Directory of Open Access Journals (Sweden)

    Jian Yang

    2013-01-01

    Full Text Available Currently, antidepressants are the dominative treatment for depression, but they have limitations in efficacy and may even produce troublesome side effects. Electroacupuncture (EA has been reported to have therapeutic benefits in the treatment of depressive disorders. The present study was conducted to determine whether EA could enhance the antidepressant efficacy of a low dose of citalopram (an SSRI antidepressant in the chronic unpredictable stress-induced depression model rats. Here, we show that a combined treatment with 2 Hz EA and 5 mg/kg citalopram for three weeks induces a significant improvement in depressive-like symptoms as detected by sucrose preference test, open field test, and forced swimming test, whereas these effects were not observed with either of the treatments alone. Further investigations revealed that 2 Hz EA plus 5 mg/kg citalopram produced a remarkably increased expression of BDNF and its receptor TrkB in the hippocampus compared with those measured in the vehicle group. Our findings suggest that EA combined with a low dose of citalopram could produce greater therapeutic effects, thereby, predictive of a reduction in drug side effects.

  6. Citalopram indtaget under graviditet og barn født med mb. Hirschsprung

    DEFF Research Database (Denmark)

    Nielsen, Sebastian Werngreen; Qvist, Niels

    2013-01-01

    A woman treated with citalopram during the entirety of her pregnancy bore a child with Hirschsprung's disease. Theories on the development of the enteric nervous system support a possible negative effect of SSRI usage. Epidemiological studies confirm a correlation between pregnant women's use of ...

  7. Behavioral and neurochemical effects of anpirtoline and citalopram in isolated and group housed mice.

    Science.gov (United States)

    Rilke, O; Will, K; Jähkel, M; Oehler, J

    2001-07-01

    Acute effects of serotonergic drugs acting via different mechanisms were investigated by a social interaction test and subsequent determination of serotonin and dopamine metabolisms in mice housed in groups or isolated for 6 weeks. A resident/intruder test was performed with anpirtoline (5-HT1B receptor agonist in rodents; 1 mg/kg), citalopram (SSRI; 0.5 mg/kg) and saline treatment before animals were decapitated and different brain regions were frozen for subsequent HPLC-analyses. Behavioral investigations indicated a strong increase of aggressive behavior after 6 weeks of isolation housing. Acute citalopram treatment did not influence behavioral parameters of isolated and group housed mice. In contrast, anpirtoline antagonized isolation induced aggressive behavioral components in a specific manner. Analysis of dopamine and serotonin metabolism revealed that citalopram treatment did not affect dopamine metabolism, but reduced serotonin metabolism in the striatum, hippocampus, cortex and midbrain independent of housing conditions. In contrast, anpirtoline treatment increased dopamine metabolism in cortex, striatum and midbrain as well as influenced serotonin metabolism in a structure- and state-specific manner. Whereas anpirtoline decreased serotonin metabolism in the cortex, the midbrain and the hippocampus independent of housing conditions, in the striatum anpirtoline abolished the isolation induced decrease of serotonin metabolism. These results indicate that anpirtoline might induce antiaggressive effects via postsynaptic receptor- and structure-specific activation of serotonergic but also dopaminergic processes, whereas structure independent increase of synaptic serotonin via citalopram was ineffective to reverse aggressivity in isolated mice.

  8. Electrochemical study of oxidation process of promethazine using sensor based on carbon nanotubes paste containing immobilized DNA on inorganic matrix

    Directory of Open Access Journals (Sweden)

    João Paulo Marco

    2014-10-01

    Full Text Available In the present work the voltammetric behavior and the oxidation process of promethazine (PHZ in electrochemical sensor based on carbon nanotubes paste containing DNA immobilized on the inorganic matrix prepared by sol-gel process (SiO2/Al2O3/Nb2O5. The method of Laviron verified that the system is irreversible and high speed of electron transfer between the electrode and DNA. The study of the oxidation of PHZ and influence of pH showed slope of 0.054 V / pH (near the nernstian system: 0.0592 V / pH suggesting that it involves the transfer of two protons and two electrons.

  9. On-Demand Treatment of Premature Ejaculation with Citalopram: A Randomized Double-Blind Study

    Directory of Open Access Journals (Sweden)

    Ghafuri Zahra

    2009-10-01

    Full Text Available "nAs the most common male sexual disorder premature ejaculation (PE, also referred to as early ejaculation (EE or rapid ejaculation (RE, affects 30%-40% of sexually active men. Despite the limited number of available studies comparing the efficacy of selective serotonin re-uptake inhibitors (SSRI they have been thought to have beneficial effects for the treatment of patients with PE. In the present study, we assessed the efficacy of on-demand use of citalopram, in the treatment of premature ejaculation. A randomized double blind study of fixed dose on-demand use of citalopram was performed in Roozbeh Psychiatry Hospital, Tehran University of Medical Sciences. The sample was consisted of 80 married patients diagnosed with PE according to Diagnostic and Statistical Manual of Mental Disorders. The patients were randomly assigned to two groups: group 1 consisting of 42 patients received 20mg citalopram, and group 2 consisting of 38 patients received placebo four hours before intercourse for a 4-week treatment course. The effects of drug on the ejaculatory function in each group were assessed by the intravaginal ejaculation latency time (IELT, and the Chinese Index of Premature Ejaculation (CIPE before and at the end of treatment course. The mean IELT increased from 66.78±36.94 to 80.85±43.05 seconds in group 1 and from 63.44±33.16 to 65.71±34.26 seconds in group 2 (P = 0.000. Mean CIPE score increased 1.14±1.04 and 0.52±0.50 in group 1 and 2 respectively (P = 0.002. The patients treated with on demand citalopram showed significantly greater improvement in IELT and CIPE score compared to the patients receiving placebo. It seems that citalopram may be an effective treatment of premature ejaculation with on-demand usage. However further studies are warranted.

  10. Combination treatment of tamoxifen with risperidone in breast cancer.

    Directory of Open Access Journals (Sweden)

    Wei-Lan Yeh

    Full Text Available Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the accumulation of cells in the G0/G1 phase of the cell cycle. Apoptotic activity can also be exerted by tamoxifen which involves cleavage of caspase 9, caspase 7, caspase 3, and poly-ADP-ribose polymerase (PARP. Down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of pro-apoptotic proteins Bax and Bak have also been observed. In addition, stress response protein of GRP 94 and GRP 78 have also been induced by tamoxifen in our study. However, side effects occur during tamoxifen treatment in breast cancer patients. Researching into combination regimen of tamoxifen and drug(s that relieves tamoxifen-induced hot flushes is important, because drug interactions may decrease tamoxifen efficacy. Risperidone has been shown to be effective in reducing or eliminating hot flushes on women with hormonal variations. In this present study, we demonstrated that combination of tamoxifen with risperidone did not interfered tamoxifen-induced cytotoxic effects in both in vitro and in vivo models, while fluoxetine abrogated the effects of tamoxifen. This is the first paper suggesting the possibility of combination treatment of tamoxifen with risperidone in breast cancer patients, providing a conceivable resolution of tamoxifen-induced side effects without interfering the efficacy of tamoxifen against breast cancer.

  11. Evidence based administration of risperidone and paliperidone for the treating conduct disorder

    Directory of Open Access Journals (Sweden)

    Ahmad Ghanizadeh

    2013-01-01

    Full Text Available Background: This study evaluates the evidence-based administration of risperidone and paliperidone for the treating children and adolescents with conduct disorder (CD. Materials and Methods: A review of the current literature from clinical trials that investigated the efficacy of risperidone and paliperidone on CD considering the inclusion criteria and search strategies was performed by a search of PubMed and Google Scholar databases. Results: Out of 53 titles, 31 were irrelevant. The abstract of 22 potentially related articles were studied. Only six articles reported the results of clinical trial. However, one of them reported the effect of risperidone on conduct behaviors in autistic disorders. One study was a re-analysis of two previous studies, one study reported the effects of maintenance versus withdrawal of risperidone treatment and two studies included children with sub-average intelligence. Headache, somnolence and increased appetite are among the most common reported adverse effects. No study examined the effect of paliperidone on CD was found. Conclusion: Current literature suggests that risperidone could be effective for treating some conduct behaviors in children and adolescents. The effect of risperidone on CD is not a well-researched area. There is no well-controlled evidence based reports about the safety and efficacy of risperidone for the treatment of CD. Further trials should examine the efficacy of these medications on CD rather than conduct behaviors or disruptive behavior disorders.

  12. Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment

    OpenAIRE

    2013-01-01

    Background: According to both in vitro and in vivo data P-glycoprotein (P-gp) may restrict the uptake of several antidepressants into the brain, thus contributing to the poor success rate of current antidepressant therapies. The therapeutic activity of citalopram resides in the Senantiomer, whereas the R-enantiomer is practically devoid of serotonin reuptake potency. To date, no in vivo data are available that address whether the enantiomers of citalopram and its metabolites are substrates of...

  13. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis

    Directory of Open Access Journals (Sweden)

    Schooler Nina

    2011-02-01

    Full Text Available Abstract Background To compare the efficacy and tolerability of paliperidone extended-release (ER with risperidone immediate-release using propensity score methodology. Methods Six double-blind, randomized, placebo-controlled, short-term clinical trials for acute schizophrenia with availability of individual patient-level data were identified (3 per compound. Propensity score pairwise matching was used to balance observed covariates between the paliperidone ER and risperidone patient populations. Scores were generated using logistic regression models, with age, body mass index, race, sex, baseline Positive and Negative Syndrome Scale (PANSS total score and baseline Clinical Global Impressions–Severity (CGI-S score as factors. The dosage range of paliperidone ER (6-12 mg/day was compared with 2 risperidone dosage ranges: 2-4 and 4-6 mg/day. The primary efficacy measure was change in PANSS total score at week 6 end point. Tolerability end points included adverse event (AE reports and weight. AEs with rates ≥5% and with a ≥2% difference between paliperidone ER and risperidone were identified. Results Completion rates for placebo-treated subjects in paliperidone ER trials (n = 95 and risperidone trials (n = 122 groups were 36.8% and 51.6%, respectively; end point changes on PANSS total scores were similar (p = 0.768. Completion rates for subjects receiving paliperidone ER 6-12 mg/day (n = 179, risperidone 2-4 mg/day (n = 113 or risperidone 4-6 mg/day (n = 129 were 64.8%, 54.0% and 66.7%, respectively (placebo-adjusted rates: paliperidone ER vs risperidone 2-4 mg/day, p = 0.005; paliperidone ER vs risperidone 4-6 mg/day, p = 0.159. PANSS total score improvement with paliperidone ER was greater than with risperidone 2-4 mg/day (difference in mean change score, -6.7; p Conclusions This indirect database analysis suggested that paliperidone ER 6-12 mg/day may be more efficacious than risperidone 2-4 mg/day and as efficacious as risperidone 4-6 mg

  14. From selective to highly selective SSRIs: a comparison of the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram.

    Science.gov (United States)

    Schreiber, Shaul; Pick, Chaim G

    2006-08-01

    Most Serotonin Selective Reuptake Inhibitors (SSRIs) have been found to possess secondary binding properties, while citalopram and its S-enantiomer (escitalopram) have been reconfirmed "purest SSRIs". Using the mouse model of acute pain hotplate analgesia meter, we evaluated the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram, injected i.p. Fluvoxamine induced a dose-dependent clear antinociceptive effect (with an ED(50) value of 6.4 mg/kg). Both fluoxetine and citalopram induced (separately) only a weak antinociceptive effect with an inverse "U" shape curve. All three drug's effects were not abolished by naloxone. Escitalopram did not elicit any effect at quasi-equipotent doses. These findings show that fluoxetine, fluvoxamine and citalopram given i.p. are weak antinociceptors, (not mediated through opioid mechanisms), while escitalopram possesses no antinociceptive properties when injected i.p. This difference between citalopram and escitalopram calls for further studies in order to assess the various differences between the two enantiomers of citalopram, and between each enantiomer and the racemic mixture.

  15. The effects of carbon tetrachloride on rat liver microsomes during the first hour of poisoning in vivo, and the modifying actions of promethazine

    Science.gov (United States)

    Slater, T. F.; Sawyer, B. C.

    1969-01-01

    The effects of an oral administration of carbon tetrachloride on various liver microsomal and supernatant components were studied 1hr. and 2hr. after dosing. The modifications of such early changes resulting from a concomitant administration of promethazine together with the carbon tetrachloride were also investigated. The microsomal components studied were: cytochromes P-450 and b5; inorganic pyrophosphatase; NADH– and NADPH–cytochrome c reductases; NADH– and NADPH–neotetrazolium reductases; a lipid-peroxidation system associated with the oxidation of NADPH and stimulated by ADP and Fe2+. NAD– and NADP– DT-diaphorases were measured in the supernatant solution remaining after isolation of liver microsomes, and the distribution of RNA phosphorus between the microsomes and supernatant solution was also determined. Carbon tetrachloride produced a rapid fall in inorganic pyrophosphatase activity, a rather slower decrease in cytochrome P-450 content of the microsomes and small increases in the activities of NADH–cytochrome c reductase and neotetrazolium reductases. The activities of NADPH–cytochrome c reductase, the NADPH–ADP/Fe2+-linked lipid-peroxidation system, DT-diaphorases and the content of cytochrome b5 in the microsomes were unchanged. There was also a loss of RNA phosphorus from the microsomes into the supernatant solution. The RNA phosphorus redistribution, the decrease in inorganic pyrophosphatase and the increases in neotetrazolium reductase activities were at least partially prevented by a concomitant dosing with promethazine. However, the decrease in cytochrome P-450 was not affected by promethazine treatment. These early changes are discussed in terms of the liver necrosis produced by carbon tetrachloride and which is greatly retarded in its onset by the administration of promethazine. PMID:5767054

  16. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.

    Science.gov (United States)

    Lepola, Ulla; Wade, Alan; Andersen, Henning Friis

    2004-05-01

    Escitalopram is the S-enantiomer of citalopram. In this study, we compared the efficacy of equivalent dosages of escitalopram and citalopram in the treatment of moderate to severe major depressive disorder (MDD), based on data from two, pooled, randomized, double-blind, placebo-controlled studies of escitalopram in which citalopram was the active reference. The primary efficacy parameter was the mean change from baseline in the Montgomery Asberg Depression Rating Scale (MADRS) total score. Significant differences in favour of escitalopram were observed for the MADRS [PEscitalopram separated from placebo at week 1 on the primary efficacy parameter, whereas citalopram first separated from placebo at week 6. An analysis of time to response showed that escitalopram-treated patients responded significantly faster to treatment than citalopram-treated patients (Pescitalopram than to citalopram (Pescitalopram-treated patients had a significant reduction in HAMD-17 total score at week 8 compared to citalopram-treated patients (P or = 30), escitalopram-treated patients showed greater improvement than citalopram-treated patients (PEscitalopram showed consistently superior efficacy compared to citalopram in the treatment of moderate to severe MDD on all efficacy parameters, and was similarly well tolerated.

  17. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats

    DEFF Research Database (Denmark)

    Mørk, A; Kreilgaard, Mads; Sánchez, C

    2003-01-01

    The selective serotonin (5-HT) reuptake inhibitor, citalopram, is a racemic mixture of an S(+)- and R(-)-enantiomer, escitalopram and R-citalopram, respectively. The present study compares the effects of escitalopram, R-citalopram and citalopram on extracellular levels of 5-HT in the frontal cortex...... of freely moving rats. In addition, co-injection of escitalopram and R-citalopram (ratios 1:2 and 1:4) were assessed. In some experiments escitalopram and R-citalopram were infused into the frontal cortex by reverse microdialysis. Finally, the extracellular level of escitalopram in the frontal cortex...... was studied after administration of escitalopram alone or in combination with R-citalopram. Escitalopram (1.0-3.9 mg/kg, s.c.) produced a greater maximal increase in extracellular 5-HT than citalopram (2.0-8.0 mg/kg, s.c.). R-citalopram (15.6 mg/kg s.c.) did not affect the 5-HT levels. When co-injected, R...

  18. Evaluation of the stability of promethazine hydrochloride in pluronic lecithin organogel and the determination of an appropriate beyond-use date.

    Science.gov (United States)

    Peacock, Gina F; Sauvageot, Jurgita

    2014-01-01

    Previous reports indicate that pharmacists are assigning a wide variety of beyond-use dates to extemporaneously compounded medications in topical Pluronic lecithin organogel. The objective of this study was to evaluate the stability of promethazine in Pluronic lecithin organogel over a period of six months and to determine an appropriate beyond-use date. A stability-indicating high-performance liquid chromatography method for promethazine in Pluronic lecithin organogel was validated in our laboratory. Samples of each formulation were analyzed by high- performance liquid chromatography at 0, 7, 14, 21, 28, 45, 60, 90, and 180 days. At each time point, the average concentration and average percent of initial concentration were calculated. The beyond-use date was determined at the time period that the samples were physically stable and maintained at least 90% of the initial concentration. Promethazine hydrochloride was chemically stable in Pluronic lecithin organogel for the period of six months. However, the formulation was physically stable only up to 60 days, and the gel matrix showed signs of physical instability at 90 days, therefore, a 60-day beyond-use date is appropriate for this formulation.

  19. R-citalopram prevents the neuronal adaptive changes induced by escitalopram.

    Science.gov (United States)

    Mnie-Filali, Ouissame; Faure, Céline; Mansari, Mostafa El; Lambás-Señas, Laura; Bérod, Anne; Zimmer, Luc; Sánchez, Connie; Haddjeri, Nasser

    2007-10-08

    This study examined the long-term effects of the antidepressant escitalopram on rat serotonin (5-HT) neuronal activity and hippocampal neuroplasticity. In the dorsal raphe nucleus, a 2-week treatment with escitalopram (10 mg/kg/day, subcutaneous) did not modify the firing activity of 5-HT neurons, whereas a cotreatment with R-citalopram (20 mg/kg/day, subcutaneous) decreased it. In the dentate gyrus of dorsal hippocampus, escitalopram increased significantly (57%) the number of de novo cells and this was prevented by a cotreatment with R-citalopram. The present results support the role of the allosteric modulation of the 5-HT transporter in the regulation of the recovery of 5-HT neuronal activity and long-lasting hippocampal cellular plasticity induced by escitalopram, two adaptive changes presumably associated with the antidepressant response.

  20. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.

    Science.gov (United States)

    Ochi, Shinichiro; Kawasoe, Koichiro; Abe, Masao; Fukuhara, Ryuji; Sonobe, Kantaro; Kawabe, Kentaro; Ueno, Shu-ichi

    2011-01-01

    We present a schizophrenic patient who experienced neuroleptic malignant syndrome with risperidone treatment due to variants of the CYP2D6 gene with reduced function. Clinicians need to be aware of this potential complication.

  1. Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone : a review

    NARCIS (Netherlands)

    Knegtering, H; Lambers, PA; Prakken, G; ten Brink, C

    2000-01-01

    Classical antipsychotic drugs increase the level of serum prolactin. The atypical antipsychotic clozapine barely increases prolactin levels. An open naturalistic study in the University Hospital of Groningen suggests that treatment with risperidone in comparison to classical antipsychotics seems to

  2. Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice

    Directory of Open Access Journals (Sweden)

    David Holthoewer

    2010-06-01

    Full Text Available Pharmacokinetic interactions, e.g. modulation of drug transporters like P-glycoprotein at the blood-brain barrier, can be a reason for treatment non-response. This study focuses on the influence of induction of drug transporters on the disposition of the antipsychotic drugs risperidone and 9-hydroxyrisperidone. Brain and serum concentrations of risperidone and its active metabolite 9-hydroxyrisperidone, which are known P-glycoprotein substrates, were measured after drug transporter induction with rifampicin, dexamethasone or 5-pregnene-3beta-ol-20-on-16alpha-carbonitrile using high performance liquid chromatography. Disposition of risperidone and 9-hydroxyrisperidone was dramatically decreased in mouse brain and serum after drug transporter induction. The metabolism of risperidone was also affected.

  3. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

    NARCIS (Netherlands)

    Knegtering, R; Baselmans, P; Castelein, S; Bosker, F; Bruggeman, R; van den Bosch, RJ

    2005-01-01

    Objective: The atypical antipsychotic risperidone significantly raises plasma prolactin levels in patients, but clozapine, olanzapine, and quetiapine do not. The differences in neuroendocrine response may be connected with the metabolism of the medications. The authors examined the contributory role

  4. 78 FR 52777 - Draft Guidance for Industry on Bioequivalence Recommendations for Risperidone Injection...

    Science.gov (United States)

    2013-08-26

    ... on Bioequivalence Recommendations for Risperidone Injection; Availability AGENCY: Food and Drug... provides specific recommendations on the design of bioequivalence (BE) studies to support abbreviated new... availability of a draft guidance for industry entitled ``Bioequivalence Recommendations for Specific...

  5. Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study

    Science.gov (United States)

    Qirjazi, Elena; McArthur, Eric; Nash, Danielle M.; Dixon, Stephanie N.; Weir, Matthew A.; Vasudev, Akshya; Jandoc, Racquel; Gula, Lorne J.; Oliver, Matthew J.; Wald, Ron; Garg, Amit X.

    2016-01-01

    Background The risk of ventricular arrhythmia with citalopram and escitalopram is controversial. In this study we investigated the association between these two drugs and the risk of ventricular arrhythmia. Methods We conducted a population-based retrospective cohort study of older adults (mean age 76 years) from 2002 to 2012 in Ontario, Canada, newly prescribed citalopram (n = 137 701) or escitalopram (n = 38 436), compared to those prescribed referent antidepressants sertraline or paroxetine (n = 96 620). After inverse probability of treatment weighting using a propensity score, the baseline characteristics of the comparison groups were similar. The primary outcome was a hospital encounter with ventricular arrhythmia within 90 days of a new prescription, assessed using hospital diagnostic codes. The secondary outcome was all-cause mortality within 90 days. Results Citalopram was associated with a higher risk of a hospital encounter with ventricular arrhythmia compared with referent antidepressants (0.06% vs. 0.04%, relative risk [RR] 1.53, 95% confidence intervals [CI]1.03 to 2.29), and a higher risk of mortality (3.49% vs. 3.12%, RR 1.12, 95% CI 1.06 to 1.18). Escitalopram was not associated with a higher risk of ventricular arrhythmia compared with the referent antidepressants (0.03% vs. 0.04%, RR 0.84, 95% CI 0.42 to 1.68), but was associated with a higher risk of mortality (2.86% vs. 2.63%, RR 1.09, 95% CI 1.01 to 1.18). Conclusion Among older adults, initiation of citalopram compared to two referent antidepressants was associated with a small but statistically significant increase in the 90-day risk of a hospital encounter for ventricular arrhythmia. PMID:27513855

  6. The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites

    Energy Technology Data Exchange (ETDEWEB)

    Zeng Zhizhen [Imaging Department, Merck Research Laboratories, West Point, PA 19486 (United States)]. E-mail: zhizhen_zeng@merck.com; Chen, T.-B. [Imaging Department, Merck Research Laboratories, West Point, PA 19486 (United States); Miller, Patricia J. [Imaging Department, Merck Research Laboratories, West Point, PA 19486 (United States); Dean, Dennis [Labeled Compound Synthesis Group, Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065-0900 (United States); Tang, Y.S. [Labeled Compound Synthesis Group, Drug Metabolism, Merck Research Laboratories, Rahway, NJ 07065-0900 (United States); Sur, Cyrille [Imaging Department, Merck Research Laboratories, West Point, PA 19486 (United States); Williams, David L. [Imaging Department, Merck Research Laboratories, West Point, PA 19486 (United States)

    2006-05-15

    We have characterized the interaction of the serotonin transporter ligand [{sup 3}H]-N,N-dimethyl-2-(2-amino-4-cyanophenylthio)-benzylamine (DASB) with rhesus monkey brain in vitro using tissue homogenate binding and autoradiographic mapping. [{sup 3}H]-DASB, a tritiated version of the widely used [{sup 11}C] positron emission tomography tracer, was found to selectively bind to a single population of sites with high affinity (K {sub d}=0.20{+-}0.04 nM). The serotonin transporter density (B {sub max}) obtained for rhesus frontal cortex was found to be 66{+-}8 fmol/mg protein using [{sup 3}H]-DASB, similar to the B {sub max} value obtained using the reference radioligand [{sup 3}H]-citalopram, a well-characterized and highly selective serotonin reuptake inhibitor (83{+-}22 fmol/mg protein). Specific binding sites of both [{sup 3}H]-DASB and [{sup 3}H]-citalopram were similarly and nonuniformly distributed throughout the rhesus central nervous system, in a pattern consistent with serotonin transporter localization reported for human brain. Regional serotonin transporter densities, estimated from optical densities of the autoradiographic images, were well correlated between the two radioligands. Finally, DASB and fluoxetine showed dose-dependent full inhibition of [{sup 3}H]-citalopram binding in a competition autoradiographic study, with K {sub i} values in close agreement with those obtained from rhesus brain homogenates. This side-by-side comparison of [{sup 3}H]-DASB and [{sup 3}H]-citalopram binding sites in rhesus tissue homogenates and in adjacent rhesus brain slices provides additional support for the use of [{sup 11}C]-DASB to assess the availability and distribution of serotonin transporters in nonhuman primates.

  7. Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.

    Science.gov (United States)

    Kamei, Hiroyuki; Isaji, Ami; Noda, Yukihiro; Ishikawa, Kazuhiro; Senzaki, Koji; Yamada, Kiyofumi; Sugiura, Kazumitsu; Tomita, Yasushi; Nabeshima, Toshitaka

    2012-05-01

    Since most first-generation antihistamines have undesirable sedative effects on the central nervous systems (CNS), newer (second-generation) antihistamines have been developed to improve patients' quality of life. However, there are few reports that directly compare the antihistaminic efficacy and impairment of psychomotor functions. We designed a double-blind, placebo controlled, crossover study to concurrently compare the clinical effectiveness of promethazine, a first-generation antihistamine, and fexofenadine and olopatadine, second-generation antihistamines, by measuring their potency as peripheral inhibitors of histamine-induced wheal and flare. Further, we investigated their sedative effects on the CNS using a battery of psychomotor tests. When single therapeutic doses of fexofenadine (60 mg), olopatadine (5 mg) and promethazine (25 mg) were given in a double-blind manner to 24 healthy volunteers, all antihistamines produced a significant reduction in the wheal and flare responses induced by histamine. In the comparison among antihistamines, olopatadine showed a rapid inhibitory effect compared with fexofenadine and promethazine, and had a potent effect compared with promethazine. In a battery of psychomotor assessments using critical flicker fusion, choice reaction time, compensatory tracking, rapid visual information processing and a line analogue rating scale as a subjective assessment of sedation, promethazine significantly impaired psychomotor function. Fexofenadine and olopatadine had no significant effect in any of the psychomotor tests. Promethazine, fexofenadine and olopatadine did not affect behavioral activity, as measured by wrist actigraphy. These results suggest that olopatadine at a therapeutic dose has greater antihistaminergic activity than promethazine, and olopatadine and fexofenadine did not cause cognitive or psychomotor impairment.

  8. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria

    OpenAIRE

    FAYYAZi, Afshin; Salari, Elham; Ali KHAJEH; GAJARPOUR, Abdi

    2014-01-01

    How to Cite This Article: Fayyazi A, Salari E, Khajeh A, Ghajarpour A. A Comparison of Risperidone and Buspirone for Treatment ofBehavior Disorders in Children with Phenylketonuria. Iran J Child Neurol. 2014 Autumn; 8(4):33-38.AbstractObjectiveMany patients with late-diagnosed phenylketonuria (PKU) suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.Materials & MethodsIn this crossover clinical...

  9. In Vitro-In Vivo Correlation of Parenteral Risperidone Polymeric Microspheres

    OpenAIRE

    2015-01-01

    The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal® Consta® was used to prepare risperidone microspheres. Various manufacturing processe...

  10. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies

    OpenAIRE

    2014-01-01

    The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC) studies. Different implants (F1-F8) containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000) either alone or as their blends, and PLGA (75:25). The implants contained 40% of the drug. After f...

  11. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.

    Science.gov (United States)

    Shen, Jie; Choi, Stephanie; Qu, Wen; Wang, Yan; Burgess, Diane J

    2015-11-28

    The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal® Consta® was used to prepare risperidone microspheres. Various manufacturing processes were investigated to produce the risperidone microspheres with similar drug loading (approx. 37%) but distinctly different physicochemical properties (e.g. porosity, particle size and particle size distribution). In vitro release of the risperidone microspheres was investigated using different release testing methods (such as sample-and-separate and USP apparatus 4). In vivo pharmacokinetic profiles of the risperidone microsphere formulations following intramuscular administration were determined using a rabbit model. Furthermore, the obtained pharmacokinetic profiles were deconvoluted using the Loo-Riegelman method and the calculated in vivo release was compared with the in vitro release of these microspheres. Level A IVIVCs were established and validated for the compositionally equivalent risperidone microspheres based on the in vitro release data obtained using USP apparatus 4. The developed IVIVCs demonstrated good predictability and were robust. These results showed that the developed USP apparatus 4 method was capable of discriminating PLGA microspheres that are equivalent in formulation composition but with manufacturing differences and predicting their in vivo performance in the investigated animal model.

  12. Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.

    Science.gov (United States)

    O'Sullivan, David; Green, Laura; Stone, Sarrabeth; Zareie, Pirooz; Kharkrang, Marie; Fong, Dahna; Connor, Bronwen; La Flamme, Anne Camille

    2014-01-01

    Recent studies have demonstrated that atypical antipsychotic agents, which are known to antagonize dopamine D2 and serotonin 5-HT2a receptors, have immunomodulatory properties. Given the potential of these drugs to modulate the immune system both peripherally and within the central nervous system, we investigated the ability of the atypical anti-psychotic agent, risperidone, to modify disease in the animal model of multiple sclerosis (MS)4, experimental autoimune encephalomyelitis (EAE). We found that chronic oral administration of risperidone dose-dependently reduced the severity of disease and decreased both the size and number of spinal cord lesions. Furthermore, risperidone treatment substantially reduced antigen-specific interleukin (IL)-17a, IL-2, and IL-4 but not interferon (IFN)-γ production by splenocytes at peak disease and using an in vitro model, we show that treatment of macrophages with risperidone alters their ability to bias naïve T cells. Another atypical antipsychotic agent, clozapine, showed a similar ability to modify macrophages in vitro and to reduce disease in the EAE model but this effect was not due to antagonism of the type 1 or type 2 dopamine receptors alone. Finally, we found that while risperidone treatment had little effect on the in vivo activation of splenic macrophages during EAE, it significantly reduced the activation of microglia and macrophages in the central nervous system. Together these studies indicate that atypical antipsychotic agents like risperidone are effective immunomodulatory agents with the potential to treat immune-mediated diseases such as MS.

  13. Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder.

    Science.gov (United States)

    Nikvarz, Nikvarz; Alaghband-Rad, Javad; Tehrani-Doost, Mehdi; Alimadadi, Abbas; Ghaeli, Padideh

    2017-01-01

    Introduction: This study was aimed to compare the efficacy and side effects of memantine, an antagonist of the NMDA receptor of glutamate, with risperidone given the fact that glutamate has been noted for its possible effects in the pathogenesis of autism. Risperidone, an atypical antipsychotic, has been approved by FDA for the management of irritability associated with autism. Methods: 30 children, aged 4-17 years, entered an 8-week, randomized trial. Patients were randomly assigned to receive either risperidone or memantine. Autism Behavior Checklist (ABC), Childhood Autism Rating Scale (CARS), Clinical Global Impressions - Improvement (CGI-I) and Clinical Global Impression-Severity (CGI-S) scales were used to assess behavioral symptoms of the patients. Results: Both risperidone and memantine reduced the scores of 4 subscales of ABC as well as the 10-item and the total score of CARS significantly. However, differences between the 2 drugs in the scores of each evaluating scale were not found to be significant. Relatively, larger number of patients on risperidone showed "very much improvement" when assessed by CGI-I scale when compared with those on memantine. Discussion and conclusion: The present study suggests that memantine may have beneficial effects in the treatment of many core symptoms of autism. Therefore, memantine may be considered as a potential medication in the treatment of those autistic children who do not respond or cannot tolerate side effects of risperidone.

  14. A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia

    Directory of Open Access Journals (Sweden)

    Saeed Shoja Shafti

    2014-01-01

    Full Text Available Introduction. Since a variety of comparisons between risperidone and olanzapine have resulted in diverse outcomes, so safety and efficacy of them were compared again in a new trial. Method. Sixty female schizophrenic patients entered into one of the assigned groups for random allocation to olanzapine or risperidone (n=30 in each group in a double-blind, 12-week clinical trial. Scale for Assessment of Positive Symptoms (SAPS and Scale for Assessment of Negative Symptoms (SANS were used as the primary outcome measures. Clinical Global Impressions-Severity Scale (CGI-S, Schedule for Assessment of Insight (SAI, and finally Simpson Angus Scale (SAS as well were employed as secondary scales. Results. While both of olanzapine and risperidone were significantly effective for improvement of positive symptoms (P<0.0001, as regards negative symptoms, it was so only by means of olanzapine (P<0.0003. CGI-S and SAI, as well, were significantly improved in both of the groups. SAS increment was significant only in the risperidone group (P<0.02. Conclusion. While both of olanzapine and risperidone were equally effective for improvement of positive symptoms and insight, olanzapine showed superior efficacy with respect to negative symptoms, along with lesser extrapyramidal side effects, in comparison with risperidone.

  15. Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder.

    Science.gov (United States)

    Peitl, Marija Vucić; Peitl, Vjekoslav; Grahovac, Tanja; Pavlović, Eudard

    2010-03-01

    Risperidone, as all atypical antipsychotics, can cause hyperprolactinemia which can in turn lead to galactorrhea. Mood stabilizers, one of which is valproic acid and its derivate "Depakine Chrono", are rarely linked with symptomatic hyperprolactinemia and do not alter prolactin concentrations. This case is based around a patient suffering from a bipolar disorder that has been psychiatrically treated in an outpatient clinic during four years. Bipolar disorder treatment was started with carbamazepine, but later it was discontinued due to adverse events and extreme increase of liver transaminases. Treatment was continued with introduction of lithium, but the patient stated that she could not tolerate it. Subsequently, her endocrinologist advised for lithium discontinuation due to very severe osteoporosis. At the beginning of 2009, lithium was discontinued and Depakine Chrono was introduced. Due to patient's psychotic decompensation it was necessary to introduce risperidone into treatment and soon afterwards her psychotic symptoms settled. After several months of treatment her mood lowered, she began to feel sedated, psychomotorically retarded and that lead to dose lowering of Depakine Chrono and risperidone, at which point galactorrhea as a serious adverse event occurred. Occurrence of galactorrhea at lower risperidone doses in this case might be partially explained by recent studies that showed that lower doses of risperidone can also improve psychic state, but could also cause adverse events. Although galactorrhea, as a direct consequence of hyperprolactinemia caused by risperidone has mainly been researched with higher doses of this atypical antipsychotic, we have to keep in mind that lower doses could also cause serious adverse events.

  16. Haloperidol mais prometazina para pacientes agitados - uma revisão sistemática Haloperidol plus promethazine for agitated patients - a systematic review

    Directory of Open Access Journals (Sweden)

    Gisele Huf

    2009-09-01

    Full Text Available OBJETIVO: A tranquilização farmacológica rápida e segura de episódios de agitação/agressividade é muitas vezes inevitável. Esta revisão investiga a efetividade da combinação haloperidol e prometazina intramuscular, muito utilizada no Brasil. MÉTODO: Através de busca nos registros do Cochrane Schizophrenia Group, foram incluídos todos os ensaios clínicos nos quais a combinação haloperidol e prometazina foi avaliada em pacientes agressivos com psicose. Todos os estudos relevantes foram avaliados quanto à qualidade e tiveram seus dados extraídos de forma confiável. RESULTADOS: Foram identificados quatro estudos relevantes de alta qualidade. A combinação haloperidol e prometazina foi comparada com midazolam, lorazepam, haloperidol isolado e olanzapina, todos administrados por via intramuscular. No Brasil, a combinação foi efetiva, com mais de 2/3 dos pacientes tranquilos em 30 minutos, mas midazolam foi mais rápido. Na Índia, comparado a lorazepam, a combinação haloperidol e prometazina foi mais efetiva. Após as primeiras horas, as diferenças foram negligenciáveis. O uso de haloperidol isolado acarretou maior incidência de efeitos adversos. Olanzapina promove tranquilização tão rapidamente quanto a combinação, mas não tem efeito tão duradouro e mais pessoas necessitaram medicação adicional nas quatro horas subseqüentes. CONCLUSÃO: Todos os medicamentos avaliados são eficazes, mas esta revisão demonstra vantagens no uso da combinação haloperidol e prometazina.OBJECTIVE: Rapid and safe tranquillisation is sometimes unavoidable. We conducted this systematic review to determine the value of the combination haloperidol plus promethazine, frequently used in Brazil. METHOD: We searched the Cochrane Schizophrenia Group's Register and included all randomised clinical trials involving aggressive people with psychosis for which haloperidol plus promethazine was being used. We reliably selected, quality assessed

  17. Early onset of treatment effects with oral risperidone

    Directory of Open Access Journals (Sweden)

    Naber Dieter

    2007-01-01

    Full Text Available Abstract Background The dogma of a delayed onset of antipsychotic treatment effects has been maintained over the past decades. However, recent studies have challenged this concept. We therefore performed an analysis of the onset of antipsychotic treatment effects in a sample of acutely decompensated patients with schizophrenia. Methods In this observational study, 48 inpatients with acutely decompensated schizophrenia were offered antipsychotic treatment with oral risperidone. PANSS-ratings were obtained on day 0, day 1, day 3, day 7 and day 14. Results Significant effects of treatment were already present on day 1 and continued throughout the study. The PANSS positive subscore and the PANSS total score improved significantly more than the PANSS negative subscore. Conclusion Our results are consistent with the growing number of studies suggesting an early onset of antipsychotic treatment effects. However, non-pharmacological effects of treatment also need to be taken into consideration.

  18. Synergistic Effects of Citalopram and Morphine in the Renal Colic Pain Relief; a Randomized Clinical Trial

    Directory of Open Access Journals (Sweden)

    Mehrdad Esmailian

    2014-03-01

    Full Text Available Introduction: Although the synergistic effects of opioids and other analgesic drugs such as non-steroidal anti-inflammatory drugs (NSAIDs have been established in relieving acute pain due to renal calculi, no studies today have evaluated the concomitant administration of opiates and other drugs with analgesic effects, such as serotonin re-uptake inhibitors. Considering the high prevalence of renal colic, the present study was carried out to compare the effect of concomitant prescription of morphine and a placebo with that of morphine and citalopram on the management of acute pain due to renal calculi. Methods: The present double-blind randomized clinical trial was carried out from October 2012 to March 2013 in the Al-Zahra educational Hospital in Isfahan, Iran. A total of 90 patients with acute renal colic pain were randomly divided into two groups of 45 subjects. The subjects in one group received morphine/ placebo and another one morphine/citalopram. The patients’ pain severity was determined by visual analogue scale (VAS before and 20 minutes after administration of medications. In case of persistent pain the second or even third dose was administered and the pain severity was once again determined. Data were analyzed with STATA 11.0 using chi-squared, two-way ANOVA, Bonferroni post hoc test, and log rank test. Results: The decrease in pain severity in the morphine/citalopram group was significantly compared to the morphine/placebo group and the time before administration of the medications (p<0.001. In contrast, administration of morphine/placebo did not have a significant effect on pain severity at this interval (p=0.32. Kaplan-Meier curve showed that the first injection was successful in relieving pain in 15 (33.3% and 26 (57.8% subjects in the morphine/placebo and morphine/citalopram groups, respectively. The second injection of these medications resulted in therapeutic success in 35 (87.8% and 42 (95.6% subjects in the above groups

  19. [Development of a method for estimation of citalopram and desmethylcitalopram in nails and hair and its usefulness in forensic toxicology].

    Science.gov (United States)

    Pufal, Ewa; Sykutera, Marzena; Nowacka, Teresa; Stefanowicz, Anna; Sliwka, Karol

    2010-01-01

    The report presents the possibility of using an alternative material of determining citalopram and its metabolite (desmethylcitalopram) in hair and nails. Citalopram (Cipramil, Citaratio, Citaxin, Oropram, Cital, Cilon, Aurex) is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class, employed in treatment of depression, prevention of depressive disorders recurrence and in some anxiety disorders. The investigations were performed using liquid chromatography coupled with electrospray-ionization mass spectrophotometry (LC-ESI-MS). In the course of the study, the authors developed a method for isolation and identification of Citaprolam and its metabolite (desmethylcitaprolam) from hair and nails. Determination were performed in hair and nail samples collected from individuals who had been administered citalopram in therapeutic doses at least for 12 months before sample collection. Hair and nail samples were obtained 4, 6, 9 and 15 months after discontinuing drug administration. The concentration of citalopram in nails was 0.40-10.49 ng/mg and the concentration of desmethylcitalopram was 0.32-3.70 ng/mg. In hair, citalopram concentration was 1.04-8.69 ng/mg and for desmethylcitalopram, the concentration range was 0.07-1.27 ng/mg.

  20. Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs : overview of 26 cases

    NARCIS (Netherlands)

    Jimmink, Afra; Caminada, Klaartje; Hunfeld, Nicole G M; Touw, Daan J

    2008-01-01

    There is discussion concerning the cardiac safety of citalopram in an overdose. The aim of this study was to investigate the toxic effects and toxicokinetic parameters of citalopram in an overdose as a single drug and in combination with other drugs. Cases observed between 1997 and 2006 were evaluat

  1. A Randomized Open Label Comparison of the Effects ofRisperidone and Haloperidol on Sexual Function

    Directory of Open Access Journals (Sweden)

    S. Jaber Mousavi

    2009-12-01

    Full Text Available "n Objective: "nSexual dysfunction in patients who take antipsychotics causes adecline in their quality of life and medication acceptance. Considering the restrictions in cross sectional design of many earlier researches, we used a clinical trial aimed at assessing sexual dysfunction by substituting Risperidone, an atypical antipsychotic drug, with Haloperidol, a typical one . "n "n "nMethod: This clinical trial was conducted on 51 patients who had been using Risperidone with a minimum dose of 2 mg/daily for at least 2 months. The patients were randomly divided into 2 groups. The first group continued taking Risperidone, whereas the second group was given Haloperidol. Sexual function prior to and after the drug substitution was assessed using a sexual questionnaire designed to assess four stages of sexual function . "nResults: Compared to those who changed their medication to Haloperidol, the patients who remained on Risperidone therapy suffered from more sexual dysfunction, especially in their tendency towards having sexual activities (P= 0.01, post menstrual sexual activity (P= 0.002, and reaching orgasm in their sexual activities (P= 0.04; however in the Haloperidol group, no significant difference was observed before and after the change in medication . "nConclusion: Although Risperidone and Haloperidol can both disturb patients'sexual function, the side effects of Risperidone are stronger. Hence toprevent the decline of medication acceptance or irregular consumption by patients which may lead to possible relapse, substitution of Risperidone withanother drug with fewer side effects on sexual activities is definitely to the advantage of the patients .

  2. CYP2D6 polymorphisms and their influence on risperidone treatment

    Directory of Open Access Journals (Sweden)

    Puangpetch A

    2016-12-01

    Full Text Available Apichaya Puangpetch,1 Natchaya Vanwong,1 Nopphadol Nuntamool,2 Yaowaluck Hongkaew,1 Monpat Chamnanphon,1 Chonlaphat Sukasem1 1Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, 2Molecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand Abstract: Cytochrome P450 enzyme especially CYP2D6 plays a major role in biotransformation. The interindividual variations of treatment response and toxicity are influenced by the polymorphisms of this enzyme. This review emphasizes the effect of CYP2D6 polymorphisms in risperidone treatment in terms of basic knowledge, pharmacogenetics, effectiveness, adverse events, and clinical practice. Although the previous studies showed different results, the effective responses in risperidone treatment depend on the CYP2D6 polymorphisms. Several studies suggested that CYP2D6 polymorphisms were associated with plasma concentration of risperidone, 9-hydroxyrisperidone, and active moiety but did not impact on clinical outcomes. In addition, CYP2D6 poor metabolizer showed more serious adverse events such as weight gain and prolactin than other predicted phenotype groups. The knowledge of pharmacogenomics of CYP2D6 in risperidone treatment is increasing, and it can be used for the development of personalized medication in term of genetic-based dose recommendation. Moreover, the effects of many factors in risperidone treatment are still being investigated. Both the CYP2D6 genotyping and therapeutic drug monitoring are the important steps to complement the genetic-based risperidone treatment. Keywords: CYP2D6, risperidone, polymorphisms, adverse drug reaction, pharmacogenetics, pharmacokinetics, pharmacodynamics

  3. Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: report of twenty-one cases.

    Science.gov (United States)

    Capozzo, Maria Anna; Schillani, Giulia; Aguglia, Eugenio; De Vanna, Maurizio; Grassi, Luigi; Conte, Maria Anna; Giraldi, Tullio

    2009-01-01

    The aim of this study was to examine the effects of the SSRI antidepressant drug citalopram on anxiety, depression and mental adjustment to cancer in terminally ill cancer patients, considering also the 5-HTTLPR genetic polymorphism. A group of twenty-one consecutive patients admitted to the hospice of the Casa di Cura Pineta del Carso (Trieste, Italy) with different types of advanced cancer, who were clinically judged to require treatment with an antidepressive drug, was treated with citalopram for two weeks. The response was determined and related to 5-HTTLPR. Citalopram significantly reduced the scores on the depression and anxiety subscales of the Hospital Anxiety and Depression Scale (HADS). When the effects of citalopram were analyzed in relation to the 5-HTTLPR polymorphism, the HADS depression score was significantly decreased only in patients with the "l/l" allelic variant of the serotonin transporter conferring high functional activity, while the score of the Mini-MAC fatalism scale was significantly increased in patients carrying at least one "s" allele. These preliminary findings seem to indicate that two weeks of treatment with citalopram are effective in reducing depressive symptoms in terminally ill cancer patients. Moreover, the effects of citalopram on fatalism as a strategy of mental adaptation to cancer, and on depressive symptoms depend on the allelic variants of the 5-HTTLPR genotype of the patients. These results seem to encourage the examination of a larger patient sample and of different treatment schedules, as well as a more thorough characterization of fatalism as a coping strategy in cancer patients.

  4. Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia

    Directory of Open Access Journals (Sweden)

    Zhao Y

    2013-10-01

    Full Text Available Yueren Zhao,1–3 Taro Kishi,1 Nakao Iwata,1 Manabu Ikeda3,4 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care Center, Toyoake, Aichi, Japan; 3Department of Neuropsychiatry, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan; 4Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan Abstract: A recent meta-analysis showed that long-acting injectable (LAI antipsychotics were not superior to oral antipsychotics for preventing relapse in patients with schizophrenia. We therefore designed a treatment strategy combining risperidone LAI and COMPASS (COMprehensive Psycho-educational Approach and Scheme Set, an original psychoeducational program supporting treatment with risperidone LAI and evaluating subjective treatment satisfaction, transition of symptoms, and effectiveness in preventing symptomatic relapse. The aim of this study was to examine whether addition of COMPASS to risperidone LAI was more effective in preventing relapse in schizophrenia patients than risperidone LAI alone, with the latter group consisting of patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients were followed up for 6 months, with COMPASS continuously implemented from the transition to the observation phase. The primary efficacy measurements were relapse rate (rates of rehospitalization and discontinuation due to inefficacy. Secondary efficacy measurements were the Brief Psychiatric Rating Scale (BPRS and Global Assessment of Functioning (GAF scores. Of the 96 patients originally enrolled, 19 (19.8% were discontinued from all causes. During the 6-month study period, ten of the 96 patients (10.4% relapsed, compared with a 12.2% relapse rate in patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients showed significant improvements in BPRS total

  5. Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

    Science.gov (United States)

    Pandina, Gahan J.; Bossie, Cynthia A.; Youssef, Eriene; Zhu, Young; Dunbar, Fiona

    2007-01-01

    Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n =…

  6. Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

    Science.gov (United States)

    Kent, Justine M.; Kushner, Stuart; Ning, Xiaoping; Karcher, Keith; Ness, Seth; Aman, Michael; Singh, Jaskaran; Hough, David

    2013-01-01

    Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg] or high-dose: 1.25 mg/day [20 to 45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change…

  7. The Treatment of Minor Depression with St. John’s Wort or Citalopram: Failure to Show Benefit over Placebo

    OpenAIRE

    Rapaport, Mark Hyman; Nierenberg, Andrew A.; Howland, Robert; Dording, Christina; Pamela J. Schettler; Mischoulon, David

    2011-01-01

    This paper presents new data addressing two important controversies in psychiatry: the construct of Minor Depression (MinD) and the efficacy of St. John’s Wort for milder forms of depressive disorders. Data are from a three-arm, 12 week, randomized clinical trial of investigating the efficacy of St. John’s Wort (810 mg/day), citalopram (20 mg/day), or placebo for acute treatment of MinD. Due to a high placebo response on all outcome measures, neither St. John’s Wort nor citalopram separated f...

  8. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia

    Directory of Open Access Journals (Sweden)

    Jeffrey R Bishop

    2008-03-01

    Full Text Available Jeffrey R Bishop1,2, Mani N Pavuluri21Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA; 2Department of Psychiatry, Pediatric Mood Disorders Program and Center for Cognitive Medicine, University of Illinois at Chicago College of Medicine, Chicago, IL, USAAbstract: Risperidone is a commonly used medication for the treatment of bipolar disorder and schizophrenia in children and adolescents. It has been studied as a monotherapy treatment in early onset schizophrenia and as both monotherapy and combination therapy for pediatric bipolar disorder. Studies to date indicate that risperidone is an effective treatment for positive and negative symptoms of schizophrenia and mania symptoms of bipolar disorder. In young patient populations, side effects such as weight gain, extrapyramidal side effects, and prolactin elevation require consideration when evaluating the risk benefit ratio for individual patients. Here we review published studies of risperidone for the treatment of bipolar disorder and schizophrenia in children and adolescents to provide practitioners with an overview of published data on the efficacy and safety of risperidone in these patient populations.Keywords: risperidone, bipolar disorder, schizophrenia, children, adolescents

  9. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.

    Science.gov (United States)

    Vaisburd, Sinaya; Shemer, Zeev; Yeheskel, Adva; Giladi, Eliezer; Gozes, Illana

    2015-11-10

    Mutated disrupted in schizophrenia 1 (DISC1), a microtubule regulating protein, leads to schizophrenia and other psychiatric illnesses. It is hypothesized that microtubule stabilization may provide neuroprotection in schizophrenia. The NAP (NAPVSIPQ) sequence of activity-dependent neuroprotective protein (ADNP) contains the SxIP motif, microtubule end binding (EB) protein target, which is critical for microtubule dynamics leading to synaptic plasticity and neuroprotection. Bioinformatics prediction for FDA approved drugs mimicking SxIP-like motif which displace NAP-EB binding identified Risperidone. Risperidone or NAP effectively ameliorated object recognition deficits in the mutated DISC1 mouse model. NAP but not Risperidone, reduced anxiety in the mutated mice. Doxycycline, which blocked the expression of the mutated DISC1, did not reverse the phenotype. Transcripts of Forkhead-BOX P2 (Foxp2), a gene regulating DISC1 and associated with human ability to acquire a spoken language, were increased in the hippocampus of the DISC1 mutated mice and were significantly lowered after treatment with NAP, Risperidone, or the combination of both. Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.

  10. Risperidone – Solid-state characterization and pharmaceutical compatibility using thermal and non-thermal techniques

    Energy Technology Data Exchange (ETDEWEB)

    Daniel, Josiane Souza Pereira; Veronez, Isabela Pianna; Rodrigues, Larissa Lopes [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil); Trevisan, Marcello G. [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil); National Institute of Bioanalytics Science and Technology – INCTBio, Institute of Chemistry – UNICAMP, 13084-653, Campinas, São Paulo (Brazil); Garcia, Jerusa Simone, E-mail: jerusa.garcia@unifal-mg.edu.br [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil)

    2013-09-20

    Highlights: • DSC was used to characterize Risperidone and study its compatibility with excipients. • FT-IR associated with PCA was used to complement DSC data. • LC analyzes confirmed the DSC and FT-IR/PCA results. • Risperidone was incompatible with three among five excipients evaluated. - Abstract: A full solid-state characterization of risperidone was conducted using differential scanning calorimetry (DSC), thermogravimetry (TG), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM) to examine its physicochemical properties and polymorphism. The primary aim of this work was to study the compatibility of risperidone with pharmaceutical excipients using DSC to obtain and compare the curves of the active pharmaceutical ingredient (API) and the excipients with their 1:1 (w/w) binary mixtures. These same binary mixtures were turned to room temperature and analyzed by FT-IR combined with principal component analysis (PCA) to evaluate solid-state incompatibilities. The chemical incompatibilities of these samples were verified using a stability-indicating liquid chromatography (LC) method to assay for the API and evaluate the formation of degradation products. All of these methods showed incompatibilities between risperidone and the excipients magnesium stearate, lactose and cellulose microcrystalline.

  11. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.

    Directory of Open Access Journals (Sweden)

    Maria Jimena Prieto

    Full Text Available Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%. Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer was achieved with a mixture of chloroform:methanol 50∶50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.

  12. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.

    Science.gov (United States)

    Prieto, Maria Jimena; del Rio Zabala, Nahuel Eduardo; Marotta, Cristian Hernán; Carreño Gutierrez, Hector; Arévalo Arévalo, Rosario; Chiaramoni, Nadia Silvia; del Valle Alonso, Silvia

    2014-01-01

    Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%). Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer) was achieved with a mixture of chloroform:methanol 50∶50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.

  13. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster.

    Science.gov (United States)

    Gulick, Danielle; Chau, David T; Khokhar, Jibran Y; Dawson, Ree; Green, Alan I

    2014-08-30

    The atypical antipsychotic clozapine reduces alcohol drinking in patients with schizophrenia. We have proposed that clozapine׳s ability to decrease alcohol drinking relates to its weak blockade of the dopamine D2 receptor and potent blockade of the norepinephrine α-2 receptor, as well as its ability to elevate plasma and brain norepinephrine. Another atypical antipsychotic, risperidone, which is a potent blocker of both the dopamine D2 receptor and norepinephrine α-2 receptor, does not decrease alcohol drinking. In this study, we used the Syrian golden hamster to test whether the ability of risperidone to reduce alcohol drinking would be enhanced if it was used in combination with the norepinephrine reuptake inhibitor desipramine. Hamsters were given free access to water and alcohol (15% v/v) until they reached a steady drinking baseline. They were then treated daily with each drug or drug combination for 20 days. Risperidone (0.2mg/kg) only transiently decreased alcohol drinking. However, 5.0mg/kg, and possibly 1.0mg/kg, desipramine added to 0.2mg/kg risperidone appeared to produce a more substantial and relatively sustained effect than risperidone alone. Data from this study provide leads toward the development of new treatments for patients with schizophrenia and alcoholism, and also for those with alcoholism alone.

  14. Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder.

    Science.gov (United States)

    Kozicky, Jan-Marie; Torres, Ivan J; Bond, David J; Lam, Raymond W; Yatham, Lakshmi N

    2012-03-01

    Although associations between antipsychotic use and neuropsychological impairment in bipolar I disorder have been observed, there is a lack of studies comparing the effects of specific agents used in this population. We compared performance between patients receiving maintenance treatment with mood stabilizer monotherapy (n=15), adjunctive risperidone (n=15) or quetiapine (n=17), and a group of demographically matched healthy controls (n=28) on tests of executive function (working memory, set shifting, and inhibition) and verbal learning. Despite having a similar clinical profile, patients being treated with risperidone showed significantly impaired working memory, set-shifting, and verbal learning (Pdisorder, preliminary results indicate that addition of risperidone to a mood stabilizer has a negative impact on executive function and verbal learning, an effect not shared with quetiapine.

  15. Enantioselective analysis of citalopram and escitalopram in postmortem blood together with genotyping for CYP2D6 and CYP2C19.

    Science.gov (United States)

    Carlsson, Björn; Holmgren, Anita; Ahlner, Johan; Bengtsson, Finn

    2009-03-01

    Citalopram is marketed as a racemate (50:50) mixture of the S(+)-enantiomer and R(-)-enantiomer and the active S(+)-enantiomer (escitalopram) that possess inhibitory effects. Citalopram was introduced in Sweden in 1992 and is the most frequently used antidepressant to date in Sweden. In 2002, escitalopram was introduced onto the Swedish market for treatment of depression and anxiety disorders. The main objective of this study was to investigate S(+)-citalopram [i.e., the racemic drug (citalopram) or the enantiomer (escitalopram)] present in forensic autopsy cases positive for the presence of citalopram in routine screening using a non-enantioselective bioanalytical method. Fifty out of the 270 samples found positive by gas chromatography-nitrogen-phosphorus detection were further analyzed using enantioselective high-performance liquid chromatography. The 50 cases were genotyped for CYP2D6 and CYP2C19, as these isoenzymes are implicated in the metabolism of citalopram and escitalopram. In samples positive for racemic citalopram using the screening method for forensic autopsy cases, up to 20% would have been misinterpreted in the absence of an enantioselective method. An enantioselective method is thus necessary for correct interpretation of autopsy cases, after the enantiomer has been introduced onto the market. The percentage of poor metabolizers was 6% for CYP2D6 and 8% for CYP2C19.

  16. Selective labeling of serotonin uptake sites in rat brain by (/sup 3/H)citalopram contrasted to labeling of multiple sites by (/sup 3/H)imipramine

    Energy Technology Data Exchange (ETDEWEB)

    D' Amato, R.J.; Largent, B.L.; Snowman, A.M.; Snyder, S.H.

    1987-07-01

    Citalopram is a potent and selective inhibitor of neuronal serotonin uptake. In rat brain membranes (/sup 3/H)citalopram demonstrates saturable and reversible binding with a KD of 0.8 nM and a maximal number of binding sites (Bmax) of 570 fmol/mg of protein. The drug specificity for (/sup 3/H)citalopram binding and synaptosomal serotonin uptake are closely correlated. Inhibition of (/sup 3/H)citalopram binding by both serotonin and imipramine is consistent with a competitive interaction in both equilibrium and kinetic analyses. The autoradiographic pattern of (/sup 3/H)citalopram binding sites closely resembles the distribution of serotonin. By contrast, detailed equilibrium-saturation analysis of (/sup 3/H)imipramine binding reveals two binding components, i.e., high affinity (KD = 9 nM, Bmax = 420 fmol/mg of protein) and low affinity (KD = 553 nM, Bmax = 8560 fmol/mg of protein) sites. Specific (/sup 3/H)imipramine binding, defined as the binding inhibited by 100 microM desipramine, is displaced only partially by serotonin. Various studies reveal that the serotonin-sensitive portion of binding corresponds to the high affinity sites of (/sup 3/H)imipramine binding whereas the serotonin-insensitive binding corresponds to the low affinity sites. Lesioning of serotonin neurons with p-chloroamphetamine causes a large decrease in (/sup 3/H)citalopram and serotonin-sensitive (/sup 3/H)imipramine binding with only a small effect on serotonin-insensitive (/sup 3/H)imipramine binding. The dissociation rate of (/sup 3/H)imipramine or (/sup 3/H)citalopram is not altered by citalopram, imipramine or serotonin up to concentrations of 10 microM. The regional distribution of serotonin sensitive (/sup 3/H)imipramine high affinity binding sites closely resembles that of (/sup 3/H)citalopram binding.

  17. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    Directory of Open Access Journals (Sweden)

    Amir Akhavan Rezayat

    2014-01-01

    Full Text Available Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients with acute episodes of mania were enrolled in this study, and they were randomly assigned into a risperidone group of 24 cases and an aripiprazole group of 26 cases. In group A, aripiprazole with a dose of 5-30 mg/day and in group B, risperidone with a dose of 2-8 mg/day was given to patients. The average dose of aripiprazole was 27 mg/day, and the average dose of risperidone was 6 mg/day. The effects of each drug for the treatment of acute mania were assessed on the 1 st day of admission and on days 2, 4, 6, 8 and at weeks 2, 4 and 6 after therapy using the young mania rating scale (YMRS and at the baseline and on weeks 3 and 6 after admission using the clinical global impression (CGI scale. Results: The mean age of the group of risperidone was 34 ± 8.6 years and in a group of aripiprazole it was 34 ± 9.1 years (P = 0.83. Comparison of YMRS scores over the period of 6 weeks revealed a statistically significant difference in both groups (P < 0.0001.There was also a statistically significant difference in YMRS scores between risperidone and aripiprazole at day 8 (P = 0.026 and weeks 2 (P = 0.035 and 4 (P = 0.042. There was also a statistically significant difference in CGI-Severity scale score at weeks 3 (P = 0.003 and 6 (P = 0.000 and in CGI-Improvement scale score at weeks 3 (P = 0.005 and 6 (P = 0.002. The most common side-effect observed in both groups was headache (0%15/4 in aripiprazole vs. %16/7 in risperidone Conclusion: Aripiprazole that is readily

  18. A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter

    DEFF Research Database (Denmark)

    Zhang, Peng; Jørgensen, Trine Nygaard; Løland, Claus Juul

    2013-01-01

    A novel fluorescent ligand was synthesized as a high-affinity, high specificity probe for visualizing the serotonin transporter (SERT). The rhodamine fluorophore was extended from an aniline substitution on the 5-position of the dihydroisobenzofuran ring of citalopram (2, 1-(3-(dimethylamino)prop...

  19. Partial purification of the 5-hydroxytryptophan-reuptake system from human blood platelets using a citalopram-derived affinity resin

    Energy Technology Data Exchange (ETDEWEB)

    Biessen, E.A.L; Horn, A.S.; Robillard, G.T. (Univ. of Groningen (Netherlands))

    1990-04-03

    This paper describes a procedure for the synthesis and application of a citalopram-derived affinity resin in purifying the 5HT-reuptake system from human blood platelets. A two-step scheme has been developed for partial purification, based on wheat germ agglutinin-lectin (WGA) affinity and citalopram affinity chromatographies. Upon solubilization of the carrier with 1% digitonin, a 50-70-fold increase in specific ({sup 3}H) imipramine binding activity with a 70% recovery could be accomplished through WGA-lectin chromatography. The WGA pool was then subjected to affinity chromatography on citalopram-agarose. At least 90% of the binding capacity adsorbed to the column. Specific elution using 10 {mu}M citalopram resulted in a 22% recovery of binding activity. A 10,000-fold overall purification was obtained by using this two-step procedure. Analysis of the fractions on SDS-PAGE after {sup 125}I labeling revealed specific elution of 78- and 55-kDa proteins concomitant with the appearance of ({sup 3}H) imipramine binding activity. The pharmacological profile of the partially purified reuptake system correlated well with that derived from the crude membrane-bound reuptake system, suggesting a copurification of the 5HT binding activity and ({sup 3}H)imipramine binding activity.

  20. Preliminary evidence that sub-chronic citalopram triggers the re-evaluation of value in intimate partnerships.

    Science.gov (United States)

    Bilderbeck, Amy C; Wakeley, Judi; Godlewska, Beata R; McGlone, Francis; Harris, Tirril; Cowen, Phillip J; Rogers, Robert D

    2014-09-01

    Depression frequently involves disrupted inter-personal relationships, while treatment with serotonergic anti-depressants can interfere with libido and sexual function. However, little is known about how serotonin activity influences appraisals of intimate partnerships. Learning more could help to specify how serotonergic mechanisms mediate social isolation in psychiatric illness. Forty-four healthy heterosexual adults, currently in romantic relationships, received 8 days treatment with the selective serotonin re-uptake inhibitor citalopram (N = 21; 10 male) or placebo (N = 23; 12 male). Participants viewed photographs of unknown, heterosexual couples and made a series of judgements about their relationships. Participants also indicated the importance of relationship features in their own close partnerships, and close partnerships generally. Citalopram reduced the rated quality of couples' physical relationships and the importance attributed to physical and intimate aspects of participants' own relationships. In contrast, citalopram also enhanced the evaluated worth of mutual trust in relationships. Amongst males, citalopram was associated with judgements of reduced turbulence and bickering in others' relationships, and increased male dominance. These data constitute preliminary evidence that enhancing serotonin activity modulates cognitions about sexual activity as part of a re-appraisal of sources of value within close intimate relationships, enhancing the judged importance of longer-term benefits of trust and shared experiences.

  1. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.

    Science.gov (United States)

    Clayton, Anita H; Gommoll, Carl; Chen, Dalei; Nunez, Rene; Mathews, Maju

    2015-07-01

    Sexual dysfunction commonly occurs with major depressive disorder (MDD). Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist antidepressant approved for the treatment of MDD in adults, was evaluated to determine its effects on sexual function. The primary study was a double-blind, randomized, controlled trial comparing vilazodone 20 and 40 mg/day with placebo; citalopram 40 mg/day was an active control (NCT01473381; http://www.clinicaltrials.gov). Post-hoc analyses evaluated change from baseline to week 10 on the Changes in Sexual Functioning Questionnaire (CSFQ); no inferential statistics were performed. CSFQ scores increased for women [1.2 (citalopram) to 3.0 (vilazodone 40 mg)] and men [1.2 (vilazodone 40 mg) to 3.5 (placebo)] in all treatment groups. Greater changes in CSFQ scores were seen in responders [women: 2.33 (citalopram) to 5.06 (vilazodone 40 mg); men: 2.26 (vilazodone 40 mg) to 4.35 (placebo)] versus nonresponders. CSFQ change from baseline was small for patients with normal baseline sexual function; in patients with baseline sexual dysfunction, CSFQ scores improved across groups [women: 2.35 (citalopram) to 4.52 (vilazodone 40 mg); men 2.83 (vilazodone 40 mg) to 6.43 (placebo)]. Across treatment groups, baseline sexual function improved in women and men, MDD responders, and patients with baseline sexual dysfunction.

  2. Quantification of citalopram or escitalopram and their demethylated metabolites in neonatal hair samples by liquid chromatography-tandem mass spectrometry.

    Science.gov (United States)

    Frison, Giampietro; Favretto, Donata; Vogliardi, Susanna; Terranova, Claudio; Ferrara, Santo Davide

    2008-08-01

    Citalopram and escitalopram are highly selective serotonin reuptake inhibitors widely used in the treatment of depression. They exhibit adverse drug reactions and side effects, however, and the development of specific methods for their determination is of great interest in clinical and forensic toxicology. A liquid chromatography-tandem mass spectrometry method has been developed and validated for the assay of citalopram, escitalopram, and their demethylated metabolites in 10-mg hair samples. The analytes were extracted by incubation in methanol and liquid/liquid extraction with diethyl ether/dichloromethane. Gradient elution on a narrow bore C18 column was realized using clomipramine-d3 as an internal standard. Positive ion electrospray ionization and tandem mass spectrometry determination by collision-induced dissociation were performed in an ion trap mass spectrometer. The method exhibited a linear range of 25 to 2000 pg/mg, a quantification limit of 25 pg/mg for all analytes, relative standard deviations in the range of 12.10 to 9.80 (intraassay), and 13.80 to 11.78 (interassay), and accuracies (as percent recovery of the spiked standards) in the range of 90% to 110%; it was applied to the determination of citalopram and escitalopram and their metabolites in hair samples of two newborns to document their in utero exposure to the drugs. The method proved suitable for neonatal hair analysis of citalopram or escitalopram and was applied to two real cases of gestational exposure.

  3. The Effects of the Adenosine Receptor Antagonists on the Reverse of Cardiovascular Toxic Effects Induced by Citalopram In-Vivo Rat Model of Poisoning

    Science.gov (United States)

    Büyükdeligöz, Müjgan; Hocaoğlu, Nil; Oransay, Kubilay; Tunçok, Yeşim; Kalkan, Şule

    2015-01-01

    Background: Citalopram is a selective serotonin reuptake inhibitor that requires routine cardiac monitoring to prevent a toxic dose. Prolongation of the QT interval has been observed in acute citalopram poisoning. Our previous experimental study showed that citalopram may be lead to QT prolongation by stimulating adenosine A1 receptors without affecting the release of adenosine. Aims: We examined the effects of adenosine receptor antagonists in reversing the cardiovascular toxic effects induced by citalopram in rats. Study Design: Animal experimentation. Methods: Rats were divided into three groups randomly (n=7 for each group). Sodium cromoglycate (20 mg/kg) was administered to all rats to inhibit adenosine A3 receptor mast cell activation. Citalopram toxicity was achieved by citalopram infusion (4 mg/kg/min) for 20 minutes. After citalopram infusion, in the control group (Group 1), rats were given an infusion of dextrose solution for 60 minutes. In treatment groups, the selective adenosine A1 antagonist DPCPX (Group 2, 8-cyclopentyl-1,3-dipropylxanthine, 20 μg/kg/min) or the selective A2a antagonist CSC (Group 3, 8-(3-chlorostyryl)caffeine, 24 μg/kg/min) was infused for 60 minutes. Mean arterial pressure (MAP), heart rate (HR), QRS duration and QT interval measurements were followed during the experiment period. Statistical analysis was performed by ANOVA followed by Tukey’s multiple comparison tests. Results: Citalopram infusion reduced MAP and HR and prolonged the QT interval. It did not cause any significant difference in QRS duration in any group. When compared to the control group, DPCPX after citalopram infusion shortened the prolongation of the QT interval after 40, 50 and 60 minutes (p<0.01). DPCPX infusion shortened the prolongation of the QT interval at 60 minutes compared with the CSC group (p<0.05). CSC infusion shortened the prolongation of the QT at 60 minutes compared with the control group (p<0.05). Conclusion: DPCPX improved QT interval

  4. Ionophore-Based Potentiometric Sensors for the Flow-Injection Determination of Promethazine Hydrochloride in Pharmaceutical Formulations and Human Urine

    Directory of Open Access Journals (Sweden)

    Suad Mustafa Al-Araji

    2011-01-01

    Full Text Available Plasticised poly(vinyl chloride-based membranes containing the ionophores (α-, β- and γ-cyclodextrins (CD, dibenzo-18-crown-6 (DB18C6 and dibenzo-30-crown-10 (DB30C10 were evaluated for their potentiometric response towards promethazine (PM in a flow injection analysis (FIA set-up. Good responses were obtained when β- and γ-CDs, and DB30C10 were used. The performance characteristics were further improved when tetrakis(4-chlorophenyl borate (KTPB was added to the membrane. The sensor based on β-CD, bis(2-ethylhexyl adipate (BEHA and KTPB exhibited the best performance among the eighteen sensor compositions that were tested. The response was linear from 1 x 10−5 to 1 x 10−2 M, slope was 61.3 mV decade−1, the pH independent region ranged from 4.5 to 7.0, a limit of detection of 5.3 x 10−6 M was possible and a lifetime of more than a month was observed when used in the FIA system. Other plasticisers such as dioctyl phenylphosphonate and tributyl phosphate do not show significant improvements in the quality of the sensors. The promising sensors were further tested for the effects of foreign ions (Li+, Na+, K+, Mg2+, Ca2+, Co2+, Cu2+, Cr3+, Fe3+, glucose, fructose. FIA conditions (e.g., effects of flow rate, injection volume, pH of the carrier stream were also studied when the best sensor was used (based on β-CD. The sensor was applied to the determination of PM in four pharmaceutical preparations and human urine that were spiked with different levels of PM. Good agreement between the sensor and the manufacturer’s claimed values (for pharmaceutical preparations was obtained, while mean recoveries of 98.6% were obtained for spiked urine samples. The molecular recognition features of the sensors as revealed by molecular modelling were rationalised by the nature of the interactions and complexation energies between the host and guest molecules.

  5. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure

    Directory of Open Access Journals (Sweden)

    Sarah M. Bahr

    2015-11-01

    Full Text Available Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.

  6. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.

    Science.gov (United States)

    Lancelin, Frédérique; Bourcier, Elsa; Le Masson, Valérie; Lemeille, Yolande; Brovedani, Sophie; Paubel, Pascal; Piketty, Marie-Liesse

    2010-12-01

    Administration of cyamemazine, an antipsychotic drug with anxiolytic properties, together with other antipsychotic agents is common in patients with schizophrenia. This retrospective study investigated the effects of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in 47 patients treated with 1 to 12 mg/day of risperidone. Of these 47 patients, 24 were receiving cyamemazine comedication ("cyamemazine" group) and 23 patients were treated with risperidone alone ("control" group). Plasma concentrations were measured using a high-performance liquid chromatographic method with photodiode-array ultraviolet detection. The median plasma concentration of risperidone was significantly higher in the cyamemazine group (31.5 ng/mL) than in the control group (5.0 ng/mL), whereas the 9-hydroxyrisperidone median concentration was significantly lower in the cyamemazine group (16.5 ng/mL versus 39.0 ng/mL in the control group). However, the sum of risperidone plus 9-hydroxyrisperidone (active moiety) plasma concentration was not significantly affected by cyamemazine comedication. A combination with cyamemazine resulted in an inverted metabolic ratio (risperidone/9-hydroxyrisperidone). These findings suggest that cyamemazine inhibits the 9-hydroxylation of risperidone and is probably an inhibitor of cytochrome P450 2D6 as are many other phenothiazine drugs.

  7. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.

    Science.gov (United States)

    Ghanizadeh, Ahmad; Haghighi, Alireza

    2014-10-01

    There are some uncontrolled studies about the efficacy and safety of both aripiprazole and risperidone for treating tic disorder. Moreover, the efficacy of these medications has never been compared. This is the first double blind randomized clinical trial comparing the safety and efficacy of aripiprazole and risperidone for treating patients with tic disorder. Sixty children and adolescents with tic disorder were randomly allocated into one of the two groups to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was the score of Yale Global Tic Severity Scale. In addition, health related quality of life and adverse events were assessed. Both aripiprazole and risperidone decreased the Yale Global Tic Severity Scale score during this trial. Moreover, both medications increased the health related quality of life score. Both aripiprazole and risperidone were tolerated well. Aripiprazole [3.22 (1.9) mg/day] decreased tic score as much as risperidone [0.6 (0.2) mg/day]. Their adverse effects and their effects on health related quality of life were comparable. However, risperidone increased the patients' social functioning more than aripiprazole in short term.

  8. 奥美拉唑对利培酮和9-羟利培酮血药浓度影响的研究%Influence study of omeprazole on blood drug concentration of risperidone and 9-hydroxy risperidone

    Institute of Scientific and Technical Information of China (English)

    巫艳芬; 王玉梅; 陈宝燕

    2014-01-01

    目的:观察奥美拉唑对利培酮和9-羟利培酮血药浓度的影响。方法20例精神分裂症合并胃溃疡患者,给予利培酮联合奥美拉唑治疗1周。检测奥美拉唑治疗后利培酮以及9-羟利培酮血药浓度。结果未使用奥美拉唑前,利培酮与9-羟利培酮血药浓度为(29.25±7.82)μg/L;使用奥美拉唑后,利培酮与9-羟利培酮血药浓度为(37.15±11.68)μg/L,差异有统计学意义(P<0.05)。结论奥美拉唑能够提高利培酮与9-羟利培酮血药浓度,因此,临床上治疗精神分裂症合并胃溃疡患者,给予奥美拉唑联合利培酮治疗时,应该监测患者利培酮与9-羟利培酮血药浓度,及时对药物剂量进行调整。%Objective To observe the influence of omeprazole on blood drug concentration of risperidone and 9-hydroxy risperidone. Methods A total of 20 schizophrenia with gastric ulcer cases were treated by risperidone combined with omeprazole for 1 week. Detections of blood drug concentration of risperidone and 9-hydroxy risperidone were made after the omeprazole treatment. Results Before application of omeprazole, blood drug concentration of risperidone and 9-hydroxy risperidone was (29.25±7.82)μg/L. After using omeprazole, blood drug concentration of risperidone and 9-hydroxy risperidone was (37.15±11.68) μg/L. The difference had statistical significance (P<0.05). Conclusion Omeprazole can increase the blood drug concentration of risperidone and 9-hydroxy risperidone, which should be monitored in the risperidone combined with omeprazole treatment of schizophrenia with gastric ulcer, and timely adjustment of drug dose is necessary.

  9. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria

    Directory of Open Access Journals (Sweden)

    Afshin FAYYAZI

    2014-12-01

    Full Text Available How to Cite This Article: Fayyazi A, Salari E, Khajeh A, Ghajarpour A. A Comparison of Risperidone and Buspirone for Treatment ofBehavior Disorders in Children with Phenylketonuria. Iran J Child Neurol. 2014 Autumn; 8(4:33-38.AbstractObjectiveMany patients with late-diagnosed phenylketonuria (PKU suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.Materials & MethodsIn this crossover clinical trial study, patients with severe behavior disorders after medical examination were randomly divided into two groups of two 8-week crossover treatments with risperidone or buspirone. Patient behavioral disorders before and after treatment by each drug was rated by parents on the Nisonger Child Behavior Rating Form (NCBRF, and after treatment by each drug, were assessed by a physician through clinical global impression (CGI.ResultsThirteen patients were able to complete the therapy period with these two medications.The most common psychiatric diagnoses were intellectual disability accompanied by pervasive developmental disorder NOS, and intellectual disability accompanied by autistic disorder. Risperidone was significantly effective in reducing the NCBRF subscales of hyperactivity disruptive/ stereotypic, and conduct problems. Treatment by buspirone only significantly decreased the severity of hyperactivity, but other behavior aspects showed no significant differences. Assessment of the severity of behavior disorder after treatment by risperidone and buspirone showed significant differences in reducing hyperactivity and masochistic/stereotype.ConclusionAlthough buspirone is effective in controlling hyperactivity in patients with PKU, it has no preference over risperidone. Therefore, it is recommended as an alternative to risperidone.ReferencesSmith I, Nowles JK. Behaviour in early treated phenylketonuria: a systematic review. Eur J Pediatr 2000;159:89-93.Targum SD

  10. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.

    Science.gov (United States)

    An, Taekun; Choi, Juhyuen; Kim, Aram; Lee, Jin Ho; Nam, Yoonjin; Park, Junsung; Sun, Bo kyung; Suh, Hearan; Kim, Cherng-ju; Hwang, Sung-Joo

    2016-04-30

    Risperidone-loaded poly (D,L-lactide-co-glycolide) (PLGA) microspheres were prepared with a suspension-evaporation process with an aqueous suspension containing an in situ-formed aluminum hydroxide inorganic gel (SEP-AL process) and evaluated for encapsulation efficiency, particle size, surface morphology, glass transition temperature, in vitro drug release profile, and in vivo behavior. The SEP-AL microspheres were compared with conventional oil-in-water (O/W) emulsion solvent evaporation method using polyvinylalcohol (PVA) as an emulsifier (CP-PVA process). The microspheres were spherical in shape. DSC measurements showed that risperidone crystallinity was greatly reduced due to the homogeneous distribution of risperidone in PLGA microspheres. In vitro drug release profile from the microspheres showed a sigmoidal pattern of negligible initial burst up to 24h and minimal release (time-lag) for 7 days. After the lag phase, slow release took a place up to 25 days and then rapid release occurred sharply for 1 week. In vivo rat pharmacokinetic profile from the microspheres showed very low blood concentration level at the initial phase (up to 24h) followed by the latent phase up to 21 days. At the 3rd week, main phase started and the blood concentration of the drug increased up to the 5th week, and then gradually decreased. The risperidone-loaded PLGA microspheres produced by SEP-AL process showed excellent controlled release characteristics for the effective treatment of schizophrenia patients.

  11. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.

    Science.gov (United States)

    Liu, Pang-Yen; Wu, Pei-Chuan; Chen, Chun-Yen; Chen, Yi-Chyan

    2011-01-01

    We present the case of a woman with paranoid schizophrenia who was receiving oral risperidone. She developed neuroleptic malignant syndrome (NMS) following the addition of depot fluphenazine for the treatment of refractory delusions. NMS subsided and psychotic features were controlled after both antipsychotics were discontinued and the patient was treated instead with olanzapine.

  12. Paediatric European Risperidone Studies (PERS) : context, rationale, objectives, strategy, and challenges

    NARCIS (Netherlands)

    Glennon, Jeffrey; Purper-Ouakil, Diane; Bakker, Mireille; Zuddas, Alessandro; Hoekstra, Pieter; Schulze, Ulrike; Castro-Fornieles, Josefina; Santosh, Paramala J.; Arango, Celso; Koelch, Michael; Coghill, David; Flamarique, Itziar; Penzol, Maria J.; Wan, Mandy; Murray, Macey; Wong, Ian C. K.; Danckaerts, Marina; Bonnot, Olivier; Falissard, Bruno; Masi, Gabriele; Fegart, Joerg M.; Vicari, Stefano; Carucci, Sara; Dittmann, Ralf W.; Buitelaar, Jan K.

    2014-01-01

    In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and

  13. Spontaneous seizures after ECT in a patient medicated with bupropion, sertraline and risperidone

    Directory of Open Access Journals (Sweden)

    Orlando von Doellinger

    Full Text Available Abstract Objective: To report a case of post-electroconvulsive therapy spontaneous seizures in a patient medicated with sertraline, bupropion and risperidone. Case description: A 53-year-old woman with recurrent major depression was admitted to our psychiatry department for a major depressive episode of 6 weeks' duration, with psychotic symptoms. She was already on 200 mg/day of sertraline and 2 mg/day of risperidone. After 8 weeks on 200 mg/day of sertraline, 4 mg/day of risperidone and slow release bupropion (titrated to 300 mg/day, with no objective improvements, the decision was taken to initiate a course of 8-10 electroconvulsive therapy (ECT sessions. Two days after the first treatment, three generalized tonic-clonic seizures occurred within 6 hours. Phenytoin and sodium valproate were added to the patient's daily medication and no further spontaneous seizures were observed. After neurologic assessment and discussion of the case, phenytoin and bupropion were withdrawn at once (two days after the spontaneous seizures and the decision was taken to resume the ECT treatment. No further spontaneous seizures occurred and, at discharge, the patient exhibited significant improvements and was free from major depressive symptoms. Comments: This report illustrates a case of post-ECT spontaneous seizures that might have been due to a specific pharmacological etiological pathway, namely, bupropion's proconvulsive properties, although both sertraline and risperidone also lower the convulsive threshold.

  14. Switching to quetiapine for risperidone-induced amenorrhea: Report of two cases

    Directory of Open Access Journals (Sweden)

    P K Pardal

    2010-01-01

    Full Text Available Almost all the antipsychotics can cause hyperprolactinemia-related side-effects like amenorrhea. Quetiapine has been reported to have minimal propensity to cause hyperprolactinemia. We report here two cases of risperidone-induced amenorrhea, who resumed their normal cycle on switching over the medication to quetiapine.

  15. Stability Indicating HPLC Determination of Risperidone in Bulk Drug and Pharmaceutical Formulations

    Directory of Open Access Journals (Sweden)

    Zarna R. Dedania

    2011-01-01

    Full Text Available The objective of the current study was to develop a validated stability-indicating assay method (SIAM for risperidone after subjecting it to forced decomposition under hydrolysis, oxidation, photolysis, and thermal stress conditions. The liquid chromatographic separation was achieved isocratically on a symmetry C18 column (5 μm size, 250 mm × 4.6 mm i.d. using a mobile phase containing methanol: acetonitrile (80 : 20, v/v at a flow rate of 1 mL/min and UV detection at 280 nm. Retention time of risperidone was found to be 3.35±0.01. The method was linear over the concentration range of 10–60 μg/mL(2=0.998 with a limit of detection and quantitation of 1.79 and 5.44 μg/mL, respectively. The method has the requisite accuracy, specificity, sensitivity, and precision to assay risperidone in bulk form and pharmaceutical dosage forms. Degradation products resulting from the stress studies did not interfere with the detection of Risperidone, and the assay is thus stability indicating.

  16. Long-term effects of risperidone in children with autism spectrum disorders : A placebo discontinuation study

    NARCIS (Netherlands)

    Troost, PW; Lahuis, BE; Steenhuis, MP; Ketelaars, CEJ; Buitelaar, JK; Van Engeland, H; Scahill, L; Minderaa, RB; Hoekstra, PJ

    2005-01-01

    Objective: The short-term benefit of risperidone in ameliorating severe disruptive behavior in pediatric patients with autism spectrum disorders is well established; however, only one placebo-controlled, long-term study of efficacy is available. Method: Thirty-six children with an autism spectrum di

  17. Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder

    NARCIS (Netherlands)

    Dinnissen, Mariken; Dietrich, Andrea; van den Hoofdakker, Barbara J.; Hoekstra, Pieter J.

    2015-01-01

    Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is often accompanied by psychiatric comorbidity. Although there is no medication currently available to treat the core symptoms of ASD, risperidone was the first drug to be approved for use in ASD and is still the bes

  18. Antipsychotic-induced extrapyramidal syndromes - Risperidone compared with low- and high-potency conventional antipsychotic drugs

    NARCIS (Netherlands)

    Schillevoort, [No Value; de Boer, A; Herings, RMC; Roos, RAC; Jansen, PAF; Leufkens, HGM

    2001-01-01

    Aim: To compare the risk of extrapyramidal syndromes (EPS) between patients using risperidone and those using low-potency conventional antipsychotic drugs (APDs) in outpatient clinical practice, as measured by the use of anticholinergic medication. We tried to replicate results from previous clinica

  19. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review

    DEFF Research Database (Denmark)

    Ennis, Zandra Nymand; Damkier, Per

    2015-01-01

    To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first-trimester expos......To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first......-trimester exposure and pregnancy outcome with respect to congenital malformations. Cumulated data for olanzapine were 1090 first-trimester-exposed pregnancies with 38 malformations resulting in a malformation rate of 3.5%. The corresponding numbers for quetiapine, risperidone and aripiprazole were 443/16 (3.6%), 432....../22 (5.1%) and 100/5 (5.0%), respectively. Relative risk estimates and 95% confidence intervals were 1.0 (0.7-1.4) (olanzapine), 1.0 (0.6-1.7) (quetiapine), 1.5 (0.9-2.2) (risperidone) and 1.4 (0.5-3.1) (aripiprazole). First-trimester exposure to olanzapine is not associated with an increased risk...

  20. Risperidone treatment for ADHD in children and adolescents with bipolar disorder

    Directory of Open Access Journals (Sweden)

    Joseph Biederman

    2008-03-01

    Full Text Available Joseph Biederman, Paul Hammerness, Robert Doyle, Gagan Joshi, Megan Aleardi, Eric MickPediatric Psychopharmacology Research Department, Massachusetts General Hospital, Boston, MA, USAObjective: Children and adolescents with bipolar disorder are also at high risk of having comorbid attention-deficit hyperactivity disorder (ADHD. The objective of this study was to estimate improvement in ADHD symptoms in children with bipolar disorder.Methods: This was an open-label, study of risperidone monotherapy for the treatment of pediatric bipolar disorder. Thirty-one children and adolescents 4–15 years of age (7.2 ± 2.8 years of both sexes (71%, N = 22 male with pediatric bipolar disorder (YMRS score = 32.9 ± 8.8 and ADHD (ADHD-RS score = 37.9 ± 8.9 were included in these analyses.Results: Improvement in ADHD symptoms was contingent on improvement in manic symptoms. Although both hyperactive/impulsive (−7.5 ± 5.5.6, p < 0.05 and inattentive (−6.8 ± 5.0, p < 0.05 ADHD symptoms were significantly improved with risperidone, improvement was modest, and only 29% of subjects (N = 6 showed a 30% reduction in ADHD rating scale scores and had a CGI-I ≤ 2.Conclusions: These results suggest that that treatment with risperidone is associated with tangible but generally modest improvement of symptoms of ADHD in children with bipolar disorder.Keywords: ADHD, bipolar disorder, children, risperidone

  1. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.

    NARCIS (Netherlands)

    Troost, P.W.; Althaus, M.; Lahuis, B.E.; Buitelaar, J.K.; Minderaa, R.B.; Hoekstra, P.J.

    2006-01-01

    OBJECTIVE: Little is known about the neuropsychological effects of risperidone in children with pervasive developmental disorders. METHOD: Twenty-four children (aged 5-17 years) with pervasive developmental disorders and co-morbid disruptive behavior who responded favorably to open-label treatment w

  2. Dietary Status and Impact of Risperidone on Nutritional Balance in Children with Autism: A Pilot Study

    Science.gov (United States)

    Lindsay, Ronald L.; Arnold, L. Eugene; Aman, Michael G.; Vitiello, Benedetto; Posey, David J.; McDougle, Christopher J.; Scahill, Lawrence; Pachler, Maryellen; McCracken, James T.; Tierney, Elaine; Bozzolo, Dawn

    2006-01-01

    Background: Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain. Method: Using a quantitative Food Frequency Questionnaire (FFQ), we prospectively examined the nutritional intake of 20 children with autism participating in a randomised…

  3. Tic Reduction with Risperidone Versus Pimozide in a Randomized, Double-Blind, Crossover Trial

    Science.gov (United States)

    Gilbert, Donald L.; Batterson, J. Robert; Sethuraman, Gopalan; Sallee, Floyd R.

    2004-01-01

    Objective: To compare the tic suppression, electrocardiogram (ECG) changes, weight gain, and side effect profiles of pimozide versus risperidone in children and adolescents with tic disorders. Method: This was a randomized, double-blind, crossover (evaluable patient analysis) study. Nineteen children aged 7 to 17 years with Tourette's or chronic…

  4. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.

    Science.gov (United States)

    El-Sayed El-Sisi, Alaa; Sokkar, Samia Salem; El-Sayed El-Sayad, Magda; Sayed Ramadan, Ehab; Osman, Enass Yossef

    2016-08-01

    The implications of oxidative stress and neuro-inflammation in the pathogenesis of schizophrenia have been elucidated. Despite their effectiveness against positive symptoms of schizophrenia, antipsychotics have limited effectiveness against negative and cognitive symptoms and are associated with remarkable adverse effects. The use of celecoxib or omega-3 in schizophrenia may have beneficial effects. This study aimed to evaluate the possible efficacies of celecoxib, omega-3 or the combination of celecoxib+risperidone and omega-3+ risperidone compared to risperidone on the behavior and brain biochemistry in rats. In the present study, an amphetamine-induced model of schizophrenia in adult male rats was used to evaluate the effects of celecoxib, omega-3, celecoxib+risperidone and omega-3+ risperidone on the behavior of animals and on brain lipid peroxidation or tumor necrosis factor-alpha. In the water maze task, celecoxib, omega-3, celecoxib+risperidone, omega-3+ risperidone significantly decreased the latency time compared to amphetamine-treated group. Celecoxib, omega-3, celecoxib+risperidone, omega-3+risperidone also significantly reversed the decreased spontaneous alternation induced by amphetamine in the Y-maze task. In the social interaction task, groups treated with celecoxib, omega-3, celecoxib+risperidone, omega-3+ risperidone spent less time to recognize foreign animals than animals in the amphetamine-treated group. Increased brain MDA and TNF-α levels due to amphetamine were significantly reduced in groups treated with celecoxib+risperidone or omega-3+ risperidone. The present findings showed that celecoxib or omega-3 can attenuate amphetamine- induced behavioral impairment and these effects may be associated with their ability to decrease lipid peroxidation and cytokine release. Celecoxib or omega-3 may be promising candidates as adjuvant therapy for schizophrenia.

  5. Enantioselective analysis of citalopram and demethylcitalopram in human whole blood by chiral LC-MS/MS and application in forensic cases

    DEFF Research Database (Denmark)

    Johansen, Sys Stybe

    2017-01-01

    , a chiral liquid chromatography-tandem mass spectrometry (LC-MS/MS) method is developed for the measurement of citalopram and demethylcitalopram enantiomers in whole blood and is applied to forensic cases. Whole blood samples (0.10 g) were extracted with butyl acetate after adjusting the pH with 2 M Na...... to authentic blood samples from forensic investigations demonstrating that escitalopram was less frequent than citalopram among all forensic cases....

  6. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.

    Science.gov (United States)

    Kato, Takahiro; Monji, Akira; Hashioka, Sadayuki; Kanba, Shigenobu

    2007-05-01

    Microglia has recently been regarded to be a mediator of neuroinflammation via the release of proinflammatory cytokines, nitric oxide (NO) and reactive oxygen species (ROS) in the central nervous system (CNS). Microglia has thus been reported to play an important role in the pathology of neurodegenerative disease, such as Alzheimer's disease (AD) and Parkinson's disease (PD). The pathological mechanisms of schizophrenia remain unclear while some recent neuroimaging studies suggest even schizophrenia may be a kind of neurodegenerative disease. Risperidone has been reported to decrease the reduction of MRI volume during the clinical course of schizophrenia. Many recent studies have demonstrated that immunological mechanisms via such as interferon (IFN)-gamma and cytokines might be relevant to the pathophysiology of schizophrenia. In the present study, we thus investigated the effects of risperidone on the generation of nitric oxide, inducible NO synthase (iNOS) expression and inflammatory cytokines: interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha by IFN-gamma-activated microglia by using Griess assay, Western blotting and ELISA, respectively. In comparison with haloperidol, risperidone significantly inhibited the production of NO and proinflammatory cytokines by activated microglia. The iNOS levels of risperidone-treated cells were much lower than those of the haloperidol-treated cells. Antipsychotics, especially risperidone may have an anti-inflammatory effect via the inhibition of microglial activation, which is not only directly toxic to neurons but also has an inhibitory effect on neurogenesis and oligodendrogenesis, both of which have been reported to play a crucial role in the pathology of schizophrenia.

  7. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo

    DEFF Research Database (Denmark)

    Stein, Dan J; Andersen, Elisabeth Anne Wreford; Overo, Kerstin Fredricson

    2007-01-01

    OBJECTIVE: There is increasing evidence that the symptoms of obsessive-compulsive disorder lie on discrete dimensions. Relatively little work has, however, explored the relationship between such factors and response to pharmacotherapy. METHOD: Data from a multi-site randomized placebo......-controlled study of citalopram in obsessive-compulsive disorder were analyzed. Factor analysis of individual items and symptom categories of the Yale-Brown Obsessive-Compulsive Scale Checklist were undertaken, and the impact of symptom dimensions on treatment outcomes was analysed. RESULTS: Factor analysis of Yale......-Brown Obsessive-Compulsive Scale Checklist individual items yielded 5 factors (contamination/cleaning, harm/checking, aggressive/sexual/religious, hoarding/symmetry, and somatic/hypochondriacal). Hoarding/symmetry was associated with male gender, longer duration of obsessive-compulsive disorder and early onset...

  8. Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.

    Science.gov (United States)

    Tosto, Giuseppe; Talarico, Giuseppina; Lenzi, Gian Luigi; Bruno, Giuseppe

    2008-09-01

    Hypersexuality in Alzheimer's disease (AD) has been rarely investigated. Hypersexual behaviours should be classified as a sexual obsession and included in the "obsessive-compulsive disorder-like" spectrum. Hypersexuality has no proven treatment, although reports have described reductions of this behaviour using antiandrogen treatment, H2-receptor antagonists and antipsychotic drugs. Serotonin reuptake blockers seem to be effective in the treatment of sexual obsessions or compulsions and less on paraphilic disturbances. We present the case of a 54-year-old male patient with Alzheimer's disease with compulsive sexual behaviour as reported by his wife. A 18-FDG PET scan evidenced prevalent hypometabolism of the right hemisphere, congruent with neuropsychological evaluation. Donepezil, 10 mg per day, produced cognitive improvement but no effects on sexual behaviour. Therapy with SSRI was subsequently started (citalopram): after 60 days, the patient showed improvement in both the compulsive pursuit of sex acts and the level of frustration when refused.

  9. Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants

    Directory of Open Access Journals (Sweden)

    Alkhafaji Ali A

    2012-11-01

    Full Text Available Abstract Background "Evergreening" refers to the numerous strategies whereby owners of pharmaceutical products use patent laws and minor drug modifications to extend their monopoly privileges on the drug. We aimed to evaluate the impact of evergreening through the case study of the antidepressant citalopram and its chiral switch form escitalopram by evaluating treatment efficacy and acceptability for patients, as well as health insurance costs for society. Methods To assess efficacy and acceptability, we performed meta-analyses for efficacy and acceptability. We compared direct evidence (meta-analysis of results of head-to-head trials and indirect evidence (adjusted indirect comparison of results of placebo-controlled trials. To assess health insurance costs, we analyzed individual reimbursement data from a representative sample of the French National Health Insurance Inter-regime Information System (SNIIR-AM from 2003 to 2010, which allowed for projecting these results to the whole SNIIR-AM population (53 million people. Results In the meta-analysis of seven head-to-head trials (2,174 patients, efficacy was significantly better for escitalopram than citalopram (combined odds ratio (OR 1.60 (95% confidence interval 1.05 to 2.46. However, for the adjusted indirect comparison of 10 citalopram and 12 escitalopram placebo-controlled trials, 2,984 and 3,777 patients respectively, efficacy was similar for the two drug forms (combined indirect OR 1.03 (0.82 to 1.30. Because of the discrepancy, we could not combine direct and indirect data (test of inconsistency, P = 0.07. A similar discrepancy was found for treatment acceptability. The overall reimbursement cost burden for the citalopram, escitalopram and its generic forms was 120.6 million Euros in 2010, with 96.8 million Euros for escitalopram. Conclusions The clinical benefit of escitalopram versus citalopram remains uncertain. In our case of evergreening, escitalopram represented a substantially

  10. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial

    DEFF Research Database (Denmark)

    Lublin, Henrik; Haug, Hans-Joachim; Koponen, Hannu

    2009-01-01

    The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic tr...

  11. Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults

    DEFF Research Database (Denmark)

    Pasternak, Björn; Svanström, Henrik; Ranthe, Mattis F

    2014-01-01

    risperidone (n = 14,134). The primary outcome was any major cardiovascular event (composite of cardiovascular mortality, acute coronary syndrome, or ischemic stroke) within 1 year following treatment initiation. Cox regression was used to estimate hazard ratios (HRs) while on current antipsychotic monotherapy...... in the outpatient setting, adjusting for an outcome-specific disease risk score. RESULTS: The crude rate of any major cardiovascular event was 5.3 per 1,000 person-years among olanzapine users, 3.4 in quetiapine users, and 5.2 in risperidone users. Compared with risperidone, the risk of any major cardiovascular.......9 to 2.0) events for quetiapine. CONCLUSIONS: Among young and middle-aged outpatients, the risk of acute major cardiovascular events was similar with use of olanzapine, quetiapine, and risperidone. Although moderate relative differences cannot be ruled out, any differences are small in absolute terms....

  12. A case of resistant schizophrenia responding at a higher than recommended dose of risperidone without significant side effects

    Directory of Open Access Journals (Sweden)

    Anirban Ray

    2013-01-01

    Full Text Available A patient, diagnosed with schizophrenia, non-responsive to two atypical antipsychotics and partially responsive to the third (risperidone in therapeutic dose, ultimately showed complete response without any unacceptable side-effect in a dose (20mg that was untried previously. This case makes an important observation that high dose of risperidone can be tried in a patient with good results if his clinical condition permits.

  13. Fabrication a new modified electrochemical sensor based on Au-Pd bimetallic nanoparticle decorated graphene for citalopram determination.

    Science.gov (United States)

    Daneshvar, Leili; Rounaghi, Gholam Hossein; Es'haghi, Zarrin; Chamsaz, Mahmoud; Tarahomi, Somayeh

    2016-12-01

    This paper proposes a simple approach for sensing of citalopram (CTL) using gold-palladium bimetallic nanoparticles (Au-PdNPs) decorated graphene modified gold electrode. Au-PdNPs were deposited at the surface of a graphene modified gold electrode with simple electrodeposition method. The morphology and the electrochemical properties of the modified electrode were characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), atomic force microscopy (AFM), energy dispersion spectroscopy (EDS), electrochemical impedance spectroscopy (EIS), cyclic voltammetry (CV) and square wave voltammetry (SWV). The novel sensor exhibited an excellent catalytic activity towards the oxidation of CTL. The oxidation peak current of CTL, was linear in the range of 0.5-50μM with a detection limit 0.049μM with respect to concentration of citalopram. The proposed sensor was successfully applied for determination of CTL tablet and human plasma samples with satisfactory results.

  14. Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test.

    Science.gov (United States)

    Andreasen, Jesper T; Nielsen, Elsebet Ø; Christensen, Jeppe K; Olsen, Gunnar M; Peters, Dan; Mirza, Naheed R; Redrobe, John P

    2011-10-01

    Nicotine increases serotonergic and noradrenergic neuronal activity and facilitates serotonin and noradrenaline release. Accordingly, nicotine enhances antidepressant-like actions of reuptake inhibitors selective for serotonin or noradrenaline in the mouse forced swim test and the mouse tail suspension test. Both high-affinity α4β2 and low-affinity α7 nicotinic acetylcholine receptor subtypes are implicated in nicotine-mediated release of serotonin and noradrenaline. The present study therefore investigated whether selective agonism of α4β2 or α7 nicotinic acetylcholine receptors would affect the mouse forced swim test activity of two antidepressants with distinct mechanisms of action, namely the selective serotonin reuptake inhibitor citalopram and the noradrenaline reuptake inhibitor reboxetine. Subthreshold and threshold doses of citalopram (3 and 10 mg/kg) or reboxetine (10 and 20 mg/kg) were tested alone and in combination with the novel α4β2-selective partial nicotinic acetylcholine receptor agonist, NS3956 (0.3 and 1.0 mg/kg) or the α7-selective nicotinic acetylcholine receptor agonist, PNU-282987 (10 and 30 mg/kg). Alone, NS3956 and PNU-282987 were devoid of activity in the mouse forced swim test, but both 1.0 mg/kg NS3956 and 30 mg/kg PNU-282987 enhanced the effect of citalopram and also reboxetine. The data suggest that the activity of citalopram and reboxetine in the mouse forced swim test can be enhanced by agonists at either α4β2 or α7 nicotinic acetylcholine receptors, suggesting that both nicotinic acetylcholine receptor subtypes may be involved in the nicotine-enhanced action of antidepressants.

  15. The differential effects of chronic imipramine or citalopram administration on physiological and behavioral outcomes in naïve mice.

    Science.gov (United States)

    Strekalova, Tatyana; Anthony, Daniel C; Dolgov, Oleg; Anokhin, Konstantin; Kubatiev, Aslan; Steinbusch, Harry M W; Schroeter, Careen

    2013-05-15

    Tricyclics and selective serotonin reuptake inhibitors (SSRIs) are probably the most widely employed reference antidepressants in animal studies on depression. Using imipramine and citalopram, we sought to assess which drug would be more appropriate as pharmacological reference in paradigms of depression in C57BL6N mice by measuring their effect on liquid consumption, home cage activity, body weight and long-term memory in naïve animals treated with each compound at generally used dose of 15 mg/kg/day. Continuous logging of home cage movement, weekly monitoring of vertical activity in a novel cage, and body weight was recorded during four-week treatment period and for four weeks after discontinuation of the antidepressant; sucrose preference was evaluated at weekly intervals during drug administration. A novel object recognition memory test was performed in mice treated the antidepressants for two weeks. Compared to control, imipramine-treated mice displayed increased sucrose and water intake, as well as enhanced home-cage and novelty exploration activities, and reduced body weight. Imipramine also impaired learning in the object recognition task, but citalopram diminished object exploration sufficiently to invalidate the test. Citalopram-treated animals demonstrated no changes in a sucrose test and had elevated body mass. Thus basic physiological and behavioral outcomes in naïve mice were significantly altered by the chronic administration of imipramine and, to a lesser extent, citalopram. As altered variables are crucial for the evaluation of antidepressant-like effects in mice, our data suggest that, at commonly used doses, both drugs must be applied in mouse models of depression with caution.

  16. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial

    OpenAIRE

    Clayton, Anita H.; Gommoll, Carl; Chen, Dalei; Nunez, Rene; Mathews, Maju

    2015-01-01

    Sexual dysfunction commonly occurs with major depressive disorder (MDD). Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist antidepressant approved for the treatment of MDD in adults, was evaluated to determine its effects on sexual function. The primary study was a double-blind, randomized, controlled trial comparing vilazodone 20 and 40 mg/day with placebo; citalopram 40 mg/day was an active control (NCT01473381; http://www.clinicaltrials.gov). Post-hoc...

  17. The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo.

    Science.gov (United States)

    Rapaport, Mark Hyman; Nierenberg, Andrew A; Howland, Robert; Dording, Christina; Schettler, Pamela J; Mischoulon, David

    2011-07-01

    This paper presents new data addressing two important controversies in psychiatry: the construct of Minor Depression (MinD) and the efficacy of St. John's Wort for milder forms of depressive disorders. Data are from a three-arm, 12 week, randomized clinical trial of investigating the efficacy of St. John's Wort (810 mg/day), citalopram (20 mg/day), or placebo for acute treatment of MinD. Due to a high placebo response on all outcome measures, neither St. John's Wort nor citalopram separated from placebo on change in depressive symptom severity, quality of life, or well-being. However, systematic assessment of potential adverse effects (AEs) led to three important observations: (1) prior to the administration of study compound, 60% of subjects endorsed items that would be characterized as AEs once study compound was administered, (2) St. John's Wort and citalopram were each associated with a significant number of new or worsening AEs during treatment, and (3) using a structured interview for identifying AEs at baseline and during treatment is informative. MinD was not responsive to either a conventional antidepressant or a nutraceutical, and both compounds were associated with a notable side effects burden. Other treatment approaches for MinD should be investigated.

  18. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.

    Science.gov (United States)

    Liechti, M E; Baumann, C; Gamma, A; Vollenweider, F X

    2000-05-01

    3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") is a recreational drug that has been shown to release serotonin (5-HT) and dopamine (DA) in animals. The effect of MDMA on 5-HT release can be blocked by 5-HT uptake inhibitors such as citalopram, suggesting that MDMA interacts with the 5-HT uptake site. It is unknown whether this mechanism is also responsible for the psychological effects of MDMA in humans. We investigated the effect of citalopram pretreatment (40 mg iv) on the psychological effects of MDMA (1.5 mg/kg po) in a double-blind placebo-controlled psychometric study in 16 healthy human volunteers. MDMA produced an emotional state with heightened mood, increased self-confidence and extroversion, moderate derealization, and an intensification of sensory perception. Most of these effects were markedly reduced by citalopram. This finding suggests that the psychological effects of MDMA are mediated via action at the 5-HT uptake site to increase 5-HT release through the carrier, as expected from animal studies.

  19. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.

    Science.gov (United States)

    Liechti, M E; Vollenweider, F X

    2000-01-01

    MDMA (3,4-methylenedioxymethamphetamine) or 'Ecstasy' is a widely used recreational drug that produces a state of heightened mood but also cardiovascular and vegetative side-effects. In animals, MDMA releases serotonin and, to a lesser extent, dopamine and norepinephrine. The release of serotonin can be blocked by serotonin uptake inhibitors such as citalopram. It is unknown to what extent this mechanism is also responsible for the physiological side-effects of MDMA seen in humans. We investigated the effect of citalopram pretreatment (40 mg i.v.) on vegetative and cardiovascular effects of MDMA (1.5 mg/kg p.o.) in a double-blind placebo-controlled study in 16 healthy volunteers. MDMA moderately increased blood pressure and heart rate, slightly elevated body temperature and produced a broad range of acute and short-term side-effects. Citalopram reduced all these MDMA-induced physiological changes except for body temperature. These findings suggest that physiological effects of MDMA in humans are partially due to an interaction of MDMA with the serotonin carrier and a subsequent release of serotonin.

  20. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain.

    Science.gov (United States)

    El Mansari, Mostafa; Sánchez, Connie; Chouvet, Guy; Renaud, Bernard; Haddjeri, Nasser

    2005-07-01

    The present study was undertaken to compare the acute and long-term effects of escitalopram and citalopram on rat brain 5-HT neurotransmission, using electrophysiological techniques. In hippocampus, after 2 weeks of treatment with escitalopram (10 mg/kg/day, s.c.) or citalopram (20 mg/kg/day, s.c.), the administration of the selective 5-HT(1A) receptor antagonist WAY-100,635 (20-100 microg/kg, i.v.) dose-dependently induced a similar increase in the firing activity of dorsal hippocampus CA(3) pyramidal neurons, thus revealing direct functional evidence of an enhanced tonic activation of postsynaptic 5-HT(1A) receptors. In dorsal raphe nucleus, escitalopram was four times more potent than citalopram in suppressing the firing activity of presumed 5-HT neurons (ED(50)=58 and 254 mug/kg, i.v., respectively). Interestingly, the suppressant effect of escitalopram (100 microg/kg, i.v.) was significantly prevented, but not reversed by R-citalopram (250 microg/kg, i.v.). Sustained administration of escitalopram and citalopram significantly decreased the spontaneous firing activity of presumed 5-HT neurons. This firing activity returned to control rate after 2 weeks in rats treated with escitalopram, but only after 3 weeks using citalopram, and was associated with a desensitization of somatodendritic 5-HT(1A) autoreceptors. These results suggest that the time course of the gradual return of presumed 5-HT neuronal firing activity, which was reported to account for the delayed effect of SSRI on 5-HT transmission, is congruent with the earlier onset of action of escitalopram vs citalopram in validated animal models of depression and anxiety.

  1. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia

    Directory of Open Access Journals (Sweden)

    Hongyan Zhang

    2011-03-01

    Full Text Available Hongyan Zhang1, Huafang Li2, Liang Shu1, Niufan Gu2, Gang Wang3, Yongzhen Weng3, Shiping Xie4, Xinbao Zhang4, Ting Li5, Cui Ma5, Wei Yu6, Bruce Parsons7, Manjula Schou81Institute of Mental Health, Peking University, Beijing, China; 2Shanghai Mental Health Center, Shanghai, China; 3Capital Medical University, Beijing An Ding Hospital, Beijing, China; 4Nanjing Brain Hospital, Nanjing, China; 5Guangzhou Brain Hospital, Guangzhou, China; 6Pfizer China, Beijing, China; 7Pfizer Inc, New York, NY, USA; 8Pfizer Australia, Sydney, AustraliaBackground: The aim of the study was to evaluate the efficacy and safety of ziprasidone versus risperidone in Chinese subjects with acute exacerbation of schizophrenia.Methods: In patients meeting the Chinese Classification of Mental Disorders criteria for schizophrenia and with a Positive and Negative Syndrome Scale (PANSS total score ≥60 were randomly assigned to six weeks of double-blind treatment with ziprasidone 40–80 mg twice daily or risperidone 1–3 mg bid, flexibly dosed. Noninferiority was demonstrated if the upper limit of the two-sided 95% confidence interval (CI for the difference in PANSS total score improvement from baseline in the evaluable population was smaller than the prespecified noninferiority margin of 10 units.Results: The intent-to-treat population comprised 118 ziprasidone-treated and 121 risperidone-treated subjects. Improvement (reduction from baseline to week 6 in PANSS total score was (-35.6 [95% CI: -38.6, -32.6] for ziprasidone and (-37.1 [95% CI: -39.9, -34.4] for risperidone. Noninferiority was demonstrated in the evaluable population with a difference score of 1.5 [95% CI: -2.5, 5.5]. Mean prolactin levels decreased at week 6 compared with baseline for ziprasidone (-3.5 ng/mL, but significantly increased for risperidone (61.1 ng/mL; P < 0.001. More risperidone-treated subjects (14.9% than ziprasidone-treated subjects (4.2% reported weight gain ≥7%. Akathisia and somnolence in

  2. Risperidone Long-Acting Injections: Successful Alternative Deltoid Muscle Injections for Refractory Schizophrenia

    OpenAIRE

    Saxena, Arjun; Grace, Jeffery; Olympia, Josie L.; Trigoboff, Eileen; Watson, Thomas; Cushman, Sharon; Newcomer, David

    2008-01-01

    Treatment-resistant paranoid schizophrenia is often addressed with long-term intramuscular preparations of conventional antipsychotics (haloperidol and fluphenazine), which can be associated with the development of painful, lumpy nodules at the injection site. In this article, we present a case example of a 58-year-old male patient with paranoid schizophrenia who was treated with risperidone long-acting injection given into the deltoid muscle instead of the US Food and Drug Administration (FD...

  3. Risperidone-induced priapism in an autistic child: a case report

    OpenAIRE

    Aabbassi, Bouchra; Benali, Abdeslam; Asri, Fatima

    2016-01-01

    Background Priapism is a prolonged stimulation with painful, persistent penile erection unaccompanied by sexual desire. It is a rare but serious urological emergency. Risperidone is an atypical antipsychotic widely prescribed for the treatment of behavior problems in children with autism spectrum disorder. It seems associated with priapism in children. Case presentation We present a case of a 12-year-old Moroccan boy diagnosed with autism spectrum disorder who developed priapism while on an e...

  4. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.

    Science.gov (United States)

    Ruaño, G; Goethe, J W; Caley, C; Woolley, S; Holford, T R; Kocherla, M; Windemuth, A; de Leon, J

    2007-05-01

    Atypical antipsychotics induce pre-diabetic symptoms in some but not all patients, characterized most notably by elevated weight. The side effect profiles of the various drugs in the class differ, however, raising the possibility of drug-specific mechanisms for similar side effects. We used physiogenomic analysis, an approach previously employed to study the genetics of drug and diet response, to discover and compare genetic associations with weight profiles observed in patients treated with olanzapine and risperidone as an approach to unraveling contrasting mechanistic features of both drugs. A total of 29 single nucleotide polymorphisms (SNPs) were selected from 13 candidate genes relevant to two potential pharmacological axes of psychotropic-related weight profiles, appetite peptides and peripheral lipid homeostasis. We applied physiogenomic analysis to a cross-section of 67 and 101 patients being treated with olanzapine and risperidone, respectively, and assessed genetic associations with the weight profiles. Weight profiles in patients treated with olanzapine were significantly associated with SNPs in the genes for apolipoprotein E, apolipoprotein A4 and scavenger receptor class B, member 1. Weight profiles in patients treated with risperidone were significantly associated with SNPs in the genes for leptin receptor, neuropeptide Y receptor Y5 and paraoxonase 1. These results are consistent with contrasting mechanisms for the weight profile of patients treated with these drugs. Genes associated with olanzapine weight profiles may be related to peripheral lipid homeostatic axes, whereas those associated with risperidone's may be related to brain appetite peptide regulation. Future physiogenomic studies will include neurotransmitter receptor SNPs and validation in independent samples.

  5. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies.

    Science.gov (United States)

    Navitha, Aerrolla; Jogala, Satheesh; Krishnamohan, Chinnala; Aukunuru, Jithan

    2014-04-01

    The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC) studies. Different implants (F1-F8) containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000) either alone or as their blends, and PLGA (75:25). The implants contained 40% of the drug. After fabrication, the implants were characterized for various in vitro properties such as drug release and physical strength. Prior to conducting drug release studies, optimum drug release method was developed based on IVIVC studies. An optimized formulation based on drug release and physical strength at the end of fabrication was selected from the various implants fabricated. The bioactivity, reversibility, and IVIVC of optimized formulation were determined using pharmacokinetic studies in rats. Short-term stability studies were conducted with optimized formulation. Drug release depended on polymer molecular weight. Implant fabricated using 50:50 polycaprolactone 45,000 and polycaprolactone 80,000 was considered optimized implant. Optimized formulation selected released the drug for 3-months in vitro and was physically rigid. The optimized implant was able to release the drug in vivo for a period of 3 months, the implants are reversible throughout the delivery interval and, a 100% IVIVC was achieved with optimized implant, suggesting the development of 3-month drug-releasing implant for risperidone. The optimized implant was stable for 6 months at room temperature (25°C) and 45°C. A novel implant for risperidone was successfully prepared and evaluated.

  6. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies

    Directory of Open Access Journals (Sweden)

    Aerrolla Navitha

    2014-01-01

    Full Text Available The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC studies. Different implants (F1-F8 containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000 either alone or as their blends, and PLGA (75:25. The implants contained 40% of the drug. After fabrication, the implants were characterized for various in vitro properties such as drug release and physical strength. Prior to conducting drug release studies, optimum drug release method was developed based on IVIVC studies. An optimized formulation based on drug release and physical strength at the end of fabrication was selected from the various implants fabricated. The bioactivity, reversibility, and IVIVC of optimized formulation were determined using pharmacokinetic studies in rats. Short-term stability studies were conducted with optimized formulation. Drug release depended on polymer molecular weight. Implant fabricated using 50:50 polycaprolactone 45,000 and polycaprolactone 80,000 was considered optimized implant. Optimized formulation selected released the drug for 3-months in vitro and was physically rigid. The optimized implant was able to release the drug in vivo for a period of 3 months, the implants are reversible throughout the delivery interval and, a 100% IVIVC was achieved with optimized implant, suggesting the development of 3-month drug-releasing implant for risperidone. The optimized implant was stable for 6 months at room temperature (25°C and 45°C. A novel implant for risperidone was successfully prepared and evaluated.

  7. Single photon emission computed tomography (SPECT of anxiety disorders before and after treatment with citalopram

    Directory of Open Access Journals (Sweden)

    Seedat Soraya

    2004-10-01

    Full Text Available Abstract Background Several studies have now examined the effects of selective serotonin reuptake inhibitor (SSRI treatment on brain function in a variety of anxiety disorders including obsessive-compulsive disorder (OCD, posttraumatic stress disorder (PTSD, and social anxiety disorder (social phobia (SAD. Regional changes in cerebral perfusion following SSRI treatment have been shown for all three disorders. The orbitofrontal cortex (OFC (OCD, caudate (OCD, medial pre-frontal/cingulate (OCD, SAD, PTSD, temporal (OCD, SAD, PTSD and, thalamic regions (OCD, SAD are some of those implicated. Some data also suggests that higher perfusion pre-treatment in the anterior cingulate (PTSD, OFC, caudate (OCD and antero-lateral temporal region (SAD predicts subsequent treatment response. This paper further examines the notion of overlap in the neurocircuitry of treatment and indeed treatment response across anxiety disorders with SSRI treatment. Methods Single photon emission computed tomography (SPECT using Tc-99 m HMPAO to assess brain perfusion was performed on subjects with OCD, PTSD, and SAD before and after 8 weeks (SAD and 12 weeks (OCD and PTSD treatment with the SSRI citalopram. Statistical parametric mapping (SPM was used to compare scans (pre- vs post-medication, and responders vs non-responders in the combined group of subjects. Results Citalopram treatment resulted in significant deactivation (p = 0.001 for the entire group in the superior (t = 4.78 and anterior (t = 4.04 cingulate, right thalamus (t = 4.66 and left hippocampus (t = 3.96. Deactivation (p = 0.001 within the left precentral (t = 4.26, right mid-frontal (t = 4.03, right inferior frontal (t = 3.99, left prefrontal (3.81 and right precuneus (t= 3.85 was more marked in treatment responders. No pattern of baseline activation distinguished responders from non-responders to subsequent pharmacotherapy. Conclusions Although each of the anxiety disorders may be mediated by different

  8. Extended release promethazine HCl using acrylic polymers by freeze-drying and spray-drying techniques: formulation considerations

    Directory of Open Access Journals (Sweden)

    Ruchi Tiwari

    2009-12-01

    Full Text Available The present study investigated a novel extended release system of promethazine hydrochloride (PHC with acrylic polymers Eudragit RL100 and Eudragit S100 in different weight ratios (1:1 and 1: 5, and in combination (0.5+1.5, using freeze-drying and spray-drying techniques. Solid dispersions were characterized by Fourier-transformed infrared spectroscopy (FT-IR, differential scanning calorimetry (DSC, Powder X-ray diffractometry (PXRD, Nuclear magnetic resonance (NMR, Scanning electron microscopy (SEM, as well as solubility and in vitro dissolution studies in 0.1 N HCl (pH 1.2, double-distilled water and phosphate buffer (pH 7.4. Adsorption tests from drug solution to solid polymers were also performed. A selected solid dispersion system was developed into capsule dosage form and evaluated for in vitro dissolution studies. The progressive disappearance of drug peaks in thermotropic profiles of spray-dried dispersions were related to increasing amount of polymers, while SEM studies suggested homogenous dispersion of drug in polymer. Eudragit RL100 had a greater adsorptive capacity than Eudragit S100, and thus its combination in (0.5+1.5 for S100 and RL 100 exhibited a higher dissolution rate with 97.14% drug release for twelve hours. Among different formulations, capsules prepared by combination of acrylic polymers using spray-drying (1:0.5 + 1.5 displayed extended release of drug for twelve hours with 96.87% release followed by zero order kinetics (r²= 0.9986.O presente trabalho compreendeu estudo de um novo sistema de liberação prolongada de cloridrato de prometazina (PHC com polímeros acrílicos Eudragit RL100 e Eudragit S100 em diferentes proporções em massa (1:1 e 1:5 e em combinação (0,5+1,5, utilizando técnicas de liofilização e de secagem por aspersão As dispersões sólidas foram caracterizadas por espectrofotometria no infravermelho por transformada de Fourier (FT-IR, calorimetria diferencial de varredura (DSC, difratometria

  9. Amenorrhoea - consequence of combined treatment with sulpiride and risperidone in a patient suffering from schizophrenia.

    Science.gov (United States)

    Peitl, Marija Vucić; Pavlović, Eudard; Peitl, Antun; Peitl, Vjekoslav

    2010-03-01

    It is well documented that sulpiride causes hormonal adverse events, like amenorrhoea and galactorrhea, due to its mechanism of action. Furthermore, risperidone can produce amenorrhoea and galactorrhea also, due to its mechanism of action, which differs from that of sulpiride. This case report is of a patient that was treated with large doses of sulpiride, but did not develop an adverse event like amenorrhoea. However, when risperidone was introduced into therapy it leads to the onset of amenorrhoea. Gynecologist saw it as the beginning of menopause. General practitioner questioned the existence of an intra-cerebral process that could produce amenorrhoea as well. Therefore, the patient was sent to perform an MRI of the brain, under work diagnosis of pituitary adenoma, which was later ruled out as a cause of the illness. Well experienced psychiatrist linked the loss of menstruation with the adverse event profile of sulpiride and therefore gradually discontinued sulpiride from therapy, while risperidone was left and subsequently menstrual cycle was restored. Good knowledge of adverse events profile of antipsychotic medication used, especially when used in a combination, allows us to correctly question appearance of adverse events, to adequately treat them and lowers the cost of unneeded medical procedures.

  10. Risperidone oral disintegrating mini-tablets: A robust-product for pediatrics

    Directory of Open Access Journals (Sweden)

    El-Say Khalid M.

    2015-12-01

    Full Text Available This study was aimed at developing risperidone oral disintegrating mini-tablets (OD-mini-tablets as age-appropriate formulations and to assess their suitability for infants and pediatric use. An experimental Box-Behnken design was applied to assure high quality of the OD-mini-tablets and reduce product variability. The design was employed to understand the influence of the critical excipient combinations on the production of OD-mini-tablets and thus guarantee the feasibility of obtaining products with dosage form uniformity. The variables selected were mannitol percent in Avicel (X1, swelling pressure of the superdisintegrant (X2, and the surface area of Aerosil as a glidant (X3. Risperidone-excipient compatibilities were investigated using FTIR and the spectra did not display any interaction. Fifteen formulations were prepared and evaluated for preand post-compression characteristics. The prepared ODmini- tablet batches were also assessed for disintegration in simulated salivary fluid (SSF, pH 6.2 and in reconstituted skimmed milk. The optimized formula fulfilled the requirements for crushing strength of 5 kN with minimal friability, disintegration times of 8.4 and 53.7 s in SSF and skimmed milk, respectively. This study therefore proposes the risperidone OD-mini-tablet formula having robust mechanical properties, uniform and precise dosing of medication with short disintegration time suitable for pediatric use.

  11. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study].

    Science.gov (United States)

    Schmitt, L; Arbus, C; Tonnoir, B

    2006-01-01

    Intravenous (iv) administration of an antidepressant is a common practice in some European countries, particularly in France, Spain, and Italy in the initial treatment phase of hospitalised, severe depressed patients. After a beneficial response is observed, patients are switched to an oral formulation. The approved treatment period of the iv form of citalopram is limited to 8-10 days. The high bioavailability of citalopram permits the use of identical iv and oral doses. Citalopram is a racemate, consisting of a 1:1 mixture of the S- and R-enantiomers. The therapeutically active component is the S-enantiomer (escitalopram). Pharmacokinetic single dose administration studies in healthy subjects have demonstrated that daily oral administration of 20 mg of escitalopram or 40 mg citalopram results in similar plasma concentrations of the S-enantiomer of citalopram. This open-label multicentre French prospective study investigated the tolerability and efficacy of oral escitalopram 10 and 20 mg/day, administered for a 6-week period as continuation treatment of citalopram (20 mg or 40 mg daily) intravenous (iv), in patients with Major Depressive Disorder. A total of 171 patients were enrolled, of whom 147 (85%) completed the study. The mean MADRS score at inclusion (last citalopram dose) was 31.6 +/- 9.9. The total MADRS score decreased after 3 days of oral treatment with escitalopram. Escitalopram demonstrated a continuous effect in treating depressive symptoms throughout the study. The decrease in MADRS mean total score from baseline was statistically significant to each visit (day 3, 15; p or = 50%), and the majority of them were considered remitters (final MADRS score escitalopram was well tolerated in the study population. In all, 57 patients (33%) reported at least one adverse event (AE) during the study (21 patients in the 10 mg group and 36 patients in the 20 mg group); of these, 7 patients (4%) withdrew from the study. The most frequently reported AEs were

  12. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism

    DEFF Research Database (Denmark)

    Chen, Fenghua; Larsen, Mads; Sanchez, Connie

    2005-01-01

    The interaction of the S- and R-enantiomers (escitalopram and R-citalopram) of citalopram, with high- and low-affinity binding sites in COS-1 cell membranes expressing human SERT (hSERT) were investigated. Escitalopram affinity for hSERT and its 5-HT uptake inhibitory potency was in the nanomolar...... range and approximately 40-fold more potent than R-citalopram. Escitalopram considerably stabilised the [3H]-escitalopram/SERT complex via an allosteric effect at a low-affinity binding site. The stereoselectivity between escitalopram and R-citalopram was approximately 3:1 for the [3H]-escitalopram....../hSERT complex. The combined effect of escitalopram and R-citalopram was additive. Paroxetine and sertraline mainly stabilised the [3H]-paroxetine/hSERT complex. Fluoxetine, duloxetine and venlafaxine have only minor effects. 5-HT stabilised the [125I]-RTI-55, [3H]-MADAM, [3H]-paroxetine, [3H]-fluoxetine and [3H...

  13. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors

    DEFF Research Database (Denmark)

    Chen, Fenghua; Larsen, Mads Breum; Sánchez, Connie

    2005-01-01

    The interaction of the S- and R-enantiomers (escitalopram and R-citalopram) of citalopram, with high- and low-affinity binding sites in COS-1 cell membranes expressing human SERT (hSERT) were investigated. Escitalopram affinity for hSERT and its 5-HT uptake inhibitory potency was in the nanomolar...... range and approximately 40-fold more potent than R-citalopram. Escitalopram considerably stabilised the [3H]-escitalopram/SERT complex via an allosteric effect at a low-affinity binding site. The stereoselectivity between escitalopram and R-citalopram was approximately 3:1 for the [3H]-escitalopram....../hSERT complex. The combined effect of escitalopram and R-citalopram was additive. Paroxetine and sertraline mainly stabilised the [3H]-paroxetine/hSERT complex. Fluoxetine, duloxetine and venlafaxine have only minor effects. 5-HT stabilised the [125I]-RTI-55, [3H]-MADAM, [3H]-paroxetine, [3H]-fluoxetine and [3H...

  14. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

    DEFF Research Database (Denmark)

    Sørensen, Jan; Stage, Kurt B; Damsbo, Niels

    2007-01-01

    The objective of this study was to model the cost-effectiveness of escitalopram in comparison with generic citalopram and venlafaxine in primary care treatment of major depressive disorder (baseline scores 22-40 on the Montgomery-Asberg Depression Rating Scale, MADRS) in Denmark. A three-path dec......The objective of this study was to model the cost-effectiveness of escitalopram in comparison with generic citalopram and venlafaxine in primary care treatment of major depressive disorder (baseline scores 22-40 on the Montgomery-Asberg Depression Rating Scale, MADRS) in Denmark. A three...... in 2004 DDK. The expected overall 6-month remission rate was higher for escitalopram (64.1%) than citalopram (58.9%). From both perspectives, the total expected cost per successfully treated patient was lower for escitalopram (DKK 22,323 healthcare, DKK 72,399 societal) than for citalopram (DKK 25......,778 healthcare, DKK 87,786 societal). Remission rates and costs were similar for escitalopram and venlafaxine. Robustness of the findings was verified in multivariate sensitivity analyses. For patients in primary care, escitalopram appears to be a cost-effective alternative to (generic) citalopram, with greater...

  15. Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram.

    Science.gov (United States)

    Rossi, Dania V; Burke, Teresa F; Hensler, Julie G

    2008-03-31

    The effect of chronic citalopram or escitalopram administration on 5-HT1A receptor function in the dorsal raphe nucleus was determined by measuring [35S]GTP gamma S binding stimulated by the 5-HT1A receptor agonist (R)-(+)-8-OH-DPAT (1nM-10 microM). Although chronic administration of citalopram or escitalopram has been shown to desensitize somatodendritic 5-HT1A autoreceptors, we found that escitalopram treatment decreased the efficacy of 5-HT1A receptors to activate G proteins, whereas citalopram treatment did not. The binding of [3H]8-OH-DPAT to the coupled, high affinity agonist state of the receptor was not altered by either treatment. Interestingly, escitalopram administration resulted in greater occupancy of serotonin transporter sites as measured by the inhibition of [3H]cyanoimipramine binding. As the binding and action of escitalopram is limited by the inactive enantiomer R-citalopram present in racemic citalopram, we propose that the regulation of 5-HT1A receptor function in the dorsal raphe nucleus at the level of receptor-G protein interaction may be a result of greater inhibition of the serotonin transporter by escitalopram.

  16. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.

    Science.gov (United States)

    Kaminska, K; Rogoz, Z

    2016-06-01

    Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders. In the present study, we investigated the effect of treatment with the antidepressant escitalopram (SSRI) given separately or jointly with a low dose of risperidone (an atypical antipsychotic) in the forced swim test and in the elevated plus-maze test in rats. The obtained results showed that escitalopram at doses of 2.5 or 5 mg/kg evoked antidepressant-like effect in the forced swim test. Moreover, risperidone at low doses (0.05 or 0.1 mg/kg) enhanced the antidepressant-like activity of escitalopram (1 mg/kg) in this test by increasing the swimming time and decreasing the immobility time in those animals. WAY 100635 (a serotonin 5-HT1A receptor antagonist) at a dose of 0.1 mg/kg abolished the antidepressant-like effect induced by co-administration of escitalopram and risperidone. The active behavior in that test did not reflect an increase in general activity, since the combined treatment with escitalopram and risperidone failed to enhance the exploratory activity of rats. In the following experiment, we showed that escitalopram (5 mg/kg) and mirtazapine (5 or 10 mg/kg) or risperidone (0.1 mg/kg) induced an anxiolytic-like effect in the elevated plus-maze test, and the combined treatment with an ineffective dose of risperidone (0.05 mg/kg) enhanced the anxiolytic-like effects of escitalopram (2.5 mg/kg) or mirtazapine (1 and 2.5 mg/kg) in this test. The obtained results suggest that risperidone applied at a low dose enhances the antidepressant-like activity of escitalopram in the forced swim test, and that 5-HT1A receptors may play some role in these effects. Moreover, a low dose of risperidone may also enhance the anxiolytic-like action of the studied

  17. Risperidone and Divalproex Differentially Engage the Fronto-Striato-Temporal Circuitry in Pediatric Mania: A Pharmacological Functional Magnetic Resonance Imaging Study

    Science.gov (United States)

    Pavuluri, Mani N.; Passarotti, Alessandra M.; Fitzgerald, Jacklynn M.; Wegbreit, Ezra; Sweeney, John A.

    2012-01-01

    Objective: The current study examined the impact of risperidone and divalproex on affective and working memory circuitry in patients with pediatric bipolar disorder (PBD). Method: This was a six-week, double-blind, randomized trial of risperidone plus placebo versus divalproex plus placebo for patients with mania (n = 21; 13.6 [plus or minus] 2.5…

  18. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study

    Directory of Open Access Journals (Sweden)

    Sacristán Jose A

    2001-12-01

    Full Text Available Abstract Background In order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice. Method Outpatients with schizophrenia entered this prospective, naturalistic study when they received a new prescription for an antipsychotic drug. Treatment assignment was based on purely clinical criteria, as the study did not include any experimental intervention. Patients treated with olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was measured using the 10-item version of the Drug Attitude Inventory (DAI-10, and treatment compliance was measured using a physician-rated 4 point categorical scale. Results A total of 2128 patients initiated treatment (as monotherapy with olanzapine, 417 with risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10 scores and significantly better treatment compliance compared to both risperidone- and haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients. Conclusion Subjective response and compliance were superior in olanzapine-treated patients, compared to patients treated with risperidone and haloperidol, in routine clinical practice. Differences in subjective response were explained largely, but not completely, by differences in incidence of EPS.

  19. Adverse Effects of Risperidone in Children with Autism Spectrum Disorders in a Naturalistic Clinical Setting at Siriraj Hospital, Thailand

    Directory of Open Access Journals (Sweden)

    Vitharon Boon-yasidhi

    2014-01-01

    Full Text Available A cross-sectional study was conducted to evaluate adverse effects associated with risperidone in 45 children with autism spectrum disorders (ASD, aged 2–15 years, who were treated at Siriraj Hospital, Thailand, between the years 2006 and 2007. Adverse effects were assessed by parent interview, using a semistructure questionnaire, and medical records review. The mean ± SD age of the children at starting risperidone was 8.15±2.98 years. The mean ± SD of risperidone dose was 0.94±0.74 mg/day and the mean ± SD duration of treatment was 36.8±27.8 months. Adverse effects were reported in 39 children (86.7%. Common adverse effects included increased appetite, somnolence, and rhinorrhea and most of the adverse effects were tolerable. Tardive dyskinesia or other serious adverse events were not found in this study. The child’s mean ± SD weight gain was 4.18±2.82 kg/year, which exceeded developmentally expected norms. The results from this study suggest that risperidone treatment in children with ASD is associated with frequent mild and tolerable adverse effects. However, excessive weight gain could be found to be a concerning adverse effect and weight monitoring is warranted when risperidone is being prescribed.

  20. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression.

    Science.gov (United States)

    Bech, Per; Tanghøj, Per; Cialdella, Philippe; Andersen, Henning Friis; Pedersen, Anders Gersel

    2004-09-01

    In continuation of a previous psychometric analysis of dose-response data for citalopram in depression, the corresponding study data for escitalopram is of interest, since escitalopram is the active enantiomer of citalopram and because citalopram was used as the active control. Revisiting those corresponding data, the psychometric properties of the Montgomery-Asberg Depression Scale (MADRS) and the Hamilton Depression Scale (HAMD) were investigated by focusing on the unidimensional HAMD6 and MADRS6. Effect sizes were calculated and compared for two dosages of escitalopram (10 mg and 20 mg daily) and between each of these two dosages and 40 mg citalopram daily. The results showed that the three depression scales MADRS6, MADRS10 and HAMD6 were psychometrically acceptable (coefficient of homogeneity of 0.40 or higher). In the severely depressed patients (MADRS10> or =30) a rather clear dose-response relationship for escitalopram was seen on all three scales after 6 and 8 wk of therapy. Thus, the effect size for 10 mg escitalopram ranged from 0.28 to 0.38 while the effect sizes for 20 mg escitalopram ranged from 0.57 to 0.77. This difference was statistically significant (pescitalopram and 40 mg citalopram was seen after 8 wk of therapy for MADRS10 (effect size 0.71 vs. 0.37). An item analysis identified 'suicidal thoughts' to be the most discriminating item in this respect. These results for the severely depressed patients were confirmed by the patients self-reported quality of life evaluation. When all included patients were analysed, however, no clear dose-response relationship was seen. In conclusion, a dose-response relationship for escitalopram was seen in the severely depressed patients on all outcome scales after 6 and 8 wk of treatment. After 8 wk of treatment 20 mg escitalopram was superior to 40 mg citalopram, but not after 2 wk of treatment.

  1. Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders.

    Science.gov (United States)

    Handen, Benjamin L; Johnson, Cynthia R; Butter, Eric M; Lecavalier, Luc; Scahill, Lawrence; Aman, Michael G; McDougle, Christopher J; Arnold, L Eugene; Swiezy, Naomi B; Sukhodolsky, Denis G; Mulick, James A; White, Susan W; Bearss, Karen; Hollway, Jill A; Stigler, Kimberly A; Dziura, James; Yu, Sunkyung; Sacco, Kelley; Vitiello, Benedetto

    2013-06-01

    A Structured Observational Analog Procedure (SOAP), an analogue measure of parent-child interactions, was used to assess treatment outcome in children with Autism Spectrum Disorder and serious behavior problems. It served as a secondary outcome measure in a 24-week, randomized trial of risperidone (MED; N=49) versus risperidone plus parent training (COMB; n=75) (ages 4-13 years). At 24-weeks, there was 28 % reduction in child inappropriate behavior during a Demand Condition (p=.0002) and 12 % increase in compliance to parental requests (p=.004) for the two treatment conditions combined. Parents displayed 64 % greater use of positive reinforcement (p=.001) and fewer repeated requests for compliance (ppositive reinforcement (p=.01) and fewer restrictive statements (p<.05) than MED parents. The SOAP is sensitive to change in child and parent behavior as a function of risperidone alone and in combination with PMT and can serve as a valuable complement to parent and clinician-based measures.

  2. No change in [¹¹C]CUMI-101 binding to 5-HT(1A) receptors after intravenous citalopram in human

    DEFF Research Database (Denmark)

    Pinborg, Lars H; Feng, Ling; Haahr, Mette E

    2012-01-01

    Med Biol 38:273-277; Kumar et al. [2006] J Med Chem 49:125-134) and has previously been demonstrated to be sensitive to bolus citalopram in monkeys (Milak et al. [2011] J Cereb Blood Flow Metab 31:243-249). We studied six healthy individuals. Two PET-scans were performed on the same day in each...... individual before and after constant infusion of citalopram (0.15 mg/kg). The imaging data were analyzed using two tissue compartment kinetic modeling with metabolite corrected arterial input and Simplified Reference Tissue Modeling using cerebellum as a reference region. There was no significant difference...

  3. Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study

    Directory of Open Access Journals (Sweden)

    Victoria Omranifard

    2014-01-01

    Full Text Available Background: Proper management of depression in elderly population would improve the outcome of the disease and reduce its related disability and mortality. Use of memantine with minimal side effects and drug interaction seems reasonable in the elderly but its antidepressant activity is controversial. The aim of the current research is to investigate the effects of add-on memantine during citalopram therapy in elderly patients with depression, in Isfahan. Materials and Methods: In this double-blind, placebo controlled trial study; elderly patients aged more than 60 years who were recently diagnosed with depression, were enrolled. The selected patients were randomlysplit into two groups, viz. intervention and placebo groups. The intervention was memantine (20 mg daily or identical placebo plus citalopram for 8 weeks. The severity of depression and quality of life was evaluated using Geriatric Depression Scale (GDS-15, Hamilton Rating Scale for depression (HRSD and World Health Organization Quality of Life WHOQOL-BREF respectively. The mentioned scores were evaluated at baseline, 4 weeks and 8 weeks, after initiating the trial in two studied groups and compared with each other. Results: 28 and 29 patients were studied in the intervention and placebo groups, respectively. Score of GDS-15, HRSD and WHO-QOL-BREF scales at baseline, 4 weeks and 8 weeks, after initiating trial did not change significantly after use of memantine (P > 0.05. There was no significant difference in mean +/- SD of GDS-15, HRSD and WHO-QOL-BREF scales among intervention and placebo groups (P > 0.05. Conclusion: The outcome of this clinical trial did not support the antidepressant effect of add-on memantine in elderly patients with depression receiving citalopram. It is recommended to design further studies considering the limitations of the current study mentioned herein and the effect of memantine with other anti-depressant agents.

  4. Studies on the interaction between promethazine and human serum albumin in the presence of flavonoids by spectroscopic and molecular modeling techniques.

    Science.gov (United States)

    He, Ling-Ling; Wang, Zhi-Xin; Wang, Yong-Xia; Liu, Xian-Ping; Yang, Yan-Jie; Gao, Yan-Ping; Wang, Xin; Liu, Bin; Wang, Xin

    2016-09-01

    Fluorescence, absorption, time-correlated single photon counting (TCSPC), and circular dichroism (CD) spectroscopic techniques as well as molecular modeling methods were used to study the binding characterization of promethazine (PMT) to human serum albumin (HSA) and the influence of flavonoids, rutin and baicalin, on their affinity. The results indicated that the fluorescence quenching mechanism of HSA by PMT is a static quenching due to the formation of complex. The reaction was spontaneous and mainly mediated by hydrogen bonds and hydrophobic interactions. The binding distance between the tryptophan residue of HSA and PMT is less than 8nm, which indicated that the energy transfer from the tryptophan residue of HSA to PMT occurred. The binding site of PMT on HSA was located in sites I and the presence of PMT can cause the conformational changes of HSA. There was the competitive binding to HSA between PMT and flavonoids because of the overlap of binding sites in HSA. The flavonoids could decrease the association constant and increase the binding distance. In addition, their synergistic effect can further change the conformation of HSA. The decrease in the affinities of PMT binding to HSA in the presence of flavonoids may lead to the increase of free drug in blood, which would affect the transportation or disposition of drug and evoke an adverse or toxic effect. Hence, rationalising dosage and diet regimens should be taken into account in clinical application of PMT.

  5. Fate of citalopram during water treatment with O3, ClO2, UV and fenton oxidation

    DEFF Research Database (Denmark)

    Hörsing, Maritha; Kosjek, Tina; Andersen, Henrik Rasmus;

    2012-01-01

    In the present study we investigate the fate of citalopram (CIT) at neutral pH using advanced water treatment technologies that include O3, ClO2 oxidation, UV irradiation and Fenton oxidation. The ozonation resulted in 80% reduction after 30 min treatment. Oxidation with ClO2 removed >90% CIT...... at a dosage of 0.1 mg L−1. During UV irradiation 85% reduction was achieved after 5 min, while Fenton with addition of 14 mg L−1 (Fe2+) resulted in 90% reduction of CIT. During these treatment experiments transformation products (TPs) were formed from CIT, where five compounds were identified by using high...

  6. Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates.

    Science.gov (United States)

    Mishra, Akash C; Mohanty, Banalata

    2010-05-25

    Body weight gain, sexual/reproductive dysfunction and hematological abnormalities are serious consequences of atypical antipsychotics treatment. No attempts however have been made preclinically to elucidate the adverse hematological impacts. Presently, effects of lactational exposure of olanzapine (4, 8 and 10 mg/kg) and risperidone (1 and 2 mg/kg) on hematology as well as lymphoid organ histopathology of mice neonates were investigated. Both olanzapine and risperidone transfers through milk and make the neonates susceptible to their adverse side effects. Corticosterone elevation tendency of both the drugs further enhance the susceptibility for immune dysfunction. Analysis of total and differential leukocytes counts revealed neutropenia with all the doses of olanzapine but only with risperidone 2mg/kg. Weight analysis and histopathology of thymus and spleen indicated a state of suppression; less in the risperidone-exposed groups. Significant plasma corticosterone elevation occurred on 4 and 8 mg/kg olanzapine exposures but not with 10 mg/kg as well as with both the risperidone doses. Elevation of plasma prolactin levels occurred dose-dependently for both the drugs. Hematological toxicity (neutropenia) might be the direct toxic effects of the drugs/unstable metabolites on circulating neutrophils and/or on the bone marrow hemopoietic cells. Direct toxicity of the drugs might also have suppressed the lymphoid organs thymus and spleen. Further, it could be associated to hormonal imbalance induced by adverse pharmacological effects of the drugs on the endocrine system. Suppression of lymphoid organs in olanzapine groups might have resulted because of corticosteronemia and hyperprolactinemia, while in risperidone it could be mediated by pronounced hyperprolactinemic effect alone.

  7. Choline acetyltransferase expression in rat prefrontal cortex and hippocampus after acute and chronic exposure to amisulpride, haloperidol, and risperidone.

    Science.gov (United States)

    Huang, Guang-Biao; Zhao, Tong; Li, Chun-Rong; Sui, Zhi-Yan; Kang, Nam-In; Han, Eui-Hyeog; Chung, Young-Chul

    2012-10-24

    Recently, there has been an increasing concern that atypical antipsychotics as well as typical ones may cause detrimental effects on cognitive function. Supporting evidence comes from many preclinical studies demonstrating that long-term administration of haloperidol, risperidone, and ziprasidone reduced choline acetyltransferase (ChAT) expression in rat hippocampus (HIP). However, to the best of our knowledge, no studies have examined the effects of amisulpride on ChAT expression in rats. Therefore, the aim of this study was to investigate the effects of acute and chronic administration of amisulpride, haloperidol, and risperidone on ChAT expression in the rat prefrontal cortex (PFC) and HIP. Animals received daily intraperitoneal (i.p.) injections of amisulpride (5 or 100mg/kg), haloperidol (1 or 2mg/kg), risperidone (1 or 2mg/kg) or vehicle for 7 or 45 days. One day after the last injection, rats were sacrificed. ChAT immunoreactivity was assessed with immunofluorescence staining. Target areas of brain were PFC and HIP (CA1, CA3 and DG). The short-term administration of haloperidol and risperidone produced significant decrease of ChAT immunoreactivity in the PFC and HIP compared to vehicle whereas amisulpride had no effects on ChAT immunoreactivity in the PFC and HIP. In long-term study, haloperidol and risperidone decreased ChAT-positive cells and/or fiber pixel density in the PFC and HIP whereas amisulpride decreased ChAT-positive cells in the PFC and had no effects on fiber pixel density of ChAT in the HIP. The results suggest that both short-term and long-term administration of haloperidol and risperidone, and long-term administration of amisulpride may produce detrimental effects on cognitive function by reducing ChAT expression in the PFC and/or HIP.

  8. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.

    Science.gov (United States)

    Carter, C S; Mulsant, B H; Sweet, R A; Maxwell, R A; Coley, K; Ganguli, R; Branch, R

    1995-01-01

    Risperidone, a new antipsychotic drug, was recently approved by the Food and Drug Administration (FDA) on the basis of its having comparable efficacy and less toxicity than haloperidol. In a preliminary study to evaluate the therapeutic efficiency of this drug, we conducted a survey of resperidone utilization, cost, and safety during its first year of availability at an academic psychiatric hospital. Data were obtained from a computerized, centralized medical record system, from an adverse drug reaction monitoring system, and from pharmacy purchasing records. In its first year of availability, risperidone became the second most widely used antipsychotic agent at our institution. Most of this use extended beyond the adult schizophrenia population, for whom pre-marketing safety and efficacy data are available. The direct institutional cost of risperidone treatment exceeded the entire budget for antipsychotic drugs during the year before its release. Results from the adverse drug reaction reporting system did not indicate a strong advantage of risperidone over more established antipsychotic agents with respect to extrapyramidal side effects. Furthermore, the mean dose of risperidone associated with extrapyramidal symptoms was 3.5 mg/day, considerably lower than that suggested by pre-marketing studies in a more select patient group. These results confirm that new pharmacological agents are generally used in much broader patient populations than those for which efficacy and safety have been established prior to FDA approval. This study also raises questions about the therapeutic efficiency of risperidone compared with other antipsychotic drugs. We conclude that systematic studies of outcome, safety, and cost of new pharmaceuticals in naturalistic settings are needed to provide the data necessary to establish local standards of cost-effective care.

  9. Risperidone regulates Dopamine D2-like receptors expression in rat brain in a time-dependent manner

    Directory of Open Access Journals (Sweden)

    Ni Peiyan

    2015-03-01

    Full Text Available Background and Objectives: Antipsychotics can elicit dopamine super-sensitivity by up-regulation of D2-like receptors (DRD2, DRD3, and DRD4 expression. Nevertheless, the expression profile of dopamine D2-like receptors in different brain regions and peripheral blood mononuclear cells (PBMCs, and changes following risperidone administration were still unclear. In this study, we would investigate the expression of D2-like receptors mRNA in different brain regions and the peripheral blood mononuclear cells (PBMCs in rats after 2, 6 weeks risperidone administration. Methods: The experimental rats were given risperidone (0.25mg/kg/day, i.p., and the control rats were given 0.9% NaCl. The rats were sacrificed at 0 week, 2 weeks and 6 weeks after the drug administration. Expression of the dopamine D2-like receptors was quantified by Real-time PCR method. Results: Dopamine D2-like receptors expressed in all the examined regions of rat brain. Their expression significantly increased 2weeks after risperidone administration in different brain regions. However, the changed expression of DRD2 and DRD3 turned back to the basal level 6weeks later, while the increased DRD4 expression remained in left parietal cortex. Meanwhile, DRD2 and DRD3 but not DRD4 expressed in PBMCs, however, the risperidone could not affect their expression. Conclusions: The risperidone could change the dopamine D2-like receptors expression in a time-dependent manner in different brain regions, which might guide the clinical use in the near future.

  10. Investigation on the binding activities of citalopram with human and bovine serum albumins

    Energy Technology Data Exchange (ETDEWEB)

    Lin, Jingjing; Liu, Yan, E-mail: liuyan@fjirsm.ac.cn; Chen, Mingmao; Huang, Huayin; Song, Ling, E-mail: songling@fjirsm.ac.cn

    2014-02-15

    The binding interactions of citalopram (CIT), an efficient antidepressant, with human serum albumin (HSA) and bovine serum albumin (BSA) were investigated by a series of spectroscopic methods including fluorescence, UV–vis absorption, circular dichroism (CD) and {sup 1}H nuclear magnetic resonance ({sup 1}H NMR). The fluorescence quenching and UV–vis absorption studies reveal that CIT could form complexes with both HSA and BSA. The CIT–BSA complex exhibits higher binding affinity than CIT–HSA complex. The thermodynamic study further suggests that the interactions between CIT and SAs are mainly driven by hydrophobic forces and hydrogen bonds. The {sup 1}H NMR analysis indicates that the participation of different functional groups of CIT is unequal in the complexation of CIT–HSA and CIT–BSA. Site marker competitive experiments show that the interactions between CIT and SAs primarily locate at sub-domain II A (site I). The effects of CIT on the conformation of SAs are further analyzed via synchronous fluorescence, three-dimensional fluorescence and CD spectra techniques. The results prove that the presence of CIT decreases the α-helical content of both SAs and induces the slight unfolding of the polypeptides of protein. Additionally, the conformational change of BSA induced by CIT is larger than that of HSA. -- Highlights: • The difference of binding activity between CIT–BSA and CIT–HSA is first reported. • Use spectroscopic, thermodynamic, and NMR methods. • CIT exhibits higher binding affinity to BSA than to HSA. • The binding forces between CIT and SA have been investigated. • The complexation of CIT–SA induces the conformational change of SA.

  11. Effect of acute and chronic treatment with risperidone on the serotonin and dopamine receptors in the rat brain

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Yun Young; Moon, Dae Hyuk; Son, Hye Kyung; Kim, Chang Yoon; Lee, Chul; Lee, Hee Kyung [College of Medicine, Ulsan Univ., Seoul (Korea, Republic of)

    1997-03-01

    The therapeutic efficacy of antipsychotic drugs is generally attributed to their ability to block dopamine D{sub 2} receptors. Classical D{sub 2} antagonists are not effective to treat negative symptoms and produce extrapyramidal side effects. On the other hand, atypical antipsychotic agents ameliorate negative symptoms without producing extrapyramidal side effects, and it is reported to be associated with blockade of serotonin 5-HT{sub 2} receptors. The purpose of this study was to evaluate the effect of risperidone on neuroreceptors in the rat brain by quantitative autoradiography method. In acute treatment group, risperidone was injected into peritoneal cavity of male Wistar rats with dose of 0, 0.1, 0.25, 0.5, 1.0 and 2.0mg/kg in each group (5/group), and they were decapitated after 2 hours. In chronic treatment group, risperidone was injected with dose of 0, 0.1, and 1m/kg (I.P.) for 21 ays and decapitated after 24 hours following last treatment. The effect of risperodone on the binding of [{sup 3}H) spiperone to 5-HT{sub 2} and D{sub 2} receptors were analysed in 4 discrete regions of the striatum, nucleus accumbens, and frontal cortex by quantitative autoradiography. Acute treatment with risperidone reduced cortical 5-HT{sub 2} specific [{sup 3}H]spiperone binding to 32% of vehicle-treated control. Subcortical 5-HR{sub 2} specific [{sup 3}H]spiperone binding was not affected at all dose groups whereas a significant reduction (57%) in D{sub 2} specific [{sup 3}H]spiperone binding was observed in risperidone treated group at doses of 1-2mg/kg. Chronic treatment with risperidone produced a decrease in the maximal number of cortical 5-HT{sub 2} receptors to 51% and 46% of control in 0.1mg/kg and 1mg/kg treated group respectively. In conclusion, risperidone is a cortical serotonin receptor antagonist with relatively weak antagonistic action on dopamine receptors. These effects on neuroreceptors may explain the therapeutic effect of risperidone as a atypical

  12. An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

    Directory of Open Access Journals (Sweden)

    Pandina Gahan

    2012-06-01

    Full Text Available Abstract Background Data on the long-term efficacy, safety, and tolerability of risperidone in adolescents with schizophrenia are limited. The objective of this study was to evaluate the efficacy and safety of maintenance risperidone treatment in adolescents with schizophrenia. Methods This open-label study of adolescents aged 13 to 17 years with schizophrenia was a single extension study of two short-term double-blind risperidone studies and also enrolled subjects directly in open-label risperidone treatment. The risperidone dose was flexible and ranged from 2 to 6 mg/day. Most subjects enrolled for 6 months; a subset enrolled for 12 months. Assessment tools included the Positive and Negative Syndrome Scale total and factor scores, Clinical Global Impressions, Children’s Global Assessment Scale, adverse event (AE monitoring, vital signs, laboratory testing, and extrapyramidal symptom rating scales. Results A total of 390 subjects were enrolled; 48 subjects had received placebo in a previous double-blind study; 292 subjects had received risperidone as part of their participation in one of two previous controlled studies; and 50 subjects were enrolled directly for this study. A total of 279 subjects enrolled for 6 months of treatment, and 111 subjects enrolled for 12 months of treatment. Overall, 264 (67.7% subjects completed this study: 209 of the 279 subjects (75% in the 6-month group and 55 of the 111 subjects (50% in the 12-month group. The median mode dose was 3.8 mg/day. At 6 months, all three groups experienced improvement from open-label baseline in symptoms of schizophrenia as well as general assessments of global functioning. Improvements were generally maintained for the duration of treatment. The most common AEs (≥10% of subjects were somnolence, headache, weight increase, hypertonia, insomnia, tremor, and psychosis. Potentially prolactin-related AEs (PPAEs were reported by 36 (9% subjects. The AE profile in this study was

  13. Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study

    Directory of Open Access Journals (Sweden)

    Adel Gabriel

    2010-10-01

    Full Text Available Adel GabrielDepartments of Psychiatry and Community Health Sciences, University of Calgary, Alberta, CanadaBackground: There is a great need in the treatment of schizophrenia for a drug, or drug ­combinations, to improve clinical response with fewer serious side effects. The objective of this study was to explore the therapeutic effects and tolerability of the anticonvulsant gabapentin as an adjunctive in the treatment of patients with partially responsive schizophrenia.Methods: Ten consenting patients with a confirmed Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision diagnosis of schizophrenia were identified. All patients failed at least one 12-week treatment trial with risperidone or olanzapine. Gabapentin was added to ongoing antipsychotic treatment with olanzapine or risperidone for eight weeks. The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS. Other scales included the Calgary Depression Scale (CDSS and the Abnormal Involuntary Movement Scale (AIMS. Repeated-measures multivariate analysis of variance was utilized to examine changes in outcome measures over time with adjunctive treatment with gabapentin.Results: There was a significant drop in the PANSS and CDSS scores at endpoint (week 8. There were no significant differences between the two treatment groups with regard to changes in all outcome measures or in AIMS score. The adjunctive treatments were well tolerated and side effects were transient.Conclusion: Gabapentin could be used successfully as an adjunct to novel antipsychotics in partially responsive schizophrenia. However, large controlled studies are needed to examine the effectiveness of gabapentin in psychotic disorders.Keywords: schizophrenia, refractory, adjunctive treatment, gabapentin, risperidone, olanzapine

  14. Report of a Rare Case of Olanzapine and Risperidone Induced Hypomania

    Directory of Open Access Journals (Sweden)

    AR Zahiroddin

    2006-07-01

    Full Text Available Introduction & Objective: Hypomania is a mood disorder with symptoms of constantly high expansive or irritable mood. After a 4-day period, the patient feels to be in need of less sleep, being talkative, or feeling pressure if not treated kindly, having flight of ideas, distractibility, and increase in goal oriented activities (including social, occupational, educational or sexual activities and being extravagant. Hypomania could be a mood episode of bipolar I and II mood disorder or cyclothymia and could be resulted from consumption of drugs, materials, Electro Convulsive Therapy (ECT or photo therapy. Case: The present report is the case of a 57-year old married woman, who has had a record of bipolar I mood disorder since 30 years ago. The patient was hospitalized once in psychiatry hospital and referred to psychiatry office 2 years ago. She has been under medication therapy by lithium 600 mg, nortriptyline 75 mg, and colonazpam 1 mg. She has taken risperidone 2 mg, the symptoms of hypomania have revealed. After stopping the consumption of risperidone, the treatment continued by lithium tablet 900 mg, eskazina tablet 4 mg, nortriptyline 75 mg for one day. She was under care for 15 months and then due to muscle complications of lithium, pessimism, auditory and visual hallucination, she was recommended to take olanzapine tablet 5 mg once every night. Two days after taking olanzapine the symptoms of hypomania revealed. Consumption of olanzapine was then stopped and the symptoms disappeared and she was brought under control after taking sodiumvalproate tablet. Conclusion: Rarely could Hypomania be a mood episode induced by consuming atypical antipsychotics such as risperidone and olanzapine.

  15. Efficacy of ziprasidone and risperidone in treatment of vagrants with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    Zhan-Hua Li; Zhi-Xiang Li

    2016-01-01

    Objective:To explore the clinical efficacy of ziprasidone and risperidone in the treatment of vagrants with schizophrenia.Methods:A total of 70 vagrants with schizophrenia who were admitted in our hospital from December, 2014 to December, 2015 were included in the study and divided into the observation group (ziprasidone) and the control group (risperidone) according to different treatment protocols. In the observation group, the initial dosage of ziprasidone was 20 mg/d, and was gradually increased to 80-160 mg/d within 10 d, with an average dosage of (105.6±38.7) mg/d. In the control group, the initial dosage of risperidone was 1 mg/d, and was gradually increased to 3-5 mg/d within 10 d, with an average dosage of (3.6±0.9) mg/d. Eight-week treatment was regarded as one course. PANSS was used for grading before and after treatment. The levels of FBG, TG, TC, and HDL-C before and after treatment were detected. The adverse reactions after treatment were observed.Results:With the extending of treatment time, PANSS positive symptoms, negative symptoms, psychosis symptoms, and total scores in the two groups were significantly reduced when compared with before treatment (P0.05). After treatment, the levels of FBG, TG, TC, and HDL-C in the observation group were not significantly different from those before treatment (P>0.05), while those levels in the control group were significantly elevated when compared with before treatment (P<0.05), and those in the observation group were significantly superior to those in the control group (P<0.05). After treatment, the occurrence rate of adverse reactions in the observation was significantly lower than that in the control group (P<0.05).Conclusions: The clinical efficacy of ziprasidone and risperidone in the treatment of vagrants with schizophrenia is equal, but ziprasidone has a small effect on the blood sugar and lipid, with less adverse reactions and preferable compliance; therefore, it deserves to be widely recommended in

  16. Bioequivalence study of a generic Risperidone (Iperdal® in healthy Thai male volunteers

    Directory of Open Access Journals (Sweden)

    Werawath Mahatthanatrakul

    2008-05-01

    Full Text Available The objective of this study was to compare the rate and extent of absorption of a generic risperidone (Iperdal® with a reference formulation (Risperdal® when given orally. The study was an open label, randomized, two-period, two-sequence,single dose cross-over design with a 2 weeks washout period in 16 healthy Thai male volunteers. Single oral dose of two 2-mg tablets of risperidone were administered and serial blood samples were collected from the antecubital vein before and at0.17, 0.33, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 and 48 hours post dose. Risperidone plasma concentrations were assayed using a validated High Performance Liquid Chromatographic (HPLC-UV method modified from Avenosoet al. (2000. Pharamcokinetic parameters i.e. Cmax, AUC0à48 and Tmax were analyzed by noncompartment analysis. Variations of the data were analyzed by “Two Way Analysis of Variance” (ANOVA. Statistics were tested as stated in USP 28 guidelinefor bioequivalence study. The maximum concentration (Cmax, ng/ml of risperidone for the innovator and the generic product were 31.11±17.24 (range 5.64-56.78 and 32.58±19.77 (range 5.29-84.56 ng/ml, respectively. The area under theplasma concentration-time curve (AUC0®48 of the innovator and the generic product were 160.64±152.89 (range 18.57- 550.32 and 144.03±127.37 (range 16.27-456.0 ng.hr/ml, respectively. The time to maximum concentration (Tmax of theinnovator and the generic product were 0.97±0.41(range 0.5-2 and 1.02±0.32 (range 0.5-1.5 hr, respectively. The 90% confidence interval of the ratio of the ln-transformed of Cmax and AUC0à48 of both preparations were 89.39-112.99% and80.02-107.28% respectively which were within the acceptance range of 80.00-125.00%. Therefore, it can be concluded that both preparations used in this study are bioequivalent in terms of both the rate and extent of absorption.

  17. Evaluation of teratogenic effects of risperidone following simultaneous administration with antihypertensive and antiemetic drugs.

    Science.gov (United States)

    Tauqeer, Shaista; Khan, Rafeeq Alam; Siddiqui, Afaq Ahmed

    2012-01-01

    Multiple drug administration is an important aspect of clinical practice particularly in specific physiological situation such as in neonates, elderly or pregnancy, since in all such situations, possibility of unwanted effects increases due to altered body physiology. In present study, the teratogenic effects of multiple drug administration risperidone, meclizine/pyridoxine and hydralazine have been compared with the teratogenic effects of individual drugs in pregnant mice. Moreover the role of folic acid and α-tocopherol if any had also been investigated in reducing the teratogenic effects of these drugs in combinations.

  18. Effect of Maternal ±Citalopram Exposure on P11 Expression and Neurogenesis in the Mouse Fetal Brain.

    Science.gov (United States)

    King, Jennifer R; Velasquez, Juan C; Torii, Masaaki; Bonnin, Alexandre

    2017-01-13

    Fetal exposure to selective serotonin reuptake inhibitors (SSRI) has been associated with increased risk of adverse neurodevelopmental outcomes. In the adult brain, SSRI therapy regulates p11 (s100a10) expression and alters neurogenesis. The protein p11 indirectly regulates 5-HT signaling through 5-HT1B/D receptors. In the fetal brain, signaling through these receptors modulates axonal circuit formation. We determined whether p11 is expressed in the fetal mouse brain, and whether maternal SSRI exposure affects fetal p11 expression and neurogenesis. The SSRI ± citalopram was administered to pregnant mice from gestational day 8 to 17. Results show that p11 is expressed in fetal thalamic neurons and thalamocortical axons. Furthermore, p11 protein expression is significantly decreased in the fetal thalamus after in utero ±citalopram exposure compared to untreated controls, and neurogenesis is significantly decreased in specific fetal brain regions. These findings reveal differential regulation of p11 expression and altered neurogenesis in the fetal brain as a result of maternal SSRI exposure.

  19. Melatonin synergizes with citalopram to induce antidepressant-like behavior and to promote hippocampal neurogenesis in adult mice.

    Science.gov (United States)

    Ramírez-Rodríguez, Gerardo; Vega-Rivera, Nelly Maritza; Oikawa-Sala, Julián; Gómez-Sánchez, Ariadna; Ortiz-López, Leonardo; Estrada-Camarena, Erika

    2014-05-01

    Adult hippocampal neurogenesis is affected in some neuropsychiatric disorders such as depression. Numerous evidence indicates that plasma levels of melatonin are decreased in depressed patients. Also, melatonin exerts positive effects on the hippocampal neurogenic process and on depressive-like behavior. In addition, antidepressants revert alterations of hippocampal neurogenesis present in models of depression following a similar time course to the improvement of behavior. In this study, we analyzed the effects of both, citalopram, a widely used antidepressant, and melatonin in the Porsolt forced swim test. In addition, we investigated the potential antidepressant role of the combination of melatonin and citalopram (MLTCITAL), its type of pharmacological interaction on depressive behavior, and its effect on hippocampal neurogenesis. Here, we found decreased immobility behavior in mice treated with melatonin (29%), survival (>39%), and the absolute number of -associated new neurons (>53%) in the dentate gyrus of the hippocampus. These results indicate that the MLTCITAL combination exerts synergism to induce an antidepressant-like action that could be related to the modulation of adult hippocampal neurogenesis. This outcome opens the opportunity of using melatonin to promote behavioral benefits and hippocampal neurogenesis in depression and also supports the use of the MLTCITAL combination as an alternative to treat depression.

  20. Effects of the SSRI citalopram on behaviours connected to stress and reproduction in Endler guppy, Poecilia wingei.

    Science.gov (United States)

    Olsén, K Håkan; Ask, Katarina; Olsén, Hanna; Porsch-Hällström, Inger; Hallgren, Stefan

    2014-03-01

    Psychoactive drugs, such as selective serotonin reuptake inhibitors (SSRI) have been identified in high levels in effluents from Swedish sewage treatment plants (STP) at concentrations high enough to give pharmacological effects in fish. In humans SSRIs are used in the treatment of depression and they have anxiolytic effects. In the present study we exposed Endler guppy (Poecilia wingei) of both sexes to citalopram that showed the highest concentrations of SSRIs in STP effluents and studied reproductive and non-reproductive behaviour. Male courting behaviours were not affected compared to control fish after 14-28 days exposure to 1 μg L(-1). In two experiments exposing both sexes to 0.2, 2.3 or 15 μg L(-1) for 21 days, fish exposed to the two highest doses showed anxiolytic effects when placed in a novel environment (novel tank diving test, NT). Males were only affected by exposure to 15 μg L(-1). They had significantly longer latency to explore the upper half of the aquarium, more visits and longer time spent in the upper half, and showed less bottom freezing behaviour, all markers of anxiolytic behaviour. In females exposure to 2.3 or 15 μg L(-1) significantly increased freezing behaviour, while no effects on other behaviour variables were observed. No effects on shoaling behaviour could be discerned. These results show that citalopram have anxiolytic effects on guppy fish and thus affect ecologically relevant behaviours of importance to survival of fish.

  1. High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions

    DEFF Research Database (Denmark)

    Plenge, Per; Wiborg, Ove

    2005-01-01

    of presumed importance. Binding of S-citalopram, both to the high-affinity-binding site and to the allosteric binding site, was measured in these mutants with the purpose of investigating the connection between the two binding sites. The amino acid substitutions did not introduce large changes in the two...

  2. Association between tryptophan hydroxylase-2 genotype and the antidepressant effect of citalopram and paroxetine on immobility time in the forced swim test in mice.

    Science.gov (United States)

    Kulikov, Alexander V; Tikhonova, Maria A; Osipova, Daria V; Kulikov, Victor A; Popova, Nina K

    2011-10-01

    Tryptophan hydroxylase-2 (TPH2) is the rate limiting enzyme of serotonin synthesis in the brain. The 1473G allele of the C1473G polymorphism in mTPH2 gene is associated with reduced enzyme activity and serotonin synthesis rate in the mouse brain. Here, the influence of the 1473G allele on the antidepressant effect of selective serotonin reuptake inhibitors (SSRIs), citalopram (2.5 or 5.0mg/kg) and paroxetine (5.0 or 10.0mg/kg), in the forced swim test was studied using B6-1473G and B6-1473C congenic mouse lines with the 1473G (decreased TPH2 activity) or 1473C (normal TPH2 activity) alleles, respectively, transferred to the genome of C57BL/6 mouse strain. Paroxetine (5.0 or 10.0mg/kg) and citalopram (2.5 or 5.0mg/kg) decreased immobility time in B6-1473C mice, while both doses of paroxetine and 2.5mg/kg of citaloprame did not alter immobility time in B6-1473G mice. However, 5.0mg/kg of citalopram reduced immobility in B6-1473G mice. The results provided genetic evidence of moderate association between 1473G allele and reduced sensitivity to SSRIs in mice.

  3. “Positive allosteric modulation of AMPA receptors differentially modulates the behavioural effects of citalopram in mouse models of antidepressant and anxiolytic action”

    DEFF Research Database (Denmark)

    Fitzpatrick, Ciarán Martin; Larsen, Maria; Madsen, Louise;

    2016-01-01

    serotonin reuptake inhibitor (SSRI) citalopram (0-10 mg/kg) was investigated in mice, using the APAM LY451646 (0-3 mg/kg). Antidepressant-like effects were assessed with the forced swim test (FST), while anxiolytic-like effects were tested with the elevated zero maze (EZM) and the marble burying test (MBT...

  4. CB-1 receptors modulate the effect of the selective serotonin reuptake inhibitor, citalopram on extracellular serotonin levels in the rat prefrontal cortex

    NARCIS (Netherlands)

    Kleijn, Jelle; Cremers, Thomas I. F. H.; Hofland, Corry M.; Westerink, Ben H. C.

    2011-01-01

    A large percentage of depressed individuals use drugs of abuse, like cannabis. This study investigates the impact of cannabis on the pharmacological effects of the antidepressant citalopram. Using microdialysis in the prefrontal cortex of rats we monitored serotonin levels before and after cannabino

  5. Waterborne citalopram has anxiolytic effects and increases locomotor activity in the three-spine stickleback (Gasterosteus aculeatus)

    DEFF Research Database (Denmark)

    Kellner, M; Porseryd, T; Hallgren, S;

    2016-01-01

    to analyse different aspects of behavioural effects of chronic citalopram exposure in fish. Our model species the three-spine stickleback is common in the entire northern hemisphere and is considered to be a good environmental sentinel species. Female three-spine sticklebacks were exposed to 0, 1.5 and 15μg...

  6. Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype.

    Science.gov (United States)

    Henry, Michael E; Lauriat, Tara L; Lowen, Steven B; Churchill, Jeffrey H; Hodgkinson, Colin A; Goldman, David; Renshaw, Perry F

    2013-09-30

    This study was designed to assess whether functional magnetic resonance imaging (fMRI) following antidepressant administration (pharmaco-fMRI) is sufficiently sensitive to detect differences in patterns of activation between enantiomers of the same compound. Healthy adult males (n=11) participated in a randomized, double-blind, cross-over trial with three medication periods during which they received citalopram (racemic mixture), escitalopram (S-citalopram alone), or placebo for 2 weeks. All participants had high expression serotonin transporter genotypes. An fMRI scan that included passive viewing of overt and covert affective faces and affective words was performed after each medication period. Activation in response to overt faces was greater following escitalopram than following citalopram in the right insula, thalamus, and putamen when the faces were compared with a fixation stimulus. For the rapid covert presentation, a greater response was observed in the left middle temporal gyrus in the happy versus fearful contrast following escitalopram than following citalopram. Thus, the combination of genomics and fMRI was successful in discriminating between two very similar drugs. However, the pattern of activation observed suggests that further studies are indicated to understand how to optimally combine the two techniques.

  7. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.

    Science.gov (United States)

    Sørensen, Jan; Stage, Kurt B; Damsbo, Niels; Le Lay, Agathe; Hemels, Michiel E

    2007-01-01

    The objective of this study was to model the cost-effectiveness of escitalopram in comparison with generic citalopram and venlafaxine in primary care treatment of major depressive disorder (baseline scores 22-40 on the Montgomery-Asberg Depression Rating Scale, MADRS) in Denmark. A three-path decision analytic model with a 6-month horizon was used. All patients started at the primary care path and were referred to outpatient or inpatient secondary care in the case of insufficient response to treatment. Model inputs included drug-specific probabilities derived from systematic literature review, ad-hoc survey and expert opinion. Main outcome measures were remission defined as MADRS escitalopram (64.1%) than citalopram (58.9%). From both perspectives, the total expected cost per successfully treated patient was lower for escitalopram (DKK 22,323 healthcare, DKK 72,399 societal) than for citalopram (DKK 25,778 healthcare, DKK 87,786 societal). Remission rates and costs were similar for escitalopram and venlafaxine. Robustness of the findings was verified in multivariate sensitivity analyses. For patients in primary care, escitalopram appears to be a cost-effective alternative to (generic) citalopram, with greater clinical benefit and cost-savings, and similar in cost-effectiveness to venlafaxine.

  8. A retrospective study of risperidone oral solution versus risperidone tablets in treating schizophrenia%利培酮口服液与片剂治疗精神分裂症的回顾性分析

    Institute of Scientific and Technical Information of China (English)

    钟智勇; 吴小立; 韩自力; 张晋碚

    2011-01-01

    AIM To retrospectively evaluate the efficacy and safety of risperidone oral solution and risperidone tablets in treating schizophrenia. METHODS A total of 204 patients, who met diagnostic criteria of CCMD-3 for schizophrenia and were hospitalized in our department of psychiatry from May 2007 to May 2011, included 85 patients in risperidone oral solution group and 119 patients in risperidone tablets group. Before the treatment and at the end of the 4 th week of the treatment, all patients were assessed by Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS), Treatment Emergent Symptom Scale (TESS) and laboratory tests. RESULTS There were significant differences in total scales of TESS and the rates of ECG abnormalities and extrapyramidal side effects between the risperidone oral solution group and risperidone tablets group (6.62 ± 3.65 vs. 7.97 ± 4.93, 16.5%vs. 28.6%, 23.5% vs. 40.3%, P0.05) in the total scales of BPRS, SANS, SAPS and other index of safety. CONCLUSION The efficacy of risperidone oral solution and risperidone tablets in treating schizophrenia was equal, but risperidone oral solution is superior to risperidone tablets on the safety.%目的 比较利培酮口服液与利培酮片剂治疗精神分裂症的疗效与安全性.方法 回顾性分析2007年5月至201 1年5月在本科室住院4 wk以上,符合CCMD-3精神分裂症诊断标准的患者共204例,其中利培酮口服液组85例,利培酮片剂组119例.比较2组患者治疗前与治疗4 wk末简明精神病评定量表、阳性症状量表、阴性症状量表、副反应量表总分以及实验室检查的差异.结果 2组治疗4 wk末简明精神病评定量表、阳性症状量表、阴性症状量表分值无显著差异(P>0.05).利培酮口服液组副反应量表总分、心电图异常发生率以及锥体外系反应发生率明显低于利培酮片剂组(6.62±3.65 vs.7.97±4.93,16.5

  9. A Double-Blind Placebo Controlled Trial of "Ginkgo Biloba" Added to Risperidone in Patients with Autistic Disorders

    Science.gov (United States)

    Hasanzadeh, Elmira; Mohammadi, Mohammad-Reza; Ghanizadeh, Ahmad; Rezazadeh, Shams-Ali; Tabrizi, Mina; Rezaei, Farzin; Akhondzadeh, Shahin

    2012-01-01

    "Ginkgo biloba" has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of "Ginkgo biloba" extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of…

  10. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.

    Science.gov (United States)

    Qiao, Ying; Yang, Fuzhong; Li, Chunbo; Guo, Qian; Wen, Hui; Zhu, Suoyu; Ouyang, Qiong; Shen, Weidi; Sheng, Jianhua

    2016-03-30

    This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period. The prolactin levels at the end of the 8th week were significantly lower in the treatment group than in the control group. The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. The Positive and Negative Syndrome Scale score improved significantly during the 8-week study period in both groups. The incidence of treatment-emergent adverse event was similar in two groups. Low-dose aripiprazole adjunctive treatment is effective in relieving risperidone- and paliperidone-induced hyperprolactinemia in female schizophrenic patients without increasing adverse event.

  11. Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: An open label study

    Directory of Open Access Journals (Sweden)

    Padideh Ghaeli

    2014-01-01

    Full Text Available Background: The aim of the present study was to evaluate the effect of risperidone in patients afflicted by autistic disorder especially with regards to its three core symptoms, including "relating to others", "communication skills", and "stereotyped behaviors" based on Childhood Autism Rating Scale (CARS. Materials and Methods: An 8-week open-label study of risperidone for treatment of autistic disorder in children 4-17 years old was designed. Risperidone dose titration was as follow: 0.02 mg/kg/day at the first week, 0.04 mg/kg/day at the second week, and 0.06 mg/kg/day at the third week and thereafter. The outcome measures were scores obtained by CARS, Aberrant Behavior Checklist (ABC, and Clinical Global Impression-Improvement (CGI-I scale. Results: Fifteen patients completed this study. After 8 weeks, CARS total score decreased significantly, (P=0.001. At the end of the study, social interactions and verbal communication skills of the patients were significantly improved (P<0.001, P=0.03, respectively. However, stereotypic behaviors did not show any significant change in this study. Increase in appetite and somnolence were the most reported side effects. Conclusion: This study suggests that risperidone may be an effective treatment for the management of core symptoms of autistic disorder.

  12. Risperidone long-acting injection: a review of its long term safety and efficacy

    Directory of Open Access Journals (Sweden)

    Michael K Rainer

    2008-08-01

    Full Text Available Michael K RainerMemory-Clinic and Psychiatric Department, Donauspital, Vienna, AustriaAbstract: A long-acting form of the second-generation antipsychotic drug risperidone is now broadly available for the treatment of schizophrenia and closely related psychiatric conditions. It combines the advantage of previously available depot formulations for first-generation drugs with the favorable characteristics of the modern “atypical” antipsychotics, namely higher efficacy in the treatment of the negative symptoms of schizophrenia and reduced motor disturbances. Published clinical studies show an objective clinical efficacy (as per psychiatric symptom scores and relapse data that exceeds that of oral atypical antipsychotics when patients are switched to the long-acting injectable form, a low incidence of treatment-emergent extrapyramidal side effects, and very good acceptance by patients. Available data for maintenance treatment of bipolar disorder show equivalence with the oral form instead of superiority, but are still limited. As it seems likely that efficacy benefits are mostly due to the fact that the injectable form reduces the demand for patient compliance to one physician visit every 2 weeks instead of self-administration on a daily or twice-daily basis, additional potential could exist in other psychiatric disorders where atypical antipsychotic drugs are of benefit but where patient adherence to treatment schedules is typically low.Keywords: risperidone, schizophrenia, psychotic disorders, patient compliance; delayed-action preparations, injections, intramuscular

  13. Selective acquired long QT syndrome (saLQTS upon risperidone treatment

    Directory of Open Access Journals (Sweden)

    Lazarczyk Maciej

    2012-12-01

    Full Text Available Abstract Background Numerous structurally unrelated drugs, including antipsychotics, can prolong QT interval and trigger the acquired long QT syndrome (aLQTS. All of them are thought to act at the level of KCNH2, a subunit of the potassium channel. Although the QT-prolonging drugs are proscribed in the subjects with aLQTS, the individual response to diverse QT-prolonging drugs may vary substantially. Case presentation We report here a case of aLQTS in response to small doses of risperidone that was confirmed at three independent drug challenges in the absence of other QT-prolonging drugs. On the other hand, the patient did not respond with QT prolongation to some other antipsychotics. In particular, the administration of clozapine, known to be associated with higher QT-prolongation risk than risperidone, had no effect on QT-length. A detailed genetic analysis revealed no mutations or polymorphisms in KCNH2, KCNE1, KCNE2, SCN5A and KCNQ1 genes. Conclusions Our observation suggests that some patients may display a selective aLQTS to a single antipsychotic, without a potassium channel-related genetic substrate. Contrasting with the idea of a common target of the aLQTS-triggerring drugs, our data suggests existence of an alternative target protein, which unlike the KCNH2 would be drug-selective.

  14. Delayed drug interactions in psychiatry: armodafinil and risperidone as a potential case in point.

    Science.gov (United States)

    Andrade, Chittaranjan

    2015-12-01

    Modafinil or armodafinil (ar/mod) augmentation of antipsychotic medication in schizophrenia patients may be considered with a view to reduce negative symptoms associated with the illness or excessive daytime drowsiness due to any cause. The available data suggest that there is no role for ar/mod in reducing negative symptom burden. A recent pharmacokinetic (PK) study suggested that armodafinil (250 mg/d) reduces key PK parameters of risperidone by about 50%, and key PK parameters of 9-hydroxyrisperidone (paliperidone) by about 20%-30%, probably through induction of CYP3A4. Ar/mod augmentation is therefore best avoided in patients receiving risperidone or paliperidone (and most other atypical antipsychotic drugs, as well, because most atypical antipsychotics are metabolized by enzymes that ar/mod induce). If the ar/mod-antipsychotic drug combination is necessary, for whatever reason, then the dose of the atypical antipsychotic drug may need to be appropriately raised. If this is not done, relapse may occur; because the relapse may postdate the introduction of ar/mod by many months, the causal role of a metabolic drug interaction may not be suspected, and physicians may attribute the relapse to the natural course of the illness. Physicians need to be aware that any agent that induces the metabolism of psychotropic drugs that are used in maintenance therapy may, through lowered psychotropic drug levels, result in a delayed drug interaction that is characterized by illness relapse.

  15. An open-label trial of risperidone and fluoxetine in children with autistic disorder

    Directory of Open Access Journals (Sweden)

    Desousa Avinash

    2010-01-01

    Full Text Available Objective: Various studies have shown the effectiveness of risperidone and fluoxetine in the management of behavioral problems in autism. Aim: The purpose of this study was to compare these two drugs in the management of behavioral problems in autism. Materials and Methods: Forty children with autism were divided into 2 groups in a 16-week open trial that compared these two drugs. Parents rated the children using the Aberrant Behavior Checklist (ABC and the Conners′ Parent Rating Scale - Revised (CPRS-R. The author rated the children using the Children′s Psychiatric Rating Scale and Clinical Global Impression (CGI Scale. Results: The risperidone group showed significant improvement in areas like irritability and hyperactivity, while the fluoxetine group showed significant improvement in speech deviance, social withdrawal and stereotypy. When the two drugs were compared, fluoxetine showed greater improvement in stereotypy, while both drugs showed improvement on the general autism scale; and on anger, hyperactivity and irritability scales. Conclusions : In this open trial, both drugs were well tolerated and appeared to be beneficial in the treatment of common behavioral problems in children with autism. Further controlled and double-blind studies in larger samples are warranted.

  16. Clinical doses of citalopram or reboxetine differentially modulate passive and active behaviors of female Wistar rats with high or low immobility time in the forced swimming test.

    Science.gov (United States)

    Flores-Serrano, Ana Gisela; Vila-Luna, María Leonor; Álvarez-Cervera, Fernando José; Heredia-López, Francisco José; Góngora-Alfaro, José Luis; Pineda, Juan Carlos

    2013-09-01

    The sensitivity of immobility time (IT) to antidepressant-drugs differs in rats expressing high or low motor activity during the forced swimming test (FST). However, whether this heterogeneity is expressed after the administration of the most selective serotonin and norepinephrine reuptake inhibitors (SSRIs and SNRIs, respectively) is unknown. We compared the influence of either the SSRI citalopram or the SNRI reboxetine with the tricyclic antidepressant amitriptyline on two subgroups of female Wistar rats expressing high IT (HI; at or above the mean value) or low IT (LI; below the mean) during the initial 5 min of the first session of the FST. None of the tested drugs increased motor activity in the open field test. When vehicle was applied to either HI or LI rats, IT increased in the second session of the FST. This increment concurred with a simultaneous climbing time (CT) decrement. When amitriptyline (15 mg/kg) was tested the CT increased for both HI and LI rats. This increment was accompanied by an IT decrement in HI and LI rats. Reboxetine (0.16 or 1 mg/kg) precluded IT and CT changes in both HI and LI rats and produced a swimming time reduction. Citalopram (0.4, 1, and 3 mg/kg) essentially mimicked the influence of reboxetine on the IT and CT in LI rats, as well as in HI rats, but in the latter case only at 3 mg/kg. Yet, at the dose of 10 mg/kg citalopram lacked this effect in both subgroups. No differences were detected when the IT of LI rats was evaluated with citalopram (3 mg/kg) during estrus or diestrus stage. These results show that clinical doses of citalopram produced an antidepressant-like effect selectively in LI rats, while amitriptyline or reboxetine produced this effect in both LI and HI animals.

  17. Effect of desipramine and citalopram treatment on forced swimming test-induced changes in cocaine- and amphetamine-regulated transcript (CART) immunoreactivity in mice.

    Science.gov (United States)

    Chung, Sung; Kim, Hee Jeong; Kim, Hyun Ju; Choi, Sun Hye; Kim, Jin Wook; Kim, Jeong Min; Shin, Kyung Ho

    2014-05-01

    Recent study demonstrates antidepressant-like effect of cocaine- and amphetamine-regulated transcript (CART) in the forced swimming test (FST), but less is known about whether antidepressant treatments alter levels of CART immunoreactivity (CART-IR) in the FST. To explore this possibility, we assessed the treatment effects of desipramine and citalopram, which inhibit the reuptake of norepinephrine and serotonin into the presynaptic terminals, respectively, on changes in levels of CART-IR before and after the test swim in mouse brain. Levels of CART-IR in the nucleus accumbens shell (AcbSh), dorsal bed nucleus of the stria terminalis (dBNST), and hypothalamic paraventricular nucleus (PVN) were significantly increased before the test swim by desipramine and citalopram treatments. This increase in CART-IR in the AcbSh, dBNST, and PVN before the test swim remained elevated by desipramine treatment after the test swim, but this increase in these brain areas returned to near control levels after test swim by citalopram treatment. Citalopram, but not desipramine, treatment increased levels of CART-IR in the central nucleus of the amygdala (CeA) and the locus ceruleus (LC) before the test swim, and this increase was returned to control levels after the test swim in the CeA, but not in the LC. These results suggest common and distinct regulation of CART by desipramine and citalopram treatments in the FST and raise the possibility that CART in the AcbSh, dBNST, and CeA may be involved in antidepressant-like effect in the FST.

  18. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study.

    Science.gov (United States)

    Windischberger, Christian; Lanzenberger, Rupert; Holik, Alexander; Spindelegger, Christoph; Stein, Patrycja; Moser, Ulrike; Gerstl, Florian; Fink, Martin; Moser, Ewald; Kasper, Siegfried

    2010-01-15

    Area-specific and stimulation-dependent changes of human brain activation by selective serotonin reuptake inhibitors (SSRI) are an important issue for improved understanding of treatment mechanisms, given the frequent prescription of these drugs in depression and anxiety disorders. The aim of this neuroimaging study was to investigate differences in BOLD-signal caused by administration of the SSRIs escitalopram and citalopram using pharmacological functional magnetic resonance imaging (pharmaco-fMRI). Eighteen healthy subjects participated in a placebo-controlled, randomized, double-blind study in cross-over repeated measures design. Each volunteer performed facial emotional discrimination and a sensorimotor control paradigm during three scanning sessions. Citalopram (20 mg/d), escitalopram (10 mg/d) and placebo were administered for 10 days each with a drug-free period of at least 21 days. Significant pharmacological effects on BOLD-signal were found in the amygdala, medial frontal gyrus, parahippocampal, fusiform and middle temporal gyri. Post-hoc t-tests revealed decreased BOLD-signal in the right amygdala and left parahippocampal gyrus in both pharmacological conditions, compared to placebo. Escitalopram, compared to citalopram, induced a decrease of BOLD-signal in the medial frontal gyrus and an increase in the right fusiform and left parahippocampal gyri. Drug effects were concentrated in brain regions with dense serotonergic projections. Both escitalopram and citalopram attenuated BOLD-signal in the amygdala and parahippocampal cortex to emotionally significant stimuli compared to control stimuli. We believe that reduced reactivity in the medial frontal gyrus found for escitalopram compared to citalopram administration might explain the response differences between study drugs as demonstrated in previous clinical trials.

  19. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients.

    Science.gov (United States)

    Wei, Zhiyun; Wang, Lei; Zhang, Mengmeng; Xuan, Jiekun; Wang, Yang; Liu, Baocheng; Shao, Liyan; Li, Jun; Zeng, Zhen; Li, Tao; Liu, Jie; Wang, Ti; Zhang, Ming; Qin, Shengying; Xu, Yifeng; Feng, Guoyin; He, Lin; Xing, Qinghe

    2012-06-01

    Evidence suggests that the human histamine H3 receptor (HRH3) may be involved in the pharmacodynamics of risperidone and influence clinical efficacy. More information on the pharmacogenetics of this receptor may therefore be useful in developing individualized therapy. However, to our knowledge, no study has been reported in this area. The aim of this investigation was to clarify whether H3 receptor polymorphism could affect risperidone efficacy. We genotyped tag single nucleotide polymorphisms (SNPs) of the HRH3 gene (rs3787429 and rs3787430) and analyzed their association with the reduction of Brief Psychiatric Rating Scale (BPRS) score in Chinese Han schizophrenia patients (N = 129), following an eight-week period of risperidone monotherapy. The confounding effects of non-genetic factors were estimated, and then the significant one was included as the covariate for adjustment in statistical analysis. Baseline symptom score was the only significant confounding effect and thus the covariate. After adjustment, significant association of HRH3 with antipsychotic efficacy was detected (for rs3787429, p = 0.013, 0.087 after 4 weeks and 8 weeks of treatment, respectively; for rs3787430, p = 0.024, 0.010 after 4 weeks and 8 weeks of treatment, respectively) and stood up to conservative Bonferroni correction. Our results demonstrate that polymorphism of the HRH3 gene may be a potential genetic marker for predicting the therapeutic effect of risperidone, and suggest novel pharmacological links between HRH3 and risperidone. Further studies with larger samples and different ethnic populations are warranted to confirm our results.

  20. Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.

    Directory of Open Access Journals (Sweden)

    Irina Vasilyeva

    Full Text Available BACKGROUND: Despite concerns over the potential for severe adverse events, antipsychotic medications remain the mainstay of treatment of behaviour disorders and psychosis in elderly patients. Second-generation antipsychotic agents (SGAs; e.g., risperidone, olanzapine, quetiapine have generally shown a better safety profile compared to the first-generation agents (FGAs; e.g., haloperidol and phenothiazines, particularly in terms of a lower potential for involuntary movement disorders. Risperidone, the only SGA with an official indication for the management of inappropriate behaviour in dementia, has emerged as the antipsychotic most commonly prescribed to older patients. Most clinical trials evaluating the risk of movement disorders in elderly patients receiving antipsychotic therapy have been of limited sample size and/or of relatively short duration. A few observational studies have produced inconsistent results. METHODS: A population-based retrospective cohort study of all residents of the Canadian province of Manitoba aged 65 and over, who were dispensed antipsychotic medications for the first time during the time period from April 1, 2000 to March 31, 2007, was conducted using Manitoba's Department of Health's administrative databases. Cox proportional hazards models were used to determine the risk of extrapyramidal symptoms (EPS in new users of risperidone compared to new users of FGAs. RESULTS: After controlling for potential confounders (demographics, comorbidity and medication use, risperidone use was associated with a lower risk of EPS compared to FGAs at 30, 60, 90 and 180 days (adjusted hazard ratios [HR] 0.38, 95% CI: 0.22-0.67; 0.45, 95% CI: 0.28-0.73; 0.50, 95% CI: 0.33-0.77; 0.65, 95% CI: 0.45-0.94, respectively. At 360 days, the strength of the association weakened with an adjusted HR of 0.75, 95% CI: 0.54-1.05. CONCLUSIONS: In a large population of elderly patients the use of risperidone was associated with a lower risk of EPS

  1. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial

    DEFF Research Database (Denmark)

    Bech, P; Fava, Maurizio; Trivedi, M H;

    2012-01-01

    Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Objective: To compare within the framework of a novel pharmacopsychometric triangle, augmentation treatment with bupropion...... Scale (HAM-D(17) ) and of the Inventory of Depressive Symptomatology (IDS-C(30) ), referred to as HAM-D(6) and IDS-C(6) , were focussed on pure antidepressive effect. Side-effects (tolerable vs. intolerable) and quality of life were measured using patient-administered questionnaires. A modified......-C(6) , and IDS-C(30) , but not on the HAM-D(17) . In the domain of side effects, the total scores on the Patient Rated Inventory of Side Effects (PRISE) were reduced significantly more by bupropion-SR than by buspirone (P = 0.03). In the domain of quality of life, the total scores on the Quality...

  2. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity

    DEFF Research Database (Denmark)

    Østergaard, Søren Dinesen; Bech, Per; Trivedi, Madhukar H

    2014-01-01

    BACKGROUND: Most depression rating scales are multidimensional and the resulting heterogeneity may impede identification of coherent biomarkers. The aim of this study was to compare the psychometric performance of the multidimensional 17-item Hamilton Depression Rating Scale (HAM-D17) and the 30......-item Inventory of Depressive Symptomatology (IDS-C30) to that of their unidimensional six-item melancholia subscales (HAM-D6 and IDS-C6). METHODS: A total of 2242 subjects from level 1 (citalopram) of the Sequenced Treatment Alternatives to Relieve Depression (STAR* study were included in the analysis....... Symptom change, response and remission rates were compared for HAM-D6 versus HAM-D17 and for IDS-C6 versus IDS-C30. The changes in total scores on these scales were compared to the change in Quality of Life Enjoyment and Satisfaction Questionnaire (QLES-Q) score using correlation analysis. RESULTS...

  3. [18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge

    DEFF Research Database (Denmark)

    Pinborg, L. H.; Adams, K. H.; Yndsgaard, S;

    2004-01-01

    The aim of the present study was to develop an experimental paradigm for the study of serotonergic neurotransmission in humans using positron emission tomography and the 5-HT2A selective radioligand [18F]altanserin. [18F]altanserin studies were conducted in seven subjects using the bolus...... subjects as a constant infusion for 20 minutes. To reduce 5-HT1A-mediated autoinhibition of cortical 5-HT release, four of the seven subjects were pretreated with the partial 5-HT1A agonist pindolol for 3 days at an increasing oral dose (25 mg on the day of scanning). In each subject, the baseline...... condition (120 to 180 minutes) was compared with the stimulated condition (195 to 300 minutes). Despite a pronounced increase in plasma prolactin and two subjects reporting hot flushes compatible with an 5-HT-induced adverse effect, cortical [18F]altanserin binding was insensitive to the citalopram...

  4. [18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge

    DEFF Research Database (Denmark)

    Pinborg, L. H.; Adams, K. H.; Yndsgaard, S;

    2004-01-01

    subjects as a constant infusion for 20 minutes. To reduce 5-HT1A-mediated autoinhibition of cortical 5-HT release, four of the seven subjects were pretreated with the partial 5-HT1A agonist pindolol for 3 days at an increasing oral dose (25 mg on the day of scanning). In each subject, the baseline...... condition (120 to 180 minutes) was compared with the stimulated condition (195 to 300 minutes). Despite a pronounced increase in plasma prolactin and two subjects reporting hot flushes compatible with an 5-HT-induced adverse effect, cortical [18F]altanserin binding was insensitive to the citalopram......The aim of the present study was to develop an experimental paradigm for the study of serotonergic neurotransmission in humans using positron emission tomography and the 5-HT2A selective radioligand [18F]altanserin. [18F]altanserin studies were conducted in seven subjects using the bolus...

  5. Danish physicians' preferences for prescribing escitalopram over citalopram and sertraline to treatment-naïve patients

    DEFF Research Database (Denmark)

    Poulsen, Karen Killerup; Glintborg, Dorte; Moreno, Søren Ilsøe

    2013-01-01

    PURPOSE: To investigate whether general practitioners, hospital physicians and specialized practitioners in psychiatry have similar preferences for initiating treatment with expensive serotonin-specific reuptake inhibitors (SSRIs). METHODS: All first-time prescriptions for the SSRIs escitalopram....... Of the treatment-naïve patients, 19 % were initially prescribed escitalopram. Hospital physicians prescribed escitalopram to 34 % of their treatment-naïve patients, while practitioners specialized in psychiatry prescribed it to 25 %, and general practitioners prescribed it to 17 %. General practitioners, however......, were responsible for initiating 87 % of all treatment-naïve patients. CONCLUSION: The most expensive SSRI, escitalopram, is prescribed as first choice to one in five patients receiving their first antidepressant of escitalopram, citalopram or sertraline. General practitioners made the bulk of all first...

  6. Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice.

    Science.gov (United States)

    Rogóż, Zofia

    2010-01-01

    The aim of the present study was to examine the effect of mirtazapine (MIR) and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J mice. Fluoxetine (FLU) was used as a reference drug. MIR (2.5, 5 and 10 mg/kg) and FLU (5 and 10 mg/kg), or risperidone in low doses (0.05 and 0.1 mg/kg) given alone did not change the immobility time of mice in the forced swimming test. Joint administration of MIR (5 and 10 mg/kg) or FLU (10 mg/kg) and risperidone (0.1 mg/kg) produced antidepressant-like activity in the forced swimming test. WAY100636 (a 5-HT(1A) receptor antagonist) inhibited, while yohimbine (an α(2)-adrenergic receptor antagonist) potentiated the antidepressant-like effect induced by co-administration of MIR and risperidone. Active behavior in that test did not reflect an increase in general activity, since combined administration of antidepressants and risperidone failed to enhance the locomotor activity of mice. The obtained results indicate that risperidone applied in a low dose enhances the antidepressant-like activity of MIR and that, among other mechanisms, 5-HT(1A)-, and α(2)-adrenergic receptors may play a role in this effect.

  7. Comparison Of Effect Of Addition Of Fluvoxamine Or Risperidone To Clozapine In Chronic Partially Responsive Schizophrenic Patients On Clinical Response, QTc interval And Lipid profile

    Directory of Open Access Journals (Sweden)

    Sunil Mahakalkar

    2016-07-01

    Full Text Available Objective – To study & compare the augmentation effect of addition of fluvoxamine or risperidone in chronic partially responsive schizophrenic patients receiving clozapine on clinical and laboratory parameters.Methods - A prospective, randomized, parallel, open label 12 weeks study. The schizophrenic patients, aged 20-60 years, who followed the DSM-IV diagnostic criteria and receiving clozapine therapy, showing partial response to the treatment were recruited and the study was carried out from January 2007 to June 2008. Subjects were randomized into two groups: Group A (n=28: fluvoxamine (25-50mg/day was added to clozapine (25-200mg/day & Group B (n=27: risperidone (1-5mg/day was added to clozapine therapy. The effect of drugs was assessed by PANSS, BPRS scale and ECG and lipid profile were done at 6 and 12 weeks.Result - There was significant decrease in PANSS and BPRS score in both groups.Fluvoxamine + clozapine significantly reduced PANSS score as compared to risperidone + clozapine compared to baseline and between 6 and 12 weeks. Risperidone +clozapine prolonged QTc interval (at 12 weeks and elevated serum TG, VLDL, HDL significantly at 6 and 12 weeks.Conclusion – Although addition of fluvoxamine and risperidone to clozapine are effective in management of chronic partially responsive schizophrenia on clozapine, fluvoxamine is more effective as well as safer compared to Risperidone when compared for 6 and 12 weeks in these patients.

  8. Risperidone and lorazepam concomitant use in clonazepam refractory catatonia: a case report.

    Science.gov (United States)

    Grenier, Ernesto; Ryan, Molly; Ko, Elizabeth; Fajardo, Karina; John, Vineeth

    2011-12-01

    The DSM-IV recognizes catatonia as a subtype of schizophrenia characterized by at least two of the following: motor immobility, excessive motor activity not influenced by external stimuli, and peculiarities of voluntary movement. Catatonia may also occur secondary to mania, depression, or a general medical condition including encephalitis, focal neurological lesions, metabolic disturbances, and drug intoxications and withdrawals. Benzodiazepines remain the first line of treatment; up to 80% of patients respond promptly to Lorazepam challenge; failure to respond to lorazepam may be followed by electroconvulsive therapy. Atypical antipsychotics may be a new alternative in the treatment of catatonia. Successful reduction of the catatonic symptoms has been demonstrated with atypical antipsychotics. A possible mechanism of action for the efficacy of this class of drugs involves the antagonism of the 5-HT2A receptor. We are now reporting a case of treatment response to risperidone in a patient with chronic catatonia resistant to benzodiazepines.

  9. Crystal structure of citalopram hydrobromide, C20H22FN2OBr

    Energy Technology Data Exchange (ETDEWEB)

    Kaduk, James A.; Zhong, Kai; Gindhart, Amy M.; Blanton, Thomas N.

    2016-04-29

    The crystal structure of citalopram hydrobromide has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional theory techniques. Citalopram hydrobromide crystallizes in space group P21/c(#14) with a= 10.766 45(6),b= 33.070 86(16),c= 10.892 85(5) Å,β= 90.8518(3)°,V= 3878.03(4) Å3, andZ= 8. N–H∙∙∙Br hydrogen bonds are important to the structure, but the crystal energy is dominated by van der Waals attraction. The powder pattern was submitted to International Centre for Diffraction Data for inclusion in the Powder Diffraction File™.

  10. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

    DEFF Research Database (Denmark)

    Jeppesen, U; Gram, L F; Vistisen, K

    1996-01-01

    OBJECTIVE: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine and paroxetine. METHODS: The study...... by sparteine (CYP2D6), mephenytoin (CYP2C19) and caffeine (CYP1A2) tests. Fluoxetine was given at 3-week intervals because of the long half-life of fluoxetine and its metabolite norfluoxetine. Citalopram, fluoxetine and paroxetine were given in doses of 10, 20, 40 and 80 mg and fluvoxamine was given in doses...... after fluoxetine intake, although no volunteers changed phenotype from extensive metabolisers to poor metabolisers. Three of the six volunteers changed phenotype from extensive metabolisers to poor metabolisers after intake of 40 or 80 mg paroxetine. There was a statistically significant increase...

  11. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo Resposta das dimensões dos sintomas no transtorno obsessivo-compulsivo ao tratamento com citalopram ou placebo

    Directory of Open Access Journals (Sweden)

    Dan J Stein

    2007-12-01

    Full Text Available OBJECTIVE: There is increasing evidence that the symptoms of obsessive-compulsive disorder lie on discrete dimensions. Relatively little work has, however, explored the relationship between such factors and response to pharmacotherapy. METHOD: Data from a multi-site randomized placebo-controlled study of citalopram in obsessive-compulsive disorder were analyzed. Factor analysis of individual items and symptom categories of the Yale-Brown Obsessive-Compulsive Scale Checklist were undertaken, and the impact of symptom dimensions on treatment outcomes was analysed. RESULTS: Factor analysis of Yale-Brown Obsessive-Compulsive Scale Checklist individual items yielded 5 factors (contamination/cleaning, harm/checking, aggressive/sexual/religious, hoarding/symmetry, and somatic/hypochondriacal. Hoarding/symmetry was associated with male gender, longer duration of obsessive-compulsive disorder and early onset, whereas contamination/cleaning was associated with female gender. Citalopram was more effective than placebo, but high scores on the symmetry/hoarding and contamination/cleaning subscales predicted worse outcome at the end of study while high scores on the aggressive/religious/sexual subscale predicted better outcome. Factor analysis of Yale-Brown Obsessive-Compulsive Scale Checklist symptom clusters yielded a 4 factor solution, but confirmed that symmetry/ordering was associated with male gender, early onset, and long duration of obsessive-compulsive disorder while high scores on the hoarding subscale predicted worse response to pharmacotherapy. CONCLUSION: Citalopram shows good efficacy across the range of obsessive-compulsive disorder symptom dimensions. The relatively worse response of symmetry/hoarding to a selective serotonin reuptake inhibitor is consistent with other evidence that this symptom dimension is mediated by the dopamine system. There may be associations between symmetry/hoarding, male gender, early onset, tics, and particular

  12. Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female.

    Science.gov (United States)

    Afzal, Khalid I; Briones, David F; DeVargas, Cecilia

    2007-11-01

    A 15-year-old Hispanic female was started on risperidone for new-onset psychosis. The patient responded well to the gradual dose increase but developed rapid weight gain secondary to polydipsia and polyphagia. She also began complaining of nipple discharge and griping abdominal pain on the left lower quadrant by the third week of treatment. Her prolactin level escalated to three times normal with a weight gain of 12 pounds in 16 days. Risperidone was switched to another antipsychotic. Her prolactin level then dropped to a normal level within 7 days and she lost 7 pounds in the next 2 weeks. Her abdominal pain, galactorrhea, polydipsia, and polyphagia subsided within the first few days of the cessation of risperdione.

  13. Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys.

    Science.gov (United States)

    Banks, Matthew L; Blough, Bruce E

    2015-08-01

    Preclinical and human laboratory choice procedures have been invaluable in improving our knowledge of the neurobiological mechanisms of drug reinforcement and in the drug development process for candidate medications to treat drug addiction. However, little is known about the neuropharmacological mechanisms of methamphetamine vs food choice. The aims of this study were to develop a methamphetamine vs food choice procedure and determine treatment effects with two clinically relevant compounds: the monoamine uptake inhibitor bupropion and the dopamine antagonist risperidone. Rhesus monkeys (n=6) responded under a concurrent schedule of food delivery (1-g pellets, fixed-ratio (FR) 100 schedule) and intravenous methamphetamine injections (0-0.32 mg/kg/injection, FR10 schedule) during 7-day bupropion (0.32-1.8 mg/kg/h) and risperidone (0.001-0.0056 mg/kg/h) treatment periods. For comparison, effects of removing food pellets or methamphetamine injections and FR response requirement manipulations were also examined. Under saline treatment conditions, food was preferred over no methamphetamine or small unit methamphetamine doses (0.01-0.032 mg/kg/injection). Larger methamphetamine doses resulted in greater methamphetamine preference and 0.32 mg/kg/injection methamphetamine maintained near exclusive preference. Removing food availability increased methamphetamine choice, whereas removing methamphetamine availability decreased methamphetamine choice. Methamphetamine choice was not significantly altered when the FR response requirements for food and drug were the same (FR100:FR100 or FR10:FR10). Risperidone treatment increased methamphetamine choice, whereas bupropion treatment did not alter methamphetamine choice up to doses that decreased rates of operant behavior. Overall, these negative results with bupropion and risperidone are concordant with previous human laboratory and clinical trials and support the potential validity of this preclinical methamphetamine vs food

  14. Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

    Directory of Open Access Journals (Sweden)

    Roya Samadi

    2017-01-01

    Full Text Available Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7, in 2012–2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4–8 mg/d of ondansetron (n=18 or with a placebo (n=20 for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS, Wechsler’s Adult Intelligence Scale-Revised (WAIS-R, and Hamilton’s Rating Scale for Depression (HRSD at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16 were used to analyze the data. The statistical significance was set at P<0.05. Results: Ondansetron plus risperidone was associated with a significantly larger improvement in the PANSS overall scale and subscales for negative symptoms and cognition than was risperidone plus placebo (P<0.001. The WAIS-R scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. The administration of ondansetron significantly improved visual memory based on the subtests of the WAIS (P<0.05. Ondansetron had no positive effects on depressive symptoms (effect size=0.13. Conclusion: This study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. Trial Registration Number: IRCT201112125280N7

  15. Utility of eosin Y as a complexing reagent for the determination of citalopram hydrobromide in commercial dosage forms by fluorescence spectrophotometry.

    Science.gov (United States)

    Azmi, Syed Najmul Hejaz; Al-Fazari, Ahlam; Al-Badaei, Munira; Al-Mahrazi, Ruqiya

    2015-12-01

    An accurate, selective and sensitive spectrofluorimetric method was developed for the determination of citalopram hydrobromide in commercial dosage forms. The method was based on the formation of a fluorescent ion-pair complex between citalopram hydrobromide and eosin Y in the presence of a disodium hydrogen phosphate/citric acid buffer solution of pH 3.4 that was extractable in dichloromethane. The extracted complex showed fluorescence intensity at λem = 554 nm after excitation at 259 nm. The calibration curve was linear over at concentrations of 2.0-26.0 µg/mL. Under optimized experimental conditions, the proposed method was validated as per ICH guidelines. The effect of common excipients used as additives was tested and the tolerance limit calculated. The limit of detection for the proposed method was 0.121 μg/mL. The proposed method was successfully applied to the determination of citalopram hydrobromide in commercial dosage forms. The results were compared with the reference RP-HPLC method.

  16. Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome?

    Science.gov (United States)

    Nikolaou, Kalliopi N; Gournellis, Rossetos; Michopoulos, Ioannis; Dervenoulas, Georgios; Christodoulou, Christos; Douzenis, Athanasios

    2015-01-01

    To the best of our knowledge, there are no case studies of serotonin syndrome (SS) in patients with autism spectrum disorder. We report the case of a 33-year-old male who presented SS under the combined use of clomipramine and risperidone. More specifically, within 2 days after clomipramine (10 mg/BID-two times a day) was added to risperidone (4 mg/OD-once a day), mirtazapine 45 mg/OD and alprazolam (0,5 mg/TID-three times a day) he began to present mental, neurological and autonomic symptoms. All his psychopathological manifestations and laboratory findings normalized after the above-mentioned drugs' discontinuation, and the administration of supportive medical care and lorazepam 2,5 mg/TID. The diagnosis of serotonin syndrome was challenging due to the relatively low dose of clomipramine, an increase of risperidone which had taken place before clomipramine administration and clinical symptoms which could be attributed to both serotonin and neuroleptic malignant syndrome.

  17. Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders

    Science.gov (United States)

    Johnson, Cynthia R.; Butter, Eric M.; Lecavalier, Luc; Scahill, Lawrence; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; Swiezy, Naomi B.; Sukhodolsky, Denis G.; Mulick, James A.; White, Susan W.; Bearss, Karen; Hollway, Jill A.; Stigler, Kimberly A.; Dziura, James; Yu, Sunkyung; Sacco, Kelley; Vitiello, Benedetto

    2013-01-01

    A Structured Observational Analog Procedure (SOAP), an analogue measure of parent-child interactions, was used to assess treatment outcome in children with Autism Spectrum Disorder and serious behavior problems. It served as a secondary outcome measure in a 24-week, randomized trial of risperidone (MED; N=49) versus risperidone plus parent training (COMB; n=75) (ages 4–13 years). At 24-weeks, there was 28 % reduction in child inappropriate behavior during a Demand Condition (p=.0002) and 12 % increase in compliance to parental requests (p=.004) for the two treatment conditions combined. Parents displayed 64 % greater use of positive reinforcement (p=.001) and fewer repeated requests for compliance (p<.0001). In the analysis of covariance (ANCOVA), COMB parents used significantly more positive reinforcement (p=.01) and fewer restrictive statements (p<.05) than MED parents. The SOAP is sensitive to change in child and parent behavior as a function of risperidone alone and in combination with PMT and can serve as a valuable complement to parent and clinician-based measures. PMID:23730123

  18. Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances.

    Science.gov (United States)

    Yin, You; Liu, Yan; Zhuang, Jianhua; Pan, Xiao; Li, Peng; Yang, Yuechang; Li, Yan-Peng; Zhao, Zheng-Qing; Huang, Liu-Qing; Zhao, Zhong-Xin

    2015-01-01

    Sleep disturbances (SD) accelerate the progression of Alzheimer's disease (AD) and increase the stress of caregivers. However, the long-term outcome of disturbed nocturnal sleep/wake patterns in AD and on increased stress of spousal caregivers is unclear. This study assessed the 5-year effect of nocturnal SD on the long-term outcome in AD patients. A total of 156 donepezil-treated mild-moderate AD patients (93 AD + SD and 63 AD - SD as a control group) were recruited. The AD + SD patients were formed into 4 subgroups according to the preferences of spousal caregivers for treatment with atypical antipsychotics (0.5-1 mg risperidone, n = 22), non-benzodiazepine hypnotic (5-10 mg zolpidem tartrate, n = 33), melatonin (2.55 mg, n = 9), or no-drug treatment (n = 29). SD were evaluated by polysomnography, sleep scale, and cognitive scale examinations. Moreover, all spousal caregivers of AD patients were assessed using a series of scales, including sleep, anxiety, mood, and treatment attitude scales. Our data showed that nocturnal sleep/wake disturbances were significantly associated with lower 5-year outcomes for AD patients, earlier nursing home placement, and more negative emotions of spousal caregivers. Treatment with low-dose atypical antipsychotic risperidone improved the 5-year outcome in AD + SD patients. In conclusion, low-dose atypical antipsychotic risperidone improves the 5-year outcome in AD patients with SD. Moreover, improvement of nocturnal sleep problems in AD patients will also bring better emotional stability for AD caregivers.

  19. 异丙嗪与倍他司汀联合治疗老年眩晕症的临床分析%Clinical Study on Promethazine Combined With Betahistine Medication in Treatment of Elder Patients With Vertigo

    Institute of Scientific and Technical Information of China (English)

    王欣欣

    2015-01-01

    Objective Promethazine combined with betahistine medication treatment method and its effect in treatment of elder patients with vertigo are to be studied. Methods Chose 81 elder patients with vertigo who are treated in hospital from February 2014 to May 2015 and separate them into groups at random,46 patients in study group are given promethazine combined with betahistine medication treatment and 35 patients in control group are given betahistine combined with shuxuening medication,and then observe patients’physical improvements and side-effect incidence between two groups. Results Patients’treatment efficacy in study group is 95.65%,which is much better than treatment efficacy of 80.0% in control group,there is a differential between two groups and such a differential has statistic value(P<0.05). Conclusion Promethazine combined with betahistine medication treatment is effective in treatment of elder patients with vertigo,it is conducive to increasing treatment efficiency with medication efficacy and safety and promoting patients’quality of life.%目的:探究老年眩晕症患者选择异丙嗪和倍他司汀综合治疗的方法及效果。方法选取2014年2月~2015年5月收治的81例老年眩晕症患者进行治疗,随机分组,实验组46例选择异丙嗪和倍他司汀的综合治疗,对照组35例患者选择倍他司汀和舒血宁的治疗,观察患者治疗后身体症状的改善以及不良反应情况。结果实验组患者的治疗有效率为95.65%,对照组患者的治疗有效率为80.0%,实验组患者的治疗效果高于对照组,有统计学意义(P<0.05)。结论老年眩晕症患者选择异丙嗪和倍他司汀综合治疗,可以改善不良的身体症状,提高患治疗效果,药物的安全性高,不良反应少,可促使患者生活质量的提高。

  20. 倍他司汀联合异丙嗪治疗老年眩晕症的效果观察%Study on Betahistine Combined with Promethazine in Treatment of Elderly Patients with Vertigo

    Institute of Scientific and Technical Information of China (English)

    奚广杰

    2015-01-01

    目的:探讨倍他司汀联合异丙嗪治疗老年眩晕症的效果观察。方法选取2013年10月到2014年11月我院接诊的43例老年眩晕症患者,随机分为两组,23例观察组和20例对照组,对照组采用倍他司汀联合舒血宁,观察组采用倍他司汀联合异丙嗪,观察两组患者的治疗效果。结果观察组患者的治疗总有效率、不良反应的发生率及并发症的发生率明显优于对照组,差异显著,有统计学意义(P<0.05)。结论倍他司汀联合异丙嗪治疗老年眩晕症的效果显著,可以有效提高患者的治疗总有效率,降低不良反应的发生率,值得临床推广。%Objective Ef ect of betahistine combined with promethazine in treatment of elderly patients with vertigo is to be analyzed. Methods Choose 43 elderly patients of vertigo who are treated in hospital from October 2013 to November 2014 and separate them into two groups at random with 23 patients in study group and 20 patients in control group. Patients in control group are given betahistine medication combined with Shuxuening treatment,while patients in study group are given betahistine combined with promethazine treatment. And then compare treatment ef icacy between two groups. Results Patients’treatment ef icacy,side-ef ect rate and complication incidence in study group are much less than those in control group;there is a great dif erential between two groups and such a dif erential has statistic value(P<0.05). Conclusion Betahistine combined with promethazine is of clinical ef icacy in treatment of elderly patients with vertigo;it is conducive to improving treatment ef icacy and reducing side-ef ect incidence;thus,it is quite worthwhile to be promoted and applied clinical y.

  1. The effectiveness of buprenorphine in combination with scopolamine and promethazine on conditioned place preference in SD rats%丁丙诺啡、东莨菪碱与异丙嗪联合使用对大鼠位置偏爱的影响

    Institute of Scientific and Technical Information of China (English)

    黄劲松; 王育红; 周旭辉; 王全升; 谌红献; 王绪轶; 向小军; 郝伟

    2008-01-01

    Objective To study the potentiality of psychological dependence of the so-called "1+1" compound (the elements are buprenorphine, scopolamine and promethazine). Methods One hundred and sixty-one male Sprague-Dawley rats were randomly assigned to 9 groups: buprenorphine, scopolamine, promethazine, buprenorphine plus scopolamine, buprenorphine plus promethazine, buprenorphine plus scopolamine and promethazine, scopolamine plus promethazine, morphine and saline groups respectively. All the 9 groups were trained by using the conditioned place preference(CPP) paradigm for 10 days. Results The rats in the five groups treated with buprenorphine alone or in combination with scopolamine/promethazine and morphine developed CPP. The time change spent by the rats in the buprenorphine plus scopolamine and promethazine group are (378.6±120.8)s , apparently longer than that by the rats in the buprenorphine group (302.2±133.9)s,but compared with that by rats in the morpine group(419.8±146.4)s, there is no significant difference(F=14.3,P=0.63). Conclusion The combination use of buprenorphine plus scopolamine and promethazine may act synergistically, and scopolamine and promethazine may enhance psychological dependence of buprenorphine.%目的 通过观察丁丙诺啡、东莨菪碱与异丙嗪三药联合使用(俗称"1+1")对大鼠位置偏爱的影响,探索"1+1"对实验大鼠的精神依赖性潜力.方法 161只雄性SD大鼠随机分成9组,分别采用丁丙诺啡、丁丙诺啡+东莨菪碱、丁丙诺啡+异丙嗪、丁丙诺啡+东莨菪碱+异丙嗪、东莨菪碱、异丙嗪、东莨菪碱+异丙嗪、吗啡、以及生理盐水等进行腹腔内注射,同时进行药物匹配CPP训练,共10d,比较各组大鼠训练前后以及训练后各组大鼠之间在药物训练侧(简称伴药侧)停留时间的差异,探索各处理因素的精神依赖性潜力及其差异.结果 注射吗啡、丁丙诺啡、丁丙诺啡+东莨菪碱、丁丙诺啡+异丙嗪、丁丙

  2. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

    Science.gov (United States)

    Laux, Gerd; Heeg, Bart; van Hout, Ben A; Mehnert, Angelika

    2005-01-01

    Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequences of relapse. Long-acting risperidone is a new formulation of an atypical antipsychotic drug that also offers the improvements in compliance associated with haloperidol depot. The aim of this simulation study was to compare the benefits and costs of three pharmacological treatment strategies comprising first-line treatment with long-acting risperidone injection, a haloperidol depot or an oral atypical antipsychotic agent, over a 5-year period in Germany. A discrete event simulation model was developed to compare three treatment scenarios from the perspective of major third-party payers (sickness funds and social security 'Sozialversicherung'). The scenarios comprised first-line treatment with haloperidol depot (scenario 1), long-acting risperidone (scenario 2) and oral olanzapine (scenario 3). Switches to second or third-line options were allowed when side-effects occurred or a patient suffered more than a fixed number of relapses. The model accounted for fixed patient characteristics, and on the basis of these, simulated patient histories according to several time-dependent variables. The time horizon for this model was limited to 5 years, and in accordance with German guidelines, costs and effects were discounted by between 3 and 10%. Direct costs included medication, type of physician visits and treatment location. Indirect costs were not included. Information on treatment alternatives, transition probabilities, model structure and healthcare utilization were derived from the literature and an expert panel. Outcomes were expressed in terms of the number and duration of psychotic episodes, cumulative symptom scores, costs, and quality-adjusted life-years (QALY). Univariate sensitivity analyses were carried out, as were subgroup analyses based on disease severity and

  3. Neonatal citalopram exposure decreases serotonergic fiber density in the olfactory bulb of male but not female adult rats

    Directory of Open Access Journals (Sweden)

    Junlin eZhang

    2013-05-01

    Full Text Available Manipulation of serotonin (5HT during early development has been shown to induce long-lasting morphological changes within the raphe nuclear complex and serotonergic circuitry throughout the brain. Recent studies have demonstrated altered raphe-derived 5HT transporter (SERT immunoreactive axonal expression in several cortical target sites after brief perinatal exposure to selective 5HT reuptake inhibitors such as citalopram (CTM. Since the serotonergic raphe nuclear complex projects to the olfactory bulb (OB and perinatal 5HT disruption has been shown to disrupt olfactory behaviors, the goal of this study was to further investigate such developmental effects in the OB of CTM exposed animals. Male and female rat pups were exposed to CTM from postnatal day 8-21. After animals reach adulthood (>90 days, OB tissue sections were processed immunohistochemically for SERT antiserum. Our data revealed that the density of the SERT immunoreactive fibers decreased ~40% in the OB of CTM exposed male rats, but not female rats. Our findings support a broad and long-lasting change throughout most of the 5HT system, including the OB, after early manipulation of 5HT. Because dysfunction of the early 5HT system has been implicated in the etiology of neurodevelopmental disorders such as autism spectrum disorders (ASDs, these new findings may offer insight into the abnormal olfactory perception often noted in patients with ASD.

  4. Enantioseparation of Citalopram by RP-HPLC, Using Sulfobutyl Ether-β-Cyclodextrin as a Chiral Mobile Phase Additive.

    Science.gov (United States)

    Peng, Yangfeng; He, Quan Sophia; Cai, Jiang

    2016-01-01

    Enantiomeric separation of citalopram (CIT) was developed using a reversed phase HPLC (RP-HPLC) with sulfobutylether-β-cyclodextrin (SBE-β-CD) as a chiral mobile phase additive. The effects of the pH value of aqueous buffer, concentration of chiral additive, composition of mobile phase, and column temperature on the enantioseparation of CIT were investigated on the Hedera ODS-2 C18 column (250 mm × 4.6 mm × 5.0 um). A satisfactory resolution was achieved at 25°C using a mobile phase consisting of a mixture of aqueous buffer (pH of 2.5, 5 mM sodium dihydrogen phosphate, and 12 mM SBE-β-CD), methanol, and acetonitrile with a volumetric ratio of 21 : 3 : 1 and flow rate of 1.0 mL/min. This analytical method was evaluated by examining the precision (lower than 3.0%), linearity (regression coefficients close to 1), limit of detection (0.070 µg/mL for (R)-CIT and 0.076 µg/mL for (S)-CIT), and limit of quantitation (0.235 µg/mL for (R)-CIT and 0.254 µg/mL for (S)-CIT).

  5. Enantioseparation of Citalopram by RP-HPLC, Using Sulfobutyl Ether-β-Cyclodextrin as a Chiral Mobile Phase Additive

    Directory of Open Access Journals (Sweden)

    Yangfeng Peng

    2016-01-01

    Full Text Available Enantiomeric separation of citalopram (CIT was developed using a reversed phase HPLC (RP-HPLC with sulfobutylether-β-cyclodextrin (SBE-β-CD as a chiral mobile phase additive. The effects of the pH value of aqueous buffer, concentration of chiral additive, composition of mobile phase, and column temperature on the enantioseparation of CIT were investigated on the Hedera ODS-2 C18 column (250 mm × 4.6 mm × 5.0 um. A satisfactory resolution was achieved at 25°C using a mobile phase consisting of a mixture of aqueous buffer (pH of 2.5, 5 mM sodium dihydrogen phosphate, and 12 mM SBE-β-CD, methanol, and acetonitrile with a volumetric ratio of 21 : 3 : 1 and flow rate of 1.0 mL/min. This analytical method was evaluated by examining the precision (lower than 3.0%, linearity (regression coefficients close to 1, limit of detection (0.070 µg/mL for (R-CIT and 0.076 µg/mL for (S-CIT, and limit of quantitation (0.235 µg/mL for (R-CIT and 0.254 µg/mL for (S-CIT.

  6. A novel voltammetric sensor for citalopram based on multiwall carbon nanotube/(poly(p-aminobenzene sulfonic acid)/β-cyclodextrin)

    Energy Technology Data Exchange (ETDEWEB)

    Gholivand, Mohammad-Bagher, E-mail: mbgholivand2013@gmail.com; Akbari, Arezoo

    2016-05-01

    Multi-walled carbon nanotube (MWCNTS) coated with poly p-aminobenzene sulfonic acid/β-cyclodextrin (p-ABSA/β-CD) film was used as an effective strategy for modification of the surface of glassy carbon electrode (GCE). Electrochemical study and determination of citalopram (CT) were investigated at the p (p-ABSA)/β-CD/MWCNT/GC using cyclic and differential pulse anodic stripping voltammetric techniques. The results indicate that the p (p-ABSA)/β-CD/MWCNT/GC significantly enhanced the oxidation peak current of CT. The modified electrode was characterized by electrochemical impedance spectroscopy (EIS), scanning electron microscopy(SEM) and cyclic voltammetry (CV).The fabricated electrochemical sensor exhibits a fast and reversible linear response toward CT within the concentration ranges of 90 nM–1 μM, 1–11 μM and 11–100 μM with correlation coefficients greater than 0.99 and detection limit of 44 nM. The resulting functionalized polymer film features interesting electrochemical properties such good recovery, reproducibility and selectivity toward CT. The applicability of the proposed sensor was tested by determination of CT in pharmaceutical combinations and human body fluids. - Highlights: • A novel voltammetric sensor for CT based on p (p-ABSA)/β-CD/MWCNT/GC • Electrochemical study of CT was investigated using CV and DPASV techniques. • This sensor is made easy with good sensitivity and reproducibility. • The method was developed in real sample in the presence of matrix effect.

  7. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.

    Science.gov (United States)

    Ji, Y; Hebbring, S; Zhu, H; Jenkins, G D; Biernacka, J; Snyder, K; Drews, M; Fiehn, O; Zeng, Z; Schaid, D; Mrazek, D A; Kaddurah-Daouk, R; Weinshilboum, R M

    2011-01-01

    Major depressive disorder (MDD) is a common psychiatric disease. Selective serotonin reuptake inhibitors (SSRIs) are an important class of drugs used in the treatment of MDD. However, many patients do not respond adequately to SSRI therapy. We used a pharmacometabolomics-informed pharmacogenomic research strategy to identify citalopram/escitalopram treatment outcome biomarkers. Metabolomic assay of plasma samples from 20 escitalopram remitters and 20 nonremitters showed that glycine was negatively associated with treatment outcome (P = 0.0054). This observation was pursued by genotyping tag single-nucleotide polymorphisms (SNPs) for genes encoding glycine synthesis and degradation enzymes, using 529 DNA samples from SSRI-treated MDD patients. The rs10975641 SNP in the glycine dehydrogenase (GLDC) gene was associated with treatment outcome phenotypes. Genotyping for rs10975641 was carried out in 1,245 MDD patients in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, and its presence was significant (P = 0.02) in DNA taken from these patients. These results highlight a possible role for glycine in SSRI response and illustrate the use of pharmacometabolomics to "inform" pharmacogenomics.

  8. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report

    Directory of Open Access Journals (Sweden)

    Psarros Constantin

    2006-09-01

    Full Text Available Abstract Background The use of atypical antipsychotics in schizophrenic patients has been associated with a risk of weight gain. Similarly, recovery from depression is often followed by improved appetite, greater food intake and potential increase in weight. Case presentation A Caucasian 33-year-old schizophrenic female patient was being treated with 6 mg/day of risperidone and 15 mg/day of clorazepate. She developed depressive symptomatology and 40 mg/day of fluoxetine was gradually added to her treatment regimen for about 9 months. After the remission of depression, and the discontinuation of fluoxetine, she experienced an increase in appetite and subsequently excessive weight gain of 52 kg. Re-administration of fluoxetine did not reverse the situation. The patient developed diabetes mellitus, which was successfully controlled with metformin 1700 mg/day. The addition at first of orlistat 360 mg/day and later of topiramate 200 mg/day has helped her to lose a significant part of the weight gained (30 kg. Conclusion The case suggests a probable association between the remission of depressive symptomatology and weight gain in a schizophrenic patient.

  9. Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection

    Directory of Open Access Journals (Sweden)

    Wissam El-Hage

    2010-07-01

    Full Text Available Wissam El-Hage1, Simon A Surguladze21Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; 2Institute of Psychiatry, King’s College London, UKAbstract: Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. ­Risperidone long acting injection (RLAI as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting injections will also be discussed.Keywords: second generation, antipsychotics, patient attitudes, lithium, valproate, monotherapy

  10. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.

    Science.gov (United States)

    Silva, A C; Kumar, A; Wild, W; Ferreira, D; Santos, D; Forbes, B

    2012-10-15

    A solid lipid nanoparticles (SLN) formulation to improve the oral delivery of risperidone (RISP), a poorly water-soluble drug, was designed and tested. Initially, lipid-RISP solubility was screened to select the best lipid for SLN preparation. Compritol(®)-based formulations were chosen and their long-term stability was assessed over two years of storage (at 25 °C and 4 °C) by means of particle size, polydispersity index (PI), zeta potential (ZP) and encapsulation efficiency (EE) measurements. SLN shape was observed by transmission electron microscopy (TEM) at the beginning and end of the study. The oxidative potential (OP) of the SLN was measured and their biocompatibility with Caco-2 cells was evaluated using the (4,5-dimethylthiazol-2-yl)2,5-dyphenyl-tetrazolium bromide (MTT) assay. In vitro drug release and transport studies were performed to predict the in vivo release profile and to evaluate the drug delivery potential of the SLN formulations, respectively. The RISP-loaded SLN systems were stable and had high EE and similar shape to the placebo formulations before and after storage. Classical Fickian diffusion was identified as the release mechanism for RISP from the SLN formulation. Biocompatibility and dose-dependent RISP transport across Caco-2 cells were observed for the prepared SLN formulations. The viability of SLN as formulations for oral delivery of poorly water-soluble drugs such as RISP was illustrated.

  11. Synthesis, recognition and evaluation of molecularly imprinted polymer nanoparticle using miniemulsion polymerization for controlled release and analysis of risperidone in human plasma samples

    Energy Technology Data Exchange (ETDEWEB)

    Asadi, Ebadullah; Azodi-Deilami, Saman; Abdouss, Majid [Amirkabir University of Technology, Tehran (Iran, Islamic Republic of); Kordestani, Davood [Razi University, Kermanshah (Iran, Islamic Republic of); Rahimi, Alireza [Research Institute of Petroleum Industry (RIPI), Tehran (Iran, Islamic Republic of); Asadi, Somayeh [Kermanshah University of Medical Sciences, Kermanshah (Iran, Islamic Republic of)

    2014-06-15

    We prepared high selective imprinted nanoparticle polymers by a miniemulsion polymerization technique, using risperidone as the template, MAA as the functional monomers, and TRIM as the cross-linker in acetonitrile as solvent. The morphology of the nanoparticles determined by scanning electron microscopy (SEM) images and drug release, binding properties and dynamic light scattering (DLS) of molecularly imprinted polymers (MIPs) were studied. Controlled release of risperidone from nanoparticles was investigated through in 1% wt sodium dodecyl sulfate aqueous solution and by measuring the absorbance by HPLC-UV. The results showed that the imprinted nanoparticles exhibited a higher binding level and slower release rate than non-imprinted nanoparticles, which contributed to interaction of risperidone with imprinted cavities within nanoparticles. Furthermore, the results from HPLC showed good precision (5% for 50.0 µg L{sup -1}) and recoveries (between 86-91) using MIP from human plasma samples.

  12. Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution.

    Science.gov (United States)

    Al-Hashel, Jasem Y; Ismail, Ismail Ibrahim; John, John K; Ibrahim, Mohammed; Ali, Mahmoud

    2016-01-01

    Myasthenia gravis is an autoimmune disease characterized by muscle weakness due to autoantibodies affecting the neuromuscular junction. Co-occurrence of myasthenia gravis and schizophrenia is very rare and raises a challenge in management of both diseases. Antipsychotic drugs exhibit anticholinergic side effects and have the potentials of worsening myasthenia. Long-acting risperidone is an injectable atypical antipsychotic drug that has not been previously reported to worsen myasthenia gravis in literature. We report the first case report of worsening of myasthenia after receiving long-acting risperidone injection for schizophrenia in a 29-year-old female with both diseases. She started to have worsening 2 weeks following the first injection and her symptoms persisted despite receiving plasma exchange. This could be explained by the pharmacokinetics of the drug. We recommend that long-acting risperidone should be used with caution in patients with myasthenia gravis, and clinicians must be aware of the potential risks of this therapy.

  13. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study

    Directory of Open Access Journals (Sweden)

    Galynker Igor I

    2009-05-01

    Full Text Available Abstract Background Because a large proportion of patients with panic attacks receiving approved pharmacotherapy do not respond or respond poorly to medication, it is important to identify additional therapeutic strategies for the management of panic symptoms. This article describes a randomized, rater-blind study comparing low-dose risperidone to standard-of-care paroxetine for the treatment of panic attacks. Methods Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine. The subjects were then followed for eight weeks. Outcome measures included the Panic Disorder Severity Scale (PDSS, the Hamilton Anxiety Scale (Ham-A, the Hamilton Depression Rating Scale (Ham-D, the Sheehan Panic Anxiety Scale-Patient (SPAS-P, and the Clinical Global Impression scale (CGI. Results All subjects demonstrated a reduction in both the frequency and severity of panic attacks regardless of treatment received. Statistically significant improvements in rating scale scores for both groups were identified for the PDSS, the Ham-A, the Ham-D, and the CGI. There was no difference between treatment groups in the improvement in scores on the measures PDSS, Ham-A, Ham-D, and CGI. Post hoc tests suggest that subjects receiving risperidone may have a quicker clinical response than subjects receiving paroxetine. Conclusion We can identify no difference in the efficacy of paroxetine and low-dose risperidone in the treatment of panic attacks. Low-dose risperidone appears to be tolerated equally well as paroxetine. Low-dose risperidone may be an effective treatment for anxiety disorders in which panic attacks are a significant component. Trial Registration ClinicalTrials.gov Identifier: NCT100457106

  14. Dopamine transporter density assessed with [{sup 123}]IPT SPECT before and after risperidone treatment in children with tourette's disorder

    Energy Technology Data Exchange (ETDEWEB)

    Ryu, Young Hoon; Kim, Tae Hoon; Ryu, Won Gee [College of Medicine, Yonsei Univ., Seoul (Korea, Republic of)] [and others

    2004-02-01

    Tourette's disorder (TD), which is characterized by multiple waxing and waning motor tics and one or more vocal tics, is known to be associated with abnormalities in the dopaminergic system. To testify our hypothesis that risperidone would improve tic symptoms of TD patients through the change of the dopaminergic system, we measured the dopamine transporter (DAT) densities between drug-naive children with TD and normal children, and investigated the DAT density before and after treatment with risperidone in drug-naive children with TD, using iodine-123 labelled N-(3-iodopropen-2-yl)-2{beta}-carbomethoxy-3beta-(4-chlorophenyl)tropane ([{sup 123}I]IPT) single photon emission computed tomography (SPECT). [{sup 123I}]IPT SPECT imaging and Yale Global Tic Severity Scale-Korean version (YGTSS-K) for assessing the tic symptom severity were carried out before and after treatment with risperidone for 8 weeks in nine drug-naive children with TD. Eleven normal children also underwent SPECT imaging 2 hours after an intravenous administration of [{sup 123}I]IPT. Drug-naive children with TD had a significantly greater increase in the specific/nonspecific DAT binding ratio of both basal ganglia compared with the normal children. However, no significant difference in the specific/nonspecific DAT binding ratio of the basal ganglia before and after treatment with risperidone in children with TD was found, although tic symptoms were significantly improved with risperidone. These findings suggest that DAT densities are directly associated with the pathophysiology of TD, however, that the effect of risperidone on tic symptoms in children with TD is not attributed to the change of dopaminergic system.

  15. 利培酮合并氯氮平治疗难治性精神分裂症对照研究%Comparative Study on Risperidone Combined Clozapine and Risperidone in the Treatment of Refractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    高亚娇; 安红伟; 靳红强

    2011-01-01

    Objective To compare the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia. Methods 63 cases were divided into two groups randomly,32 cases of treatment-refractory schizophrenia were treated with risperidone combined clozapine( the treatment group ) and 31 cases were treated with risperidone( the control group ). The clinical effect of patients were measured with positive and negative symptoms scale( PANSS ), and side effects were assessed with treatment emergent symptoms scale( TESS )respectively before and after 4,8,12 week treatment. Results There were significant differences in the curative effect between the two groups( P <0.05 ). After eight weeks treatment, total score of PANSS in two groups were much lower than before,the treatment group had greater decreases. After twelve weeks treatment,total score of PANSS in the treatment group was lower than that in the control group. There were statistical differences between the two groups( P <0. 05 ). Conclusion Clozapine combined with risperidone has curative effect affirmation to treat TRS,this deserves utilization in the clinical area.%目的 探讨利培酮联合氯氮平治疗难治性精神分裂症(TRS)的疗效及安全性.方法 将63例TRS患者随机分为利培酮合并氯氮平组(治疗组)32例和利培酮组(对照组)31例,两组治疗后4、8、12周均以阳性与阴性症状量表(PANSS)评定疗效,治疗意外症状量表(TESS)评定不良反应.结果 治疗组和对照组治疗TRS的疗效比较差异有统计学意义(P<0.05).治疗后8周,两组PANSS总分均较治疗前下降,治疗组下降更明显.两组治疗12周后PANSS总分比较,治疗组明显低于对照组,差异有统计学意义(P<0.05).结论 利培酮联合氯氮平治疗TRS的疗效肯定,值得临床应用.

  16. 利培酮的臨床應用與進展%Clinical Application and Advancement of Risperidone

    Institute of Scientific and Technical Information of China (English)

    查彩慧; 肖計劃

    2001-01-01

    Objective This article reviews the mechanism, pharmcokinetics and the clinical use ofrisperidone.Materials The data base on updated literature recently. Conclusion Risperidone, a benzisoxazol derivative, is a novel typical antipsychotic agent which combines 5-hydroxytryptamine-2 (5-HT2) and dopamine-2 (D2) receptors antagonism. It can improve both positive and negative symptoms of schizophrenia. The efficacy of risperidone is well positive and effective in patients with chronic schizophrenia who had been resistant to or intolerant of conventiona neuroleptics. Risperidone can be used to treat mood disorder, obsessive-compulsive disorder, metal retardation,brain injury associated behavioral and psychiatric disorder and now it is already used in clinic widely. Risperidone is absorbed rapidly when taken orally and mainly metabolized in the liver .The principal active metabolite is 9-hydroxyrisperidone which has obvious pharmacological function. The metabolized production of risperidone is mainly discharged via urine. Risperidone has high efficacy and good safety. Now it is already used in clinic widely.%目的本文對利培酮的作用機制、藥代動力學、臨床應用和不良反應作一綜述,供同道們參考.資料所有資料均來自近幾年最新的相關文獻.結論利培酮是苯異惡唑衍生物,是一種新型的非典型抗精神病藥物.利培酮對5羥色胺Ⅱ型和多巴胺Ⅱ型受體均有拮抗作用,能有效改善精神分裂症陽性和陰性症狀,對於傳統抗精神病藥物治療失敗的難治性精神分裂症患者可首選利培酮治療.利培酮還可用於治療心境障礙、強迫症、精神發育遲滯及腦損害伴發的行為和精神障礙.利培酮口服吸收迅速,主要經肝臟代謝,在體內的代謝産物為9-羥基利培酮,亦具有藥理活性.利培酮主要通過尿液排出.利培酮的常見副反應為激越、頭痛、失眠、噁心、嗜睡等,較少出現錐體外系副反應,惡性綜合徵發

  17. Validated Densitometric TLC-Method for the Simultaneous Analysis of (R)- and (S)-Citalopram and its Related Substances Using Macrocyclic Antibiotic as a Chiral Selector: Application to the Determination of Enantiomeric Purity of Escitalopram.

    Science.gov (United States)

    Soliman, Suzan Mahmoud

    2012-03-01

    A novel economic procedure for the simultaneous stereospecific separation and analysis of (R)- and (S)-citalopram and its related substances or impurities has been developed and validated. Chromatography was performed on silica gel 60 F254 plates with acetonitrile: methanol: water (15:2.5:2.5: v/v/v) as a mobile phase containing 1.5 mM norvancomycin or 2.5 mM vancomycin as a selector at ambient temperature. (R)- and (S)-citalopram enantiomers in presence of its related substances; citalopram citadiol and citalopram N-oxide were well separated with significant Rf values of 0.33 ± 0.02, 0.85 ± 0.02, 0.45 ± 0.02 and 0.22 ± 0.02, respectively. The spots were detected with either iodine vapor, or by use of a UV lamp followed by densitometric measurement at 239 nm. All variables affecting the resolution, such as concentration of chiral selectors, mobile phase system at different temperatures and pH-values were investigated and the conditions were optimized. Calibration plots for analysis of (R)- and (S)-enantiomers were linear in the range of 0.2-16.8 μg/10 μl (R≥0.9994, n=6) with acceptable precision (%RSDescitalopram, respectively). The limit of detection and quantification were 0.08 μg/10 μl and 0.25 μg/10 μl, respectively, for (R)- and (S)-citalopram. The proposed method is simple, selective, and robust and can be applied for quantitative determination of enantiomeric purity of (R)- and (S)-citalopram (escitalopram) as well as the related impurities in drug substances and pharmaceutical preparations. The method can be useful to investigate adulteration of pure isomer with the cheep racemic form.

  18. An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant.

    Science.gov (United States)

    Zhong, Huailing; Hansen, Kasper B; Boyle, Noel J; Han, Kiho; Muske, Galina; Huang, Xinyan; Egebjerg, Jan; Sánchez, Connie

    2009-10-25

    The human serotonin transporter (hSERT) has primary and allosteric binding sites for escitalopram and R-citalopram. Previous studies have established that the interaction of these two compounds at a low affinity allosteric binding site of hSERT can affect the dissociation of [(3)H]escitalopram from hSERT. The allosteric binding site involves a series of residues in the 10th, 11th, and 12th trans-membrane domains of hSERT. The low affinity allosteric activities of escitalopram and R-citalopram are essentially eliminated in a mutant hSERT with changes in some of these residues, namely A505V, L506F, I507L, S574T, I575T, as measured in dissociation binding studies. We confirm that in association binding experiments, R-citalopram at clinically relevant concentrations reduces the association rate of [(3)H]escitalopram as a ligand to wild type hSERT. We demonstrate that the ability of R-citalopram to reduce the association rate of escitalopram is also abolished in the mutant hSERT (A505V, L506F, I507L, S574T, I575T), along with the expected disruption the low affinity allosteric function on dissociation binding. This suggests that the allosteric binding site mediates both the low affinity and higher affinity interactions between R-citalopram, escitalopram, and hSERT. Our data add an additional structural basis for the different efficacies of escitalopram compared to racemic citalopram reported in animal studies and clinical trials, and substantiate the hypothesis that hSERT has complex allosteric mechanisms underlying the unexplained in vivo activities of its inhibitors.

  19. Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse.

    Science.gov (United States)

    Nackenoff, Alex G; Moussa-Tooks, Alexandra B; McMeekin, Austin M; Veenstra-VanderWeele, Jeremy; Blakely, Randy D

    2016-06-01

    Depression is a common mental illness and a leading cause of disability. The most widely prescribed antidepressant medications are serotonin (5-HT) selective reuptake inhibitors (SSRIs). Although there is much support for 5-HT transporter (SERT) antagonism as a basis of antidepressant efficacy, this evidence is indirect and other targets and mechanisms have been proposed. In order to distinguish SERT-dependent and -independent effects of SSRIs, we developed a knock-in mouse model whereby high-affinity interactions of many antidepressants at SERT have been ablated via knock-in substitution (SERT Met172) without disrupting 5-HT recognition or uptake. Here we utilize the C57BL/6J SERT Met172 model to evaluate SERT dependence for the actions of two widely prescribed SSRIs, fluoxetine and citalopram, in tests sensitive to acute and chronic actions of antidepressants. In the tail suspension and forced swim tests, fluoxetine and citalopram fail to reduce immobility in SERT Met172 mice. In addition, SERT Met172 mice are insensitive to chronic fluoxetine and citalopram administration in the novelty induced hypophagia test (NIH) and fail to exhibit enhanced proliferation or survival of hippocampal stem cells. In both acute and chronic studies, SERT Met172 mice maintained sensitivity to paroxetine, an antidepressant that is unaffected by the Met172 mutation. Together, these studies provide definitive support for an essential role of SERT antagonism in the acute and chronic actions of two commonly used SSRIs in these tests, and reinforce the utility of the SERT Met172 model for isolating SERT/5-HT contributions of drug actions in vivo.

  20. A case of psychosis due to Fahr's syndrome and response to behavioral disturbances with risperidone and oxcarbazepine

    Science.gov (United States)

    Faye, Abhijeet Dhawalram; Gawande, Sushil; Tadke, Rahul; Kirpekar, Vivek C.; Bhave, Sudhir H.

    2014-01-01

    Calcification of basal ganglia or Fahr's syndrome is a rare disease characterized by bilateral and symmetrical intracranial deposition of calcium mainly in cerebral basal ganglia. Motor and neuropsychiatric symptoms are prominent features. We report a case presented with a few motor symptoms, features of delirium and prominent psychiatric symptoms (disorganized behavior) predominantly evident after the improvement in delirium. Radiological findings were suggestive of bilateral basal ganglia calcification. Parathyroid hormone levels were low with no significant findings in other investigations and negative family history. Patient showed significant improvement in behavioral disturbances with risperidone, low dose of lorazepam, oxcarbazepine, and memantine. PMID:24891710

  1. Evaluation of S-[[sup 11]C]citalopram as a radioligand for in vivo labelling of 5-hydroxytryptamine uptake sites

    Energy Technology Data Exchange (ETDEWEB)

    Hume, S.P.; Lammertsma, A.A.; Bench, C.J.; Pike, V.W.; Pascali, C.; Cremer, J.E. (Hammersmith Hospital, London (United Kingdom). M.R.C. Cyclotron Unit); Dolan, R.J. (Royal Free Hospital, London (United Kingdom))

    1992-11-01

    The biologically active S-enantiomer of [N-methyl-[sup 11]C]citalopram was evaluated as a radioligand for in vivo labelling of the 5-hydroxytryptamine uptake site in brain, using ex vivo tissue counting in rats and positron emission tomography in man. In rats, the maximal signal for total versus non-specific binding was approx. 2 at 60-120 min after radioligand injection. Subsequent studies in man failed to identify a specific signal over a 90 min scanning period, due to prolonged retention of non-specific label. (author).

  2. Synthesis and biological evaluation of I-125/I-123-labelled analogues of citalopram and escitalopram as potential radioligands for imaging of the serotonin transporter

    DEFF Research Database (Denmark)

    Madsen, Jacob; Elfving, Betina; Frokjaer, Vibe G.

    2011-01-01

    Two novel radioligands for the serotonin transporter (SERT), [I-125]{3-[5-iodo-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl}-dimethylamine ([I-125]-2) and S-[I-125]{3-[5-iodo-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-propyl}-dimethylamine ([I-125]-(S)-2) were synthesized in a ...... of the radioligand in imaging cortical SERT distribution in vivo. These data suggest that the iodine-labelled derivatives of citalopram and escitalopram are not superior to another SPECT tracer for the SERT, namely [I-123] ADAM....

  3. Development of Nutraceutical Emulsions as Risperidone Delivery Systems: Characterization and Toxicological Studies.

    Science.gov (United States)

    Igartúa, Daniela Edith; Calienni, María Natalia; Feas, Daniela Agustina; Chiaramoni, Nadia Silvia; Valle Alonso, Silvia Del; Prieto, María Jimena

    2015-12-01

    Emulsions are gaining increasing interest to be applied as drug delivery systems. The main goal of this work was the formulation of an oil/water nutraceutical emulsion (NE) for oral administration, enriched in omega 3 (ω3) and omega 6 (ω6), and able to encapsulate risperidone (RISP), an antipsychotic drug widely used in the treatment of autism spectrum disorders (ASD). RISP has low solubility in aqueous medium and poor bioavailability because of its metabolism and high protein binding. Coadministration of ω3, ω3, and vitamin E complexed with RISP might increase its bioavailability and induce a synergistic effect on the treatment of ASD. Here, we developed an easy and quick method to obtain NEs and then optimized them. The best formulation was chosen after characterization by particle size, defects of the oil-in-water interface, zeta potential (ZP), and in vitro drug release. The formulation selected was stable over time, with a particle size of around 3 μm, a ZP lower than -20 mV and controlled drug release. To better understand the biochemical properties of the formulation obtained, we studied in vitro toxicity in the Caco-2 cell line. After 4 h of treatment, an increase in cellular metabolism was observed for all RISP concentrations, but emulsions did not change their metabolic rate, except at the highest concentration without drug (25 μg/mL), which showed a significant reduction in metabolism respect to the control. Additionally, locomotor activity and heart rate in zebrafish were measured as parameters of in vivo toxicity. Only the highest concentration (0.625 μg/mL) showed a cardiotoxic effect, which corresponds to the decrease in spontaneous movement observed previously. As all the materials contained in the formulations were US FDA approved, the NE selected would be good candidate for clinical trials.

  4. Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats.

    Science.gov (United States)

    Zuo, Jing; Liu, Zhening; Ouyang, Xuan; Liu, Haihong; Hao, Yihui; Xu, Lin; Lu, Xiao-Hong

    2008-02-15

    Antipsychotic treatment during pregnancy is indicated when risk of drug exposure to the fetus is outweighed by the untreated psychosis in the mother. Although increased risk of congenital malformation has not been associated with most available antipsychotic drugs, there is a paucity of knowledge on the subtle neurodevelopmental and behavioral consequences of prenatal receptor blockade by these drugs. In the present study, antipsychotic drugs, sulpiride (SUL, a selective D2 receptor antagonist) and risperidone (RIS, a D2/5HT2 receptor antagonist) were administered to pregnant Sprague-Dawley dams from gestational day 6 to 18. Both RIS and SUL prenatal exposed rats had lower birth body weights compared to controls. RIS exposure had a significant main effect to retard body weight growth in male offspring until postnatal day (PND) 60. Importantly, water maze tests revealed that SUL prenatal exposure impaired visual cue response in visual task performance (stimulus-response, S-R memory), but not place response as reflected in hidden platform task (spatial memory acquisition and retention). In addition, prenatal SUL treatment reduced spontaneous activity as measured in open field. Both behavioral deficits suggest that SUL prenatal exposure may lead to subtle disruption of striatum development and related learning and motor systems. RIS exposure failed to elicit deficits in both water maze tasks and increased rearing in open field test. These results suggest prenatal exposure to SUL and RIS may produce lasting effects on growth, locomotion and memory in rat offspring. And the differences may exist in the effects of antipsychotic drugs which selectively block dopamine D2 receptors (SUL) as compared to second generation drugs (RIS) that potently antagonize serotonin and dopamine receptors.

  5. Inflammation in Patients with Schizophrenia: the Therapeutic Benefits of Risperidone Plus Add-On Dextromethorphan

    Science.gov (United States)

    Chen, Shiou-Lan; Lee, Sheng-Yu; Chang, Yun-Hsuan; Chen, Shih-Heng; Chu, Chun-Hsieh; Tzeng, Nian-Sheng; Lee, I-Hui; Chen, Po-See; Yeh, Tzung Lieh; Huang, San-Yuan; Yang, Yen-Kuang; Lu, Ru-Band; Hong, Jau-Shyong

    2013-01-01

    Objectives Increasing evidence suggests that inflammation contributes to the etiology and progression of schizophrenia. Molecules that initiate inflammation, such as virus- and toxin-induced cytokines, are implicated in neuronal degeneration and schizophrenia-like behavior. Using therapeutic agents with anti-inflammatory or neurotrophic effects may be beneficial for treating schizophrenia. Methods One hundred healthy controls and 95 Han Chinese patients with schizophrenia were tested in this double-blind study. Their PANSS scores, plasma interleukin (IL)-1β, TNF-α and brain-derived neurotrophic factor (BDNF) levels were measured before and after pharmacological treatment. Results Pretreatment, plasma levels of IL-1β and TNF-α were significantly higher in patients with schizophrenia than in controls, but plasma BDNF levels were significantly lower. Patients were treated with the atypical antipsychotic risperidone (Risp) only or with Risp+add-on dextromethorphan (DM). PANSS scores and plasma IL-1β levels significantly decreased, but plasma TNF-α and BDNF levels significantly increased after 11 weeks of Risp treatment. Patients in the Risp+DM group showed a greater and earlier reduction of symptoms than did those in the Risp-only group. Moreover, Risp+DM treatment attenuated Risp-induced plasma increases in TNF-α. Conclusion Patients with schizophrenia had a high level of peripheral inflammation and a low level of peripheral BDNF. Long-term Risp treatment attenuated inflammation and potentiated the neurotrophic function but also produced a certain degree of toxicity. Risp+DM was more beneficial and less toxic than Risp-only treatment. PMID:22730040

  6. Study on the luminescence behavior of sulfobutylether-β-cyclodextrin with risperidone and its analytical application

    Science.gov (United States)

    Wu, Min; Chen, Donghua; Song, Zhenghua

    2012-10-01

    The interaction of sulfobutylether-β-cyclodextrin (SBE-β-CD) with risperidone (RISP) was first described with luminol-SBE-β-CD chemiluminescence (CL) system by flow injection analysis (FIA). In luminol-SBE-β-CD CL system, the 1:1 SBE-β-CD⋯luminol∗ complexation could enhance CL intensity of luminol and produce the effect of complexation enhancement of CL (CEC). It was found that RISP could quench the CL intensity of SBE-β-CD⋯luminol∗ and caused the effect of complexation enhancement of quenching (CEQ), the formation constant KR-CD 3.4 × 104 L mol-1 and the stoichiometric ratio 1:1 of RISP⋯SBE-β-CD complex were obtained by the proposed CL model. Association degree α 0.036 of RISP⋯SBE-β-CD complex was also given by CL method. Based on the linear relationship to the decrement of luminol-SBE-β-CD-RISP CL intensity and the logarithm of RISP concentration, RISP also can be quantified in the linear range of 3.0-500.0 nmol L-1 with a detection limit of 1.0 nmol L-1 (3σ). The proposed method was successfully applied to monitoring excreted RISP in human urine. It was found that RISP reached its maximum after oral administration for 1.5 h with the total excretion of 14.26% within 8.5 h; the elimination rate constant k and half-life time t1/2 were 0.474 and 1.5 h, respectively.

  7. Effect Study on Combined Treatment of Betahistine and Promethazine in Treatment of Senile Vertigo%倍他司汀联合异丙嗪治疗老年眩晕症的效果研究

    Institute of Scientific and Technical Information of China (English)

    魏汝俊; 刘春英

    2015-01-01

    Objective Combined treatment effect of betahistine and promethazine in treatment of senile vertigo is to be studied. Methods Choose 39 elderly patients with vertigo who are treated in hospital from July 2013 to December 2014 and separate them into two groups according to their hospitalization sequence with 20 patients in study group and 19 patients in control group which are given betahistine treatment only and combined treatment of betahistine and promethazine respectively; and then compare treatment effects between two groups after 3 treatment courses. Results Treatment efficacy and medication taking-effect time in study group are much better than those in control group;besides,patients’symptom improvement time, hospitalization days and their vertigo assessment score in study group are much more favorable than counterparts in control group; there is a treatment differential between two groups,and such a differential has statistic value(P<0.05).Conclusion Combined treatment of betahistine and promethazine is of efficiency in treatment of senile vertigo;it is conducive to shortening medication taking-effect time,enlarging its efficiency and improving treatment efficacy;therefore,such an effective treatment approach is quite worthwhile to be promoted and applied clinical y.%目的:探讨我院老年眩晕症患者应用倍他司汀联合异丙嗪进行治疗的效果。方法选取2013年7月到2014年12月我院神经科接诊的39例老年眩晕症患者,按照入院的先后顺序分为20例实验组和19例对照组,分别给予倍他司汀和倍他司汀联合异丙嗪药物治疗,经过3个疗程的治疗后观察两组患者的治疗效果。结果实验组患者的治愈率、药物起效时间、症状改善时间、住院时间及眩晕评分明显优于对照组,差异显著,有统计学意义(P<0.05)。结论老年眩晕症采用倍他司汀联合异丙嗪的治疗效果显著,药物起效快、作用时间长、症状改善明显,

  8. 利培酮微球和利培酮治疗精神分裂症对照研究%A comparative study of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    苏磊; 孙自豪; 冯凡; 李龙飞

    2015-01-01

    Objective To explore the efficacy and safety of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia.Methods A total of 160 patients with schizophrenia were randomly divided into study group ( 80 cases) with risperidone long-acting injection and control group(80 cases) with risperidone for treatment of 3 months.They were assessed with Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression-Severity of Illness(CGI-S), Clinical Global Impression-Global Improvement(CGI-I) and Extrapyramidal Symptom Rating Scale(ESRS) at baseline , 1st month end, 2nd month end and 3rd month end of treatment.Results At 1st month end, 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS in two groups were all significantly lower than those at baseline(P<0.05).At 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS and CGI in study group were all significantly lower than those in control group(P<0.05).At 1st month end, 2nd month end and 3rd month end of treatment, the scores of ESRS in study group were significantly lower than those in control group(P<0.05).Conclusion It’s effective and safe for risperidone long-acting injection to treat the patients with schizophrenia.%目的:探寻利培酮微球和利培酮治疗精神分裂症患者的疗效和安全性。方法将160例精神分裂症患者随机分为研究组和对照组各80例,研究组用利培酮微球系统治疗,对照组用利培酮系统治疗,共3个月,在基线和治疗后1、2、3个月末应用阳性和阴性综合征量表( PANSS)、临床疗效总评量表-病情严重程度( CGI-S)、临床疗效总评量表-疗效总评( CGI-I)、锥体外系症状评定量表( ESRS)评价。结果两组在治疗后第1、2、3个月末的PANSS评分均低于基线时相应评分(P<0.05)。在治疗后第2、3个月末,研究组PANSS评分以及CGI

  9. Risk of Hyperprolactinemia and Sexual Side Effects in Males 10-20 Years Old Diagnosed with Autism Spectrum Disorders or Disruptive Behavior Disorder and Treated with Risperidone

    NARCIS (Netherlands)

    Roke, Yvette; Buitelaar, Jan K.; Boot, Annemieke M.; Tenback, Diederik; van Harten, Peter N.

    2012-01-01

    Objective: The aim of this study was to investigate the long-term treatment effects of risperidone on prolactin levels and prolactin-related side effects in pubertal boys with autism spectrum disorders (ASD) and disruptive behavior disorders (DBD). Method: Physical healthy 10-20-year-old males with

  10. Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene

    NARCIS (Netherlands)

    Hoekstra, Pieter J.; Troost, Pieter W.; Lahuis, Bertine E.; Mulder, Hans; Mulder, Erik J.; Franke, Barbara; Buitelaar, Jan K.; Anderson, George M.; Scahill, Lawrence; Minderaa, Ruud B.

    2010-01-01

    Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age-and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-label, fle

  11. Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene.

    NARCIS (Netherlands)

    Hoekstra, P.J.; Troost, P.W.; Lahuis, B.E.; Mulder, H.; Mulder, E.J.H.; Franke, B.; Buitelaar, J.K.; Anderson, G.M.; Scahill, L.; Minderaa, R.B.

    2010-01-01

    Abstract Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age- and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-

  12. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.

    NARCIS (Netherlands)

    Reyes, M.; Buitelaar, J.K.; Toren, P.; Augustyns, I.; Eerdekens, M.

    2006-01-01

    OBJECTIVE: The authors compared the effects of maintenance versus withdrawal of risperidone treatment in children and adolescents with symptoms of disruptive behavior disorder. METHOD: Patients with disruptive behavior disorder (5-17 years of age and a range of intellect) who had responded to risper

  13. Literature Analysis of 153 Cases of Adverse Drug Reactions Induced by Risperidone%153例利培酮致不良反应的文献分析

    Institute of Scientific and Technical Information of China (English)

    周秋娟; 吴晓燕; 陈颖; 巢楠; 瞿发林; 黄家富

    2014-01-01

    Objective To study the clinical features of adverse reaction induced by risperidone. Methods 122 case reports of adverse drug reaction due to risperidone from 2000 to 2012 in China were collected and analyzed, which involved 153 patients. Results The adverse reactions of risperidone were correlated with individual differences, which mainly occurred in central and peripheral nervous system. Conclusion Pay attention to physical status of patients when use risperidone,slowly increase the dose and comply with the individualized principle.%目的:综合分析利培酮所致不良反应的临床特征。方法对2000~2012年国内文献中有关利培酮所致不良反应的病例报道122篇涉及153例患者进行汇总分析。结果利培酮所致不良反应主要累及的系统-器官为中枢及外周神经系统,不良反应的发生与患者的个体差异有关。结论利培酮用药时应注意给药速度不宜过快,遵循个体化原则,关注患者的身体状况。

  14. A Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Adolescents and Young Adults with Anorexia Nervosa: A Pilot Study

    Science.gov (United States)

    Hagman, Jennifer; Gralla, Jane; Sigel, Eric; Ellert, Swan; Dodge, Mindy; Gardner, Rick; O'Lonergan, Teri; Frank, Guido; Wamboldt, Marianne Z.

    2011-01-01

    Objective: The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa. Method: Forty female subjects 12 to 21 years of age (mean, 16 years) with primary anorexia nervosa in an eating disorders program were randomized to receive…

  15. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.

    Science.gov (United States)

    Savina, Ioulia; Beninger, Richard J

    2007-08-01

    Theory of mind (ToM), the ability to attribute mental states to others, is associated with medial prefrontal cortical (mPFC) activity and is impaired in schizophrenia. Olanzapine or clozapine but not typical antipsychotics or risperidone preferentially affect c-fos expression in mPFC in animals. We tested the hypothesis that schizophrenic patients treated with different antipsychotics would perform differently on ToM tasks. Groups receiving Typicals (n=23), Clozapine (n=18), Olanzapine (n=20) or Risperidone (n=23) and a Control group of healthy volunteers (n=24) were matched for age, gender, handedness and education. ToM functioning was assessed with picture sequence, second-order belief and faux-pas tests. Schizophrenic groups performed similarly to controls on non-ToM conditions. The Olanzapine and Clozapine groups performed similarly to Controls on ToM tasks. The Typicals and Risperidone groups performed worse than the other groups on ToM tasks. We concluded that ToM performance of schizophrenic patients is influenced by the antipsychotic they are taking. Our results suggest that olanzapine or clozapine but not typicals or risperidone may improve or protect ToM ability.

  16. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

    OpenAIRE

    Honey, Garry D; Edward T Bullmore; Soni, William; Varatheesan, Malini; Williams, Steve C.R.; Sharma, Tonmoy

    1999-01-01

    Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia. Atypical antipsychotics have been shown to enhance frontal dopaminergic activity in animal models. We predicted that substitution of risperidone for typical antipsychotic drugs in the treatment of schizophrenia would be associated with enhanced functional activation of frontal...

  17. Alginate gel-coated oil-entrapped alginate-tamarind gum-magnesium stearate buoyant beads of risperidone.

    Science.gov (United States)

    Bera, Hriday; Boddupalli, Shashank; Nandikonda, Sridhar; Kumar, Sanoj; Nayak, Amit Kumar

    2015-01-01

    A novel alginate gel-coated oil-entrapped calcium-alginate-tamarind gum (TG)-magnesium stearate (MS) composite floating beads was developed for intragastric risperidone delivery with a view to improving its oral bioavailability. The TG-blended alginate core beads containing olive oil and MS as low-density materials were accomplished by ionotropic gelation technique. Effects of polymer-blend ratio (sodium alginate:TG) and crosslinker (CaCl2) concentration on drug entrapment efficiency (DEE, %) and cumulative drug release after 8 h (Q8h, %) were studied to optimize the core beads by a 3(2) factorial design. The optimized beads (F-O) exhibited DEE of 75.19±0.75% and Q8h of 78.04±0.38% with minimum errors in prediction. The alginate gel-coated optimized beads displayed superior buoyancy and sustained drug release property. The drug release profiles of the drug-loaded uncoated and coated beads were best fitted in Higuchi kinetic model with Fickian and anomalous diffusion driven mechanisms, respectively. The optimized beads yielded a notable sustained drug release profile as compared to marketed immediate release preparation. The uncoated and coated Ca-alginate-TG-MS beads were also characterized by SEM, FTIR and P-XRD analyses. Thus, the newly developed alginate-gel coated oil-entrapped alginate-TG-MS composite beads are suitable for intragastric delivery of risperidone over a prolonged period of time.

  18. Use of haloperidol and risperidone in highly aggressive Swiss Webster mice by applying the model of spontaneous aggression (MSA).

    Science.gov (United States)

    Fragoso, Viviane Muniz da Silva; Hoppe, Luanda Yanaan; de Araújo-Jorge, Tânia Cremonini; de Azevedo, Marcos José; Campos, Jerônimo Diego de Souza; Cortez, Célia Martins; de Oliveira, Gabriel Melo

    2016-03-15

    Aggression is defined as the act in which an individual intentionally harms or injures another of their own species. Antipsychotics are a form of treatment used in psychiatric routine. They have been used for decades in treatment of patients with aggressive behavior. Haloperidol and risperidone promote the control of psychiatric symptoms, through their respective mechanisms of action. Experimental models are obtained by behavioral, genetic, and pharmacological manipulations, and use a reduced number of animals. In this context, we applied the model of spontaneous aggression (MSA), originating the presence of highly aggressive mice (AgR) when reassembled in adulthood. We administered haloperidol and risperidone in escalating doses, for ten consecutive days. Using positive and negative control groups, we evaluated the effectiveness of these drugs and the reversal of the aggressive behavior, performing the tail suspension test (TST) and open field test (OFT) on 10th day of treatment and 10 days after its discontinuation. The results showed that both antipsychotic drugs were effective in AgR and reversed the aggressive phenotype, reducing the number of attacks by AgR and the extent of lesions in the subordinate mice (AgD) exposed to the pattern of aggressive behavior (PAB) of the aggressors. This conclusion is based on the reduction in the animals' motor and exploratory activity, and on the reversal of patterns of aggressive behavior. The association between the MSA and experiments with other therapeutic protocols and different antipsychotics can be an important methodology in the study of aggressive behavior in psychiatric patients.

  19. No change of dopamine transporter density in basal ganglia after risperidone treatment in drug-naive children with Tourette's disorder

    Energy Technology Data Exchange (ETDEWEB)

    Ryu, W. K.; Ryu, Y. H.; Yoon, M. J.; Chun, K. A.; Lee, J. D. [College of Medicine, Univ. of Yonsei, Seoul (Korea, Republic of); Zee, D. Y. [Univ. of Inhwa, Incheon (Korea, Republic of); Choi, T. H. [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    2003-07-01

    Tourette's disorder (TD), which is characterized by multiple waxing and waning motor tics and one or more vocal tics, is known to be associated with abnormalities in the dopaminergic system. To testify our hypothesis that risperidone would improve tic symptoms of TD patients through the change of the dopaminergic system, we measured the DAT densities between drug-naive children with TD and normal children investigated the DAT density before and after treatment with risperidone in drug-naive children with TD, using lodine-123 labelled N-(3-iodopropen-2-yl)-2beta-carbomethoxy-3beta-(4-chlorophenyl) tropane(I-123 IPT) single photon emission computed tomography (SPECT). I-123 IPT SPECT imaging and Yale Global Tic Severity Scale-Korean version (YGTSS-K) for assessing the tic symptom severity were carried out before and after treatment with risperidone for 8 weeks in eight drug-naive children with TD. Eight normal children also underwent SPECT imaging 2 hours after an intravenous administration of I-123 IPT and carried out both quantitative and qualitative analyses using the obtained SPECT data, which were reconstructed for the assessment of the specific/non-specific DAT binding ratio in the basal ganglia. The drug-naive children with TD had a significantly greater increase in the specific/nonspecific DAT binding ratio of both basal ganglia compared with the normal children. However, no significant difference in the specific/nonspecific DAT binding ratio of the basal ganglia before and after treatment with riperidone in children with TD was not found, although tic symptoms were significantly improved with risperidone. These findings suggest that DAT densities are directly associated with the pathophysiology of TD, however, that the effect of risperidone on tic symptoms in children with TD is not attributed to the change of dopaminergic system.

  20. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

    Science.gov (United States)

    Honey, Garry D.; Bullmore, Edward T.; Soni, William; Varatheesan, Malini; Williams, Steve C. R.; Sharma, Tonmoy

    1999-01-01

    Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia. Atypical antipsychotics have been shown to enhance frontal dopaminergic activity in animal models. We predicted that substitution of risperidone for typical antipsychotic drugs in the treatment of schizophrenia would be associated with enhanced functional activation of frontal cortex. We measured cerebral blood oxygenation changes during periodic performance of a verbal working memory task, using functional MRI, on two occasions (baseline and 6 weeks later) in two cohorts of schizophrenic patients. One cohort (n = 10) was treated with typical antipsychotic drugs throughout the study. Risperidone was substituted for typical antipsychotics after baseline assessment in the second cohort (n = 10). A matched group of healthy volunteers (n = 10) was also studied on a single occasion. A network comprising bilateral dorsolateral prefrontal and lateral premotor cortex, the supplementary motor area, and posterior parietal cortex was activated by working memory task performance in both the patients and comparison subjects. A two-way analysis of covariance was used to estimate the effect of substituting risperidone for typical antipsychotics on power of functional response in the patient group. Substitution of risperidone increased functional activation in right prefrontal cortex, supplementary motor area, and posterior parietal cortex at both voxel and regional levels of analysis. This study provides direct evidence for significantly enhanced frontal function in schizophrenic patients after substitution of risperidone for typical antipsychotic drugs, and it indicates the potential value of functional MRI as a tool for longitudinal assessment of psychopharmacological effects on cerebral physiology. PMID:10557338

  1. 2种西酞普兰制剂的人体生物等效性研究%Study on Bioequivalence of 2 Kinds of Citalopram Preparations in Healthy Volunteers

    Institute of Scientific and Technical Information of China (English)

    黄天文; 文隽; 潘文; 李艳; 雷宇

    2012-01-01

    目的:比较西酞普兰胶囊与片剂在健康人体内的生物等效性.方法:20名健康志愿者采用双周期交叉试验,单剂量空腹口服西酞普兰胶囊(受试制剂)与西酞普兰片(参比制剂)各40 mg,以高效液相色谱法测定其西酞普兰血药浓度,药-时数据经3p97软件处理,计算主要药动学参数,并进行2种制剂的生物等效性评价.结果:西酞普兰胶囊与片剂的主要药动学参数分别为tmax(36.9±9.1)、(39.3±6.8)h,cmax(68.7±5.6)、(71.8±6.9)μg·L-1,t1/2(4.3±1.1)、(4.6±1.0)h,AUC0~144h(2 418±636)、(2 483±342)μg·h·L-1,AUC0~∞(2 576±561)、(2 742±371)μg·h·L-1.西酞普兰胶囊的相对生物利用度为(98.8±11.4)%.结论:西酞普兰胶囊与片剂具有生物等效性.%OBJECTIVE: To compare the bioequivalence of Citalopram capsules and Citalopram tablets in healthy volunteers. METHODS: In bi-periodic cross-over study, 20 healthy volunteers were given Citalopram capsule 40 mg (test preparation) and Citalopram tablet 40 mg (reference preparation) orally respectively. The blood concentration of citalopram was determined by HPLC and pharmacokinetic parameters were calculated with 3p97 software. The bioequivalence of 2 kinds of preparations was evaluated. RESULTS: Main pharmacokinetic parameters of Citalopram capsules vs. Citalopram tablets were as follows: tmax(36.9±9.1)h and (39.3 ±6.8)h;Cmax(68.7 ±5.6)ng·L-1 and (71.8 ±6.9)ug-L-1;rM(4.3± l.l)h and (4.6 ±1.0) h; AUC0~144 h(2 418 ±636)μg·h· L-1 and (2 483 ± 342)μg·h·L-1; AUC0~00 were(2 576 ± 561)μg·h·L-1 and (2 742 ± 371) μg·h·L-1. The relative bioavailability of Citalopram capsules was (98.8 ±11.4)%. CONCLUSION: Citalopram capsule and Citalopram tablet are bioequivalent.

  2. Desipramine and citalopram attenuate pretest swim-induced increases in prodynorphin immunoreactivity in the dorsal bed nucleus of the stria terminalis and the lateral division of the central nucleus of the amygdala in the forced swimming test.

    Science.gov (United States)

    Chung, Sung; Kim, Hee Jeong; Kim, Hyun Ju; Choi, Sun Hye; Cho, Jin Hee; Cho, Yun Ha; Kim, Dong-Hoon; Shin, Kyung Ho

    2014-10-01

    Dynorphin in the nucleus accumbens shell plays an important role in antidepressant-like effect in the forced swimming test (FST), but it is unclear whether desipramine and citalopram treatments alter prodynorphin levels in other brain areas. To explore this possibility, we injected mice with desipramine and citalopram 0.5, 19, and 23 h after a 15-min pretest swim and observed changes in prodynorphin expression before the test swim, which was conducted 24 h after the pretest swim. The pretest swim increased prodynorphin immunoreactivity in the dorsal bed nucleus of the stria terminalis (dBNST) and lateral division of the central nucleus of the amygdala (CeL). This increase in prodynorphin immunoreactivity in the dBNST and CeL was blocked by desipramine and citalopram treatments. Similar changes in prodynorphin mRNA levels were observed in the dBNST and CeL, but these changes did not reach significance. To understand the underlying mechanism, we assessed changes in phosphorylated CREB at Ser(133) (pCREB) immunoreactivity in the dBNST and central nucleus of the amygdala (CeA). Treatment with citalopram but not desipramine after the pretest swim significantly increased pCREB immunoreactivity only in the dBNST. These results suggest that regulation of prodynorphin in the dBNST and CeL before the test swim may be involved in the antidepressant-like effect of desipramine and citalopram in the FST and suggest that changes in pCREB immunoreactivity in these areas may not play an important role in the regulation of prodynorphin in the dBNST and CeA.

  3. 西酞普兰与氟西汀治疗脑卒中后抑郁临床对照研究%Citalopram and fluoxetine in t he treatment of post-stroke depression clinical control study

    Institute of Scientific and Technical Information of China (English)

    段媛卿; 王文泽; 王继禹

    2010-01-01

    Objective Discussion of citalopram and fluoxetine in the treatment of post-stroke depression efficacy and safety of. Methods 82 cases of post-stroke depression were randomly divided into groups of citalopram and fluoxetine groups, treatment of 6 weeks, Hamilton Depression Rating Scale (HAMD) and Emergent Symptom Scale(TESS) in pre-treatment and treatment of 1,2,4,6 weekend separately assessed the efficacy and adverse reactions. Results Citalopram and fluoxetine group the overall effect of a considerable, citalopram group effect faster than the fluoxetine group of adverse reactions due to limited light. Conclusion Citalopram in the treatment of post-stroke depression are both effective and safe.%目的 探讨西酞普兰与氟西汀治疗脑卒中后抑郁的疗效和安全性.方法 82例脑卒中后抑郁患者,随机分为西酞普兰组和氟西汀组,治疗6周,采用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)于治疗前和治疗1、2、4、6周末分别评定疗效和不良反应.结果 西酞普兰组和氟西汀组总体疗效相当,西酞普兰组起效较快,不良反应较氟西汀组少而轻.结论 西酞普兰治疗脑卒中后抑郁既有效又安全.

  4. The Comparison of the Effectiveness of Risperidone and Fluoxetine in Combination with Impulse Control Group Therapy on Improving of Impulsivity, and Relapse in Heroin Crack Addicts under Methadone Maintenance Therapy

    OpenAIRE

    Rohoallah Hadadi; Hamid reza Fathinaz; Mehdi Karimi; Saeed Akbari; Nafiseh Soltannejad

    2013-01-01

    Aim: The aim of the study was to compare the effectiveness of Risperidone and Fluoxetine in combination with impulse control group therapy on improving of impulsivity, and relapse in heroin crack addicts under methadone maintenance therapy. Method: In a semi-experimental study, 39 heroin crack addicts who were under Methadone maintenance treatment selected of addiction withdrawal centers in Tehran. The selected sample was randomly assigned to three groups. First group was under (Risperidone 1...

  5. Preparation and in-vitro characterization of Risperidone-cyclodextrin inclusion complexes as a potential injectable product

    Directory of Open Access Journals (Sweden)

    D Shukla

    2009-12-01

    Full Text Available "n  "n Background and the purpose of the study: This investigation deals with risperidone cyclodextrin (CD complexation for parenteral administration to improve its aqueous solubility which would be beneficial over immediate and sustained release formulations available in market especially for agitated and non-cooperative psychotic patients. "nMethods: The phase solubility study of the drug with β-CD, hydroxypropyl (HP-β-CD and γ-CD was conducted and CDs with higher stability constants were selected for complexation. The complexes of Risperidone with β-CD and HP-β-CD were prepared by precipitation and vacuum drying methods, respectively. Fourier transform-infrared, X-ray diffraction and differential scanning calorimetry techniques were used for characterization of complexes. Drug precipitation study of complex's solution in water for injection and 100 ml of 0.1 M pH 7.4 phosphate buffer saline and stability study in accelerated condition were also carried out. "nResults: The stability constants of the CD were in the following order: β-CD (341.953±11.87 M-1 > HP-β-CD (170.817± 5.93 M-1 > γ-CD (93.716 ± 3.25 M-1. CDs with high stability constants were selected to prepare the drug CD complex. The complexation efficiencies of β-CD and HP-β-CD were 95.23 ± 2.27% and 97.59 ±1.97%, respectively. Both types of CDs exhibited complexation at 1:2 molar stoichiometric ratio. The drug precipitation study indicated complete solubility (100% drug dissolution without a trace of precipitate within 5 mins. The complexes were found to be stable for a period of 3 months under accelerated stability conditions. Major conclusion:Stable complexes of risperidone were successfully formulated using both β-CD and HP-β-CD by simple and highly efficient methods of complexation for parenteral administration.

  6. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

    Science.gov (United States)

    Bobes, J; Garc A-Portilla, M P; Rejas, J; Hern Ndez, G; Garcia-Garcia, M; Rico-Villademoros, F; Porras, A

    2003-01-01

    Atypical antipsychotics seem to differ mainly in their tolerability profile. The aim of this cross-sectional study, the Estudio de Investigaci n de Resultados en Esquizofrenia (Outcomes Research Study in Schizophrenia; EIRE study), was to assess in a clinical setting the frequency of several side-effects related to haloperidol, risperidone, olanzapine, and quetiapine. This article addresses sexual dysfunction and other reproductive side-effects (gynecomastia, menorrhage, amenorrhea, and galactorrhea). We recruited outpatients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association, 1994) criteria and who had received a single antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) for at least 4 weeks. During a single visit, we collected data, including demographic and clinical characteristics, current antipsychotic and concomitant treatment, and adverse effects listed in a modified version of the UKU Scale. We used a Chi-squared test to determine pairs comparisons of the frequency of adverse reactions between treatments. To estimate risk of a given adverse reaction with a given treatment, we used a logistic regression method. We assessed 636 evaluable patients out of 669 recruited. Frequency of sexual dysfunction was high with haloperidol (38.1%) and also with olanzapine (35.3%), quetiapine (18.2%), and risperidone (43.2%). We found the frequency of other reproductive side-effects to be relatively low with all four drugs: haloperidol (6.9%), olanzapine (6.4%), quetiapine (2.7%), and risperidone (11.7%). Sexual dysfunction appeared to be dose-related with haloperidol, risperidone, and olanzapine. Risperidone and olanzapine showed a higher risk of sexual dysfunction and other reproductive sideeffects than haloperidol. Quetiapine showed a lower risk of sexual dysfunction during short-term treatment ( 12 weeks) are lacking. Our results suggest that none of the atypical

  7. Solid lipid nanoparticles (SLN)--based hydrogels as potential carriers for oral transmucosal delivery of risperidone: preparation and characterization studies.

    Science.gov (United States)

    Silva, A C; Amaral, M H; González-Mira, E; Santos, D; Ferreira, D

    2012-05-01

    Two different solid lipid nanoparticles (SLN)-based hydrogels (HGs) formulations were developed as potential mucoadhesive systems for risperidone (RISP) oral transmucosal delivery. The suitability of the prepared semi-solid formulations for application on oral mucosa was assessed by means of rheological and textural analysis, during 30 days. Plastic flows with thixotropy and high adhesiveness were obtained for all the tested systems, which predict their success for the oral transmucosal application proposed. The SLN remained within the colloidal range after HGs preparation. However, after 30 days of storage, a particle size increase was detected in one type of the HGs formulations. In vitro drug release studies revealed a more pronounced RISP release after SLN hydrogel entrapment, when compared to the dispersions alone. In addition, a pH-dependent release was observed as well. The predicted in vivo RISP release mechanism was Fickian diffusion alone or combined with erosion.

  8. Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

    Science.gov (United States)

    Samadi, Roya; Soluti, Susan; Daneshmand, Reza; Assari, Shervin; Manteghi, Ali Akhoundpour

    2017-01-01

    Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in 2012–2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4–8 mg/d) of ondansetron (n=18) or with a placebo (n=20) for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Wechsler’s Adult Intelligence Scale-Revised (WAIS-R), and Hamilton’s Rating Scale for Depression (HRSD) at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16) were used to analyze the data. The statistical significance was set atPWAIS-R scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. The administration of ondansetron significantly improved visual memory based on the subtests of the WAIS (P<0.05). Ondansetron had no positive effects on depressive symptoms (effect size=0.13). Conclusion: This study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. Trial Registration Number: IRCT201112125280N7 PMID:28293046

  9. Costi ed effetti di Risperidone Long Acting (RLA rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia

    Directory of Open Access Journals (Sweden)

    Lorenzo G. Mantovani

    2004-03-01

    Full Text Available Objective: to estimate the costs and effects of long-acting risperidone (LAR in the treatment of schizophrenic patients in Italy, as compared to conventional and oral atypical antipsychotics. Methods: a discrete event model was used. The model simulates patients. history for every single therapeutic alternative and selects incident events, on the basis of pre-defined probability distribution-powered, randomized repetitions. The model operates on two types of parameters: patient characteristics and time-dependent variables. Patient characteristics (age, sex, illness profile and severity, probability of incurring in an adverse event and potential dangerousness remain fixed during the 5 simulated years. Time-dependent variables are subject to changes and include outpatient visits, severity of psychotic episodes, symptom-scores, compliance, incidence of adverse effects, site of treatment and dangerousness. Three treatments have been selected: scenario 1 begins with LAR, switches to olanzapine and then to clozapine; scenario 2 starts with olanzapine, switches to oral risperidone and ends with clozapine. Direct medical costs have been computed on the basis of psychiatric visits, drug costs and costs of the institution in which the patient is treated (hospital, rehabilitation clinic, etc. Outcome measures were number of psychotic episodes in 5 years, total time spent during these episodes and cumulative score of positive and negative symptoms at 5 years. Information on alternatives, transition probabilities, model structure and health resources utilization were derived from the literature and from a panel of experts. Results: it has been estimated that LAR is economically dominant (more effective at lower cost respect to oral atypical antipsychotics, being able to prevent 0.87 psychotic episodes per patient, with a net cost saving of 4,773 euro per patient. Sub-group analysis indicate that LAR is always more effective than the considered alternatives

  10. Risperidone Effects on Brain Dynamic Connectivity—A Prospective Resting-State fMRI Study in Schizophrenia

    Science.gov (United States)

    Lottman, Kristin K.; Kraguljac, Nina V.; White, David M.; Morgan, Charity J.; Calhoun, Vince D.; Butt, Allison; Lahti, Adrienne C.

    2017-01-01

    Resting-state functional connectivity studies in schizophrenia evaluating average connectivity over the entire experiment have reported aberrant network integration, but findings are variable. Examining time-varying (dynamic) functional connectivity may help explain some inconsistencies. We assessed dynamic network connectivity using resting-state functional MRI in patients with schizophrenia, while unmedicated (n = 34), after 1 week (n = 29) and 6 weeks of treatment with risperidone (n = 24), as well as matched controls at baseline (n = 35) and after 6 weeks (n = 19). After identifying 41 independent components (ICs) comprising resting-state networks, sliding window analysis was performed on IC timecourses using an optimal window size validated with linear support vector machines. Windowed correlation matrices were then clustered into three discrete connectivity states (a relatively sparsely connected state, a relatively abundantly connected state, and an intermediately connected state). In unmedicated patients, static connectivity was increased between five pairs of ICs and decreased between two pairs of ICs when compared to controls, dynamic connectivity showed increased connectivity between the thalamus and somatomotor network in one of the three states. State statistics indicated that, in comparison to controls, unmedicated patients had shorter mean dwell times and fraction of time spent in the sparsely connected state, and longer dwell times and fraction of time spent in the intermediately connected state. Risperidone appeared to normalize mean dwell times after 6 weeks, but not fraction of time. Results suggest that static connectivity abnormalities in schizophrenia may partly be related to altered brain network temporal dynamics rather than consistent dysconnectivity within and between functional networks and demonstrate the importance of implementing complementary data analysis techniques. PMID:28220083

  11. Micelle Enhanced Fluorimetric and Thin Layer Chromatography Densitometric Methods for the Determination of (± Citalopram and its S – Enantiomer Escitalopram

    Directory of Open Access Journals (Sweden)

    Elham A. Taha

    2009-01-01

    Full Text Available Two sensitive and validated methods were developed for determination of a racemic mixture citalopram and its enantiomer S-(+ escitalopram. The first method was based on direct measurement of the intrinsic fluorescence of escitalopram using sodium dodecyl sulfate as micelle enhancer. This was further applied to determine escitalopram in spiked human plasma, as well as in the presence of common and co-administerated drugs. The second method was TLC densitometric based on various chiral selectors was investigated. The optimum TLC conditions were found to be sensitive and selective for identification and quantitative determination of enantiomeric purity of escitalopram in drug substance and drug products. The method can be useful to investigate adulteration of pure isomer with the cheap racemic form.

  12. Decreased sensitivity to thermal pain in rats bred for high anxiety-related behaviour is attenuated by citalopram or diazepam treatment.

    Science.gov (United States)

    Jochum, Thomas; Boettger, Michael Karl; Wigger, Alexandra; Beiderbeck, Daniela; Neumann, Inga D; Landgraf, Rainer; Sauer, Heinrich; Bär, Karl-Jürgen

    2007-10-01

    Complex interactions between pain perception, anxiety and depressive symptoms have repeatedly been described. However, pathophysiological or biochemical mechanisms underlying the alterations of pain perception in patients suffering from anxiety or depression still remain a matter of debate. Thus, we aimed to perform an investigation on pain perception in an animal model of extremes in anxiety-related behaviour, which might provide a tool for future studies. Here, thermal pain thresholds were obtained from rats with a genetic predisposition to high anxiety-related behaviour (HAB), including signs of comorbid depression-like behaviour and from controls (low-anxiety rats (LAB); cross-bred HAB and LAB rats; Wistar rats). Furthermore, the effect of eight-week antidepressive treatment using citalopram and of short-term anxiolytic treatment with diazepam on pain-related behaviour was assessed. Simultaneously, anxiety-related behaviour was monitored. At baseline, HAB animals showed 35% higher thresholds for thermal pain than controls. These were normalized to control levels after eight weeks of continuous citalopram treatment paralleled by a reduction of anxiety-related behaviour, but also acutely after diazepam administration. Overall, thermal pain thresholds in HAB animals are shifted in a similar fashion as seen in patients suffering from major depressive disorder. Antidepressive, as well as anxiolytic treatments, attenuated these differences. As the relative importance of the factors anxiety and depression cannot be derived from this study with certainty, extending these investigations to additional animal models might represent a valuable tool for future investigations concerning the interrelations between anxiety, depression, and pain at a molecular level.

  13. 西酞普兰与氟西汀治疗抑郁症的疗效比较%Comparison of the effect of citalopram and fluoxetine in the treatment of depression

    Institute of Scientific and Technical Information of China (English)

    李月霞

    2012-01-01

    目的 比较西酞普兰与氟西汀治疗抑郁症的疗效及不良反应.方法 将46例符合CCMD-3诊断标准的抑郁症患者随机分为西酞普兰组和氟西汀组,疗程6周,用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)评定疗效和不良反应.结果 西酞普兰组显效率为75.4%,氟西汀组为74.8%,两组差异无统计学意义(P>0.05).两组治疗第2周末HAND评分差异有统计学意义(P<0.05).西酞普兰组TESS评分低于氟西汀组(P<0.05).结论 西酞普兰和氟西汀均有良好的抗抑郁效果.西酞普兰具有起效早、不良反应小的优点.%Objective To compare the effect and side effects of citalopram and fluoxetine in the treatment of depression.Methods 46 cases meet the diagnostic criteria of CCMD-3 in patients with depression were randomly divided into citalopram group and fluoxetine group,treatment for 6 weeks,with Hamilton Depression Rating Scale (HAMD) and Emergent Symptom Scale(TESS) assessed the efficacy and adverse reactions.Results The efficiercy in citalopram group was 75.4%,74.8% for the fluoxetine group,the difference between the two groups was not significant ( P>0.05).Affter 2weeks treatment HAMD score between the two groups was significantly different (P < 0.05),TESS score in Citalopram group was lower than the fluoxetine group,the differences were significant ( P < 0.05 ).Conclusion Citalopram and fluoxetine have good antidepressant effects.Citalopram has the advanteges of early onset,cess adverse reactions.

  14. 肌注利培酮微球与口服利培酮治疗精神分裂症疗效研究%Studies on the Eficacy of Intramuscular Risperidone Microspheres and Oral Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    梁松新; 王秋琴; 麦以成; 邓良华

    2013-01-01

      目的探讨肌注利培酮微球与口服利培酮治疗精神分裂症的疗效,为临床选择药物提供依据.方法将80例精神分裂症患者随机分成肌注利培酮微球(RLAI)组及口服利培酮片组,治疗12周.在治疗第1、4、8、12周用阳性与阴性症状量表(PANSS)、临床疗效总评量表(CGI-SI)、不良反应量表(TESS)评定疗效和不良反应.结果两组PANSS总分及CGI-SI评分均比治疗前显著下降(P<0.01),与基线比较,PANSS评分自4周末以后均出现显著差异,两组疗效相当.RLAI组的不良反应明显低于口服利培酮片组(P<0.05).结论肌注利培酮微球与口服利培酮片治疗精神分裂症的疗效相当,RLAI组的不良反应较口服利培酮少而轻.肌注利培酮微球治疗精神分裂症安全有效,患者对治疗依从性比口服利培酮更好.%Objective To investigate the efficacy of intramuscular risperidone microspheres and oral risperidone in the treatment of schizophrenia, and to provide the basis for clinical drug of choice. Methods 80 cases of patients with schizophrenia were randomly divided into intramuscular risperidone microspheres(RLAI) group and the oral risperidone piece group, 12 weeks of treatment. Evaluate the efficacy and adverse reactions in the treatment of 1, 4, 8 and 12 weeks using the Positive and Negative Syndrome Scale(PANSS), the Clinical Global Impression(CGI-SI), adverse reactions Scale(TESS). Results The PANSS total score and CGI-SI score in both groups was significantly decreased(P<0.01) than before treatment. Compared with baseline, there are significant differences in the PANSS score after 4 weeks. Treatment efficiency in two group is very close to. The adverse drug reactions of RLAI group was significantly lower than the oral risperidone group(P<0.05). Conclusion The efficacy of intramuscular risperidone microspheres and oral risperidone tablets in the treatment of schizophrenia is very close to, The RLAI group adverse reactions are

  15. 阿立哌唑与利培酮治疗精神分裂症疗效比较%Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵辉

    2014-01-01

    目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效。方法将我院2012年10月-2013年6月收治的40例精神分裂症患者按随机数字表法随机分为阿立哌唑组和利培酮组各20例,分别使用阿立哌唑和利培酮对两组患者进行治疗,将两组治疗效果按照CCMD-3精神分裂症的诊断标准进行评价,依据副反应量表( TESS )评定副反应,以阳性与阴性症状量表( PANSS)减分率对疗效进行评定。结果阿立哌唑组痊愈9例,7例显著好转,3例好转,1例无效;利培酮组痊愈10例,5例显著好转,3例好转,2例无效。两组间的疗效比较无显著性差异。阿立哌唑组5例出现不良反应,占25%;利培酮组出现不良反应的有12例,占60%,阿立哌唑组不良反应总发生率显著低于利培酮组(χ2=5.013, P<0.05)。结论阿立哌唑与利培酮治疗精神分裂症的疗效显著,在治疗过程中,两种药物各有千秋,但在不良反应发生率方面,阿立哌唑低于利培酮,阿立哌唑的安全性高于利培酮。%Objective To analyze and compare aripiprazole and risperidone in the treatment of schizophrenia treatment .Methods 40 cases of patients with schizophrenia in hospital from October 2012 to June 2013 were randomly divided into aripiprazole group and the risperidone group,respectively,the two groups of patients were evaluated according to CCMD -3 diagnostic criteria,TESS and PANSS. Results In aripiprazole group ,9 cases recure ,7 cases were significantly improved ,3 cases improved ,and one case was invalid .In risper-idone group,10 cases cured,5 cases were significantly improved,3 cases improved,2 cases were ineffective.There was no significant difference in the efficacy between the two groups (P>0.05).Aripiprazole group had 5 cases of adverse reactions (25%),risperidone group had 12 cases of adverse reactions (60%),incidence of adverse reactions in aripiprazole group was

  16. 疏血通联合异丙嗪、三磷酸腺苷、维生素B6治疗眩晕症的临床疗效观察%Curative effect observation of Shuxuetong with promethazine, ATP, vitamin B6 treat vertigo

    Institute of Scientific and Technical Information of China (English)

    刘磊

    2014-01-01

    Objective To discuss the clinical efficacy of Shuxuetong with promethazine, ATP, vitamin B6 in the treatment of vertigo, provide effective theoretical basis for the treatment of rapid treatment. Methods 60 patients with vertigo were randomly divided into treatment group and control group. Treatment group was treated with Shuxuetong, promethazine,ATP, vitamin B6; the control group was given the treatment of promethazine, 654-2. Comparison of curative effect of two groups of patients after 3h. Results Effective 28 cases in the treatment group after treatment 3h, significantly better than the 20 cases in the control group, P<0.01. Conclusion Shuxuetong combination with promethazine, adenosine triphosphate, vitamin B6 treatment of emergency vertigo is a safe and effective and fast treatment, worthy of clinical application.%目的:探讨疏血通联合异丙嗪、三磷酸腺苷、维生素B6治疗眩晕症的临床疗效,为急诊快速救治提供有效理论依据。方法将60例眩晕症患者随机分为治疗组和对照组。治疗组给予疏血通、异丙嗪、三磷酸腺苷、维生素B6治疗;对照组给予异丙嗪、654-2治疗。对比两组患者在3h后的疗效。结果治疗组在治疗3h后有效26例,明显好于对照组17例,P<0.05。结论疏血通联用异丙嗪、三磷酸腺苷、维生素B6治疗眩晕症是一种安全有效而又快速的治疗手段,值得临床推广应用。

  17. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial

    Science.gov (United States)

    Riahi, Forough; Tashakori, Ashraf; Abdi, Leila

    2016-01-01

    Background Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%. Objective To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children. Methods In a 6-week double-blind clinical trial, the efficacy of Risperidone 0.5–2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3–6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners’ Parent Rating Scale (CPRS-48), Children’s Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher’s exact tests in the SPSS 19. Results During the 6 weeks, the decline in points was seen in Conner’s rating scale and in ADHD-RS score in Risperidone and Haloperidol groups (p0.05). Conclusions Haloperidol and Risperidone possibly can be an acceptable treatment choice in the ADHD treatment of 3- to 6-year-old children. Trial registration The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2015082623766N1. Funding This work was financially supported by grant (ref. no.: U-93130) from the vice chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences. PMID:27790334

  18. Controlled clinical treatment of the domestic Ziprasidone and risperidone%国产齐拉西酮与维思通的临床对照治疗

    Institute of Scientific and Technical Information of China (English)

    李永强; 冯金河

    2013-01-01

    Objective:comparison curative effect and untoward effect between Ziprasidone and risperidone. Methods:Sixty patients with schizophrenia were randomly divided into two groups: thirty patients were in Ziprasidone's group and the other thirty patients were in risperidone's group, after treatment for six weekends, used positive and negative symptom scale (PANSS) and treatment emergent symptoms scale (TESS) to evaluate the efficacy. Results: Ziprasidone and risperidone have equal therapy, but the incidence of adverse reaction and symptom severity of Ziprasidone was significantly lower than risperidone, especially, Ziprasidone has a small influence in mammotropic hormone and weight. Conclusion: Ziprasidone for schizophrenia have a good efficacy, few untoward effects and good compliance.%目的对比国产齐拉西酮与维思通的疗效和不良反应。方法对60例精神分裂症患者随机分为国产齐拉西酮组30例和维思通组30例,进行相应的药物治疗,疗程6周,采用PANSS量表和TESS副反应量表进行评价。结果国产齐拉西酮和维思通疗效相当,但国产齐拉西酮的不良反应发生率和症状严重程度显著低于维思通,特别对催乳素和体重的影响明显较小,同时具有良好的依从性。结论国产齐拉西酮治疗精神分裂症疗效确切,不良反应少,依从性好。

  19. Establishment of the sterility test method for risperidone for depot suspension%注射用利培酮微球无菌检查法的建立

    Institute of Scientific and Technical Information of China (English)

    王似锦; 刘文杰; 高春

    2013-01-01

    Objective:To establish the method of sterility test for risperidone for depot suspension.Methods:Sterility test of risperidone for depot suspension was carried out using the technique of direct inoculation,and the validation test was accomplished according to CP 2010.Results:As a result of the method validation of sterility test,all the test strains grew well.The established method was suitable for the sterility test of risperidone for depot suspension.Conclusion:Sterility test of risperidone for depot suspension is composed of outer sterility test and inner sterility test.Dimethyl sulfoxide (DMSO) can be used for inner sterility test as a solvent because it can dissolve and break the microspheres.%目的:建立注射用利培酮微球的无菌检查法.方法:采用直接接种法进行利培酮微球的无菌检查,并按照《中华人民共和国药典》的要求进行了方法学验证试验研究.结果:经过方法学验证,各验证菌生长良好,所建立的方法可用于注射用利培酮微球的无菌检查.结论:注射用利培酮微球的无菌检查应包括表面无菌检查和内部无菌检查.二甲基亚砜(DMSO)可作为溶剂对微球进行溶解和破碎,从而进行内部无菌检查.

  20. Comparison of the effects of methylphenidate and the combination of methylphenidate and risperidone in preschool children with attention-deficit hyperactivity disorder

    Science.gov (United States)

    Safavi, Parvin; Dehkordi, Ali Hasanpour; Ghasemi, Nasim

    2016-01-01

    Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder among preschool children but the number of controlled clinical trials regarding psychopharmacological treatment in this age group is limited. The aim of this study was to compare methylphenidate with the combination of methylphenidate and risperidone in preschool children with ADHD. Forty-two preschool children, aged 3–6 years, diagnosed with ADHD by a child and adolescent psychiatrist according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-Text Revision criteria, were enrolled in a 6-week, single-blind clinical trial and administered with methylphenidate (5–30 mg/dl) or the combination of methylphenidate and risperidone (0.25–2 mg/dl) in Iran. Treatment outcomes were assessed using the Conners' Rating Scale and Clinical Global Impression (CGI) Scale at baseline and 3 and 6 weeks after starting the drugs administration. Side effects were rated by a checklist and body weight was measured at each visit. There were no significant differences between the two protocols in Parent Conners' Rating Scale scores (P > 0.05) and CGI scores (P > 0.05). Both groups showed a significant improvement in ADHD symptoms over the 6 weeks of treatment for Parent Conners' Rating Scale (P < 0.001). The combination group used significantly lower doses of methylphenidate compared to the other group (P = 0.002). The most common adverse effects were anorexia (21.7%) and daytime drowsiness (17.4%) in combination treatment group and insomnia (33.3%) and anorexia (25%) in methylphenidate group. Risperidone and methylphenidate may be effective and well tolerated in preschool children with ADHD, and adding risperidone to methylphenidate may decrease the occurrence of some side effects of methylphenidate such as insomnia and anorexia and lower the dose of methylphenidate may be needed to control symptoms. PMID:27833894

  1. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial

    Directory of Open Access Journals (Sweden)

    Parvin Safavi

    2016-01-01

    Full Text Available Although pharmacotherapy with atypical antipsychotics is common in child psychiatry, there has been little research on this issue. To compare the efficacy and safety of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorders comorbid with attention deficit-hyperactivity disorder (ADHD. Randomized clinical trial conducted in a university-affiliated child psychiatry clinic in southwest Iran. Forty 3-6-year-old children, diagnosed with oppositional defiant disorder comorbid with ADHD, were randomized to an 8-week trial of treatment with risperidone or aripiprazole (20 patients in each group. Assessment was performed by Conners′ rating scale-revised and clinical global impressions scale, before treatment, and at weeks 2, 4, and 8 of treatment. The data were analyzed by SPSS version 16. Mean scores between the two groups were compared by analysis of variance and independent and paired t-test. Mean scores of Conners rating scales were not different between two groups in any steps of evaluation. Both groups had significantly reduced scores in week 2 of treatment (P = 0.00, with no significant change in subsequent measurements. Rates of improvement, mean increase in weight (P = 0.894, and mean change in fasting blood sugar (P = 0.671 were not significantly different between two groups. Mean serum prolactin showed a significant increase in risperidone group (P = 0.00. Both risperidone and aripiprazole were equally effective in reducing symptoms of ADHD and oppositional defiant disorder, and relatively safe, but high rates of side effects suggest the cautious use of these drugs in children.

  2. Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.

    Science.gov (United States)

    Dong, Chao; Zhang, Ji-chun; Yao, Wei; Ren, Qian; Yang, Chun; Ma, Min; Han, Mei; Saito, Ryo; Hashimoto, Kenji

    2016-05-01

    Inflammation plays a role in the pathophysiology of depression. The purpose of this study is to examine whether the selective serotonin reuptake inhibitor (SSRI) escitalopram, its inactive enantiomer R-citalopram, and selective noradrenaline reuptake inhibitor (NRI) reboxetine, show anti-inflammatory and antidepressant effects in an inflammation-induced model of depression. Pretreatment with escitalopram (1, 3, or 10mg/kg, i.p.) markedly blocked an increase in the serum levels of pro-inflammatory cytokine, tumor necrosis factor-α (TNF-α), after a single administration of lipopolysaccharide (LPS; 0.5mg/kg). Furthermore, escitalopram (3 or 10mg/kg) significantly increased the serum levels of the anti-inflammatory cytokine interleukin-10 (IL-10) by a single administration of LPS. In contrast, pretreatment with R-citalopram (10mg/kg, i.p.) or reboxetine (10mg/kg, i.p.) did not affect the alterations in serum levels of TNF-α and IL-10 after LPS administration. Co-administration of reboxetine with escitalopram did not show anti-inflammatory effects. Pretreatment with escitalopram (10mg/kg) significantly attenuated LPS-induced increase of the immobility time in the tail-suspension test (TST) and forced swimming test (FST). In contrast, pretreatment with R-citalopram (10mg/kg), or reboxetine (10mg/kg) did not alter LPS-induced increase of immobility time of TST and FST. Interestingly, co-administration of reboxetine with escitalopram did not show antidepressant effect in this model. These findings suggest that escitalopram, but not R-citalopram and reboxetine, has anti-inflammatory and antidepressant effects in LPS-treated model of depression, and that reboxetine can antagonize the effects of escitalopram in the inflammation model. Therefore, it is likely that serotonergic system plays a key role in the pathophysiology of inflammation-induced depression.

  3. Effect of Smoking on Pharmacokinetics and Clinical Efficacy of Risperidone%吸烟对利培酮药代动力学及疗效的影响

    Institute of Scientific and Technical Information of China (English)

    曹民佑

    2014-01-01

    目的:探讨吸烟对利培酮药代动力学和血药浓度的影响,以及利培酮血药浓度与临床疗效及不良反应之间的关系。方法采用反相高效液相色谱法测定利培酮及9-羟利培酮血药浓度,并进行药代动力学参数研究,采用简明精神病症状评定量表(BPRS)、阳性和阴性症状量表(SAPS、SANS)和副反应量表(TESS)评定临床疗效和不良反应。结果吸烟者的利培酮和9-羟利培酮的消除速率较非吸烟者快[消除速率常数(K)更高],且其消除半衰期(T1/2)较短,达峰浓度(Cmax)和第2周末稳态浓度谷值均较低(P<0.05或P<0.01)。利培酮血药浓度及利培酮+9-羟利培酮总浓度与TESS增分值呈正相关(r=0.42~0.62,均P<0.01),与BPRS、SANS和SAPS的减分率无显著相关性(P>0.05)。以治疗8周BPRS总分减分率≥25%为界,划分有效组和无效组进行血药浓度比较,无效组利培酮及利培酮+9-羟利培酮血药浓度低于有效组(P<0.05)。结论吸烟可加快利培酮的代谢,利培酮和9-羟利培酮总的血药浓度在20~60μg·L-1范围内较为适宜,疗效较好,不良反应较少。%Objective To evaluate the influence of smoking on the pharmacokinetics and plasma concentrations of risperidone, and to investigate the relationships of blood risperidone concentrations to clinical efficacies and adverse reactions. Methods The plasma concentrations of risperidone and 9-hydroxyrisperidone were measured by RP-HPLC and pharmacokinetic studies were performed in patients. Clinical efficacies and adverse reactions were evaluated with Brief Psychiatric Reacting Scale (BPRS),Scale for the Assessment of Positive Symptoms (SAPS),Scale for the Assessment of Negative Symptoms(SANS) and Treatment Emergent Symptom Scale(TESS). Results Compared with patients who do not smoke, elimination rate constant of risperidone and 9-hydroxyrisperidone increased and

  4. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound.

    Science.gov (United States)

    Silva, A C; González-Mira, E; García, M L; Egea, M A; Fonseca, J; Silva, R; Santos, D; Souto, E B; Ferreira, D

    2011-08-01

    The suitability of solid lipid nanoparticles (SLN) for the encapsulation of risperidone (RISP), an antipsychotic lipophilic drug, was assessed for oral administration. The hot high pressure homogenization (HPH) and the ultrasound (US) technique were used as production methods for SLN. All the studies on the SLN formulations were done in parallel, in order to compare the results and conclude about the advantages and limitations of both techniques. The particle sizes were in the nanometer range for all prepared SLN formulations and the zeta potential absolute values were high, predicting good long-term stability. Optical analyses demonstrated the achievement of stable colloidal dispersions. Physicochemical characterization of dispersions and bulk lipids, performed by differential scanning calorimetry (DSC) and X-ray assays, support prediction of occurrence of drug incorporation in the SLN and good long term stability of the systems. The toxicity of SLN with Caco-2 cells and the existence of contaminations derived from the production equipments were assessed by the (4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) assay. The results showed 90% of cell viability after SLN exposure, with no significant differences within all prepared formulations (p > 0.05). From this study, we conclude that SLN can be considered as efficient carriers for RISP encapsulation. Moreover, HPH and US revealed to be both effective methods for SLN production.

  5. Stathmin reduction and cytoskeleton rearrangement in rat nucleus accumbens in response to clozapine and risperidone treatment - Comparative proteomic study.

    Science.gov (United States)

    Kedracka-Krok, S; Swiderska, B; Jankowska, U; Skupien-Rabian, B; Solich, J; Dziedzicka-Wasylewska, M

    2016-03-01

    The complex network of anatomical connections of the nucleus accumbens (NAc) makes it an interface responsible for the selection and integration of cognitive and affective information to modulate appetitive or aversively motivated behaviour. There is evidence for NAc dysfunction in schizophrenia. NAc also seems to be important for antipsychotic drug action, but the biochemical characteristics of drug-induced alterations within NAc remain incompletely characterized. In this study, a comprehensive proteomic analysis was performed to describe the differences in the mechanisms of action of clozapine (CLO) and risperidone (RIS) in the rat NAc. Both antipsychotics influenced the level of microtubule-regulating proteins, i.e., stathmin, and proteins of the collapsin response mediator protein family (CRMPs), and only CLO affected NAD-dependent protein deacetylase sirtuin-2 and septin 6. Both antipsychotics induced changes in levels of other cytoskeleton-related proteins. CLO exclusively up-regulated proteins involved in neuroprotection, such as glutathione synthetase, heat-shock 70-kDa protein 8 and mitochondrial heat-shock protein 75. RIS tuned cell function by changing the pattern of post-translational modifications of some proteins: it down-regulated the phosphorylated forms of stathmin and dopamine and the cyclic AMP-regulated phosphoprotein (DARPP-32) isoform but up-regulated cyclin-dependent kinase 5 (Cdk5). RIS modulated the level and phosphorylation state of synaptic proteins: synapsin-2, synaptotagmin-1 and adaptor-related protein-2 (AP-2) complex.

  6. Valutazione dei costi di trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici di un DSM italiano

    Directory of Open Access Journals (Sweden)

    I. Rossi

    2001-12-01

    Full Text Available Objective of the present retrospective analysis was to evaluate resources consumption for psychotic patients treatment with olanzapine (OLZ, risperidone (RIS or typical neuroleptics (NL during year 2000 in the Dipartimento di Salute Mentale (DSM of Ravenna. The screening of total number of psychotic patients followed in the Ravenna DSM during year 2000 generated 26 cases treated with OLZ, 22 treated with RIS and 17 treated with NL that were respecting criteria of equivalence for age and illness severity. For these patients we analyzed pharmacological, non pharmacological (medical visits, nurse visits, social assistance, rehabilitative sessions and hospital interventions during the year of observation, choosing the point of view of the DSM for costs attribution. The analysis of pharmacological interventions evidentiated a major usage of associated neuroleptics in the RIS and NL groups in respect to OLZ (pNL>RIS, p<0,05 for all comparisons. Hospital days during the year of observation in the three groups were 4,42 for OLZ patients, 7,71 for NL patients and 10,95 for RIS patients (p<0,05 for all comparisons: OLZ vs RIS, OLZ vs NL and RIS vs NL. The sum of pharmacological, non pharmacological and hospital costs (from 8.856.000 to 10.818.000 LIT didn’t generated statistically significant differences even if the OLZ group followed more intense rehabilitative activities (+71,65% vs RIS and +24,41% vs NL.

  7. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions.

    Science.gov (United States)

    Iasevoli, Felice; Fiore, Germano; Cicale, Maria; Muscettola, Giovanni; de Bartolomeis, Andrea

    2010-05-15

    Homer1a and Yotiao are two post-synaptic density proteins at the crossroad of dopamine-glutamate neurotransmission. Homer1a has been implicated in the pathophysiology of schizophrenia and is differentially induced by typical and atypical antipsychotics, perhaps according to their dopaminergic profile. Yotiao has been involved in glutamate and dopamine post-synaptic signalling. Here, we seek to determine whether Homer1a and Yotiao might be implicated in post-synaptic response to antipsychotics with affinity to different dopamine D(2) receptors: haloperidol (0.8mg kg(-1)), risperidone (3mg kg(-1)), olanzapine (2.5mg kg(-1)) and (-)-sulpiride (50mg kg(-1)). Homer1a expression was significantly induced by haloperidol compared to vehicle and to atypical antipsychotics in almost all striatal sub-regions. Atypical antipsychotics induced the gene in the lateral putamen and in the core of the accumbens only. All antipsychotics, with the exclusion of sulpiride, elicited a dorsolateral-to-ventromedial distribution pattern of Homer1a expression. No significant induction was detected for Yotiao. These results suggest that the quantitative and topographical pattern of Homer1a expression may putatively be related to antipsychotics affinity and/or occupancy at dopamine D(2) receptors.

  8. 氟哌啶醇与利培酮对精神分裂症患者生活质量的影响%Effect of Haloperidol and Risperidone on the Life Quality of the Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    任清涛; 闫加民; 李广

    2002-01-01

    Objective: To compare the effects between ha loperidol and rieperidon e on quality of life in patients with schizophrenia. Methods: The patients with schizophrenia treated respectively by haloperidol and risperidone were compared by double blind method. The General Quality of Life Inventory (GQOLI) was used to evaluate the life quality, while the Positive and Negative Symptoms Scale (PA NSS) and the Treatment Emergent Symptom Scale (TESS) were used to assess the eff icacy and side effects. Results: The risperidone group sho wed better effects tha n the haloperidol group in the domains of physical function ,mental health and s ocial function The difference was significant (P<0.01). Conclusion:[ WT5"BZ The quality of life of Schizophrenic patients treated by haloperidol were poorer than that o f risperidone.

  9. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test.

    Science.gov (United States)

    Sams-Dodd, F

    1998-01-01

    Phencyclidine (PCP) can induce a model psychosis in humans that mimics the positive and negative symptoms of schizophrenia. In the social interaction test PCP induces stereotyped behaviour and social isolation in rats, and these behaviours can be inhibited by antipsychotic drugs. In order to further evaluate the predictive validity of this model of schizophrenia the anxiolytic diazepam (0.02-17.5 micromol/kg; 0.005-5.0 mg/kg), the antidepressant citalopram (0.62-19.8 micromol/kg; 0.3-4.0 mg/kg), the opioid agonist methadone (0.36-5.8 micromol/kg; 0.13-2.0 mg/kg) and the opioid antagonist naloxone (0.34-22.0 micromol/kg; 0.13-8.0 mg/kg) were tested as examples of drugs without antipsychotic activity. The experiments demonstrated that these compounds did not specifically inhibit the behavioural effects of PCP. So far only antipsychotic drugs have been able to specifically inhibit the PCP-induced behaviours.

  10. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

    Science.gov (United States)

    Nagy, Katalin; Marko, Bernadett; Zsilla, Gabriella; Matyus, Peter; Pallagi, Katalin; Szabo, Geza; Juranyi, Zsolt; Barkoczy, Jozsef; Levay, Gyorgy; Harsing, Laszlo G

    2010-12-01

    The most dominant hypotheses for the pathogenesis of schizophrenia have focused primarily upon hyperfunctional dopaminergic and hypofunctional glutamatergic neurotransmission in the central nervous system. The therapeutic efficacy of all atypical antipsychotics is explained in part by antagonism of the dopaminergic neurotransmission, mainly by blockade of D(2) dopamine receptors. N-methyl-D-aspartate (NMDA) receptor hypofunction in schizophrenia can be reversed by glycine transporter type-1 (GlyT-1) inhibitors, which regulate glycine concentrations at the vicinity of NMDA receptors. Combined drug administration with D(2) dopamine receptor blockade and activation of hypofunctional NMDA receptors may be needed for a more effective treatment of positive and negative symptoms and the accompanied cognitive deficit in schizophrenia. To investigate this type of combined drug administration, rats were treated with the atypical antipsychotic risperidone together with the GlyT-1 inhibitor Org-24461. Brain microdialysis was applied in the striatum of conscious rats and determinations of extracellular dopamine, DOPAC, HVA, glycine, glutamate, and serine concentrations were carried out using HPLC/electrochemistry. Risperidone increased extracellular concentrations of dopamine but failed to influence those of glycine or glutamate measured in microdialysis samples. Org-24461 injection reduced extracellular dopamine concentrations and elevated extracellular glycine levels but the concentrations of serine and glutamate were not changed. When risperidone and Org-24461 were added in combination, a decrease in extracellular dopamine concentrations was accompanied with sustained elevation of extracellular glycine levels. Interestingly, the extracellular concentrations of glutamate were also enhanced. Our data indicate that coadministration of an antipsychotic with a GlyT-1 inhibitor may normalize hypofunctional NMDA receptor-mediated glutamatergic neurotransmission with reduced

  11. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

    Science.gov (United States)

    Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X

    2014-09-01

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.

  12. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.

    Science.gov (United States)

    Bobes, Julio; Cañas, Fernando; Rejas, Javier; Mackell, Joan

    2004-12-01

    Frequency of adverse reactions (ARs) related with antipsychotics usage is high. Along with clinical implications, economic impact might be important. The purpose of this study was to model the economic consequences of ARs related with ziprasidone, olanzapine, risperidone, and haloperidol in Spain, by means of a cost-effectiveness model developed using a Markov modeling approach. The model simulated treatment of a cohort of 1000 schizophrenics for 12 months, initiating treatment with one of four antipsychotic drugs; haloperidol, risperidone, olanzapine and ziprasidone. Conditional probabilities of developing any of four adverse events were calculated. Treatment was modified (decrease dose, switch medication) according to incidence of ARs and physician judgments, obtained from a local cross-sectional study and clinical trials previously published. The analysis was conducted in year 2002 from a third party payer perspective. Results are shown as annual cost per month with psychotic symptoms controlled and included univariate sensitivity analysis. The therapeutic strategy starting with ziprasidone showed the lower costs and the greater number of months with symptoms controlled in most scenarios evaluated versus the other options considered, although the differences were weak: 9.6, 9.3, 9.5 and 9.5 controlled months per patient in base scenario, with annual cost per patient per month with symptoms controlled of 1035 Euros, 1084 Euros, 1087 Euros and 1090 Euros for ziprasidone, haloperidol, risperidone and olanzapine, respectively. Results were robust to one-way sensitivity analysis. Despite the unlike drug prices of antipsychotics, a considerable economic impact due to adverse reactions was seen in our setting. These results should be taken into account by health decision makers and clinicians in the management of patients with schizophrenia.

  13. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.

    Science.gov (United States)

    Woerner, Margaret G; Correll, Christoph U; Alvir, Jose Ma J; Greenwald, Blaine; Delman, Howard; Kane, John M

    2011-07-01

    Tardive dyskinesia (TD) rates with second-generation antipsychotics (SGAs) are considered to be low relative to first-generation antipsychotics (FGAs), even in the particularly vulnerable elderly population. However, risk estimates are unavailable for patients naïve to FGAs. Therefore, we aimed to determine the TD incidence in particularly vulnerable, antipsychotic-naïve elderly patients treated with the SGA risperidone or olanzapine. The present work describes a prospective inception cohort study of antipsychotic-naïve elderly patients aged 55 years identified at New York Metropolitan area in-patient and out-patient geriatric psychiatry facilities and nursing homes at the time of risperidone or olanzapine initiation. At baseline, 4 weeks, and at quarterly periods, patients underwent assessments of medical and medication history, abnormal involuntary movements, and extra-pyramidal signs. TD was classified using Schooler-Kane criteria. Included in the analyses were 207 subjects (age: 79.8 years, 70.0% female, 86.5% White), predominantly diagnosed with dementia (58.9%) or a major mood disorder (30.9%), although the principal treatment target was psychosis (78.7%), with (59.4%) or without (19.3%) agitation. With risperidone (n=159) the cumulative TD rate was 5.3% (95% confidence interval (CI): 0.7, 9.9%) after 1 year (mean dose: 1.0±0.76 mg/day) and 7.2% (CI: 1.4, 12.9%) after 2 years. With olanzapine (n=48) the cumulative TD rate was 6.7% (CI: 0, 15.6%) after 1 year (mean dose: 4.3±1.9 mg/day) and 11.1% (CI: 0, 23.1%) after 2 years. TD risk was higher in females, African Americans, and patients without past antidepressant treatment or with FGA co-treatment. The TD rates for geriatric patients treated with risperidone and olanzapine were comparable and substantially lower than previously reported for similar patients in direct observation studies using FGAs. This information is relevant for all patients receiving antipsychotics, not just the especially

  14. Curative effect evaluation of betahistine,flunarizine combined with promethazine in the treatment of vestibular peripheral vertigo%倍他司汀、氟桂利嗪联合异丙嗪治疗前庭周围性眩晕的效果评价

    Institute of Scientific and Technical Information of China (English)

    臧广霞

    2015-01-01

    Objective:To observe the curative effect of betahistine, flunarizine combined with promethazine in the treatment of vestibular peripheral vertigo.Methods:68 patients with vestibular peripheral vertigo were randomly divided into the observation group and the control group.They were respectively given betahistine, flunarizine combined with promethazine treatment and betahistine,flunarizine treatment.The clinical curative effects of two groups were compared.Results:After 1 week and 4 weeks of treatment,the symptom score and the descend range of the observation group were significantly higher than those of the control group(P<0.05).After 4 weeks of treatment,the total effective rate of the observation group was significantly higher than that of the control group(P<0.05).Conclusion:The betahistine,flunarizine combined with promethazine in the treatment of vestibular peripheral vertigo has a significant clinical curative effect,less adverse reaction and high safety.%目的:观察倍他司汀、氟桂利嗪联合异丙嗪治疗前庭周围性眩晕的效果.方法:将68例前庭周围性眩晕患者随机分为观察组和对照组,分别采用倍他司汀、氟桂利嗪联合异丙嗪治疗和倍他司汀、氟桂利嗪治疗,比较两组的临床疗效.结果:治疗1周及4周后,观察组症状评分及下降幅度均明显大于对照组(P<0.05).治疗4周后,观察组总有效率明显高于对照组(P<0.05).结论:倍他司汀、氟桂利嗪联合异丙嗪治疗前庭周围性眩晕,临床效果显著,不良反应少,安全性高.

  15. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

    Directory of Open Access Journals (Sweden)

    Macfadden Wayne

    2011-04-01

    Full Text Available Abstract Background Because wide variations in mental health care utilization exist throughout the world, determining long-term effectiveness of psychotropic medications in a real-world setting would be beneficial to physicians and patients. The purpose of this analysis was to describe the effectiveness of injectable risperidone long-acting therapy (RLAT for schizophrenia across countries. Methods This was a pragmatic analysis of data from two prospective observational studies conducted in the US (Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation [SOURCE]; ClinicalTrials.gov registration number for the SOURCE study: NCT00246194 and Spain, Australia, and Belgium (electronic Schizophrenia Treatment Adherence Registry [eSTAR]. Two separate analyses were performed to assess clinical improvement during the study and estimate psychiatric hospitalization rates before and after RLAT initiation. Clinical improvement was evaluated using the Clinical Global Impressions-Severity (CGI-S and Global Assessment of Functioning (GAF scales, and change from baseline was evaluated using paired t tests. Psychiatric hospitalization rates were analyzed using incidence densities, and the bootstrap resampling method was used to examine differences between the pre-baseline and post-baseline periods. Results The initial sample comprised 3,069 patients (US, n = 532; Spain, n = 1,345; Australia, n = 784; and Belgium, n = 408. In all, 24 months of study participation, completed by 39.3% (n = 209, 62.7% (n = 843, 45.8% (n = 359, and 64.2% (n = 262 of patients from the US, Spain, Australia, and Belgium, respectively, were included in the clinical analysis. Improvements compared with baseline were observed on both clinical assessments across countries (P P P Conclusions RLAT in patients with schizophrenia was associated with improvements in clinical and functional outcomes and decreased hospitalization rates in the US, Spain, Australia, and Belgium, despite

  16. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.

    Science.gov (United States)

    Yasui-Furukori, Norio; Saito, Manabu; Tsuchimine, Shoko; Nakagami, Taku; Sato, Yasushi; Sugawara, Norio; Kaneko, Sunao

    2008-08-01

    Hyperprolactinemia is an inevitable consequence of treatment with antipsychotic agents to some extent because prolactin response to antipsychotics is related to dopamine blockade. Recent studies have suggested that polymorphisms of the dopamine receptors are associated with therapeutic response to antipsychotics. Thus, we studied the effects of major polymorphisms of dopamine-related genes on plasma concentration of prolactin. Subjects were 174 schizophrenic patients (68 males, 106 females) receiving 3 mg twice daily of risperidone for at least 4 weeks. Sample collections were conducted 12 h after the bedtime dosing. Five dopamine-related polymorphisms (Taq1A, -141C ins/del for DRD2, Ser9Gly for DRD3, 48 bp VNTR for DRD4, Val158Met for COMT) were identified. The mean (+/-SD) plasma concentration of prolactin in females was significantly higher than males (54.3+/-27.2 ng/ml versus 126.8+/-70.2 ng/ml, p<0.001). No dopamine-related polymorphisms differed the plasma concentration of prolactin in males or females. Multiple regression analyses including plasma drug concentration and age revealed that plasma concentration of prolactin correlated with gender (standardized partial correlation coefficients (beta)=0.551, p<0.001) and negatively with age (standardized beta=-0.202, p<0.01). No correlations were found between prolactin concentration and dopamine-related polymorphisms. These findings suggest that plasma prolactin concentrations in females are much higher than in males but the dopamine-related variants are not predominantly associated with plasma concentration of prolactin.

  17. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

    Directory of Open Access Journals (Sweden)

    Dirani Riad D

    2011-10-01

    Full Text Available Abstract Background To evaluate effectiveness outcomes in a real-world setting in patients with schizophrenia initiating risperidone long-acting therapy (RLAT. Methods This was a 24-month, multicenter, prospective, longitudinal, observational study in patients with schizophrenia who were initiated on RLAT. Physicians could change treatment during the study as clinically warranted. Data were collected at baseline and subsequently every 3 months up to 24 months. Effectiveness outcomes included changes in illness severity as measured by Clinical Global Impression-Severity (CGI-S scale; functional scores as measured by Personal and Social Performance (PSP scale, Global Assessment of Functioning (GAF, and Strauss-Carpenter Levels of Functioning (LOF; and health status (Medical Outcomes Survey Short Form-36 [SF-36]. Life-table methodology was used to estimate the cumulative probability of relapse over time. Adverse events were evaluated for safety. Results 532 patients were enrolled in the study; 209 (39.3% completed the 24-month study and 305 (57.3% had at least 12 months of follow-up data. The mean (SD age of patients was 42.3 (12.8 years. Most patients were male (66.4% and either Caucasian (60.3% or African American (23.7%. All changes in CGI-S from baseline at each subsequent 3-month follow-up visit were statistically significant (p Conclusions Patients with schizophrenia who were initiated on RLAT demonstrated improvements in measures of effectiveness within 3 months, which persisted over 24 months. Trial Registration ClinicalTrials.gov: NCT00246194

  18. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

    Directory of Open Access Journals (Sweden)

    Lambert Tim

    2012-03-01

    Full Text Available Abstract Background This observational study was designed to collect treatment outcomes data in patients using the electronic Schizophrenia Treatment Adherence Registry (e-STAR. Methods Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals. The intent-to-treat population, defined as all patients who received at least one dose of RLAI at baseline, was used for the efficacy and safety analyses. Results At total of 784 patients (74% with schizophrenia, 69.8% male with a mean age of 37.1 ± 12.5 years and 10.6 ± 9.5 years since diagnosis were included in this Australian cohort. A significant improvement in mean Clinical Global Impression - severity score was observed at 24-months (4.52 ± 1.04 at baseline, 3.56 ± 1.10 at 24-months. Most of this improvement was seen by 3-months and was also reflected in mean Global Assessment of Functioning score, which improved significantly at 24-months (42.9 ± 14.5 at baseline, 59 ± 15.4 at 24-months. For patients still receiving RLAI at 24-months there was an increase from a mean baseline RLAI dose of 26.4 ± 5 mg to 43.4 ± 15.7 mg. Sixty-six percent of patients discontinued RLAI before the 24-month period--this decreased to 46% once patients lost to follow-up were excluded. Conclusion Over the 24-month period, initiation of RLAI was associated with improved patient functioning and illness severity in patients with schizophrenia or schizoaffective disorder. Improved outcomes were observed early and sustained throughout the study. Trial Registration Clinical Trials Registration Number, NCT00283517.

  19. Analysis on Minimum Cost of Duloxetine and Citalopram in Treating Depression%度洛西汀与西酞普兰治疗抑郁症的最小成本分析

    Institute of Scientific and Technical Information of China (English)

    周慧民; 韦德会

    2013-01-01

    Objective To evaluate the economic effects and safety of duloxetine and citalopram in the treatment of depression to provide the guidance for clinical rational drug use.Methods Fifty patients with depression were randomly divided into the duloxetine group and the citalopram group,and treated by duloxetine and citalopram for 6 weeks,respectively.The curative efficacies and adverse reactions were compared between the two groups.The evaluation was performed by the pharmacoeconomics cost minimization analysis method.Results The total effective rates in the duloxetine group and the citalopram group were 96.00% and 92.00% respectively,without statistical difference between the two groups existed(P>0.05); the costs were 1 030.88 Yuan and 1 092.09 Yuan,cost/effect ratios(C/E) were 1 073.83 and 1 187.05 respectively.The rate of adverse reactions in the duloxetine group was lower than that in the citalopram group.Conclusion The effects of duloxetine and and citalopram in the treatment of depression are equivalent.Duloxetine has the lower cost and is a better therapeutic scheme for the treatment of depression.%目的 评价度洛西汀与西酞普兰治疗抑郁症的经济效果和安全性,以利临床合理用药.方法 将50例抑郁症患者随机分为度洛西汀组、西酞普兰组,分别给予度洛西汀、西酞普兰治疗6周,比较两组疗效和不良反应,并应用药物经济学最小成本分析法进行评价.结果 度洛西汀组和西酞普兰组总有效率分别为96.00%和92.00%,2组间疗效差异无统计学意义(P>0.05),成本分别为1 030.88元和1 092.09元,成本/效果(C/E)分别为1 073.83和1 187.05,度洛西汀组的不良反应率较西酞普兰组低.结论 度洛西汀和西酞普兰治疗抑郁症疗效相当,度洛西汀治疗成本与不良反应发生率均较低,是治疗抑郁症较佳治疗方案.

  20. 艾司西酞普兰与西酞普兰治疗抑郁症对照观察%A control study of escitalopram vs.citalopram in the treat-ment of depression

    Institute of Scientific and Technical Information of China (English)

    陆占峰; 杨伟; 孙永勋

    2016-01-01

    目的:探讨艾司西酞普兰与西酞普兰治疗抑郁症的临床疗效及安全性。方法将60例抑郁症患者按就诊顺序随机分为艾司西酞普兰组和西酞普兰组,每组30例,分别口服艾司西酞普兰、西酞普兰治疗,观察6周。于治疗前后采用汉密顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果治疗第6周末艾司西酞普兰组总有效率为86.67%,西酞普兰组为83.33%,两组比较差异无显著性(P >0.05)。艾司西酞普兰组治疗第1周末起,西酞普兰组治疗第2周末起汉密顿抑郁症量表总分较治疗前显著降低(P 0.05)。艾司西酞普兰组不良反应发生率为43.3%,西酞普兰组为50.0%,两组比较差异无显著性(P >0.05)。结论艾司西酞普兰治疗抑郁症疗效显著,安全性高,与西酞普兰相当。%Objective To explore the efficacy and safety of escitalopram and citalopram in the treatment of depression.Methods Sixty depression patients were divided into two groups of 30 ones each according to visiting order,they took orally escitalopram or citalopram for 6 weeks.Efficacies were assessed with the Hamilton Depression Scale (HAMD)before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS).Results At the end of the 6 st week treatment total effective rate was respectively 86.67% in escitalopram and 83.33% in citalopram group,which showed no significant group difference (P >0.05).The total score of the HAMD since the end of the 1 th week in escitalopram and since the 2 nd in citalopram group lowered more significantly compared with pretreatment (P 0.05).The incidence of adverse reac-tions was 43.3% in escitalopram and 50.0% in citalopram group,which showed no significant group difference (P >0.05 ).Conclusion Both escitalopram and citalopram have an evident effect and higher safety in the treatment of depression.

  1. The effect of the Taq1A variant in the dopamine D-2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

    NARCIS (Netherlands)

    Roke, Yvette; van Harten, Peter N.; Franke, Barbara; Galesloot, Tessel E.; Boot, Annemieke M.; Buitelaar, Jan K.

    2013-01-01

    Objective To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptive behavior disorders.Methods Fo

  2. A comparative study between risperidone and ritalin in the treatment of attention deficit hyperactivity disorder%利培酮治疗注意缺陷障碍对照观察

    Institute of Scientific and Technical Information of China (English)

    兰利明; 薛漳

    2001-01-01

    目的:观察小剂量利培酮治疗注意缺陷障碍(ADHD) 的疗效和安全性。 方法:前瞻性研究,以利他林作为对照,采用 康纳多动症评定量表及不良反应症状量表(TESS)评定,观察4周。 结果:利培酮有效率为77%,利他林为78%;未见锥体外系副反应。 结论:利培酮与利他林的疗效相似,小剂量使用时安全有效。%Objective:To observe the efficacy and security of small doses risperidone in the treatment of attention deficit hyperactivity diso rder(ADHD). Method:Compared with ritalin group,the patients wer e treated with small doses risperidone for 4 weeks.Conner hyperactivety rating s cale (CHRS) and the treatment emergent symptom scale (TESS) were completed by th em. Results:The efficacy rate in risperidone group was 77%, a nd in ritalin group was 78%. No extrapyramidal side effect was found. C onclusion:It suggests that small doses risperidone is effective and safe in the treatment of ADHD, being similar to ritalin.

  3. 利培酮与阿立哌唑治疗精神分裂症的效果比较%Clinical effects and security of aripiprazole and risperidone on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李正发

    2010-01-01

    Objective To assess the efficacy and safety of aripiprazole and risperidone on the treatment of schizophrenia. Method 80 patients with schizophrenia were randomly divided into risperidone group ( n = 40) and aripiprazole group( n= 40). According to random, controlled principles, all patients were treated for 8 weeks. The positive and negative syndrome scale ( PANSS ), clinical global impression ( CGI ), treatment emergent symptom scale (TESS) and laboratory examinations were used to assess the effectiveness and the safety of the treatment. Results By the end of the 8 weeks treatment,the scores of PANSS in both groups decreased significantly compared to the baseline ( P 0. 05 ). Total clinical effective rates was 90% in risperidone group and 80% in aripiprazole group, without significant difference between two groups. Digestion adverse reactions in aripiprazole group were significantly more than in risperidone group (P 0.05).治疗后,利培酮组有效率90%,阿立哌唑组有效率80%,两组差异无统计学意义(P>0.05).阿立哌唑组消化道反应发生率明显高于利培酮组(P<0.05).结论 利培酮治疗精神分裂症的疗效较阿立哌唑略好,安全性高.

  4. The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys

    NARCIS (Netherlands)

    Roke, Y.; Harten, P.N. van; Franke, B.; Galesloot, T.E.; Boot, A.M.; Buitelaar, J.K.

    2013-01-01

    OBJECTIVE: To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptive behavior disorders. METHODS:

  5. A clinical study of combined Citalopram Hydrobromide and psychotherapy in the treatment of depression%氢溴酸西酞普兰联合心理治疗对抑郁症的临床研究

    Institute of Scientific and Technical Information of China (English)

    陈泽聪; 龚飞中

    2012-01-01

      目的观察氢溴酸西酞普兰联合心理治疗对抑郁症的疗效。方法对80例符合标准的抑郁症患者随机分成两组,一组是给予氢溴酸西酞普兰联合心理治疗(研究组,n=41),另一组为氢溴酸西酞普兰治疗(对照组,n=39),疗程6周。用汉密顿抑郁量表(HAMD)在治疗前、1、2、4、6周末评定疗效。结果两组总体疗效有显著差异性,心理干预组(研究组)抗抑郁显效更快,治愈率、临床显效率明显高于对照组。结论合并心理治疗不仅可以加快抑郁症状缓解的速度,而且本身心理治疗对抑郁症有一定的疗效,明显提高抑郁症的治疗效果,值得临床推广。%  Objective To observe the clinical ef icacy of Citalopram Hydrobromide combined with Psychotherapy in the treatment of depression. Methods On 80 patients with standard depression were randomly divided into two groups,one group was given citalopram hydrobromide combined with psychological therapy (study group, n=41), another group of citalopram hydrobromide treatment (the control group, n=39), 6 weeks. With Hamilton Depression Scale (HAMD) before treatment,1,2,4,6 weekend for evaluating ef icacy. Results The two groups have significant dif erences in overal ef icacy, psychological intervention group(Study Group) antidepressant increased speed,the cure rate, the clinical ef ective rate was significantly higher than that of control group. Conclusion The therapeutic effect of combined psychological therapy take a active part earlier than only the use of Citalopram Hydrobromide,and the psychotherapy has a certain effect in depression and improve treatment ef ect in depression, it is worthy of clinical application.

  6. MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission

    Institute of Scientific and Technical Information of China (English)

    LIU Sha; YUAN Yan-bo; GUAN Li-li; WEI Hui; CHENG Zhang; HAN Xue; YANG Lei

    2013-01-01

    Background MicroRNAs (miRNAs) control gene expression by destabilizing target transcripts and inhibiting their translation.Aberrant expression of miRNAs has been described in many human diseases,including schizophrenia.However,the effects on miRNA expression in response to antipsychotic treatment in peripheral circulation have not been thoroughly examined.Methods Using quantitative real-time PCR (qRT-PCR),We quantified the expression of seven candidate miRNAs in plasma samples of 40 first-episode schizophrenics before and after antipsychotic treatment.The patients were all treated with risperidone and achieved remission in 1 year.Results Compared with the baseline,the expression levels of miR-365 and miR-520c-3p were significantly downregulated after 1 year of risperidone treatment (P <0.001).There were no significant correlations between the clinical symptoms and the expression levels of these two miRNAs (P >0.05).Conclusions This study analyzed possible circulating miRNAs in response to antipsychotic monotherapy for schizophrenia,the further mechanism need to be confirmed.

  7. The Post-Ovariectomy Interval Affects the Antidepressant-Like Action of Citalopram Combined with Ethynyl-Estradiol in the Forced Swim Test in Middle Aged Rats.

    Science.gov (United States)

    Vega Rivera, Nelly M; Gallardo Tenorio, Alfredo; Fernández-Guasti, Alonso; Estrada Camarena, Erika

    2016-05-03

    The use of a combined therapy with low doses of estrogens plus antidepressants to treat depression associated to perimenopause could be advantageous. However the use of these combinations is controversial due to several factors, including the time of intervention in relation to menopause onset. This paper analyzes whether time post-OVX influences the antidepressant-like action of a combination of ethynyl-estradiol (EE₂) and citalopram (CIT) in the forced swim test (FST). Middle-aged (15 months old) female Wistar rats were ovariectomized and after one or three weeks treated with EE₂ (1.25, 2.5 or 5.0 µg/rat, s.c.; -48 h) or CIT (1.25, 2.5, 5.0 or 10 mg/kg, i.p./3 injections in 24 h) and tested in the FST. In a second experiment, after one or three weeks of OVX, rats received a combination of an ineffective dose of EE₂ (1.25 µg/rat, s.c., -48 h) plus CIT (2.5 mg/kg, i.p./3 injections in 24 h) and subjected to the FST. Finally, the uteri were removed and weighted to obtain an index of the peripheral effects of EE₂ administration. EE₂ (2.5 or 5.0 µg/rat) reduced immobility after one but not three weeks of OVX. In contrast, no CIT dose reduced immobility at one or three weeks after OVX. When EE₂ (1.25 µg/rat) was combined with CIT (2.5 mg/kg) an antidepressant-like effect was observed at one but not three weeks post-OVX. The weight of the uteri augmented when EE₂ was administrated three weeks after OVX. The data suggest that the time post-OVX is a crucial factor that contributes to observe the antidepressant-like effect of EE₂ alone or in combination with CIT.

  8. Ageing and Chronic Administration of Serotonin-Selective Reuptake Inhibitor Citalopram Upregulate Sirt4 Gene Expression in the Preoptic Area of Male Mice

    Directory of Open Access Journals (Sweden)

    Wong eDutt Way

    2015-09-01

    Full Text Available Sexual dysfunction and cognitive deficits are markers of the ageing process. Mammalian sirtuins (SIRT, encoded by sirt 1-7 genes, are known as ageing molecules which are sensitive to serotonin (5-hydroxytryptamine, 5-HT. Whether the 5-HT system regulates SIRT in the preoptic area (POA, which could affect reproduction and cognition has not been examined. Therefore, this study was designed to examine the effects of citalopram (CIT, 10mg/kg for 4 weeks, wk, a potent selective-serotonin reuptake inhibitor and ageing on SIRT expression in the POA of male mice using real-time PCR and immunocytochemistry. Age-related increases of sirt1, sirt4, sirt5, and sirt7 mRNA levels were observed in the POA of 52 wk old mice. Furthermore, 4 wk of chronic CIT treatment started at 8 wk of age also increased sirt2 and sirt4 mRNA expression in the POA. Moreover, the number of SIRT4 immuno-reactive neurons increased with ageing in the medial septum area (12 wk = 1.00±0.15 vs 36 wk = 1.68±0.14 vs 52 wk = 1.54±0.11, p<0.05. In contrast, the number of sirt4-immunopositive cells did not show a statistically significant change with CIT treatment, suggesting that the increase in sirt4 mRNA levels may occur in cells in which sirt4 is already being expressed. Taken together, these studies suggest that CIT treatment and the process of ageing utilize the serotonergic system to up-regulate SIRT4 in the POA as a common pathway to deregulate social cognitive and reproductive functions.

  9. Acute responsivity of the serotonergic system to S-citalopram and positive emotionality – the moderating role of the 5-HTTLPR

    Directory of Open Access Journals (Sweden)

    Catrin eWielpuetz

    2013-08-01

    Full Text Available According to the idea that the central serotonergic system has a modulatory function on behavior and personality in general, we aimed to highlight its association to habitual positive emotionality. In a placebo-controlled double-blind and randomized cross-over neuroendocrine challenge design (n = 72 healthy males we investigated the association of the central serotonergic responsivity, 5-HTTLPR-genotype as well as their combined effects on positive emotionality. Regression analyses revealed an involvement of the serotonergic system in positive emotionality. There was, however, no direct association between positive emotionality and cortisol responses to S-citalopram; rather 5-HTTLPR-genotype showed an association (p < .05. That is, positive emotionality scores increased with the number of s-alleles carried by the individuals. Most notable was the moderating role of 5-HTTLPR-genotype (p < .05 on the association between acute serotonergic responsivity and positive emotionality. Indeed, this association was only found in ss-homozygotes, in which the acute responsivity of the serotonergic system additionally seems to contribute to the level of positive emotionality (r = .70, p < .05. The findings correspond to previous research demonstrating that the 5-HTTLPR is not only involved in the negative-emotional aspects of behavior and temperament, but is associated, moreover, with positive affectivity – supporting the assumption of its valence-neutrality. In addition, our data are in line with the idea of possible influences of the 5-HTTLPR-genotype on early neuronal development. They also indicate the need for further studies in order to clearly elucidate the role of the serotonergic system and its subcomponents in the regulation of positive emotionality.

  10. 利培酮治疗儿童孤独症谱系障碍11例疗效分析%Clinical efficacy of risperidone in 11 children with autism spectrum disorders

    Institute of Scientific and Technical Information of China (English)

    焦云; 刘李燕; 蔡小凡

    2013-01-01

    目的 观察利培酮治疗孤独症谱系障碍患儿的疗效.方法 11例入选患儿在原有综合治疗的基础上服用利培酮,剂量0.5~1.0 mg/d,分别在接受利培酮治疗前、治疗半年后进行孤独症治疗评定量表(ATEC)评估.结果 治疗后与治疗前比较,患儿在社交、感知觉、行为等方面均有显著改善(P<0.01),疗效明显.结论 利培酮治疗孤独症谱系障碍患儿在不良行为控制的基础上能明显改善认知,提高社交能力,而且副作用轻微,值得推广.%Objective To analyze the effect of risperidone to treat autism spectrum disorders in children. Methods Eleven children with autism spectrum disorders were treated with risperidone for 6 months. Autism treatment evaluation checklist ( ATEC) before and after the treatment was analyzed. The adverse events related to risperidone treatment were observed. Results The score of severity of illness and the ATEC total scores were significantly reduced after 6 month treatment. Great improvements had been shown on the apperception and behavioural symptoms. No severe adverse events related to risperidone treatment were observed. Conclusions Risperidone can significantly improve the behavioral disorders in children with autism spectrum disorders.

  11. 利培酮联合喹硫平治疗老年痴呆精神行为症状的研究%Study on risperidone combined with quetiapine for treating psychiatric and behavioral disturbances in senile dementia

    Institute of Scientific and Technical Information of China (English)

    赵新民; 李远

    2016-01-01

    Objective To investigate the efficacy and safety of risperidone combined with quetiapine in the treatment behavioral and psychiatric symptoms of dementia (BPSD). Methods Ninety cases of BPSD in the geriatric department of our hospital from January 2013 to December 2015 were randomly divided into the combination group , risperidone group and quetiap-ine group according to the completely random method ,30 cases in each group. The combination group was given risperidone com-bined with quetiapine, the risperidone group was given the risperidone therapy and quetiapine group received the quetiapine therapy. The treatment effects were evaluated by using the BEHAVE-AD before treatment and after 2-,4-,8-week treatment. The side effects scale(TESS) was used to evaluate the adverse reactions occurrence situation. Results The AD-BEHAVE scores after 2-,4-,8-week treatment in 3 groups were significantly lower than those before treatment ,the difference was statistically significant (P0.05),but the effect in the combination group was significantly superior to that in the quetiapine group(χ2=15.39,P0.05),但明显优于喹硫平组,差异有统计学意义(χ2=15.39,P<0.01)。利培酮组不良反应发生率明显高于联合组、喹硫平组,差异均有统计学意义(P<0.05)。结论利培酮联合喹硫平治疗老年痴呆BPSD具有较好疗效,不良反应小,更适于老年痴呆患者的治疗。

  12. Clinical Analysis of Oxiracetam combined with Risperidone Treatment of Schizophrenia.%奥拉西坦与利培酮联合治疗精神分裂症的临床分析

    Institute of Scientific and Technical Information of China (English)

    崔会欣; 赵龙; 张娜; 尹艳芳

    2013-01-01

    Objective:To investigate the efficacy of Oxiracetam combined with Risperidone in the treatment of Schizophrenia. Methods:The schizophrenia patients were divided into study group and control group randomly. Study group were given Oxiracetam combined with Risperidone. Control group given Risperidone only for the treatment of 8 weeks. The efficacy and side effects were evaluated with scores of PANSS and TESS. Result:the effective rates were 86.17% in study group and 63.33% in control group. There are statistically difference between the two groups(P<0.05). The adverse reaction of two groups was rare and mild .Conclusion:Oxiracetam combined with Risperidone in the treatment of Schizophrenia were effective and safe and take effects better than single Risperidone.%目的探讨奥拉西坦与利培酮联合治疗精神分裂症的临床效果。方法将我院比例符合标准的精神分裂症患者随即分为研究组和对照组,研究组给予奥拉西坦合并利培酮治疗,对照组单用利培酮,疗程8周。用PANSS,TESS量表评定疗效和安全性。结果研究组有效率86.17%,对照组有效率63.33%。两组比较鉴别有统计学意义(P<0.05),两组不良反应少且轻。结论奥拉西坦合并利培酮治疗精神分裂症疗效可靠,安全性好,优于单用利培酮。

  13. Efficacy and safety analysis of Ziprasidone and Risperidone in treatment of schizophrenic patients%齐拉西酮与利培酮治疗精神分裂症患者的疗效及安全性分析

    Institute of Scientific and Technical Information of China (English)

    文卫

    2015-01-01

    目的::探讨齐拉西酮与利培酮两种药物在精神分裂症患者治疗中的临床效果。方法:将64例精神分裂症患者分为齐拉西酮组和利培酮组,每组各32例。分别给予两组患者齐拉西酮或利培酮治疗,观察两组患者的疗效和安全性。结果:在治疗4周后,两组患者的两项量表评估有明显差异(P<0.05);齐拉西酮组患者不良反应率为9.38%低于利培酮组的18.75%,差异有统计学意义(P<0.05)。结论:齐拉西酮治疗精神分裂症患者的临床效果优于利培酮治疗。%Objective:To investigate clinical effects of Ziprasidone and Risperidone in treatment of schizophrenia. Methods:64 schizophrenic patients were divided into Ziprasidone group ( treated with Ziprasidone) and Risperidone group ( treated with Risperi-done) . The efficacies of safety of the two groups were observed. Results:In 4 weeks after treatment, there were significant differences in the two scales between the two group (P<0. 05). The adverse reaction rates of Ziprasidone group and Risperidone group were 9. 38% and 18. 75%. Conclusions: In the treatment of schizophrenia, Ziprasidone has good clinical effects and higher safety than Risperidone.

  14. Association studies of COMT gene polymorphisms with risperidone treatment in first-episode schizophrenia%首发精神分裂症患者利培酮疗效与COMT基因多态性关联研究

    Institute of Scientific and Technical Information of China (English)

    李波; 黎雪松; 龚道元; 谢国军; 陈家强; 彭艳; 王晓娟

    2013-01-01

    目的:探讨首发精神分裂症患者COMT基因多态性与利培酮疗效的关系.方法:100例首发精神分裂症患者使用利培酮治疗8周,以PANSS量表评定疗效;SNaPshot SNP检测COMT基因rs4680和rs4818多态性.结果:利培酮有效组与无效组相比,精神分裂症患者rs4680基因型G/G与A/G、A/A的分布差异具有显著性(x2=5.334,P<0.05),rs4680 G/G基因型与利培酮疗效之间存在明显关联(OR=1.78,P<0.05).结论:rs4680多态性与利培酮治疗首发精神分裂症的临床疗效相关.%Objective To investigate the association of catechol-O-methyltransferase (COMT) gene polymorphisms with response of risperidone treatment in first-episode schizophrenia. Methods One hundred cases of schizophrenic patients were chosen to treat with risperidone for 8 weeks. The efficacy of antipsychotic medication was evaluated by PANSS scale. Allelic typing of COMT was detected by SNaPshot SNP technique. Results The distribution of rs4680 genotype G/G, A/G and A/A had significant difference between risperidone responder group and nonresponder group (X2 = 5.334,P < 0.05) and rs4680 G/G genotype was correlated with the efficacy of risperidone (OR = 1.78,P< 0.05). Conclusion The polymorphisms of rs4680 related with effects of risperidone on first-episode schizophrenia.

  15. 利培酮与氯氮平治疗精神分裂症对照研究%Effect of risperidone and clozapine on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李月霞

    2009-01-01

    目的 比较利培酮和氯氮平治疗精神分裂症的疗效和不良反应.方法 将40例精神分裂症患者随机分成两组,利培酮组和氯氮平组各20例,于治疗前和治疗第2、4、6周末采用症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应.结果 两组PANSS减分率比较差异无统计学意义(P>0.05),利培酮组不良反应少.结论 利培酮与氯氮平治疗精神分裂症疗效相当,但利培酮不良反应少.%Objective To comparie effect of risperidone and clozapine on the treatment of schizophrenia and adverse reactions. Methods 40 cases were randomly divided into two groups of patients with schizophrenia, risperi-done and clozapine group 20 cases, pre-treatment and treatment in the first weekend 2,4,6 Symptom Rating Scale (PANSS) and the reaction volume Table (TESS) were used to assess the efficacy and adverse reactions. Results Comparison of reduction rate PANSS, there was no significant difference(P > 0. 05), compared with clozapine group, risperidone group had less adverse reactions. Conclusion Risperidone and clozapine group had considerable effect in the treatment of schizophrenia, but risperidone had fewer adverse reactions.

  16. Neonatal exposure to citalopram, a serotonin selective reuptake inhibitor, programs a delay in the reflex ontogeny in rats Exposição neonatal ao citalopram, um inibidor seletivo da recaptação de serotonina, programa retardo na ontogênese reflexa em ratos

    Directory of Open Access Journals (Sweden)

    Teresa Cristina Bomfim de Jesus Deiró

    2008-01-01

    Full Text Available Serotonin influences the growth and development of the nervous system, as well as its behavioral manifestations. The possibility exists that increased brain serotonin availability in young animals modulates their neuro-behavioral responses. This study investigated the body weight gain and reflex ontogeny of neonatal rats treated during the suckling period with two doses of citalopram (5 mg, or 10 mg/kg, sc, daily. The time of the appearance of reflexes (palm grasp righting, free-fall righting, vibrissa placing, auditory startle response, negative geotaxis and cliff avoidance as well as the body weight evolution were recorded. In general, a delay in the time of reflex development and a reduced weight gain were observed in drug-treated animals. These findings suggest that serotoninergic mechanisms play a role in modulating body weight gain and the maturation of most reflex responses during the perinatal period in rats.A serotonina influencia o crescimento e o desenvolvimento do sistema nervoso e sua expressão comportamental. O aumento da disponibilidade de serotonina no cérebro de ratos jovens parece modular as respostas neurocomportamentais. Neste estudo, foram investigados o ganho de peso corporal e a ontogênese dos reflexos em ratos neonatos, tratados diariamente, durante o período de aleitamento, com duas doses de citalopram (5 ou 10 mg/Kg de peso corporal, via subcutânea. Foram avaliados, o tempo de aparecimento dos reflexos (preensão palmar, endireitamento, colocação pelas vibrissas, resposta ao susto, geotáxico negativo e aversão ao precipício, e a evolução do peso corporal. Foi observado atraso no tempo de desenvolvimento de alguns reflexos e redução no ganho de peso corporal. Os achados em ratos sugerem que as alterações no ganho de peso corporal e na maturação dos reflexos são programadas, durante o período perinatal, com participação de mecanismos serotoninérgicos de modulação.

  17. 合用阿立哌唑及单用利培酮对精神分裂症体质量的影响%Effects of Aripiprazole Combined with Risperidone and Risperidone on the Body Mass of Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    史玲; 杨云龙; 韩笑; 于丽燕; 严保平; 韩彦超; 周玉娟; 高景娜

    2016-01-01

    Objective:To compare the effects of risperidone combined with aripiprazle with only use of risperidone on body weight and BMI in patients with schizophrenia .Methods:70 patients with schizophrenia who met the criteria were randomized to two groups receiving risperidone combined with aripiprazle(research group)and only risperidone (control group) .Each group consists of 35cases .Clinical efficacies and the indexes body weight and BMI in patients were assessed with PANSS at the base line and at the end of the 4th week ,and 8th week .Results:There were 65 cases finishing the experiment including 31 cases of research group and 34 of control group .After the treatment of the end of the 4th week and 8th week ,there were no significant differences in the scores of PANSS between two groups . There was obvious change in two groups after the treatment I.n comparison with the research group ,the change was higher in control group in body weight and BMI(P<0 0.5) I.n comparison with the control group ,the body BMI was lower in research group(t=2 6.1 ,P<0 0.5) .Conclusion:Risperidone combined with aripiprazole can obviously reduce the effect of risperidone on body quality .%目的:对比利培酮与阿立哌唑合用及单用利培酮对精神分裂症患者体重及体重指数(BM I)的影响。方法:将符合入组标准的70例精神分裂症患者随机分为阿立哌唑合并利培酮组(合用阿立哌唑组)及单用利培酮组(单一利培酮组)。两组各入组35例,在基线及4周末、8周末,用阳性和阴性症状量表(PANSS)评定疗效,并进行体重及体重指数(BM I)的测定。结果:共完成65例,合用阿立哌唑组31例,单一利培酮组34例。治疗4周末及8周末,两组PANSS评分差异均无统计学意义;治疗后两组间有明显的变化,单一利培酮组体重及BMI值均增加明显(P<00.5);组间变化值的比较,合用阿立哌唑组BMI值均较单一利培酮组低(t=26

  18. Comparison of plasma concentration of risperidone and serum prolactin level after risperidone treatment between male and female adolescents with schizophrenia%青少年男女精神分裂症患者利培酮治疗后血药浓度与血清催乳素的比较

    Institute of Scientific and Technical Information of China (English)

    韩晓虎; 郑毅; 王红星

    2012-01-01

    目的 比较男女青少年精神分裂症患者服用利培酮后利培酮、9-羟利培酮血药浓度和血清催乳素,并探讨血药浓度与血清催乳素的关系. 方法 符合DSM-V诊断标准的精神分裂症青少年患者41例(男20例,女21例),给予利培酮治疗8周.在治疗基线和第4,8周末测定血清催乳素水平,在治疗第4,8周末监测利培酮和9-羟利培酮的血药浓度. 结果 ①血清催乳素在时间上存在主效应(P<0.001),其中第4周末、第8周末男、女患者血清催乳素水平分别与基线进行自身比较,差异有统计学意义(P<0.001);②男、女患者间血药浓度和血清催乳素水平在第4周末、第8周末进行比较,无统计学差异(P>0.05).③男、女患者利培酮(Ris)、9-羟利培酮(9oh)血药浓度与血清催乳素存在正相关(男:4周末PRis<0.01、P9oh<0.01;8周末PRis<0.01、P9oh <0.05;女:4周末PRis>0.05、P9oh <0.01,8周末PRis<0.05、P9oh<0.01). 结论 ①利培酮能明显升高青少年患者血清催乳素水平;其血药浓度越高,催乳素水平也越高;②性别对血药浓度和血清催乳素水平无影响.%Objective To compare the plasma concentrations of risperidone,9-hydroxyrisperidone and serum prolactin levels after risperidone treatment between the male and female adolescents with schizophrenia, and to explore their relations. Methods A total of 41 patients(20 male and 21 female) met the DSM-IV criteria for schizophrenia. The patients were given risperidone for 8 weeks. Serum prolactin, plasma concentrations of risperidone and 9-hydroxyrisperidone were obtained at the baseline,at the end of 4th and 8th week. Results ?Serum prolactin had a significant main effect on the time of taking medicine ( P 0. 05). (5)In the male and female, serum prolactin was positively correlated with plasma concentration of risperidone( Ris) and 9-hydroxyrisperidone(9oh) ( male; at the end of 4th week PRis 0.05 and P9oh < 0.01; at the end of

  19. The Effects of Escitalopram Compared With Citalopram in the Treatment of Geriatric Depression%艾司西酞普兰与西酞普兰对老年抑郁症的疗效观察

    Institute of Scientific and Technical Information of China (English)

    孙洁; 刘瑞龙

    2015-01-01

    目的:探讨艾司西酞普兰与西酞普兰治疗老年抑郁症的临床疗效。方法将74例老年抑郁症患者随机分为观察组(艾司西酞普兰联用组)及对照组(西酞普兰联用组),比较两组疗效。结果两组治疗后汉密尔顿抑郁量表、汉密尔顿焦虑量表总分差异显著(P<0.05)。结论艾司西酞普兰治疗老年抑郁症效果显著。%Objective To investigate the clinical efifcacy of escitalopram and citalopram in the treatment of senile depression.Methods 74 cases of elderly patients with depression were randomly divided into observation group (escitalopram group) and control group (citalopram group), the effects of the two groups were compared.Results After treatment, the Hamilton depression rating scale and Hamilton anxiety scale scores of the two groups were signiifcantly different (P<0.05).Conclusion Escitalopram treatment of senile depression is signiifcant.

  20. 度洛西汀与西酞普兰治疗抑郁症的对照研究%A comparation study of duloxetine and citalopram in the treatment of depression

    Institute of Scientific and Technical Information of China (English)

    康明秀

    2011-01-01

    目的:比较度洛西汀与西酞普兰治疗不同症状抑郁症的疗效.方法:将122例符合国际疾病分类第10版抑郁症诊断标准的患者,按不同主诉(精神症状或躯体症状)分为精神症状组60例和躯体症状组62例,每组再随机分为度洛西汀组(30例/30例)和西酞普兰组(30例/32例),分别给予度洛西汀和西酞普兰治疗6周.用汉密尔顿抑郁量表17项(HAMD)评定疗效,用治疗中出现的症状量表(TESS)评定不良反应.结果:在以精神症状为主的患者中,度洛西汀组与西酞普兰组疗效比较差异无显著性(P>0.05);在以躯体症状为主的患者中,以度洛西汀组显效率(76.67%)高于西酞普兰组(53.12%),两组比较差异有显著性(P<0.05).结论:度洛西汀和西酞普兰治疗抑郁症均有效,但度洛西汀起效较快,治疗伴有躯体症状的抑郁症疗效更好.%Objective: To compare efficacy of duloxetine and citalopram in the treatment of depression with different symptoms. Method:122 patients meeting with lCD-10 for depression were divided into psychotic symptom group ( n = 60 ) and somatic symptom group ( n = 62 ), according to their different complaints. Then psychotic symptom group and somatic symptom group were randomly divided into two sub-groups respectively, duloxetine sub-group (n = 30/30) and citalopram sub-group ( n = 30/32) for 6 weeks treatment. The efficacy and the safety were assessed by Hamilton depression scale (HAMD) and the treatment emergent syruptom scale (TESS), respectively. Results:There was no significant difference in the efficacy between duloxetine sub-group and citalopram sub-group in the treatment of depressed patients predominant in psychotic symptoms. The response rate was significantly higher in patients of duloxetine sub-group compared with that in citalopram sub-group 76.67% vs. 53.12% (P < 0.05 ) in the treatment of depressed patients predominant in somatic symptoms. Conclusion: Both duloxetine and citalopram were

  1. 舒必利合用西酞普兰治疗阻滞性抑郁症的临床研究%Clinical study on sulpiride combined with citalopram in treatment of retardative depression

    Institute of Scientific and Technical Information of China (English)

    穆慧; 韩翠萍

    2014-01-01

    Objective:To observe effects and adverse reactions of sulpiridein treatment of retardative depression. Methods:62 patients with retardative depression were randomly divided into study group( sulpiride combined with citalopram,31 cases) and control group( citalopram, 31 cases) . All the patients were treated for 8 weeks. The adverse reactions were evaluated with Hamilton depression scale (HAMD) and treatment emergent symptom scale (TESS). Results:At the end of 4th, 6th, and 8th week of the treatment, the total score of HAMD and item score of retardative symptom in study group were lower than those of control group, and there werestatisti-cal differences (P<0. 01 or P<0. 05). At the end of 8th week of the treatment, the effective rates of study group and control group were 83. 87% and 58. 06%, respectively, and there was the statistical difference (P<0. 01). For TESS score, the cases in control group had gastrointestinal adverse reactions, such as nausea and vomiting;while no adverse reactions were observed instudy group, and there was the significant difference. Conclusions:The effect of low dosage of sulpiride combined with citalopram is better than citalo-pram alone in the treatment of retardative depression, and it takes effect faster as well. Sulpiride can eliminate nausea, vomiting and other gastrointestinal adverse reactions induced by citalopram.%目的:观察舒必利治疗阻滞性抑郁症的疗效和不良反应。方法:对62例阻滞性抑郁症患者,随机分为合用组(舒必利合并西酞普兰,31例患者)和单用组(单用西酞普兰,31例患者),治疗8周,采用汉密顿抑郁量表(HAMD)和副反应量表(TESS)评定不良反应。结果:治疗第4、6、8周末两组患者间HAMD总分和阻滞症状项目评分比较,合用组患者低于单用组,差异有统计学意义(P<0.01或P<0.05);治疗8周末合用组和单用组患者的显效率分别为83.87%和58.06%,差异有统计学意义(P<0.01);两组患者间TESS评分比

  2. 齐拉西酮和利培酮治疗精神分裂症比较研究%Study on comparison of ziprasidone and risperidone in treating patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    汪琳; 张涛; 白克镇; 邹文华

    2014-01-01

    Objective It is to compare the effect and the influence on metabolism index of ziprasidone and risperidone in treating patients with schizophrenia .Methods 65 patients with schizophrenia were randomly divided into ziprasidone group and risperidone group .Patients were treated with ziprasidone in ziprasidone group and with risperidone in risperidone group for 8 weeks.The curative effect and adverse reaction was assessed by using Positive and Negative symptom scale ( PANSS) and Treatment Emergent Symptom Scale ( TESS ) , and the metabolism index in both group were analyzed .Results The PANSS scores in ziprasidone group and risperidone group in the 2nd week were significantly reduced than that before treatment (P0.05).The effect of ziprasidone group and risperidone group had no significantly difference (P>0.05).The incidences rate of side effect in ziprasidone group were significantly lower than that in risperidone group (all P0.05).After treat-ment, the body weight , blood glucose and blood lipid in risperidone group were significantly higher than that in ziprasidone group (all P<0.05).Conclusion Ziprasidone has the similar therapeutic effect to risperidone in the treatment of schizophre -nia.However , Ziprasidone have well-tolerated and low effect on serum glucose and lipid metabolism .%目的:比较齐拉西酮和利培酮治疗精神分裂症的疗效及对患者生化指标的影响。方法将65例精神分裂症患者按照治疗方式不同分为齐拉西酮组和利培酮组,分别采用齐拉西酮和利培酮治疗8周,采用阳性与隐性症状量表( PANSS)和副作用量表( TESS)评定2组疗效和不良反应,并对患者实验室指标进行分析。结果治疗2周后,齐拉西酮组和利培酮组PANSS评分较治疗前均显著下降(P均<0.05)。治疗后2组同时间点PANSS总分、阳性症状分、阴性症状分及一般精神病理分比较无显著性差异(P均>0.05)。2组治疗有效率

  3. The Post-Ovariectomy Interval Affects the Antidepressant-Like Action of Citalopram Combined with Ethynyl-Estradiol in the Forced Swim Test in Middle Aged Rats

    Science.gov (United States)

    Vega Rivera, Nelly M.; Gallardo Tenorio, Alfredo; Fernández-Guasti, Alonso; Estrada Camarena, Erika

    2016-01-01

    The use of a combined therapy with low doses of estrogens plus antidepressants to treat depression associated to perimenopause could be advantageous. However the use of these combinations is controversial due to several factors, including the time of intervention in relation to menopause onset. This paper analyzes whether time post-OVX influences the antidepressant-like action of a combination of ethynyl-estradiol (EE2) and citalopram (CIT) in the forced swim test (FST). Middle-aged (15 months old) female Wistar rats were ovariectomized and after one or three weeks treated with EE2 (1.25, 2.5 or 5.0 µg/rat, s.c.; −48 h) or CIT (1.25, 2.5, 5.0 or 10 mg/kg, i.p./3 injections in 24 h) and tested in the FST. In a second experiment, after one or three weeks of OVX, rats received a combination of an ineffective dose of EE2 (1.25 µg/rat, s.c., −48 h) plus CIT (2.5 mg/kg, i.p./3 injections in 24 h) and subjected to the FST. Finally, the uteri were removed and weighted to obtain an index of the peripheral effects of EE2 administration. EE2 (2.5 or 5.0 µg/rat) reduced immobility after one but not three weeks of OVX. In contrast, no CIT dose reduced immobility at one or three weeks after OVX. When EE2 (1.25 µg/rat) was combined with CIT (2.5 mg/kg) an antidepressant-like effect was observed at one but not three weeks post-OVX. The weight of the uteri augmented when EE2 was administrated three weeks after OVX. The data suggest that the time post-OVX is a crucial factor that contributes to observe the antidepressant-like effect of EE2 alone or in combination with CIT. PMID:27153072

  4. The Post-Ovariectomy Interval Affects the Antidepressant-Like Action of Citalopram Combined with Ethynyl-Estradiol in the Forced Swim Test in Middle Aged Rats

    Directory of Open Access Journals (Sweden)

    Nelly M. Vega Rivera

    2016-05-01

    Full Text Available The use of a combined therapy with low doses of estrogens plus antidepressants to treat depression associated to perimenopause could be advantageous. However the use of these combinations is controversial due to several factors, including the time of intervention in relation to menopause onset. This paper analyzes whether time post-OVX influences the antidepressant-like action of a combination of ethynyl-estradiol (EE2 and citalopram (CIT in the forced swim test (FST. Middle-aged (15 months old female Wistar rats were ovariectomized and after one or three weeks treated with EE2 (1.25, 2.5 or 5.0 µg/rat, s.c.; −48 h or CIT (1.25, 2.5, 5.0 or 10 mg/kg, i.p./3 injections in 24 h and tested in the FST. In a second experiment, after one or three weeks of OVX, rats received a combination of an ineffective dose of EE2 (1.25 µg/rat, s.c., −48 h plus CIT (2.5 mg/kg, i.p./3 injections in 24 h and subjected to the FST. Finally, the uteri were removed and weighted to obtain an index of the peripheral effects of EE2 administration. EE2 (2.5 or 5.0 µg/rat reduced immobility after one but not three weeks of OVX. In contrast, no CIT dose reduced immobility at one or three weeks after OVX. When EE2 (1.25 µg/rat was combined with CIT (2.5 mg/kg an antidepressant-like effect was observed at one but not three weeks post-OVX. The weight of the uteri augmented when EE2 was administrated three weeks after OVX. The data suggest that the time post-OVX is a crucial factor that contributes to observe the antidepressant-like effect of EE2 alone or in combination with CIT.

  5. Characterization and in vitro and in vivo evaluation of cross-linked chitosan films as implant for controlled release of citalopram

    Indian Academy of Sciences (India)

    Patit P Kundu; Santosh Kumar Jindal; Manish Goswami

    2013-02-01

    The aim of the present study is to develop cross-linked chitosan (CH) films that can release drug over an extended period of time and that too in a controlled manner. A solution of different percentages of CH, is prepared in 1% lactic acid, followed by addition of citalopram (CTP) and then reacted with increasing amounts of glutaraldehyde (GL) to obtain films with different cross-linking densities. Prepared films are characterized for their physical and mechanical properties. The films are then subjected to in vitro drug release studies using pH 7.4 phosphate buffer saline (PBS) as dissolution medium and cumulative amount of drug released is calculated. Kinetic analysis of drug release is performed using Power law model and Higuchi’s model.With increase in concentration of CH, water absorption capacity and mechanical strength are increased; whereas, water vapour permeability and elasticity of the films are decreased. The effect of cross-linking agent, GL, is such that with an increase in the amount of GL, water vapour permeability, water absorption capacity and elasticity of the films are decreased; whereas, mechanical strength increased to some extent and then decreased. In vitro release studies indicate that films containing 3% CH, cross-linked with 2–3% GL and films containing 4%CH, cross-linked 1%GL are able to sustain the drug release for a prolonged time along with releasing almost complete drug in a desired period. Out of these batches, films containing 3% CH, cross-linked with 2–3% GL are having sufficient strength, water vapour permeation, water absorption capacity and elongation at break for implantation purpose. The in vitro degradation studies and histopathological studies were carried out with a sample film (batch C3 as in table 1) in rabbit model. In vitro degradation study indicates that the films maintained their integrity for desired implantation. The histopathological studies under optical microscope indicates that on implanting, there is no

  6. Clinical effect observation of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症临床效果观察

    Institute of Scientific and Technical Information of China (English)

    王俊; 孙毅; 卓越; 吕治宇; 严卫国

    2016-01-01

    Objective:To observe the effect of aripiprazole and risperidone in the treatment of schizophrenia.Methods:64 patients with schizophrenia were selected.32 cases treated with aripiprazole were as aripiprazole group.32 cases treated with risperidone were as risperidone group.The treatment effect and adverse reaction between groups were observed.Results:The headache,dry mouth,insomnia incidence in the aripiprazole group were higher than those in risperidone group(P<0.05).In risperidone group, increase the body weight,akathisia,menstrual changes or lactation and tremor of incidence were higher than those in aripiprazole group(P<0.05).Conclusion:The effect of aripiprazole and risperidone in the treatment of schizophrenia are relatively good, but the adverse reaction of aripiprazole is fewer and milder.%目的:观察阿立哌唑与利培酮治疗精神分裂症的效果。方法:收治精神分裂症患者64例,采用阿立哌唑进行治疗的32例患者为阿立哌唑组,应用利培酮进行治疗的32例患者为利培酮组。观察两组的治疗效果和不良反应。结果:阿立哌唑组头痛、口干、失眠的发生率均高于利培酮组(P<0.05),利培酮组体重增加、静坐不能、月经改变或泌乳和震颤的发生率均高于阿立哌唑组(P<0.05)。结论:阿立哌唑与利培酮治疗精神分裂症的效果均比较好,但阿立哌唑产生的不良反应少且轻。

  7. Treatment of behavioral disorders by risperidone in children with autism%利培酮在治疗孤独症儿童行为问题中的作用

    Institute of Scientific and Technical Information of China (English)

    韦斌垣; 黄飞; 覃小田; 梁巧琦

    2011-01-01

    Objective To study the effect of risperidone treatment on behavioral disorders in children with autism.Methods Forty children with behavioral disorders (aged from 5 to 12 years) were treated with risperidone for 8 weeks.The behavioral symptoms were evaluated by the Clinical Global Impression (CGI) and the Autism Treatment Evaluation Checklist (ATEC) before and after the treatment.The adverse events related to risperidone treatment were observed.Results The score of severity of illness and the ATEC total scores were significanfly reduced 8 weeks after risperidone treatment.Besides the social intercourse ability, great improvements have been shown on the verbal communication, apperception and behavioural symptoms by the ATEC.No severe adverse events related to risperidone treatment were observed.Conclusions Risperidone can significantly improve the behavioral disorders in children with autism and is welltolerated.%目的:研究利培酮在治疗孤独症儿童行为问题中的作用.方法:选取40例5-12岁具有行为问题的孤独症儿童,给予8周的利培酮治疗,在治疗前后进行临床疗效总评量表(CGI)和孤独症治疗评估量表(ATEC)评分,并观察利培酮治疗的不良反应.结果:利培酮治疗后第8周末的病情严重程度、ATEC总分均低于治疗前,且耐受性好;其中在ATEC评分中,除了社交评分在治疗前后无明显改变之外,言语、感知和行为评分均得到明显的改善.结论:利培酮可以显著地改善孤独症儿童的行为问题且具有良好的耐受性.

  8. A control study of olanzapine and risperidone in the treatment of senile delirium%奥氮平与利培酮治疗老年期谵妄患者的对照研究

    Institute of Scientific and Technical Information of China (English)

    冼易平; 王英

    2011-01-01

    Objective; To compare the efficacy and safety of olanzapine and risperidone in the treatment of senile delirium. Method: Fifty patients with senile delirium were randomly divided into olanzapine treatment group (n = 25 ) and risperidone treatment group ( n = 25). They were prospectively observed and assessed with the Chinese revision of confusion assessment method (CAM-CR) .clinical global impression severity scale (CGI-SI) and treatment emergent symptom scales (TESS). Results:The effective rate of olanzapine treatment group and risperidone treatment group were 64. 0% and 68. 0% respectively (P > 0. 05). CGI-SI total scores of olanzapine treatmeng group and that of risperidone treatmen group were both reduced significantly after treatment (t=5. 19,6. 95 ;P 0.05 ). The total incidence rate of side effects in the risperidone group was significantly higher than that in olanzapine group ( χ2 = 5. 88, P < 0. 05). Conclusion; Olanzapine and risperidone have similar effects in treating senile delirium,ahd has fewer side effects.%目的:比较奥氮平和利培酮治疗老年期谵妄的疗效和安全性. 方法:将50例老年期谵妄患者随机分成奥氮平治疗组(n=25),利培酮治疗组(n=25),疗程2周.治疗前后以谵妄评定方法中文修订版(CAM-CR)及临床疗效总评量表-病情严重程度(CGI-SI)评定疗效;以治疗中出现的症状量表(TESS)评定药物不良反应. 结果:奥氮平组和利培酮组显效率分别为64.0%和68.0% (P >0.05).两组CGI-SI总分治疗后均较治疗前明显降低(t=5.19、6.95,P均<0.01);两组间比较,差异无统计学意义(P>0.05).利培酮组不良反应明显高于奥氮平组(x2=5.88,P<0.05). 结论:奥氮平和利培酮治疗老年期谵妄疗效相当,不良反应轻.

  9. Treatment of posttraumatic stress disorder - related nightmares and other sleep disturbances with risperidone in combat veterans and victims of domestic and childhood abuse

    Directory of Open Access Journals (Sweden)

    Nina Khachiyants

    2010-09-01

    Full Text Available Sleep disturbances including nightmares are often reported as hallmark of posttraumatic stress disorder (PTSD. The literature related to the pharmacological treatment of PTSD-related nightmares is sparse and inconclusive. After reviewing the literature it was obvious that currently a limited data on studies supporting the use of antipsychotic medications for the treatment of PTSD are published. Moreover, even more limited scientific evidence is now available to formulate evidence-based guidelines for the treatment of PTSD-related nightmares which are often reported as the most intrusive and disruptive symptom. Objective for this study is to review comprehensively the current research literature which reflects use of antipsychotic medication risperidone for the treatment of PTSD-related nightmares of different etiology.

  10. 利培酮致恶性综合征1例%One Case of Neuroleptic Malignant Syndrome Caused by Risperidone

    Institute of Scientific and Technical Information of China (English)

    孙振晓; 孙宇新; 于相芬

    2016-01-01

    1例66岁女性器质性精神障碍患者应用利培酮0.5 mg,bid,7天后增至3 mg/d,108天后出现发热,意识模糊,肌强直、多汗、心动过速、尿潴留、呼吸加快,血压波动性大,血清肌酸激酶949.4 U/L。经停用利培酮,持续心电监护,吸氧,保持呼吸道通畅,持续导尿,给予营养支持,输液,纠正水、电解质及酸碱平衡,应用抗生素控制感染,并给予多巴胺激动剂溴隐亭治疗,14天后症状缓解。%A 66-year-old female patient with organic mental disorders was treated with risperidone at a dosage of 0 . 5 mg by oral route , twice a day for 7 d while the dosage increased gradually to 3 mg/d . The patient devel-oped fever , unconsciousness , rigidity , sweating , tachycardia , urinary retention , tachypnea , blood pressure variability 108 d after treatment , of whom the blood creatine kinase (CPK)level was 949 . 4 U/L . Risperidone was withdrawn , and the patient was given continuous oxygen inhalation , electrocardiographic monitoring and urinary catheterization , of whom the respiratory tract was kept unobstructed . Supportive treatments such as fluid infusion , correction of water electrolyte and acid base imbalance , and infection prevention were also given . Meanwhile , the patient was treated with dopamine receptor agonist bromocriptine , and the symptoms were relieved 14 d later .

  11. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews

    Directory of Open Access Journals (Sweden)

    Tamara Melnik

    Full Text Available CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline (1966-2009, Controlled Trials of the Cochrane Collaboration (2009, Issue 2, Embase (Excerpta Medica (1980-2009, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs (1982-2009. There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.

  12. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.

    Science.gov (United States)

    Chen, Jing-Xu; Su, Yun-Ai; Bian, Qing-Tao; Wei, Li-He; Zhang, Rong-Zhen; Liu, Yan-Hong; Correll, Christoph; Soares, Jair C; Yang, Fu-De; Wang, Shao-Li; Zhang, Xiang-Yang

    2015-08-01

    Hyperprolactinemia is an unwanted adverse effect associated with several antipsychotics. The addition of partial dopamine receptor agonist aripiprazole may attenuate antipsychotic-induced hyperprolactinemia effectively. However, the ideal dosing regimen for this purpose is unknown. We aimed to evaluate the dose effects of adjunctive treatment with aripiprazole on prolactin levels and hyperprolactinemia in schizophrenia patients. Stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e., >24 ng/ml for females and >20 ng/ml for males) were randomly assigned to receive 8 weeks of placebo (n=30) or oral aripiprazole 5mg/day (n=30), 10mg/day (n=29), or 20mg/day (n=30) added on to fixed dose risperidone treatment. Serum prolactin levels were measured at baseline and after 2, 4 and 8 weeks; clinical symptoms and side effects were assessed at baseline and week 8 using the Positive and Negative Syndrome Scale, Clinical Global Impressions Severity scale, Barnes Akathisia Scale, Simpson-Angus Scale and UKU Side Effects Rating Scale. Of 119 randomized patients, 107 (89.9%) completed the 8-week study. At study end, all three aripiprazole doses resulted in significantly lower prolactin levels (beginning at week 2), higher response rates (≥30% prolactin reduction) and higher prolactin normalization rates than placebo. Effects were significantly greater in the 10 and 20mg/day groups than the 5mg/day group. No significant changes were observed in any treatment groups regarding psychopathology and adverse effect ratings. Adjunctive aripiprazole treatment was effective and safe for resolving risperidone-induced hyperprolactinemia, producing significant and almost maximal improvements by week 2 without significant effects on psychopathology and side effects.

  13. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

    Directory of Open Access Journals (Sweden)

    Mario Louzã

    2010-12-01

    Full Text Available Rogelio Apiquian1, Rodrigo Córdoba2, Mario Louzã31Americas University, Behavior and Development Sciences Division, Mexico City, Mexico; 2Nervous System Research Center-CISNE, Bogota, Colombia; 3Schizophrenia Research Program, Institute of Psychiatry, Faculty of Medicine, University of São Paulo, BrazilBackground: Risperidone long-acting injection (RLAI has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America.Methods: Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S, Personal and Social Performance (PSP, and Global Assessment of Functioning (GAF scores. Relapse and treatment were also registered.Results: Patients were recruited in Mexico (n = 53, Brazil (n = 11, and Colombia (n = 15. Sixty-five percent (n = 52 were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73 or schizoaffective disorder (n = 6. The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg. The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P < 0.001. Significant changes were registered on CGI-S, GAF, and PSP scores.Conclusions: RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization.Keywords: long-acting, risperidone, schizophrenia, schizoaffective disorder, Latin America

  14. 西酞普兰治疗早泄的临床观察%Efficacy of citalopram on premature ejaculation: A clinical observation

    Institute of Scientific and Technical Information of China (English)

    商学军; 耿强; 张凯; 夏欣一; 邵永; 黄宇烽

    2012-01-01

    目的:探讨西酞普兰治疗早泄的临床疗效和安全性. 方法:将2011年5月至2012年5月男科门诊就诊的80例早泄患者随机分为治疗组和对照组,每组40例.治疗组每天口服西酞普兰20 mg,对照组口服安慰剂,记录治疗前、治疗2周和4周后患者阴道内射精潜伏时间(IELT)和性交满意度分值. 结果:治疗组治疗2、4周后IELT分别为(5.64±1.31) min和(7.12 ±1.56)min,均比治疗前[(0.91±0.18) min]明显延长(P均<0.01),且西酞普兰治疗4周后的IELT明显高于2周后(P<0.01);治疗组治疗2、4周后性交满意度分别为(6.1±1.3)分和(6.3±1.1)分,与治疗前[(2.5±0.8)分]相比有明显提高(P<0.01),而治疗2周和4周后性交满意度无显著性差异(P>0.05).对照组治疗2、4周后IELT和性交满意度分别为(1.02±0.24) min、1.01±0.21 min和(3.0±1.1)分、(3.1±1.3)分,与治疗前[(0.95±0.17) min和(3.2±1.2)分]比较,均无显著性差异(P均>0.05). 结论:每天口服西酞普兰20 mg,对早泄患者IELT和性交满意度均有明显改善,西酞普兰治疗早泄具有较好的临床疗效和安全性.%To investigate the clinical efficacy and reliability of citalopram in the treatment of premature ejaculation. Methods: We included in this study 80 patients who came to our andrological clinic for premature ejaculation from May 2011 to May 2012, and randomly assigned them to a treatment and a control group of equal number to receive citalopram (20 mg/d) and placebo, respectively. We recorded the intravaginal ejaculation latency time (IELT) and sexual intercourse satisfaction scores before and at 2 and 4 weeks after treatment, and compared them between the two groups. Results: In the treatment group, IELT was significantly longer at 2 and 4 weeks than before treatment ([5. 64 ± 1. 31 ] and [7. 12 ± 1.56] min vs [0.91 ±0. 18] min, P 0.05). The control group showed no significant differences in the mean IELT and sexal intercourse satisfaction scores

  15. Observation on the effect of Tianshu Capsule and Citalopram treating the chronic primary headache%天舒胶囊联合西酞普兰治疗慢性原发性头痛的疗效观察

    Institute of Scientific and Technical Information of China (English)

    唐宇凤; 段劲峰; 岳涛; 陈立芳

    2013-01-01

    Objective:To evaluate the effects of combination Tianshu Capsule and Citalopram on chronic primary headache.Methods:Chronic primary headache patients were collected from the outpatient and inpatient department of neurology and randomly divided into treatment group (40 patients treated with Tianshu Capsule and Citalopram) and control group (43patients treated with Sodium Valproate and Amitriptyline).All of them were assessed in NRS (numerical rating scale) for the degree of headache and life quality before 2 and 4 weeks after the therapy.Results:The severity of headache revealed effectively improvement in both groups.The effect of the treatment group was superior to the control group.The quality of life in treatment group improved more obviously than in control group.Adverse drug reactions in treatment group were lower than in control group.Conclusions:Tianshu Capsule combined with citalopram had satisfactory and safe curative effect on patients of primary headache.%目的:评价天舒胶囊联合西酞普兰治疗慢性原发性头痛的疗效.方法:在门诊及病房工作中收集原发性头痛患者,以区组随机法随机分为治疗组40例(天舒胶囊、西酞普兰)和对照组43例(丙戊酸钠、阿米替林),分别于治疗初进行头痛程度的评分及生活质量综合评分,然后于治疗后2周、4周复查头痛程度的评分及生活质量综合评分.结果:治疗后两组患者的头痛程度均有改善,治疗组疗效优于对照组.治疗组患者的生活质量改善程度优于对照组.治疗组患者的药物不良反应发生率低于对照组.结论:天舒胶囊联合西酞普兰治疗原发性头痛安全有效.

  16. Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats

    Directory of Open Access Journals (Sweden)

    Amit Taneja

    2016-09-01

    Full Text Available We provide the reader with relevant data related to our recently published paper, comparing two mathematical models to describe prolactin turnover in rats following one or two doses of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride, “A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats” (Taneja et al., 2016 [1]. All information is tabulated. Summary level data on the in vitro potencies and the physicochemical properties is presented in Table 1. Model parameters required to explore the precursor pool model are presented in Table 2. In Table 3, estimated parameter comparisons for both models are presented, when separate potencies are estimated for risperidone and paliperidone, as compared to a common potency for both drugs. In Table 4, parameter estimates are compared when the drug effect is parameterized in terms of drug concentration or receptor occupancy.

  17. 氯氮平与维思通对精神分裂患者血糖影响的比较%Different effects of clozapine and risperidone on levels of blood glucose in patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    曹栋; 谢世平

    2001-01-01

    Objective To investigate the different effects of clozapine and risperidone on levels of blood glucose in patients with schizophrenia. Method 200 qualified cases selected from psychiatric department were divided into two groups randomly, of which 100 cases accepted the treatment with clozapine and the other 100 cases with risperidone. Blood glucose tests were used before treatment ,4 weeks after treatment and 8 weeks after treatment Results There was significantly higher blood glucose level in clozapine- treated group than in risperidone- treated group after 4 or 8 weeks treatment. The number of cases who had elevated blood glucose level (>6.1 mmol/L) in clozapine- treated group was significantly more than in risperidone- treated group. Conclusion The glucoregulatory abnormality which leads to glucose elevation in clozapine- treated patients is greater than in risperidone- treated patients. Additional motivation to clinical monitor for antipsychotic treatment- related hyperglycemia is indicated.

  18. 利培酮合并氯氮平治疗难治性精神分裂症临床分析%Clinical Effect of Risperidone Combined with Clozapine in Treatment of Re-fractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵圣兰; 郭晓静

    2015-01-01

    Objective To investigate the clinical effect of risperidone combined with clozapine in the treatment of refractory schizophrenia. Methods The control group received conventional treatment with risperidone; study group received combined treat-ment of risperidone and clozapine. Outcomes and adverse reaction of the patients with refractory schizophrenia in the two groups were recorded and statistically analyzed. Results Clinical total efficiency of the study group, 88.37%, was significantly higher than that of the control group, 69.77% (P 0.05). Conclusion Risperidone combined with clozapine used in the treatment of patients with refractory schizophrenia can significantly improve the clinical effi-cacy and quality of life and protect the safety of patients.%目的:探讨利培酮合并氯氮平治疗难治性精神分裂症临床应用效果。方法对照组给予利培酮常规治疗;研究组实施利培酮联合氯氮平片疗法。将两组中难治性精神分裂症患者的疗效及不良反应发生状况记录,通过统计学分析得出结论。结果研究组临床治疗的总有效率为88.37%,明显优于对照组临床治疗总有效率69.77%(P0.05)。结论难治性精神分裂症患者经利培酮联合氯氮平治疗可显著提高其临床疗效,有效保障患者生活质量及生命安全。

  19. Analysis of the efficacy and safety of risperidone microsphere injection in treatment of schizophrenia%注射用利培酮微球治疗精神分裂症的疗效和安全性分析

    Institute of Scientific and Technical Information of China (English)

    张东升

    2015-01-01

    Objective:To investigate the efficacy and safety of risperidone microsphere injection in the treatment of schizophrenia. Methods:90 schizophrenia patients were selected.They were divided into the experimental group and the control group average. The control group were given risperidone tablets treatment,and the experimental group were treated with injection of risperidone treatment.Results:The total treatment efficiency and the quality of life score of the patients in the experimental group was significantly higher than those of the control group(P<0.05);the incidence of the adverse reactions of the experimental group was significantly lower than that of the control group(P<0.05).Conclusion:The curative effect of risperidone microspheres in the treatment of schizophrenia is significant and the safety is high.It can improve the quality of life of patients effectively.%目的:探讨注射用利培酮微球治疗精神分裂症的疗效和安全性。方法:收治精神分裂症患者90例,将其平均分为试验组和对照组,对照组采用利培酮片治疗,试验组采用注射利培酮微球治疗。结果:试验组治疗总有效率、生活质量评分明显高于对照组(P<0.05);试验组不良反应发生率明显低于对照组(P<0.05)。结论:注射用利培酮微球治疗精神分裂症的疗效显著且安全性高,有效改善了患者的生活质量。

  20. Pharmacoeconomic analysis of Booz clear and Risperidone in the treatment of schizophrenia%博思清与维思通治疗精神分裂症的药物经济学分析

    Institute of Scientific and Technical Information of China (English)

    李晶武

    2012-01-01

      Objective To compare the Aripirazole and the cost of Risperidone in the treatment of sctfizophreniaresults. Methods 50 hospitalized patients with schizophrenia with Risperidone, Aripirazole treatment,treatment for 6 weeks.Using the cost-ef ectiveness analysis of 2 groups were analyzed.Results Aripirazole and Risperidone in the treatment of schizophrenia rates were between 96.0%and 92.0%, no significant dif erence in ef icacy (P>0.05), the cost, was 638.16 yuan and 647.8 yuan. Conclusion The ef icacy of the treatment of schizophrenia Aripirazole,Risperidone equivalent,but faster onset,Aripirazole in the treatment of schizophrenia than the economy.%  目的比较博思清与维思通治疗精神分裂症的成本-效果.方法对50例住院精神分裂症患者应用博思清与维思通进行治疗,疗程6周.采用成本-效果分析法对两组进行分析.结果博思清与维思通治疗精神分裂症的有效率分别为96.0%和92.0%,两者疗效无显著性差异(P>0.05),成本分别为638.16元和647.8元.结论博思清治疗精神分裂症疗效与维思通相当,但起效更快,博思清(阿立哌唑)治疗精神分裂症较经济.

  1. The effects of risperidone on plasma glucose of the schizophrenic patients%利培酮对精神分裂症患者糖代谢的影响

    Institute of Scientific and Technical Information of China (English)

    梁路

    2012-01-01

    Objective: To study the effect of risperidone for schizophrenia patients on the weight and glycometabolism. Method: we compared the weight and the fasting blood glucose respectively,36 cases of schizophrenic patients treated with risperidone before and after 12 weeks . Result: there was significant difference in the mean weight of the patients treated with risperidone for 12 weeks,which increased by 1.36 kilometres (p<0.05). the average fasting blood glucose of the schizophrenics treated for 12 weeks significant increased by 0.13mmol/L (p<0.05). Result: There are some extent effect on the weight and the fasting blood glucose of the patients who were treated with risperidone.%目的探索利培酮对精神分裂症患者体重与糖代谢的影响.方法收集36例精神分裂症患者使用利培酮治疗,疗程为12周,分别在未用药前和用药12周后测量体重和检测空腹血糖水平进行同体比较.结果本文结果显示,治疗12周后患者平均体重增加1.36 kg,P<0.05,有显著统计学意义;同时在治疗12周后检测空糖血糖与未治疗前空腹血糖比较,平均升高0.13mmol/L,P<0.05,有显著统计学意义.结论利培酮治疗精神分裂症,对患者的体重和空腹血糖有一定程度的影响.

  2. Follow-up study on influence of metabolism by risperidone and chlorpromazine%利培酮与氯丙嗪对代谢影响随访研究

    Institute of Scientific and Technical Information of China (English)

    王强; 瞿正万

    2011-01-01

    Objective:To explore the impact of chlorpromazine ,risperidone treatment on the blood glucose and fat level and body weigh in schizophrenia patients. Method: 198 schizophrenia patients were enrolled in the study. They were randomly admitted to risperidone therapy group and chlorpromazine therapy group. They are followed up one year. Data of the blood glucose and blood fat and body weight were collected at different point in the one year course of the study. Results: Both cholorpromazine group and risperidone group increased significantly in the index of total cholesterol ( TC ), triglyceride ( TG), fasting blood glucose ( FPG),glycated hemoglobin ( HbAlc), body weight and body mass index ( B MI ) while chlorpromazine group was significantly higher in these indexes. Conclusion:While chlorpromazine and risperidone can attect the blood glucose,blood fat and body weight in different ways, but they can both elevated the blood glucose, blood fat level and body weight.%目的:研究氯丙嗪与利培酮对精神分裂症患者血糖、血脂和体质量的影响.方法:198例精神分裂症患者随机分为氯丙嗪组与利培酮组,随访1年,采集患者空腹血糖、总胆固醇、和体质量的数据.结果:氯丙嗪组和利培酮组总胆固醇、三酞甘油、空腹血糖、糖化血红蛋白、体质量、体质量指数在治疗后均显著升高;以氯丙嗪组更显著为高.结论:氯丙嗪与利培酮对血糖、血脂和体质量的影响不同,但都可使之升高.

  3. 利培酮、氯氮平治疗精神分裂症的药物经济学评估%Pharmacoeconomic Evaluation of Schizophrenia in Risperidon and Cloza-pine Treatment

    Institute of Scientific and Technical Information of China (English)

    郑冰

    2014-01-01

    目的:比较利培酮、氯氮平治疗住院精神分裂症的成本-效果。方法对82例住院精神分裂症患者应用利培酮或氯氮平进行治疗,根据PANSS量表减分率评定疗效,对住院花费运用药物经济学成本-效果分析法进行评价。结果利培酮、氯氮平治疗精神分裂症的显效率分别为77.8%、71.4%,二者比较无显著性差异( P>0.05);产生单位效果所需成本二者无显著差异。结论利培酮与氯氮平治疗住院精神分裂症的疗效及费用基本相当。%OBJECTIVE To compare the efficiency and economic cost between Risperidon and Clozapine in the treatment of schizophrenia.METHODS 82 in-patients with schizophrenia were treated with Risperidon or Clozap-ine.PANSS was used to assess the clinical efficacy and pharmacoeconomic cost-effectiveness analysis was used to e-valuate costs.RESULTS The effective rates of Risperidon and Clozapine were 77.8% and 71.4% respectively with no significant difference ( P>0.05 ).There was no significant difference in the costs for an identical effect be-tween two drugs.CONCLUSION The ef-ective and costs of Risperidon and Clozapine are almost equal in the treat-ment of schizophrenia.

  4. 齐拉西酮与利培酮治疗女性精神分裂症的对照研究%Comparative study on ziprasidone and risperidone in the treatment of female schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈永红

    2014-01-01

    Objective To explore the curative effect and safety of ziprasidone and risperidone in the treatment of female schizophrenia. Methods A total of 80 female schizophrenia patients were randomly divided into ziprasidone group and risperidone group, with 40 cases in each group. The retrospective therapies by ziprasidone and risperidone were given to the two groups for 8 weeks. Positive and negative syndrome scale for schizophrenia (PANSS) was applied for curative effect assessment, and treatment emergent symptom scale (TESS) was used to assess the adverse reactions. Results In the ziprasidone group, the excellent effect rate was 84.21%, and the effective rate was 94.74%. These two rates in the risperidone group were 78.38%and 91.89%. There was no statistically significant difference between the two groups (P>0.05). The PANSS scores of the two groups decreased significantly after treatment, compared with those before treatment. The difference had statistical significance (P0.05)。两组患者的PANSS评分治疗后均较治疗前明显下降,差异有统计学意义(P<0.01)。齐拉西酮组体重增加和内分泌改变等不良反应发生率显著低于利培酮组,差异有统计学意义(P<0.05)。结论齐拉西酮与利培酮对女性精神分裂症的疗效相当,齐拉西酮对体重的影响和内分泌改变显著少于利培酮,是治疗女性精神分裂症患者的理想药物。

  5. CONTRAST ANALYSIS OF RISPERIDONE AND CLOZAPINE ON EEG OF PATIENTS WITH SCHIZOPHRENIA%利培酮与氯氮平对精神分裂症患者脑电图的影响

    Institute of Scientific and Technical Information of China (English)

    郑育喜; 陆丽珍; 卢建国; 龙俊荣; 侯英; 梁容梅

    2014-01-01

    Objective To analyze the effects of risperidone and clozapine on EEG of patients with schizophrenia. Methods The two groups of patientstaking clozapine and risperidone respectively were given EEG examination before and af-ter 2nd and 4th week of treatment, the abnormal rate of EEG of two groups of patients were analyzed to compare the effects of the two drugs on electrical activity of the brain.Results The abnormal rate of EEG induced by clozapine was significantly higher than that induced by resperidone (p<0.05).Conclusion The influence of risperidone on EEG is lower than that of clozapine.%目的:分析利培酮与氯氮平对精神分裂症患者脑电图的影响。方法通过对两组分别服用氯氮平、利培酮的患者,在服药前、服药后第2周、第4周分别检查脑电图一次,分析两组病人脑电图的异常率,对比两种药物对脑电活动的影响。结果氯氮平引起脑电图异常率明显高于利培酮( p<0.05)。结论利培酮对脑电图的影响较氯氮平轻。

  6. Comparative Study on Tiapride and Risperidone in Treatment of Behavioral and Psychological Symptoms of Dementia%硫必利与利培酮治疗老年痴呆精神行为症状的对比研究

    Institute of Scientific and Technical Information of China (English)

    袁成勇

    2015-01-01

    Objective To study the clinical application of risperidone in the treatment of behavioral and psychological symptoms of dementia and tiapride therapy differences behavioral and psychological symptoms of dementia and related side effects. Methods Experimental group were treated with tiapride (50~400 mg / qd), the control group received risperidone (0.5~4.0 mg) /qd).6 weeks Differences between the two groups and the PANSS scale Results TESS data. Results Efifciency difference was not statistically significant (P>0.05) tiapride treatment group the number of cases of side effects than risperidone group, the Results were statistically significant (P 0.05).硫必利治疗组发生副反应的病例数少于利培酮治疗组,结果具有统计学意义(P<0.05).结论 硫必利治疗老年期痴呆精神及行为症状效果确切.

  7. Comparison of Efficacy of Ziprasidone and Risperidone in Patients with First-episode Schizophrenia%齐拉西酮与利培酮对首发精神分裂症患者对照研究

    Institute of Scientific and Technical Information of China (English)

    刘娜

    2016-01-01

    目的::探讨齐拉西酮与利培酮治疗首发精神分裂症疗效及不良反应。方法:将100例首发精神分裂症患者随机分为齐拉西酮组和利培酮组各50例,分别于治疗前、治疗12周评定 PANSS 量表,评估不良反应发生率。结果:齐拉西酮组和利培酮组疗效相仿,差异无统计学意义(P >0.05)。齐拉西酮组的不良反应显著少于利培酮组,差异有统计学意义(P 0.05),which has no statis-tical significance.The adverse reactions of ziprasidone group were significantly less than that of the risperi-done group(P <0.05),which is statistically significant.Conclusion:Ziprasidone and risperidone have equal effect in the treatment of First-episode schizophreni,however,the clinical safety and adverse reactions of zi-prasidone are superior to those of the risperidone.Therefore,ziprasidone is worth widely used in the clinical practice.

  8. Gas chromatography-tandem mass spectrometry assay for the quantification of four benzodiazepines and citalopram in eleven postmortem rabbit fluids and tissues, with application to animal and human samples.

    Science.gov (United States)

    Cartiser, N; Bévalot, F; Le Meur, C; Gaillard, Y; Malicier, D; Hubert, N; Guitton, J

    2011-10-01

    Pharmacokinetic studies and postmortem toxicological investigations require a validated analytical technique to quantify drugs on a large number of matrices. Three-step liquid/liquid extraction with online derivatization (silylation) ahead of analysis by gas chromatography-tandem mass spectrometry was developed and validated on rabbit specimens in order to quantify citalopram and 4 benzodiazepines (diazepam, nordazepam, oxazepam and temazepam) in 11 biological matrices (blood, urine, bile, vitreous humor, liver, kidney, skeletal muscle, brain, adipose tissue, bone marrow (BM) and lung). Since the 11 biological matrices came from the same animal species, full validation was performed on 1 matrix, bone marrow (considered the most complex), while the other 10 underwent partial validation. Due to non-negligible matrix effects, calibration curves were performed on each matrix. Within-day and between-day precision (less than 12.0% and 12.6%, respectively) and accuracy (from 88.9% to 106.4%) were acceptable on BM at both low and high concentrations. Assessment on the other matrices confirmed accuracy and within-day precision (less than 12%, and generally between 85.1% and 114.5%, respectively). The lower limit of quantification of the method was 1ng/g for nordazepam, 5ng/g for citalopram and 10ng/g for oxazepam, diazepam and temazepam. The combination of 3-step extraction and MS/MS detection provided good selectivity in all matrices, including the most lipid-rich. Application to real-case samples showed that the method was sensitive enough to describe distribution patterns in an animal experiment, and specific enough to detect molecules in highly putrefied samples from human postmortem cases.

  9. Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound.

    Science.gov (United States)

    Zhang, Lanqiu; Rasenick, Mark M

    2010-03-01

    Chronic antidepressant treatment has been shown to increase adenylyl cyclase activity, in part, due to translocation of Galpha(s) from lipid rafts to a nonraft fraction of the plasma membrane where they engage in a more facile stimulation of adenylyl cyclase. This effect holds for multiple classes of antidepressants, and for serotonin uptake inhibitors, it occurs in the absence of the serotonin transporter. In the present study, we examined the change in the amount of Galpha(s) in lipid raft and whole cell lysate after exposing C6 cells to escitalopram. The results showed that chronic (but not acute) escitalopram decreased the content of Galpha(s) in lipid rafts, whereas there was no change in overall Galpha(s) content. These effects were drug dose- and exposure time-dependent. Although R-citalopram has been reported to antagonize some effects of escitalopram, this compound was without effect on Galpha(s) localization in lipid rafts, and R-citalopram did not inhibit these actions of escitalopram. Escitalopram treatment increased cAMP accumulation, and this seemed due to increased coupling between Galpha(s) and adenylyl cyclase. Thus, escitalopram is potent, rapid and efficacious in translocating Galpha(s) from lipid rafts, and this effect seems to occur independently of 5-hydroxytryptamine transporters. Our results suggest that, although antidepressants display distinct affinities for well identified targets (e.g., monoamine transporters), several presynaptic and postsynaptic molecules are probably modified during chronic antidepressant treatment, and these additional targets may be required for clinical efficacy of these drugs.

  10. Micellization Behavior of an Amphiphilic Drug Promethazine Hydrochloride-Surfactant System in an Aqueous Medium%水溶液中两亲药物盐酸异丙嗪,表面活性剂体系的胶束化行为

    Institute of Scientific and Technical Information of China (English)

    KABIR-UD-DIN; KHAN Abbul Bashar; NAQVI Andleeb Z.

    2011-01-01

    The behavior of the mixed amphiphilic drug promethazine hydrochloride (PMT) and cationic as well as nonionic surfactants was studied by tensiometry.The cmc values of the PMT-surfactant systems decrease at a surfactant mole fraction of 0.1 and it then becomes constant.The critical micelle concentration (cmc) values are lower than the ideal cmc (cmc*) values for PMT/TX-100,PMT/TX-114,PMT/Tween 20,and PMT/Tween 60 systems.For the PMT/Tween 40,PMT/Tween 80,PMT/CPC,andPMT/CPB systems the cmc values are close to the cmc* values.This indicates that PMT forms mixed micelles with these surfactants by attractive interactions.The surface excess (Γmax) decreases in the presence of surfactants.The rigid structure of the drug makes adsorption easier and the contribution of the surfactant at the interface decreases.The interaction parametersβm (for the mixed micelles) andβ°(for the mixed monolayer) are negative indicating attraction among the mixed components.

  11. 阿立哌唑与利培酮治疗精神分裂症对比分析%Comparative analysis of aripiprazole and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李红远; 李义会

    2015-01-01

    Objective:To explore the clinical effect and safety of aripiprazole in the treatment of schizophrenia.Methods:120 patients with schizophrenia were randomly divided into two groups.They were treated with aripiprazole and risperidone respectively.The curative effects and adverse reactions of patients in two groups were compared.Results:The treatment total effective rate of the aripiprazole group and the risperidone group were respectively 83.3% and 81.7% .The incidence rate of adverse reaction(33.3%) in the aripiprazole group was significantly lower than 51.7% of the risperidone group(χ 2=4.126,P<0.01).Conclusion:The curative effects of aripiprazole and risperidone in the treatment of schizophrenia are considerable.The adverse reaction of aripiprazole is low than that of risperidone.The safety of aripiprazole is good.%目的:探讨阿立哌唑治疗精神分裂症的临床效果及安全性。方法:将120例精神分裂症患者随机分为两组,分别给予阿立哌唑和利培酮治疗。对两组患者的疗效及不良反应进行比较。结果:阿立哌唑组和利培酮组的总有效率分别为83.3%和81.7%。阿立哌唑组不良反应发生率33.3%明显低于利培酮组的51.7%(χ2=4.126,P<0.01)。结论:阿立哌唑与利培酮治疗精神分裂症的疗效相当,不良反应比利培酮低,安全性好。

  12. Comparison of in vitro Dissolution of Risperidone Pellets from Different Pharmaceutical Factories%不同厂家利培酮片的体外溶出度比较

    Institute of Scientific and Technical Information of China (English)

    陈颖; 汤莉娜; 瞿发林

    2012-01-01

    目的:比较4个厂家利培酮片的体外溶出度,为临床用药提供参考.方法:采用小杯法进行体外溶出度试验,以高效液相色谱法进行含量测定,计算累积溶出百分率.以威布尔方程拟合溶出参数,并用方差分析对组间溶出参数进行统计学处理.结果:四个厂家所生产的利培酮片体外溶出度均符合2010年版规定,但各厂家利培酮片的溶出参数m、T30、T50、Td、T80间差异有统计学意义 (P<0.01).结论:不同厂家利培酮片的体外溶出参数存在差异,临床用药时应加以注意.%Objective: To compare the in vitro dissolution of risperidone pellets from different pharmaceutical factories to offer suggestions for clinical use. Method: Dissolution tests were carried out with small glass method. HPLC method was used to determine the concentration of risperidone. The accumulative dissolution was calculated and the Weibull equation was applied to fit the dissolution parameters. The difference among the groups was statistically evaluated by variance analysis. Result: The in vitro dissolution of these risperidone pellets all met the requirements of Chinese Pharmacopoeia ( 2010 edition ). However, significant difference in dissolution parameters including m, T30,T50, Td and T80, was found ( P <0.01 ) among the risperidone pellets. Conclusion: There is significant difference in dissolution parameters of the risperidone pellets from different pharmaceutical factories, suggesting that attention should be paid to their clinical use.

  13. Clinical Comparison Analysis on Risperidone and Clozapine in The Treatment of Schizophrenia%利培酮与氯氮平治疗精神分裂症临床对比分析

    Institute of Scientific and Technical Information of China (English)

    赵仁香

    2015-01-01

    目的:分析利培酮和氯氮平治疗精神分裂症的临床效果。方法选取我院2013~2014年的91例患者来进行研究分析,分组为利培酮和氯氮平组,前组有42例患者,后组有49例患者,分析两组的精神病量表(BPRS)、阳性症状量表(SAPS)、副反应量表(TESS)。结果利培酮组患者的显效时间为一至两周,平均(10.56±4.23)天,氯氮平为一周左右,平均(7.23±3.57)天,差异无统计学意义,P>0.05。利培酮组有36例显效,氯氮平组有38例显效,两组的治疗效果差异无统计学意义。量表结果显示,两种药物均对精神分裂症阳性症状改善明显,氯氮平组的BPRS和SAPS评分比利培酮组高,差异有统计学意义,P0.05. There were 36 excel ent cases in risperidone group,38 excel ent cases in clozapine group, and the difference of clinical effects were not significant. The clinical effects of two drugs to the positive symptoms of schizophrenia were obvious ,the BPRS and SAPS scores in clozapine group was higher than risperidone group significantly,P<0.05. The clinical effect of risperidone to the activation and bizarre behavior symptoms was worse,and was similar for other symptoms. Conclusion The clinical effect of risperidone and clozapine in the treatment of schizophrenia are excel ent,and the advantages of risperidone are greater.

  14. A clinical study on substitution of risperidone for clozapine in the treatment of schizophrenia%利培酮替换氯氮平治疗精神分裂症临床研究

    Institute of Scientific and Technical Information of China (English)

    梅其一; 王晓龙; 杨小男; 方建中

    2001-01-01

    Objective:To explore a clinical optimal regime of substitutingrisperidone for clozapine. Method:Subjects were randomly enrolled into three groups: risperidone group, combination of risperidone and benzhexol group and combination of risperdone and alprazolam group. The efficacy and side effects were accessed with the positive and negative symptom scale (PANSS), a rating scale for extramidal side-effects (ESRS) and the treatment emergent symptom scale (TESS) before and after treatment. Results:The efficacy of all regimes was significant, and no significant differences were found among them. The female patients had more severe side effects than the male patients. The side effects were slightest in the combination of risperidone and alprazolam group and most severe in the risperidone group. Conclusion:Substituting risperidone and alprazolam for clozapine is the optimal regime in the treatment of schizophrenia.%目的:探索以利培酮替换氯氮平的临床换药方案。 方法:受试患者随机进入3组:单用利培酮组,利培酮+安坦组,利培酮+阿普唑仑组。在治疗前、治疗后1、2、4、6周用阳性症状与阴性症状量表(PANSS)、锥体外系副反应量表(ESRS)、不良反应症状量表(TESS)比较其疗效和副反应。 结果:3组换药后疗效均显著(P0.05)。女性较男性副反应大一些;利培酮+阿普唑仑组副反应最轻,单用利培酮组副反应最大。 结论:利培酮+阿普唑仑替换氯氮平方案较佳。

  15. 喹硫平与利培酮对女性精神分裂症患者血清泌乳素水平的影响%Effects of quetiapine and risperidone on serum prolactin levels of female schizophrenia

    Institute of Scientific and Technical Information of China (English)

    孙海华; 杨焕

    2013-01-01

    Objective To explore the effects of quetiapine and risperidone in the treatmemt of female schizophrenic patients and the effect of levels on serum prolactin. Methods 76 female schizophrenic patients were treated with quetiapine and risperidone randomly. The serum prolactin were measured and the scores of PANSS were evaluated before treatment and at the 1st、2nd、4th、8th week respectively. TESS was used to evaluate side effect. Results There were no significant differences in PANSS basal scores and the decreased scores after the treatment in two groups. The level of serum prolactin in risperidone group increased markedly than quetiapine group, and the serum prolactin level in quetiapine group were not increase significantly. Conclusion Quetiapine and risperidone have similar efficacy in the treatment of femal patients with schizophrenia. Risperidone produced increases in plasma prolactin levels in femal patients.%目的:评价喹硫平与利培酮对女性精神分裂症患者疗效和血清泌乳素水平的影响。方法选择女性精神分裂症患者76例,随机分为喹硫平与利培酮组治疗8周。采用阳性和阴性症状量表(PANSS)在治疗前及治疗第1周、2周、4周、8周末分别评定疗效,检测血清泌乳素水平,同时精神药物副反应量表(TESS)评定药物副反应。结果治疗前和治疗8周,两组在PANSS总分无显著差异。利培酮组血清泌乳素水平显著升高,并显著高于喹硫平组。喹硫平组血清泌乳素水平治疗前后无显著变化。结论喹硫平与利培酮对女性精神分裂症的疗效相似,利培酮对女性精神病患者的血清泌乳素水平有较大影响。

  16. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO study

    Directory of Open Access Journals (Sweden)

    Hong Jihyung

    2012-12-01

    Full Text Available Abstract Background With many atypical antipsychotics now available in the market, it has become a common clinical practice to switch between atypical agents as a means of achieving the best clinical outcomes. This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting. Methods W-SOHO was a 3-year observational study that involved over 17,000 outpatients with schizophrenia from 37 countries worldwide. The present post hoc study focused on the subgroup of patients who started taking olanzapine at baseline and subsequently made the first switch to risperidone (n=162 and vice versa (n=136. Clinical status was assessed at the visit when the first switch was made (i.e. before switching and after switching. Logistic regression models examined the impact of medication switch on tolerability outcomes, and linear regression models assessed the association between medication switch and change in the Clinical Global Impression-Schizophrenia (CGI-SCH overall score or change in weight. In addition, Kaplan-Meier survival curves and Cox-proportional hazards models were used to analyze the time to medication switch as well as time to relapse (symptom worsening as assessed by the CGI-SCH scale or hospitalization. Results 48% and 39% of patients switching to olanzapine and risperidone, respectively, remained on the medication without further switches (p=0.019. Patients switching to olanzapine were significantly less likely to experience relapse (hazard ratio: 3.43, 95% CI: 1.43, 8.26, extrapyramidal symptoms (odds ratio [OR]: 4.02, 95% CI: 1.49, 10.89 and amenorrhea/galactorrhea (OR: 8.99, 95% CI: 2.30, 35.13. No significant difference in weight change was, however, found between the two groups. While the CGI-SCH overall score improved in both groups after switching, there was a significantly greater change in those who

  17. 多次利培酮治疗致抗精神病药恶性综合征%Neuroleptic malignant syndrome after repeated treatment with risperidone

    Institute of Scientific and Technical Information of China (English)

    丁跃庆; 李华; 谢振强; 张伟娟; 代俊; 孔君; 吴洪军

    2012-01-01

    1例31岁女性患者因精神分裂症给予利培酮1 mg,2次/d口服,1周后剂量增至2 mg,2次/d.此前患者曾3次间断应用利培酮治疗.本次治疗规律服药49 d,患者精神症状缓解.第50~52天未遵医嘱规律服药.第54天患者出现大汗淋漓,体温达38.5 ℃.第55天出现意识障碍、心动过速、双上肢肌强直、肌张力增高.心电图示窦性心动过速.实验室检查示:白细胞计数12.3×109/L,胆碱酯酶 13 268 U /L,肌酸激酶 1447 U/L,利培酮血液浓度70.5 μg/L.诊断为抗精神病药恶性综合征(NMS).立即停用利培酮,进行物理降温、补液、抗心律失常、抗感染、纠正酸碱平衡、护肝等治疗.6 d后患者体温恢复正常,NMS症状消失.换用奥氮平治疗后,未再出现类似症状.%A 31-year-old woman with schizophrenia received risperidone 1 mg twice daily. One week later, the dose was increased to 2 mg twice daily. The patient had previously received risperidone intermittent treatment for three times. After a 49-day regular treatment, the psychiatric symptoms relieved. On days 50 to 52, she did not adhere to the instructions of the physician for regular use of the drug. On day 54, the patient experienced profuse sweating with a temperature of 38. 5 ℃. On day 55, she developed disturbance of consciousness, tachycardia, muscle rigidity of the upper limbs, and hypermyotonia. Her electrocardiograph showed sinus tachycardia. Laboratory tests showed the following findings: white blood cell count 12. 3 × 109/L, cholinesterase 13 268 U/L, creatine kinase 1447 U/L. The blood concentrations of risperidone was 70. 5 μg/L. Neuroleptic malignant syndrome ( NMS ) was diagnosed. The medication was stopped immediately. Physical methods for lowering body temperature, fluid supplement, antiarrhythmics, anti-infective therapy, correction of the acid-base imbalance, and liver-protective treatment were given. Six days later, the temperature returned to normal, the NMS symptoms

  18. 利培酮或阿立哌唑替换奋乃静治疗分裂症疗效与副反应研究%Risperidone or Aripiprazole Replace Perphenazine Treatment Efficacy and Side Effects of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    汪津洋

    2013-01-01

    目的评价利培酮或阿立哌唑替换奋乃静治疗精神分裂症的疗效与不良反应。方法将257例服用奋乃静治疗的分裂症患者逐渐替换为利培酮和阿立哌唑治疗,采用自然观察研究方法,对研究对象进行1年跟踪研究,评价疗效及副反应。结果治疗终点利醅酮和阿立哌唑组有效率分别为62.5%和69.8%,差异无统计学意义(P>0.05),跟踪中其他时点(2、4、6、8个月)两组有效率差异亦无统计学意义。12个月末利培酮组和阿立哌唑组的复发率(14.3%、12.3%)、持续治疗时间(9.4±3.7月、9.6±3.7月)、复发时间(4.1±2.8月、5.2±2.7月)等差异均无统计学意义(均P>0.05)。不良反应方面,利培酮组锥体外系反应比例高于阿立哌唑组,阿立哌唑组镇静作用弱。结论替换奋乃静后,利培酮与阿立哌唑治疗精神分裂症疗效均好,利培酮组锥体外系反应发生较多,阿立哌唑组镇静作用弱。%Objective To evaluate the ef icacy and adverse reaction of Aripirazole or risperidone in the original treatment of perphenazine. Methods 257 patients with original treatment of perphenazine assigned to Aripirazole group (n=131) or risperidone group(n=126), a 12 months fol ow up was used to evaluate the ef icacy and adverse ef ect. Results The response rates at the end of 12 months of Risperidone group and Aripirazole group were 62.5% and 69.8% respectively (P>0.05). There were no dif erence for the response rates between two groups at any other fol ow-up times.There were no dif erence between Risperidone and Aripirazole groups for the relapse rate (14.5%,12.5%,respectively),the time from response to relapse(9.5±3.8 months,9.7±3.8 months,respectively)and the time to treatment discontinuation for any reason(4.0± 2.9 months,5.1 ±2.8 months,respectively)at the end of 12 month.Aripirazole was associated with lower sedative ef ect and risperidone with more EPS (extrapyramidal syndrome). Conclusion Both

  19. Comparison of clinical effects of quetiapine and risperidone in the treatment of senile schizophrenia%喹硫平与利培酮治疗老年精神分裂症的临床效果对比

    Institute of Scientific and Technical Information of China (English)

    刘春容

    2015-01-01

    目的:比较喹硫平与利培酮治疗老年精神分裂症的临床效果。方法:回顾性分析170例老年精神分裂症患者的临床资料,根据治疗方法不同将其分为喹硫平组与利培酮组,其中喹硫平组74人,利培酮组96人,比较两组治疗前后的PANSS评分及不良反应情况。结果:喹硫平组与利培酮组治疗后2周、4周、6周、8周其各项指标较治疗前均有显著改善,差异具统计学意义(P0.05);喹硫平组锥体外系反应、恶主呕吐、停经泌乳等不良反应发生率显著低于利培酮组,而嗜睡发生率显著高于利培酮组,差异具统计学意义(P0.05)。结论:喹硫平与利培酮对老年精神分裂症均有确切疗效,且安全性较高;喹硫平对症状的改善相对更好。%Objective: To compare the clinical effects of quetiapine and risperidone in the treatment of senile schizophrenia. Methods:retrospective analysis of the clinical data of 170 cases of elderly patients with schizophrenia, according to the different treatment methods were divided into quetiapine group and risperidone group, wherein the quetiapine group of 74 people, 96 people of risperidone group, PANSS scores and adverse reactions were compared between two groups before and after treatment. Results:the quetiapine group and risperidone group after treatment for 2 weeks, 4 weeks, 6 weeks, 8 weeks, the indicators were significantly improved than before treatment, the difference was statistically significant ( P0.05) ;quetiapine flat group extrapyramidal adverse reactions, the evil Lord vomiting, stopping lactation was significantly lower than the risperidone group, and the incidence of somnolence was significantly higher than the risperidone group, the difference was statistically signif-icant (P0.05) . Conclusion: quetiapine and risperidone in schizophrenia have exact curative ef-fect on senile spirit, and high safety;the improvement of symptom of quetiapine is relatively

  20. 注射用利培酮微球治疗精神分裂症的疗效和安全性%The Efficacy and Safety of Injectable Risperidone Microspheres for Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨建华

    2015-01-01

    目的:探讨注射利培酮微球治疗精神分裂症的疗效和安全性。方法将50例精神分裂症病患随机分组,给予病患注射用利培酮微球,在整个治疗过程中3、6、9、12、15周时,对照组采取口服利培酮片剂,以PANSS总分增减和不良反应数量为评定疗效的标准。结果实验组和对照组病患前后治疗PANSS总分的分值无差别变化无统计学意义,实验组与对照组在12周治疗的重点与基线相比PANSS总分有明显降低具有统计学意义(P<0.05)。35例精神分裂症病患在治疗前后血常规、血生化正常变化。实验组中大多数病患在接受25 mg/2周利培酮微球用药后病情得到控制或改善,无明显的不良反应。结论对精神分裂病患以利培酮微球注射治疗3周末即起效,治疗效果与口服利培酮片的相当。注射利培酮微球具有疗效稳定、高安全性的特点。%Objective To efficacy and safety study risperidone microsphere injection in the treatment of schizophrenia.Methods 50 cases of schizophrenic patients randomized,give patient risperidone long-acting injection,in the whole course of treatment,3,6,9,12,15 weeks,the control group took oral risperidone tablets to increase or decrease the number of total PANSS score,and adverse reaction for curative effect standard.ResultsThe experimental group and the control group before and after treatment of PANSS disease score score did not change no significant difference,the experimental group and the control group in the 12 week of treatment compared with baseline PANSS scores of key significantly decreased with statistical significance(P<0.05). 35 cases of schizophrenic patients before and after treatment of blood routine,blood biochemical changes in the normal. The majority of patients in the experimental group in an 25 mg/2 weeks risperidone microsphere obtained control or improve the disease after treatment,no significant adverse reactions

  1. 喹硫平与利培酮治疗精神分裂症的疗效与安全性研究%Study on efficacy and safety of Quetiapine and Risperidone in treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    吴雪娥

    2015-01-01

    Objective To observe efficacy and safety of quetiapine and risperidone to patients with schizophrenia.Methods Participants included 80 patients with schizophrenia ,accepted quetiapine(496 ±65) mg/d and risperidone ( 3.1 ±0.3 ) mg/d respectively for eight weeks, and curative effect and safety were observed.Results The total efficiency rate of quetiapine group and risperidone group was 72.5% and 75%respectively, the effects of quetiapine and risperidone in schizophrenic patients had no significantly difference( p>0.05).The incidence of postural hypotension in quetiapine group was higher than that in risperidone group, but the incidence of extrapyramidal side effects and weight gain in quetiapine group was lower than that in risperidone group, there was significantly difference (P<0.05).Conclusions Quetiapine and risperidone have similar efficiency in the treatment of schizophrenic patients, and are safe and generally well-tolerated.%目的:研究喹硫平与利培酮治疗精神分裂症的疗效及安全性。方法按随机数字表法将2013年在本院精神病科住院的精神分裂症患者随机分为喹硫平组和利培酮组,每组各40例。喹硫平组给予喹硫平(496±65) mg/d治疗,利培酮组给予利培酮(3.1±0.3) mg/d治疗。疗程8周,从PANSS减分率评价其疗效,同时以不良反应症状量表(TESS)评定副反应。结果喹硫平组总有效率为72.5%,利培酮组总有效率为75.0%,两组疗效差异无统计学意义( P>0.05)。喹硫平组体位性低血压发生率明显高于利培酮组,利培酮组体重增加及锥体外系反应发生率显著高于喹硫平组,组间比较差异有统计学意义( P<0.05)。结论喹硫平与利培酮治疗精神分裂症疗效相当,安全性良好。

  2. 利培酮口服液治疗首发精神分裂症急性期对照观察%A control study of risperidone oral solution in treating first-episode schizophrenia patients in acute phase

    Institute of Scientific and Technical Information of China (English)

    黄卓玮; 龚传鹏

    2011-01-01

    目的:探讨利培酮13服液治疗首发精神分裂症急性期的疗效和安全性.方法:96例精神分裂症的急性期患者随机分为两组,分别给予利培酮口服液(研究组,n=49)和氯氮平(对照组,n=47)单药治疗4周.采用阳性和阴性症状量表(PANSS)评定临床疗效,临床总体印象量表(CGI-SI)评定病情严重程度,治疗中出现的症状量表(TESS)评定不良反应,自编依从性量表评定依从性.结果:治疗后两组患者PANSS及CGI-SI评分显著下降(P0.05).治疗后第4天,研究组兴奋、敌对、不合作、冲动控制缺乏因子分下降较对照组显著(P<0.05);研究组不良反应发生率明显低于对照组(P<0.05);研究组治疗依从性在治疗14 d、28 d、3个月和6个月时均优于对照组(P<0.05).结论:利培酮口服液对首发精神分裂症急性期患者的疗效和氯氮平相当,但利培酮口服液改善兴奋、敌对性等因子分较迅速,耐受性和依从性较好.%Objective: To evaluate the efficacy and safety of risperidone oral solution in the treatment of patients on the acute phase with first-episode schizophrenia. Method:96 schizophrenia patients were randomly assigned to the group treated with risperidone oral solution group ( n = 49 ) and the other group treated with clozapine (n =47 ),respectively for 4 weeks. The positive and negative syndrome scale (PANSS) and clinical global impressions-severity of illness rating scale(CGI-SI) were used to rate the efficacy;the treatment emergent symptom scale (TESS) was used to measure side effects and the compliance scale was used to assess the subjects'compliance with the treatment. Results:Both risperidone and clozapine group significantly showed score decrease on PANSS and CGI-SI after 4 weeks (P <0.01 ), but no significant difference was found between two groups ( P > 0.05 ). Excitement, hostility, uncooperativeness and poor impulse control of PANSS significantly decreased more in risperidone oral solution group

  3. Meta-analysis of efficacy and safety of citalopram and fluoxetine for depression in Chinese patients%西酞普兰与氟西汀治疗中国抑郁症患者疗效和安全性的meta分析

    Institute of Scientific and Technical Information of China (English)

    彭珍珍; 祝漫琴; 李焕德; 成日华; 刘艺平

    2012-01-01

    目的 比较西酞普兰与氟西汀在中国抑郁症患者中的疗效和安全性.方法 计算机检索CBM、CNKI、万方数据库,采用RevMan 5.0软件进行meta分析.结果 西酞普兰与氟西汀抗抑郁治疗6周后,以汉密尔顿抑郁量表(HAMD)评定疗效,总有效率的meta分析结果表明,有效率比值比OR值为1.29,其95%的可信区间为0.98~1.69,两者不存在显著性差异.疗程为1、2周时,西酞普兰治疗组的HAMD评分比氟西汀治疗组低,具有统计学差异,即西酞普兰起效速度优于氟西汀;疗程为4、6周时,西酞普兰治疗组的HAMD评分与氟西汀治疗组差异无统计学意义,即两者疗效无统计学差异性.以西酞普兰与氟西汀抗抑郁治疗失败的相对危险度RR比较其不良反应的危险度,结果显示便秘、失眠这2个不良反应的合并RR值分别为0.4 (95%CI 0.24,0.64)和0.54 (95%CI0.34,0.86),表明西酞普兰便秘和失眠不良反应的发生率均低于氟西汀,具有统计学差异.结论 西酞普兰与氟西汀长期治疗效果相当,但西酞普兰起效快于氟西汀,且西酞普兰便秘和失眠不良反应的发生率均低于氟西汀.%Objective To compare the efficacy and safety of citalopram and fluoxetine in Chinese patients with depression. Methods CBM, CNKI, and Wanfang database were searched. Meta-analysis was performed with RevMan 5. 0. Results There was no significant difference in the efficacy between citalopram and fluoxetine by Hamilton Depression Scale (HAMD) with OR= 1. 29 and 95%CI 0. 98 to 1. 69 after 6 weeks. Citalopram caused greater reduction in HAMD score than fluoxetine after 1 and 2 weeks, suggesting the onset of citalopram was faster than that of fluoxetine. There were no significant differences in the decrease of HAMD scores between citalopram and fluoxetine after 4 and 6 weeks. Incidence of astriction [RR=0. 4, 95%CI 0. 24, 0. 64], insomnia [RR=0. 54, 95%CI 0. 34, 0. 86] induced by the citalopram group was

  4. Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone Tranquilização rápida para pacientes agitados nos serviços de emergência psiquiátrica: um ensaio clínico randomisado de olanzapina, ziprasidona, haloperidol mais prometazina, haloperidol mais midazolam e haloperidol em monoterapia

    Directory of Open Access Journals (Sweden)

    Leonardo Baldaçara

    2011-03-01

    Full Text Available OBJECTIVE: To compare the effectiveness of intramuscular olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone as the first medication(s used to treat patients with agitation and aggressive behavior. METHOD: One hundred fifty patients with agitation caused by psychotic or bipolar disorder were randomly assigned under double-blind conditions to receive olanzapine, ziprasidone, haloperidol plus midazolam, haloperidol plus promethazine or haloperidol alone. The Overt Agitation Severity Scale, Overt Aggression Scale and Ramsay Sedation Scale were applied within 12 hours after the first dosage. RESULTS: All medications produced a calming effect within one hour of administration, but only olanzapine and haloperidol reduced agitation by less than 10 points, and only olanzapine reduced aggression by less than four points in the first hour. After twelve hours, only patients treated with haloperidol plus midazolam had high levels of agitation and aggression and also more side effects. Ziprasidone, olanzapine and haloperidol alone had more stable results for agitation control, while ziprasidone, haloperidol plus promethazine and olanzapine had stable results for aggression control. CONCLUSION: Olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol were effective in controlling agitation and aggression caused by mental illness over 12 hours. Although all the drugs had advantages and disadvantages, haloperidol plus midazolam was associated with the worst results in all the observed parameters.OBJETIVO: Comparar a eficácia da olanzapina, ziprasidona, haloperidol associado ao midazolam, haloperidol associado à prometazina e haloperidol isoladamente por via intramuscular como primeira escolha no tratamento de pacientes em agitação e agressividade. MÉTODO: Cento e cinquenta pacientes com agitação psicomotora por transtorno psicótico ou transtorno bipolar foram

  5. 西酞普兰合并氯氮平治疗有自杀风险的精神分裂症患者的疗效及安全性%The efficacy and safety of combined citalopram and clozapine in the treatment of schizophrenia patient with suicidal risk

    Institute of Scientific and Technical Information of China (English)

    罗娴; 邱育平; 张业祥

    2012-01-01

      To research the efficacy and safety of combined citalopram and clozapine in the treatment of schizophrenia with suicidal risk,A study was contucted in which 46 patients with schizophrenia were randomised divided to study group and control group.The result shows that the efficacy of treatment of Combined Citalopram and Clozapine is better than treatment of Clozapine. the risk of suicide also cecreace by Combined Citalopram and Clozapine.and the safety is equivalent.%  [要] 本文通过46例有自杀风险的精神分裂症患者随机分为研究组(23例)和对照组(23例)探讨西酞普兰合并氯氮平治疗有自杀风险的精神分裂症患者的疗效及安全性。验证了西酞普兰合并氯氮平治疗有自杀风险的精神分裂症患者的疗效好于单用氯氮平,自杀风险降低,安全性相仿。

  6. Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone.

    Science.gov (United States)

    Kao, Yu-Han; Chern, Yijuang; Yang, Hui-Ting; Chen, Hui-Mei; Lin, Chun-Jung

    2016-08-01

    Huntington's disease (HD) is a neurodegenerative disease marked by an expanded polyglutamine (polyQ) tract on the huntingtin (HTT) protein that may cause transcriptional dysfunction. This study aimed to investigate the regulation and function of P-glycoprotein, an important efflux transporter, in brain capillaries in HD. The results showed that, compared with the littermate controls, R6/2 HD transgenic mice with the human mutant HTT gene had higher levels of P-glycoprotein mRNA and protein and enhanced NF-κB activity in their brain capillaries. Higher P-glycoprotein expression was also observed in the brain capillaries of human HD patients. Consistent with this enhanced P-glycoprotein expression, brain extracellular levels and brain-to-plasma ratios of the antipsychotic agents risperidone and paliperidone were significantly lower in R6/2 mice than in their littermate controls. Exogenous expression of human mutant HTT protein with expanded polyQ (mHTT-109Q) in HEK293T cells enhanced the levels of P-glycoprotein transcripts and NF-κB activity compared with cells expressing normal HTT-25Q. Treatment with the IKK inhibitor, BMS-345541, decreased P-glycoprotein mRNA level in cells transfected with mHTT-109Q or normal HTT-25Q In conclusion, mutant HTT altered the expression of P-glycoprotein through the NF-κB pathway in brain capillaries in HD and markedly affected the availability of P-glycoprotein substrates in the brain.

  7. Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers

    Institute of Scientific and Technical Information of China (English)

    Ming-zhu HUANG; Jian-zhong SHENTU; Junc-hun CHEN; Jian LIU; Hui-li ZHOU

    2008-01-01

    This study presents a rapid, specific and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay for determination of risperidone (RIS) in human serum using paroxetine as an internal standard (IS). An Alltima-C 18separation. The analysis was performed by selected reaction monitoring (SRM) method, and the peak area of the m/z 411.3→ 191.1 transition for RIS was measured versus that of the m/z 330.1→192.1 transition for IS to generate the standard curves. The assay linearity of RIS was confirmed over the range 0.25~50.00 ng/ml and the limit of quantitation was 0.05 ng/ml. The linear range corresponds well with the serum concentrations of the analytes obtained in clinical pharmacokinetic studies. Intraday and interday relative standard deviations were 1.85%~9.09% and 1.56%~4.38%, respectively. The recovery of RIS from serum was in the range of 70.20%~84.50%. The method was successfully applied to investigate the bioequivalence between two kinds of tablets (test versus reference products) in 18 healthy male Chinese volunteers. The result suggests that two formulations are bioequivalent.

  8. Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study.

    Science.gov (United States)

    Siva Selva Kumar, M; Ramanathan, M

    2016-02-01

    A simple and sensitive ultra-performance liquid chromatography (UPLC) method has been developed and validated for simultaneous estimation of olanzapine (OLZ), risperidone (RIS) and 9-hydroxyrisperidone (9-OHRIS) in human plasma in vitro. The sample preparation was performed by simple liquid-liquid extraction technique. The analytes were chromatographed on a Waters Acquity H class UPLC system using isocratic mobile phase conditions at a flow rate of 0.3 mL/min and Acquity UPLC BEH shield RP18 column maintained at 40°C. Quantification was performed on a photodiode array detector set at 277 nm and clozapine was used as internal standard (IS). OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min. The method was validated for selectivity, specificity, recovery, linearity, accuracy, precision and sample stability. The calibration curve was linear over the concentration range 1-100 ng/mL for OLZ, RIS and 9-OHRIS. Intra- and inter-day precisions for OLZ, RIS and 9-OHRIS were found to be good with the coefficient of variation <6.96%, and the accuracy ranging from 97.55 to 105.41%, in human plasma. The validated UPLC method was successfully applied to the pharmacokinetic study of RIS and 9-OHRIS in human plasma.

  9. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

    Science.gov (United States)

    Apiquian, Rogelio; Córdoba, Rodrigo; Louzã, Mario

    2011-01-01

    Background Risperidone long-acting injection (RLAI) has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America. Methods Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S), Personal and Social Performance (PSP), and Global Assessment of Functioning (GAF) scores. Relapse and treatment were also registered. Results Patients were recruited in Mexico (n = 53), Brazil (n = 11), and Colombia (n = 15). Sixty-five percent (n = 52) were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73) or schizoaffective disorder (n = 6). The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg). The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P < 0.001). Significant changes were registered on CGI-S, GAF, and PSP scores. Conclusions RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization. PMID:21326651

  10. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.

    Science.gov (United States)

    Bobo, William Victor; Bonaccorso, Stefania; Jayathilake, Karuna; Meltzer, Herbert Yale

    2011-09-30

    Baseline body mass index (BMI), baseline BMI status (normal, overweight, obese) and early (1 month) BMI increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (OLZ)- and 78 risperidone (RIS)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study. Baseline BMI predicted greater fasting glucose and HgbA1c levels at 12 months for both treatments. Early BMI change predicted fasting glucose levels at 6 months, but not HgbA1c or BMI, at either time point. For patients who received no concomitant mood stabilizers, early BMI change predicted 12 month HgbA1c values in the OLZ group, and 6- (but not 12-) month fasting glucose and HgbA1c values in the RIS group. Neither baseline BMI nor early BMI change consistently predicted increases in lipids with either drug. OLZ-treated patients with normal baseline BMI had greater increases in total cholesterol, triglycerides, and non-HDL-cholesterol than those who were overweight or obese. In conclusion, higher baseline BMI predicted adverse glycemic changes after 12 months with OLZ and RIS. Individuals with normal baseline BMI may be most susceptible to OLZ-induced hyperlipidosis. Frequency of metabolic screening should be independent of baseline BMI or rapid increases in BMI.

  11. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism.

    Science.gov (United States)

    Ghaleiha, Ali; Rasa, Soudeh Mohebbi; Nikoo, Mohammadali; Farokhnia, Mehdi; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin

    2015-09-30

    To assess the safety and efficacy of pioglitazone added to risperidone in the treatment of irritability in autistic disorder (AD), we conducted this study. In a 10-week, randomized, double-blind, parallel-group, placebo-controlled clinical trial, 44 outpatients of both genders aged 4-12 years with a diagnosis of AD and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale were included. Mean change of ABC-C irritability subscale score as primary outcome, change in other ABC-C subscale scores and partial and complete responses were compared between two groups. Twenty patients completed the trial in each group. Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group. Vomiting and headache were the most frequent reported side-effects. Results of this preliminary study indicate positive effects of pioglitazone compared with placebo in improving the behavioral symptoms of AD.

  12. 齐拉西酮与利培酮治疗女性精神分裂症的对照研究%A comparative study of Ziprasidone and Risperidone in the treatment of female patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张桂华; 赵祖安; 李淑香; 丁琳; 白玉红

    2011-01-01

    目的:比较齐拉西酮与利培酮治疗女性精神分裂症的疗效及安全性.方法:将72例女性精神分裂症患者随机分为齐拉两酮组[(131.6±10.3)mg/d]36例,利培酮组[(5.9±1.3)mg/d]36例,疗程均为12周,采用阳性及阴性症状量表(PANSS),治疗中需处理的不良反应症状量表(TESS),在治疗前及治疗第2、4、8、12周末分别评定疗效和不良反应.结果:治疗第2周末开始,两组PANSS评分较入组时均显著降低,差异有统计学意义(P0.05).不良反应的发生率齐拉西酮组为47.2%(17/36)、利培酮组为52.8%(19/36),两组比较,差异无统计学意义(P>0.05).但齐拉西酮组锥体外系反应、体重增加、血脂增高、高泌乳素的发生率明显低于利培酮组,差异有统计学意义(P<0.05).结论:齐拉西酮治疗女性精神分裂症疗效好,不良反应轻微.%Objective: To compare the efficacy and safety of Ziprasidone and Risperidone in the treatment of female patients with schizophrenia.Methods: A total of 72 female patients were randomly assigned to Ziprasidone group (n=36) and Risperidone group (n=36), and received Ziprasidone (131.6±10.3) mg/d and Risperidone (5.9±1.3) mg/d treatment for 12 weeks respectively.The efficacy and adverse reaction were assessed with the Positive and Negative Syndrome Sale (PANSS), the Treatment Emergency Syndrome Scale (TESS) after the tveatment of 2,4, 8, 12 week.Results: The PANSS scores significantly decreased compared with the baseline sores in both groups since the second week (P<0.05); the marked improvement rate was 50.0% and the total clinical effective rate was 77.8% in Ziprasidone group while 47.3% and 75.0% in Risperidone group, there were not significant differences between two groups (P>0.05).There were similar rates of side effects between both groups (P>0.05), Ziprasidone group was 47.2% (17/36) and Risperidone group was 52.8% (19/36) (P>0.05).But the incidence of extrapyramidal symptoms, weight

  13. 利培酮联合舍曲林治疗精神分裂症阴性症状临床研究%Combination of Risperidone and Sertraline in Negative Symptoms of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    江永

    2013-01-01

    Objective:To explore the efficacies and safety of combination of risperidone and sertraline in negative symptoms of schizo -phrenia.Methods:60 schizophrenics were randomly divided into treatment (n=30,took risperidone combined with sertraline ) and control group (n=30,took risperidone ) dose of risperidone was 2~6mg/d and that of sertraline 100~200mg/d for 8 weeks.Before and after treatment , efficacies and side effects were assessed using the Negative Syndrome Scale ( NSS) and the Treatment Emergent Symptom Scale ( TESS) .Results:After treatment total score and factors , score of the NSS of both 2 groups obviously reduced and differences were signifi-cant (P<0.05).compared with the control group the total score of the NSS and factors',score of apathy poverty of thought abulia and in-terest blank obviously reduced in the treatment group and differences were significant (P<0.05).there was no difference in side effects between the 2 groups.Conclusion:combination of risperidone and sertraline is better than single risperidone in the treatment of negative symptoms of schizophrenia .%目的:探讨利培酮联合舍曲林治疗精神分裂症阴性症状的临床疗效和安全性。方法:将60例精神分裂症患者随机分为治疗组(利培酮+舍曲林)和对照组(利培酮)各30例,利培酮治疗剂量2~6mg/d,舍曲林50mg~200mg/d,疗程8周,治疗后采用阴性症状量表和副反应量表[1]评定临床疗效与不良反应。结果:2组治疗后阴性症状量表总分和因子分均显著下降,差异有统计学意义(P<0.05),治疗组阴性症状量表总分、情感平淡、思维贫乏、意志缺乏、兴趣缺乏等因子分较对照组下降明显,差异有统计学意义(P<0.05)。不良反应2组无显著性差异(P>0.05)。结论:利培酮联合舍曲林治疗精神分裂症阴性症状疗效优于单用利培酮治疗。

  14. 利培酮与氯氮平对精神分裂症患者糖脂代谢的影响%Influences of risperidone and clozapine on glucolipid metabo-lism of patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    周海平; 钟远惠; 李桂云; 付美华

    2016-01-01

    Objective To explore the influences of risperidone and clozapine on glucolipid metabolism of patients with schizophrenia.Methods A total of 120 schizophrenia patients were assigned to two groups according to random number table and treated with risperidone or clozapine for 6 weeks.Blood sugar and fat changes were detected before and after treatment.Results After treatment all indexes of only blood sugar in risperidone group increased more significantly compared with pretreatment (P < 0.01 ),so did those of both blood sugar and fat in clozapine group and were significantly higher than those in risperidone group (P <0.01).After treatment the heightening rate of fasting plasma glucose abnormality was 1.7%in risperidone group and 41.7% in clozapine group,the former significantly lower than the latter (P <0. 01).increased abnormality,no diabetes standard has been found.,the difference of two groups of blood. Conclusion Both risperidone and clozapine have influences of different degrees,especially clozpaine,chan-ges of all metabolic indexes should be closely observed when patients are treated with clozapine.%目的:探讨利培酮与氯氮平对精神分裂症患者糖脂代谢的影响。方法将120例精神分裂症患者按照随机数字表法分为两组,分别口服利培酮、氯氮平治疗,观察6周。于治疗前后检测两组患者血糖、血脂水平的变化。结果治疗后利培酮组仅血糖各项指标较治疗前显著升高(P <0.01),而氯氮平组血糖、血脂各项指标均较治疗前显著升高,且显著高于利培酮组(P <0.01)。利培酮组治疗后空糖血糖异常增高率为1.7%,氯氮平组为41.7%,利培酮组显著低于氯氮平组(P <0.01)。结论利培酮与氯氮平对精神分裂症患者的糖脂代谢均有不同程度的影响,氯氮平的影响更明显,临床上选用氯氮平治疗时应密切监测各项代谢指标的变化。

  15. 哌罗匹隆与利培酮治疗首发精神分裂症对照研究%A control study of perospi rone vs .risperidone in the treatment of first-episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨冬冰; 马元业; 王军

    2014-01-01

    目的:探讨哌罗匹隆与利培酮治疗首发精神分裂症患者的临床疗效和安全性。方法将70例首发精神分裂症患者随机分为两组,分别口服哌罗匹隆和利培酮治疗,观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末,哌罗匹隆组总有效率87.9%,利培酮组为85.3%,两组比较差异无显著性(χ2=0.10,P>0.05)。哌罗匹隆组不良反应发生率为60.0%,利培酮组为62.9%,两组比较差异无显著性(χ2=0.06,P>0.05),但哌罗匹隆组内分泌改变及体质量增加发生率显著低于利培酮组(χ2=5.08、5.08,P<0.05)。结论哌罗匹隆与利培酮治疗首发精神分裂症疗效显著,安全性高,依从性好,但哌罗匹隆较少引起内分泌改变和体质量增加,尤其适用于女性首发精神分裂症患者。%Objective To explore the efficacy and safety of perospirone and risperidone in first-episode schizophrenia (FES) .Methods Seventy FES patients were randomly divided into two groups ,they took orally perospirone and risperidone respectively for 8 weeks .Clinical efficacies were assessed with the Posi-tive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week total effective rate was respectively 87 .9% in perospi-rone and 85 .3% in risperidone group ,which showed no significant difference (χ2 =0 .10 ,P>0 .05) .Inci-dences of adverse reactions were 60 .0% in perospirone and 62 .9% in risperidone group ,which showed no significant difference (χ2 =0 .06 ,P>0 .05) ,but those of endocrine alteration and weight gain were signifi-cantly lower in perospirone than risperidone group (χ2 =5 .08 ,5 .08 ;P<0 .05) .Conclusion Perospirone has an evident effect equivalent to risperidone ,higher safety and better compliance in FES ,but the former causes

  16. 利培酮与舒必利对精神分裂症患者血脂代谢的影响%The side-effects of Risperidone and Sulpiride on the lipid metabolism in the schizophrenic patients

    Institute of Scientific and Technical Information of China (English)

    黄建萍; 崔东红; 张晨; 王祖承; 粟幼嵩

    2011-01-01

    目的:探讨利培酮和舒必利对首发精神分裂症患者血脂代谢的影响.方法:对2008年1月~2010年1月我院住院的精神分裂症患者547例测定利培酮和舒必利治疗8周前后的血胆固醇(TC)及三酰甘油(TG)浓度.结果:①利培酮治疗后,血胆固醇及血三酰甘油明显升高(t=2.94,P=0.003;t=2.56,P=0.011),且男性患者组升高较女性明显(t=2.47,P=0.015;t=2.29,P=0.023);②舒必利组治疗后血胆固醇及血三酰甘油明显升高(t=2.35,P=0.019;t=2.16,P=0.032),且女性TG升高的程度显著大于男性患者(t=3.11,P=0.002).③利培酮对于血胆固醇及三酰甘油的影响大于舒必利(t=3.24,P=0.001;t=2.27,P=0.021).结论:利培酮使血胆固醇及三酰甘油水平升高,对男性影响大.舒必利使血胆固醇及三酰甘油水平升高,对女性影响大.利培酮对TC的影响大于舒必利.%Objective: To explore the side-effects of Risperidone and Sulpiride on the lipid metabolism in schizophrenic patients.Methods: 547 schizophrenic inpatients were recruited from January 2008 to January 2010.The concentrations of TC and TG after 8 week Risperidone or Sulpiride treatment were detected.Results: ①After Risperidone treatment, TC and TG concenations were significantly increased (t=2.94, P=0.003; t=2.56, P=0.011).Moreover, male patients had the more severe side-effects on the lipid metabolism than female (t=2.47, P=0.015; t=229, P=0.023).②After Sulpiride treatment,TC and TG concentrations were significantly increased (t=2.35, P=0.019; t=2.16, P=0.032).Moreover, TG concentrations of female patients increased more highly than those of male (t=3.11, P=0.002).③Risperidone had the more effects on TC and TG than Sulpiride (t=3.24, P=0.001; t=2.27, P=0.021).Conclusion: Risperidone could raise the TC and TG concentrations,and more greatly in male patients.Sulpiride raises the TC and TG concentrations, and more greatly in female patients.Risperidone has the more effects on TC and TG than Sulpiride.

  17. Longitudinal Observation on Brain Structure in Patients with Dependence on Sublingual Buprenorphine, Scopolamine and Promethazine in Different Stages of Abstinence%丁丙诺啡舌下片合并东莨菪碱、异丙嗪药物依赖者脑灰质密度的研究

    Institute of Scientific and Technical Information of China (English)

    周旭辉; 王绪轶; 刘军; 郝伟

    2011-01-01

    目的:观察盐酸丁丙诺啡舌下片(sublingual buprenorphine)合并东莨菪碱(scopolamine)、异丙嗪(promethazine)药物依赖者(简称BSP依赖者)脑灰质密度的变化,并比较其与海洛因依赖者脑结构损害的异同.方法:采用基于像素的形态学测量(voxel-based morphometry,VBM)方法对16例BSP依赖者、20例海洛因依赖者停药第3天、第2个月的脑灰质密度进行了组间以及组内自身前后对比研究,并设立18例正常对照者.结果:与正常对照组相比,BSP滥用可导致成瘾者大脑广泛性脑结构损害,表现为灰质密度下降,涉及额叶、顶叶、颞叶、枕叶、岛叶、纹状体等脑区;与海洛因依赖组相比,停药3天BSP依赖组脑区灰质受损程度重于海洛因依赖组,且随着停药时间的延长,BSP依赖者灰质恢复进程慢于海洛因依赖者.结论:BSP滥用可造成依赖者广泛性、严重的脑皮质结构异常,主要集中在额叶等与成瘾关系密切的脑区.BSP滥用较海洛因更易损伤大脑皮质神经元,且大脑灰质恢复进程慢于海洛因依赖组,这提示BSP滥用对大脑皮质神经元的损害在短时间难以恢复.%Objective: Recently, an intravenous abuse of buprenorphine tablets, scopolamine and promethazine solution (BSP) has been emerging among heroin-dependent individuals in some areas of Southern China. The aim of this study was to explore the brain structural pathological changes in the patients with BSP dependence, by three dimensional MRI(3D)and compare their impairment of the brain with that of the heroin addicts. Methods: BSP-dependent patients(n=16), heroin-dependent individuals (n=20) and age/eduction-matched healthy control subjects (n=18) were assessed by 3D during resting state. Patients with BSP and heroin dependence were examined by MRI scanning after 3 days and 2 months of abstinence, while control subjects were tested only once. Results: Compared with health controls, GMD was significantly lower in

  18. 氨磺必利与利培酮治疗首发精神分裂症的疗效对照研究%Amisulpride and Risperidone Treatment First-episode Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李婕

    2014-01-01

    Objective To analysis efficacy of amisulpride and risperidone treatment first -episode schizophrenia.Methods 74 patients with first -episode schizo-phrenia were given Amisulpride and risperidone therapy,BPRS score,adverse reaction were compared.Result BPRS rating scale values were significantly reduced,be-tween groups was no significant difference;observation group adverse reactions(18.92%) was obviously lower than the control group.Conclusion Amisulpride and risper-idone can be effective in the treatment of first-episode schizophrenia,Amisulpride low adverse reaction,good safety.%目的:分析氨磺必利与利培酮治疗首发精神分裂症的疗效差异。方法选择74例首发精神分裂症患者为研究对象,分别给予氨磺必利及利培酮治疗,比较BPRS量表评分、不良反应发生率。结果观察组与对照组BPRS量表评分值均明显降低,组间比较无明显差异(P>0.05);观察组不良反应发生率(18.92%)明显低于对照组(P<0.05)。结论氨磺必利与利培酮均可有效治疗首发精神分裂症,氨磺必利不良反应较少,具有优良的治疗安全性。

  19. 齐拉西酮与利培酮治疗女性精神分裂症的研究%The study of Ziprasidone and Risperidone in the Treatment of Women Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    潘国良

    2013-01-01

    目的比较齐拉西酮与利培酮治疗女性精神分裂症的疗效及副反应.方法100例符合ICD-10诊断标准的女性精神分裂症患者随机分为两组各50例,分别给与齐拉西酮和利培酮治疗8周,采用阳性症状与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应.结果治疗8周后,齐拉西酮组的显效率为82%,有效率为94%;利培酮组的显效率为80%,有效率为92%.两组疗效无显著性差异(P>0.05).齐拉西酮组的阴性症状减分率更高,齐拉西酮组的不良反应发生率为18%,利培酮组为28%,有显著性差异(P0.05). The reduction rate of negative syndrome was higher in ziprasidone group. The incidence rate of adverse effect was 18% in ziprasidone group and that was 28% in risperidone group, and there had a significant difference between them(P<0.05).The level of PRL in ziprasidone was lower than that of risperidone. Conclusion Ziprasidone is as effective as risperidone for the treatment of women schizophrenia, but ziprasidone can’t affect the level of PRL and it was more fit for women patients.

  20. Efficacy observation of Aripiprazole and Risperidone in treatment of schizophrenia%阿立哌唑和利培酮治疗精神分裂症的疗效观察

    Institute of Scientific and Technical Information of China (English)

    曲秀颖

    2015-01-01

    目的::探讨阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法:选取76例符合CCMD-3精神分裂症诊断标准的患者随机分为阿立哌唑组和利培酮组,每组38例。两组患者分别给予阿立哌唑和利培酮治疗,6周后进行临床疗效评价及不良反应评定。结果:阿立哌唑组患者总有效率为89.47%,利培酮组患者总有效率为86.84%,两组患者总体疗效相当(P>0.05)。两组患者治疗前后PANSS评分比较,差异有统计学意义(P0.05)。治疗6周,阿立哌唑组患者不良反应发生率低于利培酮组(P0. 05). There was a statistical difference in the PANSS score between the two group before and after the treatment (P0. 05). Six weeks after the treatment, the inci-dence rates of adverse reactions of Aripiprazole group were lower than those of Risperidone group (P<0. 05). Conclusions: In the treatment of schizophrenia, Aripiprazole has a similar efficacy with Risperidone, but is superior in influences on extrapyramidal reac-tions, endocrine and weight than Risperidone.

  1. Risperidone and Clozapine on Blood Glucose and Lipid Metabolism in Patients With Schizophrenia%利培酮和氯氮平对精神分裂症患者血糖和脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    刘召英

    2016-01-01

    目的:研究利培酮和氯氮平对精神分裂症患者血糖和脂代谢的影响。方法选择2014年1月~2015年1月来我院精神科治疗精神分裂症的患者62例,随机分成利培酮组和氯氮平组,各31例,观察两组患者治疗效果。结果治疗后,利培酮组 TC 水平为(4.81±0.15) mmol/L 低于氯氮平组 TC 水平(5.25±0.24)mmol/L,两组血糖及血脂指标相比,差异均有统计学意义(P <0.05)。结论采用利培酮和氯氮平治疗精神分裂症对患者的血糖和脂代谢水平均有影响,相对而言氯氮平影响较大,临床医生在治疗精神分裂症时应该慎重使用药物。%Objective To observe the efficacy of risperidone and clozapine on blood glucose and lipid metabolism in patients with schizophrenia. Methods Selected 62 patients with schizophrenia from January 2014 to January 2015 in our hospital were randomly divided into risperidone group and clozapine group,31 cases,the treatment groups were observed. Results After treatment,the levels of TC risperidone group(4.81±0.15)mmol/L group was significantly lower than clozapine TC levels(5.25±0.24)mmol/L,glucose and lipid levels compared to the two groups,the differences were statistical y significance(P< 0.05). Conclusion Use wil significantly affect the treatment of schizophrenia with risperidone and clozapine on blood glucose and lipid metabolism in patients with relatively greater impact in terms of clozapine,clinicians in the treatment of schizophrenia drugs should be used with caution.

  2. 利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状%Paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients

    Institute of Scientific and Technical Information of China (English)

    王永萍; 尤加永; 赵长银

    2012-01-01

    目的:探讨利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状的临床疗效以及安全性.方法:将126例以阴性症状为主的慢性精神分裂症住院患者随机分为研究组(利培酮联合帕罗西汀治疗)和对照组(单用利培酮治疗),疗程12周,采用阳性和阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和安全性. 结果:治疗后两组PANSS评分均较治疗前有显著降低(P<0.05).治疗后4、8、12周末,研究组阴性因子分及情感迟钝、情感退缩、情感交流障碍及社会退缩因子分均显著低于对照组,差异具有统计学意义(P<0.05或P<0.01).两组不良反应均为轻至中度. 结论:利培酮联合帕罗西汀较单用利培酮治疗慢性精神分裂症阴性症状具有起效更快、疗效更好、依从性好的特点.%Objective:To evaluate clinical efficacy and safety of paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients. Method; 126 patients with predominantly negative symptoms of chronic schizophrenia were randomly divided into study group (paroxetine combined risperidone) and the control group (risperidone alone) with 12 weeks'treatment. PANSS and TESS were used to assess the efficacy and safety respectively. Results: compared with before treatment, PANSS scores decreased significantly after treatment (P < 0.05). The scores on blunted affect,emotional withdrawal, poor rapport and passive/apathetic social withdrawal were lower in the study group than in the control group at week 4,8 and 12, the score difference was statistically significant (P < 0.05 or P < 0.01). The adverse events of two groups were mild or moderate. Conclusion; Paroxetine combined risperidone in the treatment of chronic schizophrenia with negative symptoms showed rapid response, better efficacy and good patient compliance.

  3. The Effects of Risperidone on Patients about Plasma Glucose,HOMA-IR,ISI,HBCI%药物利培酮对患者血糖、HOMA-IR、ISI、HBCI的影响研究

    Institute of Scientific and Technical Information of China (English)

    张振

    2013-01-01

      目的:探索药物利培酮对患者体重与糖代谢的影响.方法:收集78例患者使用利培酮治疗,疗程为12周,分别在未用药前和用药12周后测量体重和检测空腹血糖水平、HOMA-IR、ISI、HBCI,进行同体比较.结果:治疗12周后,患者平均体重增加2.61 kg,与治疗前比较,差异有统计学意义(P<0.05);同时在治疗12周后检测空腹血糖,与治疗前空腹血糖比较,平均升高0.84 mmol/L,差异有统计学意义(P<0.05).HOMA-IR 与 HBCI 治疗后均升高,差异有统计学意义(P<0.05).ISI 降低,差异有统计学意义(P<0.05).结论:利培酮治疗精神分裂症,对患者的体重和空腹血糖有一定程度的影响.%Objective:To study the effect of risperidone for patients on the weight and glycometabolism. Method:78 cases of patients treated with risperidone before and after 12 weeks,we compared the weight and the fasting blood glucose 、HOMA-IR、ISI、HBCI respectively.Result:There was significant difference in the mean weight of the patients treated with risperidone for 12 weeks,which increased by 2.41 kilometres(P<0.05).The average fasting blood glucose of the patients treated for 12 weeks significant increased by 0.84mmol/L(P<0.05). HOMA-IR and HBCI were significantly increased after treatment there was statistically significant(P<0.05).ISI reduced,there was statistically significant(P<0.05). Conclusion:There are some extent effect on the weight and the fasting blood glucose of the patients who were treated with risperidone.

  4. Efficacy and adverse reactions of Aripiprazole and Risperidone in treatment of patients with schizophrenia%阿立哌唑与利培酮治疗精神分裂症患者的疗效及不良反应

    Institute of Scientific and Technical Information of China (English)

    臧双九

    2015-01-01

    目的::观察阿立哌唑、利培酮治疗精神分裂症患者的疗效、不良反应及安全性。方法:将60例符合CCMD-3诊断标准的精神分裂症患者随机分为两组,分别给予患者阿立哌唑、利培酮治疗8周,于治疗前以及治疗2、4和8周采用阳性与阴性症状量表( PANSS)评定患者的疗效,不良反应量表( TESS)评定患者的不良反应。结果:两组患者治疗的疗效相当。利培酮组患者的锥体外系反应、内分泌以及体重增加多于阿立哌唑组。结论:阿立哌唑治疗精神分裂症患者的疗效与利培酮相似,但不良反应更少。%Objective: To observe efficacy, adverse reactions and safety of Aripiprazole and Risperidone in treatment of pa-tients with schizophrenia. Methods: 60 cases meeting CCMD3 diagnostic criteria for schizophrenia were randomly divided into 2 groups. They were treated with Aripiprazole and Risperidone for 8 weeks, respectively. Before and 2, 4 and 8 weeks after the treat-ment, PANSS (positive and negative symptom scale) and TESS (treatment emergent symptom scale) were used to evaluate the efficacy and adverse reactions. Results:The two groups had a similar efficacy;however, the extrapyramidal system reactions, endocrine, and weight gain in Risperidone group were more than those of Aripiprazole group. Conclusions:Aripiprazole in the treatment of the patients with schizophrenia has a similar efficacy with Risperidone, but has fewer adverse reactions.

  5. 利培酮抑制3T3-L1前脂肪细胞的分化%Risperidone inhibits 3T3-L1 pre-adipocytes differentiation

    Institute of Scientific and Technical Information of China (English)

    张高丽; 张弋; 于海川; 张新雅

    2016-01-01

    Objective To investigate the influence of risperidone on differentiation of 3T3‐L1 pre‐adipocytes .Methods 3T3‐L1 pre‐adipocytes were induced to differentiate into mature adipocytes by adopting the classic hormone cocktail method and observed by the oil red O staining .Meanwhile ,the inducing medium was added with risperidone for studying its influence on 3T3‐L1 pre‐adi‐pocytes differentiation .Results 3T3‐L1 pre‐adipocytes were successfully differentiated into the mature adipocytes ,0 .1 ,1 ,10μmol/L risperidone all could inhibit the differentiation of 3T3‐L1 pre‐adipocytes .Conclusion Risperidone can inhibit the differentiation of 3T3‐L1 pre‐adipocytes .%目的:研究利培酮对3T3‐L1前脂肪细胞分化的影响。方法采用经典的激素鸡尾酒法诱导3T3‐L1前脂肪细胞分化为成熟的脂肪细胞,油红O染色观察。向诱导培养基中加入利培酮研究其对3T3‐L1前脂肪细胞分化的影响。结果用激素鸡尾酒法成功地将3T3‐L1前脂肪细胞诱导为成熟的脂肪细胞。0.1、1、10μmol/L的利培酮均能够抑制3T3‐L1前脂肪细胞的分化。结论利培酮能够抑制3T3‐L1前脂肪细胞的分化。

  6. Observation of the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症的临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘卫平

    2015-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的疗效。方法:收治精神分裂症患者60例,随机分为对照组和观察组,对照组采用利培酮治疗,观察组采用阿立哌唑治疗,比较两组治疗效果。结果:对照组总有效率86.7%,观察组总有效率90.0%,P>0.05;对照组出现不良反应18例(60.0%),观察组出现不良反应6例(20.0%),P<0.05。结论:在精神分裂症的治疗中利培酮与阿立哌唑均具有显著的疗效,然而相对于利培酮而言,阿立哌唑具有较低的不良反应发生率,因此其具有较高的安全性。%Objective:To explore the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia.Methods:60 patients with schizophrenia were selected.They were randomly divided into the control group and the observation group.The control group was treated with risperidone,and the observation group was treated with aripiprazole.We compared the treatment effect of the two groups.Results:In the control group,the total efficiency was 86.7%;in the observation group,the total efficiency was 90%,P>0.05.In the control group,18 cases(60%) had adverse reactions;in the observation group,6 cases(20%) had adverse reactions,P<0.05.Conclusion:In the treatment of schizophrenia,risperidone and aripiprazole all had significant curative effect,but compared with risperidone,aripiprazole had low adverse reaction rate,so it had a high safety.

  7. The disability in patients with schizophrenia treated with chlorpromazine and risperidone%氯丙嗪与利培酮片对精神分裂症患者致残影响的对比研究

    Institute of Scientific and Technical Information of China (English)

    李和军; 杨杰

    2012-01-01

    目的 探讨氯丙嗪与利培酮片对精神分裂症患者致残的影响.方法 200例门诊或住院的精神分裂症患者完全随机分为对照组与研究组,各100例,采用残疾水平评定量表( WHODASⅡ)、社会功能缺陷筛选量表(SDSS)、生活质量评定量表(WHOQOL)分别于0.5、1、2年时对患者的残疾程度进行多维度评定并进行对比.结果 究组治疗后0.5、1、2年WHOQOL-BREF评分优于对照组,WHODAS评分[分别为(27±15)分比(38±13)分、(28±13)分比(39±15)分、(26±14)分比(36±18)分]、SDSS评分[分别为(11±2)分比(18±6)分、(8±2)分比(12±3)分、(8±2)分比(11±4)分]均优于对照组,差异均有统计学意义(均P<0.01).结论 利培酮片对改善精神分裂症患者社会功能,减轻残疾程度,降低致残率方面明显 优于氯丙嗪.%Objective To explore the disability in patients treated with schizophrenia with using respectively chlorpromazine and risperidone.Methods Two hundred outpatients or hospitalization patients with schizophrenia were randomly divided into chlorpromazine group( 100 cases) and risperidone group( 100 cases) ; the degree of disability by WHO disability assessment scale Ⅱ (WHO-DAS Ⅱ ),social disability screening schedule(SDSS),WHO quality of life(WHOQOL) at the time of half a year,one year and two years were ananlyzed.Results The scores of risperidone group in all scales were significantly higher in chlorpromazine group in each period ( P < 0.05 or P <0.001 ).The validity of consistency and correlation was high in all scales.Conclusion Risperidone is significantly better than chlorpromazine in terms of reducing the rate of disability,improving the social function and reducing the degree of disability.

  8. Different effects of taking aripiprazole and risperidone on spontaneous brain activity in schizophrenics%阿立哌唑和利培酮对精神分裂症患者自发脑活动的不同影响

    Institute of Scientific and Technical Information of China (English)

    常鑫; 罗程; 侯昌月; 陈琳; 陈曦; 贺辉; 段明君; 蒋宇超; 尧德中

    2015-01-01

    Objective To explore the difference in effects of taking two different kinds of drugs aripiprazole and risperidone on spontaneous brain activity among schizophrenics. Methods Nineteen patients(9 patients taking aripiprazole and 10 patients taking risperidone),who were recruited in the Fourth Peopleˊs Hospital of Chengdu were underwent a resting - state scanning at the Center for Information in Medicine of University of Electronic Science and Technology of China. Two groupsˊfractional amplitude of low - frequency (fALFF)value were calculated and compared using two sample t - test. Results Compared with the aripiprazole group,risperidone group showed significantly decreasing areas of fALFF,including bilateral putamen,olfactory,caudate,orbitofrontal and right palli-dum;left middle temporal gyrus and left supramarginal gyrus where also shown to have increasing areas. Conclusion Indeed,there are different effects of taking aripiprazole and risperidone on spontaneous brain activity in schizophrenics,which is consistent with the pharmacological mechanism of two drugs.%目的:探究临床常用抗精神病药物阿立哌唑和利培酮对精神分裂症患者自发性脑活动的不同影响。方法纳入就诊于成都市第四人民医院的长期服用阿立哌唑进行单药治疗的精神分裂症患者9例,服用利培酮单药治疗的精神分裂症患者10例,进行静息态功能磁共振(fMRI)扫描。分析两组患者 fMRI 信号的分数低频振幅(fALFF)的组间差异。结果与阿立哌唑组比较,利培酮组 fALFF 显著降低的脑区有双侧壳核、嗅皮质、尾状核、眶部额下回和右侧苍白球;fALFF 显著增高脑区有左侧颞中回和左侧缘上回(P <0.05)。结论阿立哌唑和利培酮会对大脑产生不同影响,差异脑区符合两种药物的不同药理机制。

  9. Il trattamento dei disturbi psicotici con olanzapina, risperidone e neurolettici tipici: una valutazione comparativa di costo/efficacia in una realtà psichiatrica locale

    Directory of Open Access Journals (Sweden)

    Egidio Filippelli

    2005-09-01

    Full Text Available BACKGROUND: Several clinical trials demonstrated that atypical antipsychotics are more effective but also more expensive (as drug cost compared with the typical neuroleptics by treating psychotic disorders. The present study aimed to evaluate this result using an observational approach which better reflects the real clinical practice. OBJECTIVE: To evaluate clinical effectiveness (including work and social functioning and overall direct costs in a group of patients affected by psychotic disorders (schizophrenia and bipolar and treated with typical and atypical (olanzapine and risperidone antipsychotics. METHODS: With a multicentre observational design - two years long - 89 patients (in charge by Psychiatric Centers of Regione Campania - Italy were assessed using CGI (Clinical Global Impression and GAF (Global Assessment of Functioning scales. Moreover economic data were collected with reference to pharmacological and non-pharmacological (hospitalization, medical/nurse visits, etc. resources consumption. The pharmacoeconomic analysis were conducted choosing the perspective of the local Psychiatric Services for costs attribution. RESULTS: Considering the treatment outcomes, the use of the atypical drugs provided better performances with reference to the patients quality of life. The results in terms of work and social functioning indicated an advantage in the olanzapine group of patients. Overall direct costs of treatment (drugs and healthcare resources didn’t generate significant differences among the groups of therapy despite the pharmacological cost evidentiated an economic advantage (p<0,05 in the typical group due to the cheaper cost of these drugs. The use of olanzapine was associated to a lower number of hospitalizations and showed a general reduction (- 16% of total treatment costs between 1st and 2nd year of observation. CONCLUSIONS: The lack of side effects, the improvement in work and social functioning, associated to a more efficient

  10. Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone: Preliminary Evidence.

    Science.gov (United States)

    Hendouei, Narjes; Hosseini, Seyed Hamzeh; Panahi, Amin; Khazaeipour, Zahra; Barari, Fatemeh; Sahebnasagh, Adeleh; Ala, Shahram

    2016-01-01

    Recently, extensive efforts have been made to understand the rate of energy expenditure and the weight gain associated with atypical antipsychotic treatment, including identification of markers of obesity risk. In recent years, leptin, an adipocyte hormone, has gained significant interest in psychiatric disorders. S100B has been considered as a surrogate marker for astrocyte-specific damage in neurologic disorders. Also, S100B has been detected in adipose with concentration as high as nervous tissue as a second release source. In this study we evaluated the relationship between S100B and leptin in schizophrenic patients under treatment with clozapine and risperidone.This study included 19 patients meeting the DSM-IV-TR criteria for schizophrenia, having body mass index (BMI) of 16- 25 kg/m(2) and suffering schizophrenia for more than 3 years and from this study. Twenty five healthy controls were group matched for age and gender whose BMI was 16-25 kg/m(2). Serum S100B and leptin levels and positive and negative symptom scale (PANSS) were assessed at admission and after six weeks. During the study, S100B showed a strong and negative correlation with leptin (r = -0.5, P = 0.01). Also, there were negative correlation between serum S100B level and PANSS negative subscale after 6 weeks of treatment (r = -0.048, P = 0.8). Positive correlation between leptin level and PANSS suggested a potential role for leptin which can mediate the link between antipsychotic induced weight gain and therapeutic response in schizophrenia.

  11. An ex Vivo Model for Evaluating Blood-Brain Barrier Permeability, Efflux, and Drug Metabolism

    DEFF Research Database (Denmark)

    Hellman, Karin; Aadal Nielsen, Peter; Ek, Fredrik

    2016-01-01

    , risperidone, citalopram, fluoxetine, and haloperidol were studied, and one preselected metabolite for each drug was analyzed, identified, and quantified. Metabolite identification studies of clozapine and midazolam showed that the locust brain was highly metabolically active, and 18 and 14 metabolites......, respectively, were identified. The unbound drug fraction of clozapine, NDMC, carbamazepine, and risperidone was analyzed. In addition, coadministration of drugs with verapamil or fluvoxamine was performed to evaluate drug-drug interactions in all setups. All findings correlated well with the data...

  12. 氯氮平与利培酮对血清催乳素水平的影响%The effects of clozapine and risperidone on serum prolactin levels of female schizophrenia

    Institute of Scientific and Technical Information of China (English)

    侯静; 徐贵云; 马崔; 吴福喜; 黎德美; 陆欣乔; 朱海兵

    2001-01-01

    Objective:To assess the serum prolactin levels of female firstonset schizophrenia in the treatment of clozapine and risperidone. Method:ELISA had been used to determine the serum prolactin levels. Results:The serum prolactin levels of risperidone-treated patients increased significantly 10 weeks later, while those of clozapine-treated patients showed no obvious change. Conclusion:Neither can the serum prolactin levels explain the pathogenesis and severity of schizophrenia, nor predict the clinical outcome of atypical antipsychotics.%目的:了解氯氮平或利培酮对首发女性精神分裂症患者血清催乳素水平的变化。 方法:采用ELISA方法测定血清催乳素水平。 结果:治疗后氯氮平组血清催乳素水平没有显著变化,而利培酮组血清催乳素水平显著升高。 结论:催乳素水平不能说明精神分裂症发病及严重程度,也不能作为非典型抗精神病药疗效的指标。

  13. The Comparison of the Effectiveness of Risperidone and Fluoxetine in Combination with Impulse Control Group Therapy on Improving of Impulsivity, and Relapse in Heroin Crack Addicts under Methadone Maintenance Therapy

    Directory of Open Access Journals (Sweden)

    Rohoallah Hadadi

    2013-05-01

    Full Text Available Aim: The aim of the study was to compare the effectiveness of Risperidone and Fluoxetine in combination with impulse control group therapy on improving of impulsivity, and relapse in heroin crack addicts under methadone maintenance therapy. Method: In a semi-experimental study, 39 heroin crack addicts who were under Methadone maintenance treatment selected of addiction withdrawal centers in Tehran. The selected sample was randomly assigned to three groups. First group was under (Risperidone 1 mg daily, impulse control group therapy for 8 sessions of 90 minutes, and methadone maintenance treatment, the second group was under (Fluoxetine 20 mg daily, impulse control group therapy for 8 sessions of 90 minutes, and methadone maintenance therapy, and the third group was under (impulse control group therapy for 8 sessions of 90 minutes, and methadone maintenance therapy. All participants completed the Barratt impulsivity scale (BIS-11 before and immediately after the end of intervention and follow up. Also, Morphine and stimulating drugs in urine were analyzed. Results: The results showed that total impulsivity scores was decreased in post-test but not in follow up. That is, impulsivity decreased in both experimental groups. Results also showed that relapse rate was not significantly differed. Conclusion: The combination of Fluoxetine with Methadone maintenance therapy and impulse control group therapy, was the most effective treatment on reduction of impulsivity, but not on relapse rate, in heroin crack abusers, in the short term.

  14. 利培酮、氯氮平合并碳酸锂治疗躁狂症的临床对照研究%Clinical control study of risperidone,clozapine combined with lithium carbonate in the treatment of mania

    Institute of Scientific and Technical Information of China (English)

    孙锦红

    2014-01-01

    目的:观察利培酮与氯氮平分别合并碳酸锂治疗有精神病性症状躁狂症的疗效及安全性。方法:将符合DSM-Ⅳ诊断标准的躁狂症患者60例,随机分为两组,在使用碳酸锂的同时,分别合并利培酮或氯氮平平进行为期8周的治疗。采用躁狂量表(BRMS)评定疗效,采用不良反应量表(TESS)评定不良反应。结果:利培酮与氯氮平平疗效相当,利培酮起效时间迟于氯氮平,但不良反应较轻,依从性好。结论:利培酮合并碳酸锂与氯氮平合并碳酸锂治疗躁狂症总体疗效相当,但安全性较高。%Objective:To observe the effects of risperidone and clozapine both combined with lithium in treatment efficacy and safety of psychotic symptoms of mania.Methods:60 patients with mania were selected,all of them meet the DSM-Ⅳ diagnostic criteria on mania.They were randomly divided into 2 groups,at the same time of the use of lithium carbonate combined with risperidone or clozapine respectively,the treatment time is 8 weeks.The treatment efficacy assessed by Mania Rating Scale(BRMS), the adverse reactions assessed by side effects scale(TESS).Results:The treatment efficacy of risperidone and clozapine is equalized,the onset time of risperidone later than clozapine,but the adverse reaction of risperidone less than clozapine,and the former has better compliance.Conclusion:The efficacy of risperidone combine with lithium carbonate and clozapine combined with lithium in treatment of mania are equivalent,but risperidone has higher security.

  15. Analyzing effect and safety of quetiapine and risperidone on mental and behavioral of alzheimer disease%喹硫平与利培酮治疗阿尔茨海默病精神行为异常的临床疗效及安全性

    Institute of Scientific and Technical Information of China (English)

    许晓英; 曾媛媛; 张易

    2013-01-01

    目的 探讨喹硫平与利培酮治疗阿尔茨海默病精神行为异常的临床疗效及安全性.方法 将86例阿尔茨海默病患者随机分为喹硫平组和利培酮组,分别给予喹硫平及利培酮口服治疗,疗程8周.采用痴呆病理行为评定量表评估临床疗效,并比较2组不良反应发生率.结果 喹硫平组与利培酮组治疗有效率分别为79.5%和76.2%,差异无统计学意义(P>0.05);治疗后8周,喹硫平组痴呆病理行为评定量表昼夜节律紊乱及攻击行为因子显著优于利培酮组(P<0.05);2组不良反应发生率无显著差异(P>0.05).结论 喹硫平与利培酮治疗阿尔茨海默精神行为异常临床疗效相当,但喹硫平抗焦虑及镇静的作用优于利培酮.%Objective To explore the effect and safety of quetiapine and risperidone on mental and behavioral of alzheimer disease.Methods Eighty-six patients with alzheimer disease were randomly divided into quetiapine group and risperidone group.The two groups received quetiapine and risperidone treatment respectively.The course of treatment was 8 weeks.BEHAVE-AD scale was used to evaluate the clinical effect.Adverse rates were compared between two groups.Results The effectiveness rates of treatment were 79.5 % and 76.2 % in quetiapine group and risperidone group without significant difference (P >0.05).Aggressiveness and diurnal rhythm disturbances of BEHAVE-AD 8 weeks after treatment in quetiapine group were superior to risperidone group (P < 0.0 5).There was no significant difference of adverse reactions between the two groups (P >0.05).Conclusion Quetiapine and risperidone have equivalent effects on mental and behavioral of alzheimer disease,while the anti-anxiety effects and sedative effect of quetiapine is superior to risperidone.

  16. Clinical Study on Shaoyao Gancao Decoction for Treating Risperidone-induced Hyperprolactinemia%芍药甘草汤治疗利培酮所致高催乳素的临床研究

    Institute of Scientific and Technical Information of China (English)

    向小妹; 潘彬斌; 李红; 丁跃庆; 桂琴; 虞贝贝; 吴洪军

    2013-01-01

    目的:探讨芍药甘草汤治疗利培酮所致的高催乳素血症的临床应用价值及安全性。方法:回归性分析研究2011年1月-2012年3月在本院接受治疗的92例因服用利培酮导致高催乳素血症的精神病患者(催乳素水平≥1888.5μg/ml),分析所有患者服用芍药甘草汤后利培酮血浆浓度及9-羟利培酮血浆浓度、催乳素、血药浓度、PANSS评定等指标。结果:与治疗前相比,患者在治疗后的血清泌乳素水平显著下降(P<0.05),但雌二醇、睾酮、孕酮浓度治疗前后的浓度、TESS评分和治疗后的利培酮血浆浓度及9-羟利培酮血浆浓度无显著差异。结论:芍药甘草汤治疗利培酮所致的高催乳素血症可快速改善月经不调、闭经、男性女性化等症状,提高患者服药依从性,且服药方便,疗效明显,价格低廉,安全可靠,值得临床推广应用。%Objective:To investigate the clinical application value shaoyao-gancao decoction in the treatment of hyperprolactinemia induced by risperidone and its safety.Method:92 psychiatric patients with hyperprolactinemia induced by risperidone from 2011 January to 2012 March in our hospital were analyzed resrospectively(prolactin levels≥1888.5μg/ml),analyzed the indices of plasma concentration of risperidone and 9-hydroxyrisprridone, prolactin,blood concentration,PANSS evaluation were observed in all patients.Result:Compared with before treatment,the serum prolactin level after treatment decreased significantly(P<0.05),but there were no differences in the estradiol,testosterone,progesterone concentrations,the TESS score before and after treatment and the plasma concentration of risperidone and 9-hydroxyrisprridone after treatment.Conclusion:Shaoyao-gancao decoction treatment of risperidone caused by high blood prolactin can rapidly improve the male feminine irregular menstruation,amenorrhea,Male female etc, enhance patient medication adherence

  17. Clinical Observation of Risperidone in the Treatment of Postoperative Delirium in Elderly Orthopedics Patients%利培酮治疗老年骨科患者术后谵妄的临床观察

    Institute of Scientific and Technical Information of China (English)

    吴晓; 王利宏

    2013-01-01

    目的:观察利培酮治疗老年骨科患者术后谵妄的临床疗效和安全性.方法:将符合标准的骨科术后并发谵妄的老年患者68例按年龄、性别、病种、手术种类为条件均分为对照组和观察组.对照组肌肉注射氟哌啶醇注射液,起始剂量为2.0 mg/d,经调整剂量后平均用量(7.0±0.4)mg/d,每日1~2次;观察组口服利培酮片,起始剂量为0.5 mg/d,经调整剂量后平均用量(1.5±0.3)mg/d,每日1~2次.两组患者均治疗7d.治疗过程中采用谵妄分级量表进行谵妄症状(DRS)评分,并观察不良反应发生情况.结果:两组患者治疗期间DRS评分较治疗前均显著下降(P<0.05),但两组患者同期DRS评分比较差异无统计学意义(P>0.05);对照组2例患者出现锥体外系反应,而观察组未见不良反应发生,两组患者不良反应发生率比较差异有统计学意义(P<0.05).结论:利培酮治疗老年骨科患者手术后谵妄与氟哌啶醇疗效相近,但利培酮较氟哌啶醇更安全.%OBJECTIVE:To observe clinical efficacy and safety of risperidone in the treatment of delirium in elderly orthopedic patients after surgery.METHODS:68 elderly patients with delirium after orthopedic surgery met criteria were randomly divided into control group and observation group according to age,gender,disease type and operation tyes.Control group was given Haloperidol injection intramuscularly with starting dose of 2.0 mg/d,1 to 2 times a day,average dose of (7.0 ± 0.4) mg/d after adjustment; observation group was given Risperidone tablet orally with t starting dose of 0.5 mg/d,1 to 2 times a day,average dose of (1.5 + 0.3) mg/d after adjustment.Treatment course of 2 groups both were 7 days.The symptems was scored by using Delirium Rating Scale (DRS) score and adverse drug reactions were observed during treatment.RESULTS:DRS scores of two groups were decreased significantly during treatment (P<0.05),there was no statistical significance between 2

  18. 银杏叶提取物合并利培酮口腔崩解片治疗精神分裂症的临床研究%A clinical study of combined utization of ginkgo biloba extract and risperidone orally disintegrating tablets in the treatment of schlzophrenia

    Institute of Scientific and Technical Information of China (English)

    龚飞中; 曾骥; 余瑞; 龚昌群; 刘均富

    2012-01-01

    Objective To compare clinical efficacy and the side effects between combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets and only the use of risperidone orally disintegrating tablets in the treatment of schizophrenia. Methods Seventy-five patients with schizophrenia were treated randomly with combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets or risperidone orally disintegrating tablets only for six weeks,and measured with the brief psychiatric rating scale (BPRS) and treatment emergent symptom scale(TESS) before treatment and 1,2,4,6 weeks after treatment. Results The both programes were different in efficacy, combined utilization of ginkgo biloba extract and risperidone o-rally disintegrating tablets is more effective than risperidone orally disintegrating tablets only in treating schizophrenia, and the side effects combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets is no more effective than risperidone orally disintegrating tablets only in treating schizophrenia. Conclusion The therapeutic effect of combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets take a active part earlier than only the use of risperidone orally disintegrating tablets in the treatment of schizophrenia, however, the reduced rate of BPRS was no significant difference after 2 weeks, itcould be necessary to continue the joint use of ginkgo biloba extract.%目的 比较银杏叶提取物合并利培酮口腔崩解片与单用利培酮口腔崩解片治疗精神分裂症的疗效及不良反应.方法 将符合标准的75例精神分裂症患者分为两组,一组给予银杏叶提取物合并利培酮口腔崩解片治疗(治疗组,n=40),另一组给予利培酮口腔崩解片治疗(对照组,n=35),疗程6周.用简明精神量表(BPRS)在治疗前及治疗1、2、4、6周末评定疗效,用副反应量表(TESS)评定不良反应.结果

  19. 西酞普兰联合舒必利在有精神病性症状抑郁症治疗中的临床价值分析%Citalopram combined with sulpiride in the analysis of the clinical value of psychotic symptoms in the treatment of depression

    Institute of Scientific and Technical Information of China (English)

    孙建

    2015-01-01

    目的:对西酞普兰联合舒必利在有精神病性症状抑郁症治疗中的临床价值进行分析和研究。方法选择2013年4月~2014年4月在本院住院治疗的有精神病性症状的抑郁症患者50例,随机分为对照组和实验组,各25例,对照组行西酞普兰治疗,实验组行西酞普兰联合舒必利治疗,观察两组患者的疗效。结果对照组患者经西酞普兰治疗后,总有效率为68%,明显低于实验组经西酞普兰联合舒必利治疗后的总有效率96%,对照组患者的汉密尔顿抑郁量表(HAMD)评分也明显优于实验组,两组间有效率的比较,差异具有统计学意义(P<0.05)。结论针对有精神病性症状的抑郁症患者行西酞普兰联合舒必利治疗,具有显著的疗效,值得各医院临床推广使用。%Objective Of citalopram in combination with sulpiride with psychotic symptoms of clinical value in the treatment of depression is analyzed and studied. Methods The data in April 2013-April 2014 in our hospital hospitalization with 50 patients with psychotic symptoms of depression, randomly divided into two groups, each 25 cases, the control line citalopram treatment, the experimental group lines of citalopram in combination with sulpiride treatment, to observe the efifcacy of two groups of patients. Results The patients with the control group after treatment with citalopram, the total effective rate was 68.00%, signiifcantly lower than the experimental group after treatment with citalopram combined sulpiride the total effective rate of 96.00%, the experimental group is obviously better than the control group patients with HAMD scores also, efifcient comparative differences between the two groups have statistical significance (P<0.05). Conclusion For patients with psychotic symptoms of depression citalopram combined therapy with sulpiride, has signiifcant curative effect, is worth the clinical promotion use.

  20. A randomized controlled study of Fluoxetine and Citalopram on the treatment of depressive symptom due to Alzheimer's disease%盐酸氟西汀与西酞普兰治疗阿尔茨海默病所致抑郁症状随机对照研究

    Institute of Scientific and Technical Information of China (English)

    刘辉; 王京丽; 张海林; 刘英; 吴炬

    2011-01-01

    Objective: To compare the efficacy and safety of Fluoxetine and Citalopram in treatment of the depressive symptom due to Alzheimer's Disease. Methods: 80 cases of patients were randomly divided into two groups, the patients of two groups were treated with Fluoxetine and Citalopram respectively; the course was 8 weeks; HAMD and TESS was adopted to assess the clinical effect and adverse reaction. Results: HAMD of Citalopram group decreased significantly after two weeks' treatment (P<0.05), and HAMD of Fluoxetine group decreased significantly after four weeks' treatment (P< 0.05). The two groups showed the same effect after 8 weeks. Adverse reactions of two groups were lighter, the incidence of adverse reactions of Citalopram group (38.1%) was lower than Fluoxetine group (60.5%)(P<0.05). Conclusion: Citalopram has quicker effect and better safety than Fluoxetine in the depressive symptom due to AD, long-term effect of two drugs was almost the same. Citalopram is worthy of wide application in treatment of depressive symptom due to AD.%目的:比较盐酸氟西汀与西酞普兰治疗阿尔茨海默病所致抑郁症状的有效性和安全性.方法:将80例受试者随机分为两组,分别给予盐酸氟西汀和西酞普兰治疗,疗程为8周,于治疗前和治疗后2、4、6、8周末分别采用汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)评定两药的疗效及不良反应.结果:在用药2周后,西酞普兰组HAMD得分较治疗前显著下降(P<0.05),在治疗4周后盐酸氟西汀组较治疗前显著下降(P<0.05),两组在用药8周后,疗效相当(P>0.05).两组不良反应均较轻,西酞普兰组的总体不良反应发生率(38.1%)低于盐酸氟西汀组(60.5%)(P<0.05).结论:在治疗阿尔茨海默病所致抑郁症方面,西酞普兰起效较快,且较盐酸氟西汀安全性好.两组长期使用疗效相当.西酞普兰适合阿尔茨海默病所致抑郁患者服用.

  1. 艾司西酞普兰与氯硝安定治疗广泛性焦虑症的临床对照分析%A Comparative Study of Citalopram and Clonazepam in the Treatment of Patients with Generalized anxiety Disorder

    Institute of Scientific and Technical Information of China (English)

    王春芝; 侯海燕

    2016-01-01

    ABSTRACT:Objective To evaluate the efifcacy and side effects of citalopram in the treatment of general anxiety disorder.Methods 76 patients who met the criteria of CCMD-3 for generalized anxiety disorder were randomly assigned into citalopram group and clonaz-epam group for treatment of 8 weeks.The effects and side effects of two groups were assessed by HAMD,SAS and TESS. Results Both drugs had marked efifcacy in the treatment of generalized anxiety disorder. Conclusion Citalopram is a safe and efifcient drug with fewer side effects for the treatment of generalized anxiety disorder.%目的:评价西酞普兰治疗广泛性焦虑症的临床疗效和副反应。方法将76例符合CCMD--3诊断标准的广泛性焦虑症患者,随机分为两组,分别应用西酞普兰(38例)、氯硝安定(38例)进行对照治疗,疗程8周。采用焦虑自评量表(SAS)、Hamilton焦虑量表(HAMA)和副反应量表(TESS)评定疗效和副反应。结果西酞普兰与氯硝安定对广泛性焦虑症均有显著疗效,两组间疗效差异无显著性(P>0.05),西酞普兰组副反应明显少于氯硝安定组(P<0.01)。结论西酞普兰治疗广泛性焦虑症安全有效,副反应少。

  2. To Study the Clinical Effect of Sulpiride Combined Citalopram in the Treatment of Depression with Psychotic Symptoms%舒必利联合西酞普兰治疗伴精神病性症状抑郁症的临床效果研究

    Institute of Scientific and Technical Information of China (English)

    汪锦华

    2016-01-01

    目的::研究舒必利联合西酞普兰治疗伴精神病性症状抑郁症的临床效果。方法:将某院2013年6月~2015年6月收治的伴精神病性症状抑郁症患者76例,随机分为两组各38例,观察组采用舒必利联合西酞普兰进行治疗,对照组采用西酞普兰治疗,比较两组治疗前后 HAMD、HAMA评分变化和疗效。结果:观察组治疗后 HAMD、HAMA评分均低于对照组,差异均具有统计学意义(均P<0.05);观察组总有效率高于对照组,差异具有统计学意义(P<0.05)。结论:舒必利联合西酞普兰治疗伴精神病性症状抑郁症效果较单纯西酞普兰治疗更好,值得临床上推广。%Objective:To study the clinical effect of Sulpiride combined citalopram in the treatment with psychotic symptoms.Methods:A total of 76 patients of depression with psychotic symptoms received in a hospital from June 2013 to June 2015 were randomly divided into two groups,each of 38 cases.The observa-tion group were treated with Sulpiride combined citalopram,while the control group were treated with citalo-pram.Then compare the HAMD,HAMA score changes and the clinical effect.Results:After treatment,the HAMD,HAMA score of the observation group were lower than those of the control group,and the differ-ences were statistically significant(P<0.05).The total effective rate of the observation group were higher than that of the control group,and the difference was statistically significant (P<0.05).Conclusion:The clinical effect of sulpiride combined citalopram in the treatment of psychotic symptoms of depression is better than that of treating with only citalopram,which is worth of clinical promotion.

  3. Clinical Observation of Citalopram in the Treatment of Depression after Lung Cancer Operation%西酞普兰治疗肺癌术后抑郁症的临床观察

    Institute of Scientific and Technical Information of China (English)

    孙振卿; 郭强; 李鹤飞; 王海波; 祖金池; 石林; 张越; 李亚静; 桑文华

    2016-01-01

    目的:观察西酞普兰治疗肺癌术后抑郁症的临床疗效及安全性。方法:选取肺癌术后伴发抑郁症的患者114例,按随机数字表法分为观察组和对照组,各57例。对照组患者术后给予营养支持、平衡电解质等常规治疗,未服用抗抑郁药物;观察组患者术后口服氢溴酸西酞普兰片20 mg,qd。两组患者均连续治疗6周。观察两组患者临床疗效及治疗前后汉密尔顿抑郁量表(HAMD)评分、汉密尔顿焦虑量表(HAMA)评分、健康调查量表(SF-36)评分,并记录不良反应发生情况。结果:观察组总有效率为87.72%,显著高于对照组的71.93%,差异有统计学意义(P<0.05);两组患者治疗前HAMD评分、HAMA评分及SF-36各项评分和总分比较,差异无统计学意义(P>0.05);两组患者治疗后HAMA评分、HAMD评分显著降低,且观察组显著低于对照组, SF-36各项评分和总分显著升高,且观察组显著高于对照组,差异均有统计学意义(P<0.05)。两组患者均未见明显不良反应发生。结论:西酞普兰治疗肺癌术后抑郁症的疗效显著,能明显改善患者精神状态和生存质量,且安全性较好。%OBJECTIVE:To observe clinical efficacy and safety of citalopram in the treatment of depression patients after lung cancer operation. METHODS:114 depression patients after lung cancer operation were selected and randomly divided into observa-tion group and control group (n=57). Control group was given routine treatment as nutrition support and electrolyte balance,but had no anti-depression drugs;observation group was given Citalopram tablet 20 mg orally,qd. Two groups were treated for 6 weeks. Clinical efficacy,HAMD and HAMA scores,each score and total score of SF-36 were observed before and after treatment. The occurrence of ADR was recorded. RESULTS:The total effective rate of observation group was 87.72%,which was significant

  4. Clinical efficacy of citalopram on coronary heart disease patients with depressive disorder%西酞普兰治疗冠心病合并抑郁患者的疗效观察

    Institute of Scientific and Technical Information of China (English)

    赵清珍; 刘超; 刘刚; 刘坤申

    2013-01-01

    目的:观察西酞普兰对冠状动脉粥样硬化性心脏病(冠心病)合并抑郁症患者治疗后抑郁状态的改变,对高敏CRP (hsCRP)与心血管事件的影响,评估其安全性。方法将120例确诊为冠心病合并抑郁症患者随机分为对照组(n=58)和治疗组(n=62),两组患者均给予冠心病常规治疗加心理干预,治疗组患者加用西酞普兰20 mg/晚,两组患者于治疗前及治疗8周末进行汉密尔顿抑郁量表(HAMD)评分,测定血浆hsCRP,观察心绞痛发作、 AMI、急性心力衰竭发生情况,及不良药物发生情况。结果治疗8周后,治疗组HAMD评分(7.60±3.49)分,与对照组(20.58±3.20)分比较,差异有统计学意义( P<0.01);两组hsCRP均下降,治疗组hsCRP (2.57±0.64) mg/L,对照组(2.90±0.81) mg/L,两组比较差异有统计学意义( P<0.05);治疗组心绞痛发作、AMI、急性心力衰竭发生率分别为10%、2%、2%,对照组分别为18%、5%、9%,两组比较差异有统计学意义( P<0.05)。两组治疗前后药物不良反应未见明显差异。结论西酞普兰可以明显改善冠心病症合并抑郁患者的抑郁症状,更显著降低hsCRP水平,降低心血管事件发生率,且药物安全。%Objective To study the efficacy , safety and mechanism of Citalopram on coronary artery disease ( CAD) patients with depressive disorder by observing depressive state , Cardiovascular events and high sensitive CRP (hsCRP).Methods We enrolled 120 CAD patients admitted to our hospital with depres-sive disorder.All patients were randomized to control group ( n=58 ) and treatment group ( n=62 ) for 8 weeks.Both groups were given conventional treatment on CAD combined with psychological intervention , Cita-lopram tablets of 20 mg were additionally supplemented to treatment group every night.Hamilton depression rating scale (HAMD) and hsCRP of the patients were

  5. Effect of Risperidone Combined with Sertraline on Curative Effect of Patients with Obsessive-Compulsive Disorder%利培酮合并舍曲林对强迫症患者疗效的影响

    Institute of Scientific and Technical Information of China (English)

    段海水; 吕贝

    2016-01-01

    ABSTRACT:Objective To observe the effect of risperidone combined with sertraline on the obsessive-compulsive disorder patients. Methods 80 cases of obsessive-compulsive disorder in our hospital were selected as the observation objects, the patients were divided into the observation group and the control group according to the random grouping method, 40 cases in each group, the control group were treated with sertraline treatment alone, patients in the observation group were treated with risperidone on the basis of the contral group. The Yale Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD) were used to evaluate the curative effect. Results After treatment, the indexes of the two groups were signiifcantly decreased, and the observation group was signiifcantly higher than the control group, the difference between the groups was signiifcant (P<0.05). Conclusion Patients with obsessive-compulsive disorder accepting sertraline combined with risperidone treatment can receive signiifcant effect, can improve the symptoms of patients, high safety, it is worth to be popularized in clinical application.%目的:观察利培酮合并舍曲林对强迫症患者的影响。方法选取本院收治的80例强迫症患者作为观察对象,并按照随机分组法将患者分为观察组和对照组,每组40例,对照组患者给予单纯的舍曲林治疗,观察组患者在对照组治疗的基础上联合应用利培酮。采用耶鲁-布郎强迫量表(Y-BOCS)、汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评定疗效。结果经过治疗后两组患者的以上指标均有明显的下降,且观察组的下降幅度显著大于对照组,组间差异具有显著性(P均<0.05)。结论对于强迫症患者在舍曲林的基础上联合应用利培酮治疗能够收到显著的效果,有助于改善患者的症状,安全性高,值得在临床中进行推广应用。

  6. 比较氨磺必利与利培酮治疗精神分裂症的效果评价%Analysis of clinical effects and adverse reactions of amisulpride and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈建新; 王艳娉

    2014-01-01

    Objective To analyze clinical effects and adverse reactions of amisulpride and risperidone in the treatment of schizophrenia.Methods A total of 130 patients diagnosed with schizophrenia were divided into research group and control group. 65 cases in the research group were treated with amisulpride, and the other 65 cases in the control group were treated with risperidone. The course of treatment lasted for 8 weeks, and the positive and negative symptoms scale (PANSS) and adverse event scale (TESS) were applied to evaluate the clinical effects and adverse reactions.Results The total effective rate of the research group was 83%, and that of the control group was 77%. Difference between the two groups was not statistically significant (P>0.05). After 8 weeks, PANSS score values were significantly decreased both in the research group and the control group (P0.05). Conclusion The clinical effect of amisulpride is better than risperidone in the treatment of schizophrenia, and they have similar adverse reactions.%目的:分析氨磺必利与利培酮治疗精神分裂症的临床效果和不良反应。方法精神分裂症患者130例,分为研究组和对照组,研究组65例予以氨磺必利治疗,对照组65例采用利培酮治疗,疗程共计8周,采用阳性与阴性症状量表( PANSS)和副反应量表(TESS)评定其疗效和不良反应。结果研究组总有效率为83%,对照组总有效率为77%,两组间差异无统计学意义(P>0.05)。8周末研究组和对照组PANSS总分值均显著下降(P0.05)。结论氨磺必利治疗精神分裂症疗效优于利培酮,且不良反应与利培酮相似。

  7. 氨磺必利与利培酮治疗精神分裂症对照研究%A control study of amisulpride vs .risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张华江; 徐清

    2014-01-01

    Objective To explore the efficacy and safety of amisulpride vs .risper-idone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly divided into two groups of 30 ones each ,research group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and adverse re-actions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week obvious effective and effective rate were respectively 70 .0% and 93 .3% in research and 66 .7% and 93 .3% in con-trol group ,which showed no significant differences (P> 0 .05) .Incidences of extrapyramidal reactions , dysfunction of liver and weight gain were significantly lower in research than in control group (P<0 .05) . Conclusion Amisulpride has an evident effect equivalent to risperidone ,higher safety and better compli-ance in the treatment of schizophrenia .%目的:探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组,每组30例,研究组口服氨磺必利治疗,对照组口服利培酮治疗。观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末,研究组显效率为70.0%、有效率为93.3%,对照组分别为66.7%、93.3%,两组比较差异无显著性(P>0.05)。研究组锥体外系反应、肝功能异常及体质量增加发生率均显著低于对照组(P<0.05)。结论氨磺必利治疗精神分裂症疗效显著且与利培酮相当,安全性高,依从性好。

  8. 氯氮平与利培酮对精神分裂症患者认知功能的影响比较%Comparison of effect between clozapine and risperidone in treating social cognition of patients with schizophrenia.

    Institute of Scientific and Technical Information of China (English)

    高磊

    2016-01-01

    目的 比较氯氮平与利培酮对精神分裂症患者认知功能的影响.方法 选取徐州精神病院 2014 年2 月—2015 年 2 月收治的 82 例精神分裂症患者,按照随机数字表法将患者分为氯氮平组和利培酮组,各 41 例.氯氮平组患者给予氯氮平治疗,利培酮组患者给予利培酮治疗,比较两组患者的阴性和阳性症状量表( PANSS)评分、简易智力量表(MMSE)评分、临床疗效和锥体外系反应发生情况.结果 治疗前后两组患者 PANSS 阳性和阴性症状及一般病理评分比较,差异均无统计学意义(P > 0. 05).两组患者总有效率比较,差异无统计学意义(P > 0. 05);治疗前两组患者 MMSE 评分比较,差异无统计学意义(P > 0. 05);治疗后利培酮组 MMSE 评分高于氯氮平组,差异有统计学意义(P 0. 05) . The total effective rate showed no significant differences between the two groups(P > 0. 05). Before treatment,MMSE score showed no significant differences between the two groups(P > 0. 05);after treatment,MMSE score of risperidone group was higher than that of clozapine group(P < 0. 05). Incidence of extrapyramidal reactions of risperidone group was higher than that of clozapine group(P < 0. 05). Conclusion Risperidone in the treatment of social cognition of patients with schizophrenia is better than that of clozapine,but has high incidence of extrapyramidal reactions

  9. 利培酮治疗难治性分裂情感性精神病临床研究%Clinical research on risperidone in the treatment of refractory schizoaffective psychosis

    Institute of Scientific and Technical Information of China (English)

    刘元华

    2014-01-01

    Objective To evaluate the clinical efficacy of risperidone for the treatment of refractory schizoaffective psychosis. Methods 84 patients with refractory schizoaffective psychosis were randomly divided into observation group and control group, and 42 cases were in each group.The two groups were received lithium treatment, and risperidone was added in observation group, while the control group added clozapine. The clinical efficacy of two groups were compared. Results After treatment, the HAMD, BRMS and the PANSS factor scores were significantly lower, but the observation group was significantly lower than the control group(P<0.05);the total effective rate of HAMD,BRMS and PANSS in observation group were significantly higher than the control group (P<0.05);the TESS score of observation group was significantly lower than the control group(P<0.05). Conclusion Risperidone for the treatment of refractory schizoaffective psychosis has a significant effect and less adverse reactions, it should be widely applied.%目的:探讨利培酮用于治疗难治性分裂情感性精神病的临床疗效。方法84例分裂情感性精神病患者随机分为观察组与对照组,各42例,两组均予以碳酸锂治疗,观察组加用利培酮,对照组加用氯氮平,比较两组的临床疗效。结果两组治疗后HAMD、BRMS以及PANSS各项因子评分均降低,且观察组各因子评分低于对照组,差异具统计学意义(P<0.05);观察组的临床总有效率均高于对照组,差异具统计学意义(P<0.05);观察组的TESS评分显著低于对照组,差异具统计学意义(P<0.05)。结论利培酮用于治疗难治性分裂情感性精神病疗效显著,不良反应少。

  10. CONTROL STUDY BETWEEN RISPERIDONE ORAL SOLUTION AND OLANZAPINE FOR ALCOHOL -INDUCED MENTAL DISORDER%利培酮口服液与奥氮平治疗酒精所致精神障碍对照研究

    Institute of Scientific and Technical Information of China (English)

    王丽莉; 吕浩; 杨建立

    2012-01-01

    目的:探讨利培酮口服液与奥氮平治疗酒精所致精神障碍的疗效和安全性.方法:将68例男性酒精所致精神障碍患者随机分为利培酮口服液治疗组和奥氮平治疗组.采用阳性与阴性症状量表( PANSS)评定临床疗效;采用治疗副反应量表( TESS)评定药物不良反应.结果:利培酮口服液与奥氮平两组疗效差异无显著性.利培酮口服液主要不良反应为锥外系反应,奥氮平为体重增加.结论:利培酮口服液与奥氮平治疗酒精所致精神障碍疗效及耐受性均好,可根据用药对象对不良反应的耐受等情况进行选择.%Objective: To compare the efficacy and safety of risperidone oral solution and olanzapine in the treatment of alcohol - induced mental disorder. Methods: Sixty - eight male patients with alcohol - induced mental disorder were randomly divided into risperidone oral solution group and olanzapine group. Clinical effect was evaluated by Positive and Negative Syndrome Scale (PANSS) ,and the adverse drug reactions were assessed with Treatment Emergent Symptom Scale ( TESS) . Results: No significant differences were observed in the clinical effect of the two groups. The main side effect experienced by the olanzapine group was body weight gain, while the resperidone oral solution group showed extrapyramidal responses. Conclusion: Both olanzapine and risperidone oral solution are safe and effective for the treatment of alcohol - induced mental disorder,and can be clinically selected according to patients' tolerance of the side effects.

  11. Cost-effectiveness analysis of Risperidone and Aripiprazole in the treat-ment of outpatients with schizophrenia%利培酮、阿立哌唑治疗门诊精神分裂症患者成本-效果分析

    Institute of Scientific and Technical Information of China (English)

    吴宇杰; 李君; 杜鹏; 饶顺曾; 吴彦

    2015-01-01

    Objective To compare therapeutic cost-effects and safety between Risperidone and Aripiprazole in treatment of outpatients with schizophrenia. Methods The schizophrenia patients, who were going on treating with Risperidone or Aripiprazole at discharge, were followed-up 1 year in outpatient. While economic cost-effectiveness and adverse reaction were observed and analyzed. Results Comparing the efficacy between the two groups, it was better in Risperidone group than Aripiprazole group, but there was no statistically significant difference (字2= 0.804, P= 0.84). Drug costs in the Risperidone group was slightly lower than the Aripiprazole group, but there was no statistically significant difference (t = 0.39, P=0.69). The cost-effectiveness of Risperidone was better than Aripiprazole (62.41 v s 64.40). The incidence of high prolactin was up to 26.19% (11/42) in Risperidone group, while in Aripiprazole group had no high prolactin occurring. Conclusion The expenses and efficacy are considerably between Risperidone and Aripiprazole, but the adverse reaction of high prolactin often appears in Risperidone treatment, must be cause caution, for young female patients chosen Risperidone is better.%目的:比较单用利培酮或阿立哌唑治疗门诊精神分裂症患者的经济效果及安全性。方法对出院时使用利培酮治疗方案或阿立哌唑治疗方案的精神分裂症患者门诊随访1年,运用经济学成本-效果分析比较两组优劣,观察治疗不良反应。结果两组在疗效方面比较,利培酮组较阿立哌唑组差,但差异无统计学意义(字2=0.804,P=0.84);利培酮组药物费用略低于阿立哌唑组,但差异无统计学意义(t=0.39,P=0.69);成本-效果方面利培酮组优于阿立哌唑组(62.41比64.40);利培酮组高泌乳素发生率高达26.19%(11/42),而阿立哌唑无高泌乳素发生。结论使用利培酮及阿立哌唑费用及疗效相当,而利培酮引起的高泌乳素副作用发生率较高,

  12. Comparison of Efficacy and Prolactin Concentrations between Aripiprazole and Risperidone Treat-ments in Patients with Schizophrenia%阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    马筠; 李轶琛; 李毅; 房茂胜; 钟宝亮

    2013-01-01

    Objective: To compare the prolactin concentrations between aripiprazole and risperidone treatment in patients with schizophrenia. Methods: One hundred and twenty-eight schizophrenic patients with hy-perprolactinemia were randomly divided into risperidone group and aripiprazole group. Patients in the risperidone group were treated with risperidone and in the aripiprazole group were treated with aripiprazol instead of risperidone for 8 weeks. The prolactin concentrations were assessed and compared between two groups at weeks 0, 1,2, 4, 6, and 8. The clinical status was assessed by using the positive and negative syndrome scale (PANSS) and the clinical global impressions scale (CGIS) atweeks0 and 8. Results: Fifty-three in the risperidone group and 48 in the aripiprazole group were available for analyzing. Shift risperidone to aripiprazole was effective in reducing serum prolactin levels. The serum prolactin levels in the risperidone group was significantly lower than that in the aripiprazole group at week 8 (P<0.001). No significant changes was found in the PANSS and CGI-S scores between the two groups. Conclusion: Shift risperidone to aripiprazole was effective in reducing serum prolactin levels of schizophrenia patients with hyperprolactinemia.%目的:研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响.方法:伴有高催乳素血症的精神分裂症患者128 例,随机分为利培酮组(维持利培酮治疗)和阿立哌唑(阿立哌唑替代利培酮治疗)组,治疗8 周.于第0、1、2、4、6 及8 周测血清催乳素水平及身体质量指数(BMI);在入组时和治疗8 周时采用阳性与阴性症状量表(PANSS)和临床总体印象量表(CGIS)测定疗效.结果:可用于评估的数据101 例,利培酮组53 例,阿立哌唑组48 例.阿立哌唑组替换治疗后第1 周血清催乳素水平即明显下降,第8 周时,显著低于利培酮组(P<0.001);2 组BMI 、PANSS 及CGIS 评分及变化差异无统计

  13. Comparison of efficacy and safety of ziprasidone hydrochloride and risperidone in treatment of schizophrenia%盐酸齐拉西酮与利醅酮治疗精神分裂症的疗效及安全性比较

    Institute of Scientific and Technical Information of China (English)

    卢殿军; 宁洁; 吴胜

    2011-01-01

    Objective To evaluate clinical efficacy and safety of ziprasidone hydrochloride and risperidone in treatment of schizophrenia. Methods 60 patients with schizophrenia in hospital were selected and randomly divided into ziprasidone group (n=30,ziprasidone administrated orally) and risperidone group(n=30 ,risperidone tablet administrated orally), with a 6 week course of treatment. Positive and negative syndrome scale(PANSS) was used to assess their clinical efficacy and the treatment emergent symptom scale(TESS) was adopted to investigate their safety. Results At the end of treatment, PANSS reduced score rate of ziprasidone group was(60.98±24.04)% ,and that of risperidone group was (62.03±28.29)% ,with no statistically significant difference between the two groups(P>0.05). Compared incidence rate of side effects of patients in ziprasidone group with that in risperidone group,no statistically significant difference was found between the two groups(P>0.05). Conclusion Ziprasidone hydrochloride is an effective and safe antipsychotic agent with similar curative efficacy and adverse reaction to risperidone.%目的 评价盐酸齐拉西酮与利培酮治疗精神分裂症的临床疗效及安全性.方法 选择住院精神分裂症患者60例,随机分为齐拉西酮组(n=30,口服盐酸齐拉西酮片)与利培酮组(n=30,口服利培酮片),疗程6周.采用精神分裂症阳性与阴性症状评定量表(PANSS)评价其临床疗效,不良反应量表(TESS)评价其安全性.结果 治疗结束时,齐拉西酮组PANSS减分率为(60.98±24.04)%,利培酮组PANSS减分率为(62.03±28.29)%,组间比较差异无统计学意义(P>0.05);齐拉西酮组不良反应发生率与利培酮组比较差异无统计学意义(P>0.05).结论 盐酸齐拉西酮的疗效及不良反应与利培酮相当,是有效、安全的抗精神病药物.

  14. Clinical comparison and investigation of curative effects by olanzapine and risperidone in the treatment of behavioral and psychological symptoms of Alzheimer’s disease%奥氮平、利培酮治疗老年痴呆精神行为症状疗效的临床比较探讨

    Institute of Scientific and Technical Information of China (English)

    慕经纬

    2016-01-01

    Objective To compare clinical effects by olanzapine and risperidone in the treatment of behavioral and psychological symptoms of Alzheimer’s disease. Methods A total of 102 patients with Alzheimer’s disease were randomly divided into olanzapine group and risperidone group, with 51 cases in each group. The olanzapine group received olanzapine tablets for treatment, and the risperidone group received risperidone tablets for treatment. Improvements of clinical symptoms were observed in 2, 4, and 8 weeks of treatment. Mini mental state examination (MMSE), dementia pathological behavior score (BE-HAVE) and positive and negative syndrome scale (PANSS) were taken. Condition of adverse drug reactions was evaluated. Results The olanzapine group had total effective rate as 92.2%, and the risperidone group had that as 90.2%. Their difference had no statistical significance (P>0.05). There was no statistically significant difference of scores in hostile suspicion, disturbance of thought, behavior disorders, anxiety-depression, and bigotry between the two groups after 2, 4 and 8 weeks of treatment (P>0.05). The olanzapine group had lower PANSS score in 2 and 4 weeks of treatment than the risperidone group, and the difference had statistical significance (P0.05)。两组治疗后2、4、8周敌对猜疑、思维障碍、行为紊乱、焦虑抑郁、偏执等评分比较差异均无统计学意义(P>0.05)。奥氮平组在治疗2、4周时 PANSS 评分低于利培酮组,差异有统计学意义(P<0.05)。利培酮组发生锥体外系反应和恶心例数多于奥氮平组,差异有统计学意义(P<0.05)。结论奥氮平和利培酮治疗老年痴呆精神行为症状均有较好的疗效,但奥氮平起效更快,不良反应较少,患者耐受性更好。

  15. 乌鸡白凤丸与阿立哌唑治疗利培酮所致闭经临床对比研究%Comparative clinical study on effect of Wuji Baifeng pills and aripiprazole in the treatment of risperidone induced amenorrhea

    Institute of Scientific and Technical Information of China (English)

    许勤伟; 刘向来; 黄胜; 黄兹高

    2013-01-01

    Objective:To explore clinical therapeutic effect and adverse reaction of Wuji Baifeng pills on risperidone induced amenorrhea.Methods:85 female schizophrenia patients with amenorrhea induced by risperidone were randomly divided into the treatment group of Wuji Baifeng pills (43 cases) and risperidone for aripiprazole contrast group (42 cases),90 days was a course.Results:Wuji Baifeng pills in the treatment of risperidone induced amenorrhea total clinical curative effect was obviously superior to risperidone,there was significant difference in effective rate between two groups (P < 0.05).Common adverse reactions were mild in two groups,and there was no significant difference in the score of TESS scale between the two groups (P > 0.05).Conclusion:Wuji Baifeng pills in the treatment of amenorrhea induced by risperidone has good clinical curative effect and adverse reaction is mild.%目的:探讨乌鸡白风丸治疗利培酮所致闭经的临床疗效及不良反应.方法:对85例利培酮治疗出现闭经的女性精神分裂症患者随机分为乌鸡白凤丸治疗组(43例)及停利培酮换用阿立哌唑的对比组(42例),以90天为一疗程.结果:乌鸡白凤丸治疗利培酮所致闭经的临床总疗效明显优于利培酮换用阿立哌唑的治疗,两治疗组有效率比较差异有统计学意义(P<0.05);两治疗组常见不良反应均较轻微,两组治疗不良反应采用TESS量表定期跟踪测评比较差异无统计学意义(P>0.05).结论:乌鸡白凤丸治疗利培酮所致闭经的临床疗效好,不良反应轻.

  16. 60例脑血管疾病所致精神障碍奥氮平与利培酮治疗效果对比%Effect of olanzapine and risperidone in the treatment of 60 cases of mental disorder caused by cerebrovascular disease comparison

    Institute of Scientific and Technical Information of China (English)

    高晨

    2015-01-01

    Objective To observe the effect of mental disorder caused by olanzapine and risperidone in the treatment of cerebral vascular disease. Methods will randomly olanzapine group and risperidone group. According to the grouping of olanzapine in the treatment group received olanzapine treatment of risperidone in treatment group were given risperidone, treatment. Results In the total effective rate of treatment group was 96.66%, treatment with olanzapine, risperidone group 93.33%, two groups are basically the same. However, olanzapine has fewer adverse effects of the treatment group was 16.66%, risperidone in treatment group was 30%, statistically significant difference contrast. Conclusion Olanzapine can significantly reduce the incidence of adverse reaction of patients, more worthy of clinical promotion and practice of strengthening the.%目的:分析奥氮平与利培酮治疗脑血管疾病所致精神障碍的疗效。方法将该院于2013年1月—2013年12月选取的60例患者随机划分为奥氮平治疗组与利培酮治疗组。根据分组对奥氮平治疗组患者予以奥氮平进行治疗,对利培酮治疗组予以利培酮进行治疗。结果在治疗的总有效率方面,奥氮平治疗组为96.66%,利培酮治疗组为93.33%,两组基本一致,对比差异不具有统计学意义。但奥氮平治疗组患者的不良反应更少为16.66%,利培酮治疗组为30%,对比差异具有统计学意义。结论奥氮平治疗脑血管疾病所致精神障碍的效果与利培酮基本一致,但是却能够明显降低患者的不良反应发生率,更加值得加强临床推广与实践。

  17. The effects of aripiprazole,risperidone and clozapine administrated for schizophrenia treatment on glucose and lipid metabolism%阿立哌唑、利培酮和氯氮平治疗精神分裂症对糖脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    马达休; 李永华; 冉庆国; 陈大坤; 周琳钧

    2011-01-01

    Objective To compare the effects of aripiprazole, risperidone and clozapine used for treating schizophrenia on serum glucose and lipids of patients. Methods 270 patients with schizophrenia were divided randomly into 3 groups of 90 patients each; aripiprazole group, risperidone group and clozapine group, and aripiprazole, risperidone and clozapine were administrated for 12 weeks,respectively. Levels of fast blood glucose (FBG) ,total cholesterol (TC) ,triglycericle(TG) and body mass index (BMX) before and after treatment were compared. Results FBG levels of patients in 3 groups after treatment were increased as compared to those before treatment(P0. 05) ,all those in risperidone and clozapine groups increased after treatment as compared with treatment before(P<0. 05) ,and those in clozapine group increased greater than in risperidone group(P<0. 05). Conclusion Aripiprazole,risperidone and clozapine used for schizophrenia treatment can lead to adverse effects of glucose and lipid metabolism which are relatively milder for aripiprazole.%目的 比较阿立哌唑、利培酮和氯氮平治疗精神分裂症对患者血糖、血脂影响.方法 将270例精神分裂症患者随机分为3组:阿立哌唑组、利培酮组及氯氮平组(各90例),分别给予口服阿立哌唑、利培酮及氯氮平治疗12周.比较治疗前后空腹血糖(FBG)、总胆固醇(TC)、三酰甘油(TG),体质量指数(BMI)的变化.结果 3组患者治疗后,FBG较治疗前增高(P<0.05),氯氮平组增高最明显;阿立哌唑组治疗后TC、TG,BMI值较治疗前差异无统计学意义(P>0.05);利培酮及氯氮平组治疗后TC、TG、BMI较治疗前均有升高(P<0.05),且氯氮平组增高大于利培酮组(P<0.05).结论 阿立哌唑、利培酮及氯氮平治疗精神分裂症均可导致糖脂代谢异常的不良反应,阿立哌唑的不良反应相对较小.

  18. Risperidone combined with clozapine in the treatment of refractory schizophrenia research%利培酮联合氯氮平治疗难治性精神分裂症的临床研究

    Institute of Scientific and Technical Information of China (English)

    谢玲银; 张智勇

    2015-01-01

    目的:探讨使用利培酮联合氯氮平两种药物来治疗难治性精神分裂症的临床效果。方法选取我院收治的难治性精神分裂症患者100例为研究对象,随机将其分为观察组和对照组,其中观察组50例,采用利培酮联合氯氮平进行治疗,对照组50例则只服用氯氮平进行治疗,观察12周,分别于入组前、治疗6周末、12周末应用简明精神病评定量表(BPRS)评定治疗效果,同时应用副反应量表(TESS)评价不良反应发生情况。结果观察组在治疗6周末及12周末的BPRS 评定总分明显低于对照组,差异有统计学意义(P<0.05)。两组TESS总分比较差异无统计学意义(P>0.05)。结论临床上对于难治性精神分裂症这一疾病的治疗可采用利培酮联合氯氮平两种药物进行尝试,其临床效果显著,且安全性有较大程度的保障,值得临床推广应用。%Objective To discuss the clinical effect of risperidone combined with clozapine in the use of two kinds of drugs for the treatment of refractory schizophrenia.Methods 100 patients with refractory schizophrenia of our hospital was selected as the research object, randomly divided into observation group and control group,50 cases in each group,the cases in the observation group was treated by risperidone combined with clozapine,while the cases in the control group only received risperidone treatment,observation of 12 weeks,before entering the group,respectively treatment of 6 weeks and 12 weeks,the efficacy of treatment was assessed by the Brief Psychiatric Rating Scale (BPRS). And using the TESS to evaluate adverse reaction.ResultsIn the observation group,BPRS total score after 6 weeks and 12 weeks were significantly lower than the control group,the difference was statistically significant (P0.05).Conclusion For refractory schizophrenia,we may try to treat them with the combination of risperidone and clozapine,it is safety and

  19. 氯氮平联合利培酮治疗难治性精神分裂症临床对照研究%A Clinical Control Study on Effects of Clozapine with Risperidone on Refractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    姚献虎; 陈敬兰; 沈建华

    2012-01-01

    Objective To explore the curative effect and safety of Risperidone with Clozapine in the treatment of refractory schizophrenia,and to provide the basis for clinical medication. Methods The 76 patients with refractory schizophrenia were randomly divided into the study group(36 cases) and the control group(40 cases) .the study group was treated by Risperidone and Clozapine, while the control group by Risperidone alone. The curative effect and side effect were evaluated by BPRS and TESS at the time points: before treatment,4,8 and 12 weeks after the treatment. Results The BPRS total scores of the study group were obviously lower than that of the control group at the end of the fourth week,eighth week and twelfth week. The TESS total scores between the two groups had no significant difference (P > 0.05 ) ; The side effect such as salivation, sleepiness, white blood cell reduction were obviously higher in the study group than as compared to the control group, but it' s well tolerated. Conclusion The combination of Clozapine and Risperidone for the refractory schizophrenia can shorten the response latency in the treatment, it is effective and safe.%目的 研究探索氯氮平联合利培酮治疗难治性精神分裂症的疗效及安全性,为临床用药提供依据.方法 76例难治性精神分裂症患者随机分为研究组和对照组,分别服用氯氮平联合利培酮(36例)、利培酮(40例)治疗,于入组前、治疗4周、治疗8周、治疗12周分别应用BPRS及TESS来观察评定疗效及副作用.结果 研究组于治疗4周末、8周末及12周末BPRS评定总分明显低于对照组,差异有统计学意义(P<0.05),两组TESS总分比较差异无统计学意义(P>0.05),但流涎、嗜睡、白细胞减少等副反应两组比较差异具有统计学意义(P<0.05),研究组较对照组明显为重,临床患者尚可以耐受.结论 氯氮平联合利培酮治疗难治性精神分裂症缩短治疗反应期、安全且疗效可靠,可以用

  20. 溴隐亭治疗利培酮致女性中度高催乳素血症的临床研究%Clinical study of Bromocriptine in treatment of moderate hyperprolactinemia caused by Risperidone

    Institute of Scientific and Technical Information of China (English)

    秦卫红; 魏时懿; 张军勐

    2014-01-01

    Objective:To discuss the efficacy of Bromocriptine in treatment of hyperprolactinemia cause by Risperidone and an-alyze the possibility of psychiatric symptom fluctuation for female patients with schizophrenia. Methods:According to the ICD-10, 59 female inpatients diagnosed as schizophrenia and got the mild hyperprolactinemia (100ug/ Lt0. 001(59), Pt0.001(59),P<0.001〕,BPRS 量表前后3次评定结果进行比较无显著差异。结论:本研究证实溴隐亭治疗利培酮所致女性中度高催乳素血症有实际临床应用价值,其有效性和安全性均非常可靠。

  1. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine Taxas de re-hospitalização de pacientes após alta hospitalar em uso de haloperidol, risperidona ou clozapina

    Directory of Open Access Journals (Sweden)

    Ana Paula Werneck de Castro

    2007-09-01

    Full Text Available OBJECTIVE:The purpose of this study was to evaluate the rehospitalization rates of patients discharged from the Institute of Psychiatry of the Hospital das Clínicas of the Universidade de São Paulo Medical School while being treated with haloperidol, risperidone or clozapine. METHOD: This is a naturalistic study designed to monitor rehospitalization rates for patients discharged on haloperidol (n = 43, risperidone (n = 22 or clozapine (n = 31. Time to readmission over the course of three years was measured by the product-limit (Kaplan-Meier method. Risk factors associated with rehospitalizations were examined. RESULTS: At 36 months, remained in the community 74% of the haloperidol-treated patients, 59% of the risperidone-treated patients and 84% of the clozapine-treated patients. The haloperidol group showed a higher proportion of women, a late age of onset and shorter length of illness than the other groups, whereas the opposite was observed in the clozapine group. CONCLUSIONS: This study suggests that the rehospitalization rates of patients taking clozapine are lower than the rate for patients treated with haloperidol and risperidone. However confounding variables such as gender distribution and age of onset represent limitations that should be taken into account for the interpretation of the results.OBJETIVO: O propósito desse estudo foi observar as taxas de re-hospitalização de pacientes com esquizofrenia que receberam alta do Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo em uso de haloperidol, risperidona ou clozapina. MÉTODO: Este foi um estudo naturalístico conduzido de forma a observar as taxas de re-hospitalizações dos pacientes que receberam alta em uso de haloperidol (n = 43, risperidona (n = 22 ou clozapina (n = 31. O tempo de re-hospitalização foi analisado de acordo com a fórmula produto-limite (Kaplan-Meier por três anos. Fatores de risco associados

  2. 利培酮治疗不同型精神分裂症患者疗效及安全性研究%Study on efficacy and safety of risperidone in treatment of different kinds of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王继禹; 白丽娟; 段媛卿; 原洁; 李志锐; 李新义

    2013-01-01

    目的 探讨利培酮治疗不同型精神分裂症的疗效及安全性.方法 收集100例偏执型及未分化型精神分裂症患者,分别给予利培酮治疗,观察8周,分别于治疗前及治疗第1,2,4,6,8周末分别进行阳性和阴性症状量表(PANSS)、临床总体印象量表、不良反应量表、锥体外系不良反应量表评分,比较不同型精神分裂症患者对利培酮的疗效及不良反应.结果 不同型精神分裂症患者治疗后同一时间点PANSS评分比较差异无统计学意义(P>0.05);不同型精神分裂症患者同一时间点所用剂量比较差异无统计学意义(P>0.05);利培酮治疗前后PANSS评分比较差异有统计学意义(P<0.01);入组前体重基线值为(63.91±11.75) kg,治疗8周后为(65.48±10.92) kg,差异有统计学意义(P<0.01).结论 利培酮对偏执型及未分化型精神分裂症疗效肯定,并具有较好的安全性及耐受性.%Objective To explore the safety and efficacy of risperidone in treatment of different kinds of schizophrenia.Methods Collected 100 cases of paranoid and undifferentiated schizophrenia patients,all patients were given risperidone treatment and observed for 8 weeks.Before treatment and at the 1st,2nd,4th,6th,8th weeks respectively by means of positive and negative symptom scale (PANSS),the Clinical Global Impression scale,adverse reaction scale,extrapyramidal system adverse reactions to scale score,comparison of different types of schizophrenia patients on risperidone' s efficacy and adverse reaction.Results The total PANSS score of different kinds of schizophrenia didn' t have great difference (P>0.05); the dose also didn' t have great statistical difference between different kinds of schizophrenia (P>0.05); the total PANSS score had great statistical difference between treatment (P<0.01); the group before the baseline weight value was (63.91 ± 11.75) kg,after 8 weeks of treatment it was (65.48 ± 10.92) kg,the difference was

  3. 阿立哌唑联合利培酮治疗慢性精神分裂症对照研究%A controlled study on aripiprazole combined with risperidone in the treatment of chronic schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨永秀; 陈斌华; 徐小杰; 陶云海; 施剑飞

    2013-01-01

    目的 评价阿立哌唑联合利培酮治疗慢性精神分裂症的疗效和安全性.方法 212例慢性精神分裂症患者随机分为阿立哌唑联合利培酮组(治疗组,105例)和利培酮组(对照组,107例).分别于治疗前及治疗后第2,4,8周末用阳性症状和阴性症状量表(PANSS)评价疗效,副反应量表(TESS)评价药物不良反应.结果 治疗组完成105例,对照组完成104例.治疗组有效率为92.38%,显著率为77.14%;对照组有效率为85.58%,显著率为66.35%,2组疗效差异无统计学意义(P>0.05).PANSS总分减分及PANSS阴性因子减分在第2,4,8周末治疗组均优于对照组(P <0.05或P<0.01).2组药物不良反应均较轻微,经对症处理大多能缓解,其中在震颤、静坐不能、体重增加及泌乳、月经紊乱等发生率,治疗组明显低于对照组(P<0.05).结论 利培酮联合阿立哌唑治疗慢性精神分裂症疗效良好,不良反应小,患者治疗依从性好.%Objective To evaluate the effectiveness and safety of aripiprazole combined risperidone in the treatment of chronic schizophrenia.Methods A total of 212 patients diagnosed as chronic schizophrenia were randomly divided into aripiprazole combined risperidone group (treatment group,n =105) and risperidone group (control group,n =107).Clinical effectiveness was assessed with the positive and negative syndrome scale(PANSS)and adverse reactions with the treatment emergent symptom scale (TESS) before treatment and at the end of the 2,4,8 week.Results One hundred and five patients of the